organic heterobicyclic ring - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	organic heterobicyclic ring	go back to main search page
Accession:	CHEBI:73541	browse the term
Definition:	A bicyclic organic group that contains both carbon and hetero atoms.
Synonyms:	related_synonym:	organic heterobicyclic rings

show annotations for term's descendants Sort by:
Rat (1943) Mouse (1953) Human (2007) Chinchilla (0) Bonobo (0) Dog (6) Squirrel (0) Pig (40) Green Monkey (0) Naked Mole-rat (0) All
Genes (1943)

2-methylserotonin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

5-hydroxytryptamine receptor 3A

multiple interactions

2-methyl-5-HT binds to and results in increased activity of HTR3A protein

NCBI chr 8:49,242,018...49,254,475
Ensembl chr 8:49,242,020...49,254,389

G

interleukin 1 beta

multiple interactions

2-methyl-5-HT promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

2-methyl-5-HT promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

5-methoxy-N,N-diisopropyltryptamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases activity
multiple interactions

5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2B6 protein
[5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2B6 protein] which results in decreased metabolism of Bupropion

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions
decreases activity

[5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 1

increases metabolic processing

CYP2D1 protein results in increased metabolism of 5-methoxy-N,N-diisopropyltryptamine

NCBI chr 7:113,908,950...113,913,420
Ensembl chr 7:113,908,947...113,922,084

G

cytochrome P450, family 2, subfamily d, polypeptide 2

increases metabolic processing

CYP2D2 protein results in increased metabolism of 5-methoxy-N,N-diisopropyltryptamine

NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions
decreases activity

[5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
decreases activity

[5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

5-methoxytryptamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions

CYP2D6 protein binds to and results in decreased methylation of 5-Methoxytryptamine

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

5-hydroxytryptamine receptor 7

multiple interactions

[5-Methoxytryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

kynurenine 3-monooxygenase

increases expression

5-Methoxytryptamine results in increased expression of KMO mRNA

NCBI chr13:87,557,080...87,589,334
Ensembl chr13:87,557,286...87,588,881

G

protein phosphatase 1, regulatory (inhibitor) subunit 1B

decreases phosphorylation
increases phosphorylation

5-Methoxytryptamine results in decreased phosphorylation of PPP1R1B protein
5-Methoxytryptamine results in increased phosphorylation of PPP1R1B protein

NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775

G

superoxide dismutase 2

decreases expression

5-Methoxytryptamine results in decreased expression of SOD2 mRNA

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

trace-amine-associated receptor 1

increases activity
multiple interactions

5-Methoxytryptamine results in increased activity of TAAR1 protein
[5-Methoxytryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

G

tryptophan hydroxylase 1

decreases expression

5-Methoxytryptamine results in decreased expression of TPH1 mRNA

NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344

6-hydroxymelatonin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

sulfotransferase family 1A member 1

multiple interactions

Mefenamic Acid inhibits the reaction [SULT1A1 protein results in increased sulfation of 6-hydroxymelatonin]

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

9-hydroxycanthin-6-one

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases cleavage

9-hydroxycanthin-6-one results in increased cleavage of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases cleavage

9-hydroxycanthin-6-one results in increased cleavage of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases cleavage

9-hydroxycanthin-6-one results in increased cleavage of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine ligand 2

decreases expression

9-hydroxycanthin-6-one results in decreased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

decreases expression

9-hydroxycanthin-6-one results in decreased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

ajmalicine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily d, polypeptide 4

decreases activity
multiple interactions

raubasine results in decreased activity of CYP2D6 protein
raubasine inhibits the reaction [CYP2D6 protein affects the metabolism of Dextromethorphan]

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

raubasine inhibits the reaction [Calcitriol results in increased expression of CYP3A4 protein]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

ajmaline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

Ajmaline inhibits the reaction [Calcitriol results in increased expression of CYP3A4 protein]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Ajmaline results in decreased activity of KCNH2 protein

PMID:15599706 PMID:24052561

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

sodium voltage-gated channel alpha subunit 5

decreases activity
affects response to substance

Ajmaline results in decreased activity of SCN5A protein
SCN5A protein affects the susceptibility to Ajmaline

PMID:10662748 PMID:15520322 PMID:20174578

NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769

alcuronium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cholinergic receptor, muscarinic 4

multiple interactions
affects binding

WIN 62577 inhibits the reaction [Alcuronium binds to CHRM4 protein]

NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159

G

cholinergic receptor nicotinic alpha 4 subunit

multiple interactions

Alcuronium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Alcuronium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Alcuronium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Alcuronium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]

NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619

alpha-ergocryptine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases activity

ergocryptine results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

bromocriptine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases expression
multiple interactions

Bromocriptine results in increased expression of ABCB1 protein
Clozapine inhibits the reaction [Bromocriptine results in increased expression of ABCB1 protein]; Spiperone inhibits the reaction [Bromocriptine results in increased expression of ABCB1 protein]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

increases activity
increases expression
multiple interactions

Bromocriptine results in increased activity of ABCB1B promoter
Bromocriptine results in increased expression of ABCB1B mRNA
Clozapine inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; eticlopride inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; Pertussis Toxin inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; Spiperone inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

aldo-keto reductase family 1, member C3

increases expression
multiple interactions

Bromocriptine results in increased expression of AKR1C3 mRNA
methyl cellosolve inhibits the reaction [Bromocriptine results in increased expression of AKR1C3 mRNA]

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

activating transcription factor 3

increases expression

Bromocriptine results in increased expression of ATF3 mRNA; Bromocriptine results in increased expression of ATF3 protein

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

Bromocriptine results in increased expression of BAX protein
[Bromocriptine co-treated with Octreotide] results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

brain-derived neurotrophic factor

decreases secretion

Bromocriptine results in decreased secretion of BDNF protein

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

catenin beta 1

multiple interactions

[Bromocriptine co-treated with Estradiol] results in decreased expression of CTNNB1 protein

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions
decreases expression

Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of CYP11A1 mRNA]
Bromocriptine results in decreased expression of CYP11A1 protein

PMID:12742521 PMID:21427058

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity

Bromocriptine results in decreased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Bromocriptine results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects binding
affects metabolic processing
multiple interactions

Bromocriptine binds to CYP3A4 protein
CYP3A4 protein affects the metabolism of Bromocriptine
Bromocriptine inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]

PMID:15286053 PMID:17198380 PMID:19299527

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

dopamine beta-hydroxylase

decreases activity

Bromocriptine results in decreased activity of DBH protein

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

dopamine receptor D2

affects expression
affects response to substance
multiple interactions
decreases expression
increases expression
increases response to substance

Bromocriptine affects the expression of DRD2 mRNA
DRD2 protein affects the susceptibility to Bromocriptine
Bromocriptine binds to and results in increased activity of DRD2 mRNA; Bromocriptine promotes the reaction [Clozapine results in decreased expression of DRD2 mRNA]
Bromocriptine results in decreased expression of DRD2 mRNA
[Clozapine co-treated with Bromocriptine] results in decreased expression of DRD2 mRNA
Bromocriptine results in increased expression of DRD2 mRNA
DRD2 polymorphism results in increased susceptibility to Bromocriptine

PMID:1534540 PMID:8103596 PMID:15781964 PMID:16901644 PMID:20063113

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D3

multiple interactions
decreases expression

[1-Methyl-4-phenylpyridinium co-treated with Bromocriptine] results in decreased expression of DRD3 mRNA
Bromocriptine results in decreased expression of DRD3 mRNA

NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596

G

estrogen receptor 1

multiple interactions

[Bromocriptine co-treated with Estradiol] results in increased expression of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

follicle stimulating hormone subunit beta

increases expression

Bromocriptine results in increased expression of FSHB protein

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

glial cell derived neurotrophic factor

decreases expression
decreases secretion

Bromocriptine results in decreased expression of GDNF mRNA
Bromocriptine results in decreased secretion of GDNF protein

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

growth hormone 1

increases expression
decreases expression

Bromocriptine results in increased expression of GH1 protein
Bromocriptine results in decreased expression of GH1 protein

PMID:772175 PMID:3226523 PMID:3745407 PMID:7293648 PMID:19420816

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

heme oxygenase 1

increases expression

Bromocriptine results in increased expression of HMOX1 mRNA; Bromocriptine results in increased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

5-hydroxytryptamine receptor 7

multiple interactions

[Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Bromocriptine binds to and results in decreased activity of HTR7 protein

PMID:18996971 PMID:19509219

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

insulin 2

decreases expression

Bromocriptine results in decreased expression of INS protein

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

luteinizing hormone subunit beta

increases expression

Bromocriptine results in increased expression of LHB protein

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

mitogen activated protein kinase 1

multiple interactions

Bromocriptine promotes the reaction [Estrogens results in increased phosphorylation of and affects the localization of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Bromocriptine promotes the reaction [Estrogens results in increased phosphorylation of and affects the localization of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

NFE2 like bZIP transcription factor 2

increases localization

Bromocriptine results in increased localization of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nerve growth factor

increases secretion

Bromocriptine results in increased secretion of NGF protein

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nitric oxide synthase 2

multiple interactions

Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

Bromocriptine affects the reaction [methyl cellosolve results in increased expression of NR5A2 mRNA]

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

proliferating cell nuclear antigen

multiple interactions

[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of PCNA protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PCNA protein]

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

proopiomelanocortin

decreases expression
increases expression
multiple interactions

Bromocriptine results in decreased expression of POMC protein alternative form
Bromocriptine results in increased expression of POMC mRNA; Bromocriptine results in increased expression of POMC protein modified form
Bromocriptine inhibits the reaction [POMC protein results in decreased secretion of Corticosterone]

PMID:1325994 PMID:6274577 PMID:12742521

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

protein kinase C, delta

multiple interactions
affects localization

Bromocriptine promotes the reaction [Estrogens results in increased expression of and results in increased cleavage of PRKCD protein]
Bromocriptine affects the localization of PRKCD protein

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

prolactin

multiple interactions
decreases secretion
decreases expression

Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Nalorphine results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [VIP protein results in increased expression of PRL protein]
Bromocriptine results in decreased secretion of PRL protein
Bromocriptine results in decreased expression of PRL protein
Bromocriptine inhibits the reaction [Amisulpride results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PRL mRNA]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Estradiol results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of PRL protein]; Estradiol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Ethanol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Sulpiride inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]

PMID:86031 PMID:86795 PMID:90217 PMID:1407345 PMID:1874184 More...

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

scavenger receptor class B, member 1

multiple interactions

Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of SCARB1 mRNA]

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

superoxide dismutase 1

multiple interactions

Bromocriptine inhibits the reaction [[SOD1 protein mutant form co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of NOS2 protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of TNF protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

steroidogenic acute regulatory protein

decreases expression

Bromocriptine results in decreased expression of STAR protein

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

signal transducer and activator of transcription 5A

affects localization

Bromocriptine affects the localization of STAT5A protein

NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866

G

transforming growth factor alpha

multiple interactions

Bromocriptine inhibits the reaction [Estradiol results in increased expression of TGFA mRNA]

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

transforming growth factor, beta 1

multiple interactions

[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of TGFB1 protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in decreased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

Bromocriptine inhibits the reaction [[SOD1 protein mutant form co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of TNF protein]
Bromocriptine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

PMID:11752888 PMID:21867702

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular endothelial growth factor A

multiple interactions

[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of VEGFA protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in decreased expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vasoactive intestinal peptide

multiple interactions

Bromocriptine inhibits the reaction [VIP protein results in increased expression of PRL protein]
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of VIP protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of VIP mRNA]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of VIP protein]

PMID:6441721 PMID:15677882

NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216

brucine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-fetoprotein

multiple interactions

brucine inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein]

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

BCL2 associated X, apoptosis regulator

increases expression

brucine results in increased expression of BAX protein

PMID:16443926 PMID:21684292

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

brucine results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

increases activity
increases expression
multiple interactions

[brucine results in increased activity of CASP9 protein] which results in increased activity of CASP3 protein; brucine results in increased activity of CASP3 protein
brucine results in increased expression of CASP3 protein
brucine results in increased expression of and results in increased activity of CASP3 protein; Cyclosporine inhibits the reaction [[brucine results in increased activity of CASP9 protein] which results in increased activity of CASP3 protein]

PMID:16442763 PMID:16443926 PMID:17449162 PMID:21684292

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions
increases activity

brucine results in increased activity of and results in increased cleavage of CASP9 protein; Cyclosporine inhibits the reaction [[brucine results in increased activity of CASP9 protein] which results in increased activity of CASP3 protein]; Cyclosporine inhibits the reaction [brucine results in increased activity of and results in increased cleavage of CASP9 protein]
[brucine results in increased activity of CASP9 protein] which results in increased activity of CASP3 protein; brucine results in increased activity of CASP9 protein

PMID:16443926 PMID:21684292

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

brucine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CAT protein]; brucine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]

PMID:24060683 PMID:30027798

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cholinergic receptor, muscarinic 1

multiple interactions

brucine affects the reaction [muscarinic toxin 7 binds to CHRM1 protein]; brucine affects the reaction [Pirenzepine analog binds to CHRM1 protein]; brucine analog affects the reaction [Acetylcholine binds to CHRM1 protein]; brucine analog affects the reaction [N-Methylscopolamine binds to CHRM1 protein]; brucine promotes the reaction [(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride binds to CHRM1 protein]; brucine promotes the reaction [5-methylfurtrethonium binds to CHRM1 protein]; brucine promotes the reaction [Acetylcholine binds to CHRM1 protein]; brucine promotes the reaction [Acetylcholine results in increased activity of CHRM1 protein]; brucine promotes the reaction [Bethanechol binds to CHRM1 protein]; brucine promotes the reaction [Carbachol binds to CHRM1 protein]; brucine promotes the reaction [furtrethonium binds to CHRM1 protein]; brucine promotes the reaction [oxotremorine M binds to CHRM1 protein]; brucine promotes the reaction [Pilocarpine binds to CHRM1 protein]; Quinuclidinyl Benzilate inhibits the reaction [brucine promotes the reaction [Acetylcholine results in increased activity of CHRM1 protein]]

PMID:9224827 PMID:9495826 PMID:10069518 PMID:10101037 PMID:15294002 More...

NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356

G

cholinergic receptor, muscarinic 2

multiple interactions
affects binding

brucine analog affects the reaction [Acetylcholine binds to CHRM2 protein]; brucine analog affects the reaction [N-Methylscopolamine binds to CHRM2 protein]; brucine promotes the reaction [N-Methylscopolamine binds to CHRM2 protein]
brucine binds to CHRM2 protein

PMID:9495826 PMID:10069518 PMID:15647330

NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103

G

cholinergic receptor, muscarinic 3

multiple interactions
affects binding

brucine analog affects the reaction [Acetylcholine binds to CHRM3 protein]; brucine analog affects the reaction [N-Methylscopolamine binds to CHRM3 protein]; brucine binds to and results in increased activity of CHRM3 protein mutant form; brucine promotes the reaction [(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride binds to CHRM3 protein]; brucine promotes the reaction [5-methylfurtrethonium binds to CHRM3 protein]; brucine promotes the reaction [Acetylcholine binds to CHRM3 protein]; brucine promotes the reaction [Arecoline binds to CHRM3 protein]; brucine promotes the reaction [Bethanechol binds to CHRM3 protein]; brucine promotes the reaction [Carbachol binds to CHRM3 protein]; brucine promotes the reaction [Carbachol results in increased activity of CHRM3 protein mutant form]; brucine promotes the reaction [furtrethonium binds to CHRM3 protein]; brucine promotes the reaction [oxotremorine M binds to CHRM3 protein]; brucine promotes the reaction [Pilocarpine binds to CHRM3 protein]
brucine binds to CHRM3 protein

PMID:9224827 PMID:10069518 PMID:15647330 PMID:20466821

NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278

G

cholinergic receptor, muscarinic 4

multiple interactions
affects binding

brucine analog affects the reaction [Acetylcholine binds to CHRM4 protein]; brucine analog affects the reaction [N-Methylscopolamine binds to CHRM4 protein]; brucine promotes the reaction [(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride binds to CHRM4 protein]; brucine promotes the reaction [5-methylfurtrethonium binds to CHRM4 protein]; brucine promotes the reaction [Bethanechol binds to CHRM4 protein]; brucine promotes the reaction [Carbachol binds to CHRM4 protein]; brucine promotes the reaction [furtrethonium binds to CHRM4 protein]; brucine promotes the reaction [oxotremorine M binds to CHRM4 protein]; brucine promotes the reaction [Pilocarpine binds to CHRM4 protein]; WIN 62577 inhibits the reaction [brucine binds to CHRM4 protein]

PMID:9224827 PMID:10069518 PMID:16709648

NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159

G

cathepsin D

decreases expression

brucine results in decreased expression of CTSD mRNA
brucine results in decreased expression of CTSD mRNA; brucine results in decreased expression of CTSD protein

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily b, polypeptide 1

increases expression

brucine results in increased expression of CYP2B1 protein

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 2

increases expression

brucine results in increased expression of CYP2B2 protein

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

brucine results in increased expression of CYP2B3 protein

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
increases activity

[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP2E1 protein; [brucine co-treated with liquiritin] results in decreased activity of CYP2E1 protein
brucine results in increased activity of CYP2E1 protein

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

fibronectin 1

decreases expression

brucine results in decreased expression of FN1 mRNA
brucine results in decreased expression of FN1 mRNA; brucine results in decreased expression of FN1 protein

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

glycine receptor, alpha 1

multiple interactions

brucine analog binds to and results in decreased activity of GLRA1 protein; brucine binds to and results in decreased activity of GLRA1 protein

PMID:15081878 PMID:16687139

NCBI chr10:39,625,853...39,727,897
Ensembl chr10:39,629,459...39,727,162

G

glutamic--pyruvic transaminase

increases expression

brucine results in increased expression of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

brucine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of GPX1 protein]

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione-disulfide reductase

multiple interactions

brucine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 1

multiple interactions

brucine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of GSTA1 protein]

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

lysyl oxidase

decreases expression

brucine results in decreased expression of LOX mRNA
brucine results in decreased expression of LOX mRNA; brucine results in decreased expression of LOX protein

NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477

G

myelin basic protein

affects expression

brucine affects the expression of MBP mRNA

NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404

G

matrix metallopeptidase 2

decreases expression

brucine results in decreased expression of MMP2 mRNA
brucine results in decreased expression of MMP2 mRNA; brucine results in decreased expression of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

neuronal PAS domain protein 2

multiple interactions

NPAS2 protein affects the metabolism of and affects the susceptibility to brucine

NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320

G

proliferating cell nuclear antigen

multiple interactions

brucine inhibits the reaction [Diethylnitrosamine results in increased expression of PCNA protein]

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

prostaglandin-endoperoxide synthase 2

decreases expression

brucine results in decreased expression of PTGS2 protein

PMID:16442763 PMID:17449162

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

superoxide dismutase 1

multiple interactions

brucine inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

tumor necrosis factor

decreases secretion

brucine results in decreased secretion of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

caracurine VII

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cholinergic receptor, muscarinic 2

affects binding

caracurine binds to CHRM2 protein

NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103

G

cholinergic receptor, muscarinic 3

affects binding

caracurine binds to CHRM3 protein

NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278

cryptolepine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

increases expression

cryptolepine results in increased expression of BAX mRNA; cryptolepine results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

baculoviral IAP repeat-containing 3

decreases expression

cryptolepine results in decreased expression of BIRC3 mRNA

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

BUB1 mitotic checkpoint serine/threonine kinase

decreases expression

cryptolepine results in decreased expression of BUB1 mRNA

NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650

G

BUB1 mitotic checkpoint serine/threonine kinase B

decreases expression

cryptolepine results in decreased expression of BUB1B mRNA

NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547

G

cyclin A2

decreases expression

cryptolepine results in decreased expression of CCNA2 mRNA; cryptolepine results in decreased expression of CCNA2 protein

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

decreases expression

cryptolepine results in decreased expression of CCNB1 mRNA; cryptolepine results in decreased expression of CCNB1 protein

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

increases expression

cryptolepine results in increased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cell division cycle 25C

decreases expression

cryptolepine results in decreased expression of CDC25C mRNA

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

G

cell division cycle 34, ubiqiutin conjugating enzyme

decreases expression

cryptolepine results in decreased expression of CDC34 mRNA

NCBI chr 7:10,017,588...10,023,586
Ensembl chr 7:10,017,588...10,023,186

G

cell division cycle 45

decreases expression

cryptolepine results in decreased expression of CDC45 mRNA

NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619

G

cell division cycle 6

decreases expression

cryptolepine results in decreased expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cyclin-dependent kinase inhibitor 1A

increases expression

cryptolepine results in increased expression of CDKN1A mRNA; cryptolepine results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 3

decreases expression

cryptolepine results in decreased expression of CDKN3 mRNA

NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945

G

centromere protein F

decreases expression

cryptolepine results in decreased expression of CENPF mRNA

NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669

G

growth differentiation factor 15

increases expression

cryptolepine results in increased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

minichromosome maintenance complex component 2

decreases expression

cryptolepine results in decreased expression of MCM2 mRNA

NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847

G

minichromosome maintenance complex component 6

decreases expression

cryptolepine results in decreased expression of MCM6 mRNA

NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960

G

minichromosome maintenance complex component 7

decreases expression

cryptolepine results in decreased expression of MCM7 mRNA

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063

G

minichromosome maintenance 8 homologous recombination repair factor

decreases expression

cryptolepine results in decreased expression of MCM8 mRNA

NCBI chr 3:120,086,741...120,117,008
Ensembl chr 3:120,086,763...120,117,008

G

MDM2 proto-oncogene

increases expression

cryptolepine results in increased expression of MDM2 mRNA; cryptolepine results in increased expression of MDM2 protein

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

myelin transcription factor 1

decreases expression

cryptolepine results in decreased expression of MYT1 mRNA

NCBI chr 3:168,890,466...168,950,341
Ensembl chr 3:168,886,089...168,950,341

G

NIMA-related kinase 2

decreases expression

cryptolepine results in decreased expression of NEK2 mRNA

NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051

G

tumor protein p53

increases expression
increases activity

cryptolepine results in increased expression of TP53 protein
cryptolepine results in increased activity of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

Ttk protein kinase

decreases expression

cryptolepine results in decreased expression of TTK mRNA

NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651

demethoxyfumitremorgin C

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

decreases expression

demethoxyfumitremorgin C results in decreased expression of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

BCL2 associated X, apoptosis regulator

increases expression

demethoxyfumitremorgin C results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

demethoxyfumitremorgin C results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression

demethoxyfumitremorgin C results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

caspase 3

increases activity

demethoxyfumitremorgin C results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases activity

demethoxyfumitremorgin C results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity

demethoxyfumitremorgin C results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

poly (ADP-ribose) polymerase 1

increases cleavage

demethoxyfumitremorgin C results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

dihydro-beta-erythroidine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

atonal bHLH transcription factor 1

multiple interactions

Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in increased expression of ATOH1 mRNA]

NCBI chr 4:93,912,068...93,914,163
Ensembl chr 4:93,912,068...93,914,154

G

cyclin D1

multiple interactions

Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in decreased expression of CCND1 mRNA]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin-dependent kinase 4

multiple interactions

Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in decreased expression of CDK4 protein]

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

dihydro-beta-erythroidine affects binding to Chrna2 protein; dihydro-beta-erythroidine inhibits the reaction [epibatidine affects binding to Chrna2 protein] in rat retina

RGD

NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

Dihydro-beta-Erythroidine results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]
dihydro-beta-erythroidine affects binding [Epibatidine binds to Chrna3 protein]

CTD
RGD

PMID:9687574 PMID:16129735 PMID:15016836

RGD:2303195, RGD:2303194

NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165

G

cholinergic receptor nicotinic alpha 4 subunit

multiple interactions
affects binding

Carbachol inhibits the reaction [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [1-Butanol binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
dihydro-beta-erythroidine affects binding to Chrna4 protein; dihydro-beta-erythroidine inhibits the reaction [epibatidine affects binding to Chrna4 protein] in rat retina
dihydro-beta-erythroidine affects binding to Chrna4 protein; dihydro-beta-erythroidine competes with [Epibatidine binds to Chrna4 protein]
[Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine; Dihydro-beta-Erythroidine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in increased expression of CHRNA4 mRNA]; Dihydro-beta-Erythroidine inhibits the reaction [[pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine]; Dihydro-beta-Erythroidine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [3-(2-(pyrrolidinyl)methoxy)pyridine analog results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]
[CHRNA4 protein binds to CHRNB4 protein] which binds to Dihydro-beta-Erythroidine

CTD
RGD

PMID:9687574 PMID:10945867 PMID:11600638 PMID:12604691 PMID:14645658 More...

RGD:2303195, RGD:2303194

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic alpha 7 subunit

increases activity
multiple interactions
affects response to substance

Dihydro-beta-Erythroidine results in increased activity of CHRNA7 protein mutant form
Dihydro-beta-Erythroidine affects the reaction [iodo-alpha-bungarotoxin binds to CHRNA7 protein]
CHRNA7 protein mutant form affects the susceptibility to Dihydro-beta-Erythroidine
Dihydro-beta-Erythroidine binds to and results in decreased activity of CHRNA7 protein

PMID:10082212 PMID:19448648

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Carbachol inhibits the reaction [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [1-Butanol binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine inhibits the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased uptake of Calcium]; Dihydro-beta-Erythroidine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
dihydro-beta-erythroidine affects binding to Chrnb2 protein; dihydro-beta-erythroidine inhibits the reaction [epibatidine affects binding to Chrnb2 protein] in rat retina
dihydro-beta-erythroidine affects binding to Chrnb2 protein; dihydro-beta-erythroidine competes with [Epibatidine binds to Chrnb2 protein]
Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [3-(2-(pyrrolidinyl)methoxy)pyridine analog results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]
[Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine; Dihydro-beta-Erythroidine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]; Dihydro-beta-Erythroidine inhibits the reaction [[pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine]; Dihydro-beta-Erythroidine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]

CTD
RGD

PMID:10945867 PMID:11600638 PMID:12604691 PMID:14645658 PMID:16569710 More...

RGD:2303195, RGD:2303194

NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619

G

cholinergic receptor nicotinic beta 3 subunit

multiple interactions

dihydro-beta-erythroidine affects binding to Chrnb3 protein; dihydro-beta-erythroidine inhibits the reaction [epibatidine affects binding to Chrnb3 protein] in rat retina

RGD

NCBI chr16:64,713,438...64,751,360
Ensembl chr16:64,714,169...64,751,360

G

cholinergic receptor nicotinic beta 4 subunit

affects binding
multiple interactions

[CHRNA4 protein binds to CHRNB4 protein] which binds to Dihydro-beta-Erythroidine
Dihydro-beta-Erythroidine results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]

NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027

G

C-X-C motif chemokine receptor 4

multiple interactions

[Mecamylamine co-treated with Dihydro-beta-Erythroidine co-treated with Bungarotoxins] inhibits the reaction [Nicotine results in increased expression of CXCR4 protein]

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

DNA methyltransferase 1

multiple interactions

Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in decreased expression of DNMT1 mRNA]

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

glutamate decarboxylase 1

multiple interactions

Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in increased expression of GAD1 mRNA]

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

solute carrier family 6 member 3

multiple interactions

Dihydro-beta-Erythroidine affects the reaction [Nicotine results in decreased activity of SLC6A3 protein]

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

TNF receptor superfamily member 11B

multiple interactions

Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in increased expression of TNFRSF11B mRNA]

NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538

G

TNF superfamily member 11

multiple interactions

Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in decreased expression of TNFSF11 mRNA]

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

dihydroergotamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

Dihydroergotamine results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 4

decreases activity

Dihydroergotamine results in decreased activity of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases activity
increases activity

Dihydroergotamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
Dihydroergotamine results in decreased activity of CYP1A1 protein
Dihydroergotamine results in increased activity of CYP1A1 protein

PMID:18420780 PMID:18493746 PMID:33814510

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Dihydroergotamine results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily a, polypeptide 3

decreases activity

Dihydroergotamine results in decreased activity of CYP2A4 protein

NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases activity

Dihydroergotamine results in decreased activity of CYP2B10 protein

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases activity

Dihydroergotamine results in decreased activity of CYP2C29 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

decreases activity

Dihydroergotamine results in decreased activity of CYP2D6 protein
Dihydroergotamine results in decreased activity of CYP2D22 protein

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity

Dihydroergotamine results in decreased activity of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

5-hydroxytryptamine (serotonin) receptor 5B

multiple interactions

dihydroergotamine binds to protein 5-Htr5b; inhibits the reaction[5-carboxamidotryptamine binds to 5-Htr5b]

RGD

NCBI chr13:32,686,911...32,699,835
Ensembl chr13:32,687,042...32,699,835

G

interleukin 24

increases expression

Dihydroergotamine results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

nuclear receptor subfamily 1, group I, member 2

increases activity

Dihydroergotamine results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

ellipticine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

ellipticine inhibits the reaction [AHR protein promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

BCL2 associated X, apoptosis regulator

increases expression

ellipticine results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

ellipticine results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BH3 interacting domain death agonist

multiple interactions

ellipticine results in decreased expression of and results in increased cleavage of BID protein

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

caspase 3

multiple interactions
increases activity

Acetylcysteine inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP3 protein]; Butylated Hydroxyanisole inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP3 protein]; ellipticine results in increased cleavage of and results in increased activity of CASP3 protein; pyrazolanthrone inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP3 protein]
ellipticine results in increased activity of CASP3 protein

PMID:16027529 PMID:21843585

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

multiple interactions

Acetylcysteine inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP7 protein]; Butylated Hydroxyanisole inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP7 protein]; ellipticine results in increased cleavage of and results in increased activity of CASP7 protein; pyrazolanthrone inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP7 protein]; U 0126 inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

multiple interactions

ellipticine results in increased cleavage of and results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity
multiple interactions

ellipticine results in increased activity of CASP9 protein
ellipticine results in increased cleavage of and results in increased activity of CASP9 protein

PMID:16027529 PMID:21843585

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin B1

decreases expression
increases expression

ellipticine results in decreased expression of CCNB1 protein
ellipticine results in increased expression of CCNB1 protein

PMID:16027529 PMID:21843585

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

decreases expression

ellipticine results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cell division cycle 25C

decreases expression

ellipticine results in decreased expression of CDC25C protein

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

G

cyclin-dependent kinase 1

multiple interactions

ellipticine results in decreased expression of and results in increased phosphorylation of CDK1 protein

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

ellipticine results in increased expression of CDKN1A protein
[ellipticine results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein; TP53 protein promotes the reaction [[ellipticine results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [ellipticine results in increased expression of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

decreases expression

ellipticine results in decreased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases metabolic processing
increases expression
increases activity
multiple interactions

CYP1A1 protein results in increased metabolism of ellipticine
ellipticine results in increased expression of CYP1A1 protein
ellipticine results in increased activity of CYP1A1 protein
[ellipticine results in decreased activity of CYP1A1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in increased abundance of Reactive Oxygen Species]; ellipticine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
ellipticine inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; ellipticine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; TP53 protein promotes the reaction [ellipticine inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [ellipticine results in increased expression of CYP1A1 protein]
[ellipticine results in decreased activity of CYP1A1 protein] inhibits the reaction [aristolochic acid I results in increased abundance of [7-(deoxyadenosin-N(6)-yl)aristolactam I co-treated with 7-(deoxyguanosin-N(2)-yl)aristolactam I co-treated with 7-(deoxyadenosin-N(6)--yl)aristolactam II]]; ellipticine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; ellipticine inhibits the reaction [troglitazone results in increased activity of CYP1A1 protein]

PMID:17973980 PMID:18308446 PMID:18493746 PMID:21932800 PMID:22917556 More...

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases metabolic processing
multiple interactions

CYP1A2 protein results in increased metabolism of ellipticine
ellipticine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]

PMID:18493746 PMID:22917556

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases metabolic processing
multiple interactions

CYP1B1 protein results in increased metabolism of ellipticine
ellipticine inhibits the reaction [AHR protein promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]]

PMID:11577022 PMID:22917556

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases metabolic processing

CYP2C19 protein results in increased metabolism of ellipticine

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases metabolic processing

CYP2D6 protein mutant form results in increased metabolism of ellipticine

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases metabolic processing

CYP2E1 protein results in increased metabolism of ellipticine

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases metabolic processing

[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine]; Protons inhibits the reaction [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine]
CYP3A4 protein results in increased metabolism of ellipticine

PMID:22390216 PMID:22917556 PMID:30914192

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

ferritin light chain 1

multiple interactions

[ellipticine binds to FTL protein] which results in increased expression of H2AX protein modified form; FTL protein binds to and results in decreased uptake of ellipticine

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725

G

H2A.X variant histone

increases expression
multiple interactions

ellipticine results in increased expression of H2AX protein modified form
[ellipticine binds to FTL protein] which results in increased expression of H2AX protein modified form

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [ellipticine results in increased phosphorylation of MAPK1 protein]; Butylated Hydroxyanisole inhibits the reaction [ellipticine results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [ellipticine results in increased phosphorylation of MAPK3 protein]; Butylated Hydroxyanisole inhibits the reaction [ellipticine results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MDM2 proto-oncogene

decreases response to substance

MDM2 promoter SNP results in decreased susceptibility to ellipticine

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

poly (ADP-ribose) polymerase 1

increases cleavage

ellipticine results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

cytochrome p450 oxidoreductase

multiple interactions

[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

DNA topoisomerase II beta

decreases response to substance
increases response to substance

TOP2B protein mutant form results in decreased susceptibility to ellipticine
TOP2B protein mutant form results in increased susceptibility to ellipticine

PMID:15322234 PMID:16239602

NCBI chr15:9,051,340...9,111,721
Ensembl chr15:9,051,341...9,112,085

G

tumor protein p53

multiple interactions
increases expression
increases response to substance

TP53 protein promotes the reaction [[ellipticine results in increased susceptibility to Benzo(a)pyrene] which results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [ellipticine inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]]; TP53 protein promotes the reaction [ellipticine results in increased expression of CDKN1A protein]; TP53 protein promotes the reaction [ellipticine results in increased expression of CYP1A1 protein]
ellipticine results in increased expression of TP53 protein
TP53 protein results in increased susceptibility to ellipticine

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

X-linked inhibitor of apoptosis

decreases expression

ellipticine results in decreased expression of XIAP protein

PMID:16027529 PMID:21843585

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

ergocristine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

ergocristine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
ergocristine results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

caspase 3

increases activity

ergocristine results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

ergosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases activity

ergosine results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

ergotamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

calcitonin-related polypeptide alpha

multiple interactions

Ergotamine inhibits the reaction [Nitroglycerin results in increased expression of CALCA protein]

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

caspase 3

increases activity

Ergotamine results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Ergotamine inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glutathione S-transferase pi 1

multiple interactions

Ergotamine inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

5-hydroxytryptamine receptor 2B

multiple interactions

Ergotamine binds to and results in increased activity of HTR2B protein

NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108

fumigaclavine C

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interferon gamma

decreases expression

fumigaclavine C results in decreased expression of IFNG mRNA; fumigaclavine C results in decreased expression of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 12A

decreases expression

fumigaclavine C results in decreased expression of IL12A mRNA

NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734

G

interleukin 1 beta

decreases expression

fumigaclavine C results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

decreases expression

fumigaclavine C results in decreased expression of IL2 mRNA; fumigaclavine C results in decreased expression of IL2 protein

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

matrix metallopeptidase 9

decreases activity
decreases expression

fumigaclavine C results in decreased activity of MMP9 protein
fumigaclavine C results in decreased expression of MMP9 mRNA

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

tumor necrosis factor

decreases expression

fumigaclavine C results in decreased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

Gelsemine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases metabolic processing
decreases response to substance

CYP3A4 protein results in increased metabolism of gelsemine
CYP3A4 protein results in decreased susceptibility to gelsemine

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases metabolic processing

CYP3A5 protein results in increased metabolism of gelsemine

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

glutamic--pyruvic transaminase

multiple interactions
increases expression

Ketoconazole promotes the reaction [gelsemine results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

interleukin 1 beta

multiple interactions
increases expression

Dexamethasone inhibits the reaction [gelsemine results in increased expression of IL1B protein]; Ketoconazole promotes the reaction [gelsemine results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

gramine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin receptor 1

multiple interactions

gramine binds to and results in increased activity of ADIPOR1 protein

NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241

G

peroxisome proliferator activated receptor alpha

decreases phosphorylation

gramine results in decreased phosphorylation of PPARA protein

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

protein kinase AMP-activated catalytic subunit alpha 1

increases phosphorylation

gramine results in increased phosphorylation of PRKAA1 protein

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

protein kinase AMP-activated catalytic subunit alpha 2

increases phosphorylation

gramine results in increased phosphorylation of PRKAA2 protein

NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543

harmaline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-C motif chemokine ligand 2

multiple interactions

Harmaline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cadherin 1

increases expression

Harmaline results in increased expression of CDH1 protein

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases activity
decreases stability

[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein]; Harmaline inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; Harmaline inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of CYP1A1 protein]; Harmaline inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
Harmaline results in decreased activity of CYP1A1 protein
Harmaline results in decreased stability of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

endoglin

decreases expression
multiple interactions

Harmaline results in decreased expression of ENG mRNA
Doxorubicin promotes the reaction [Harmaline results in decreased expression of ENG mRNA]

NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230

G

interferon gamma

increases secretion

Harmaline results in increased secretion of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 1 beta

multiple interactions

Harmaline inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Harmaline inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 4

affects secretion
multiple interactions

Harmaline affects the secretion of IL4 protein
Doxorubicin affects the reaction [Harmaline results in decreased secretion of IL4 protein]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

kinase insert domain receptor

multiple interactions
decreases expression

Doxorubicin promotes the reaction [Harmaline results in decreased expression of KDR mRNA]

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

monoamine oxidase A

decreases activity

Harmaline results in decreased activity of MAOA protein

PMID:15178694 PMID:24373881 PMID:28302559

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

marker of proliferation Ki-67

decreases expression

Harmaline results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 2

decreases expression

Harmaline results in decreased expression of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

nuclear factor kappa B subunit 1

multiple interactions

Harmaline inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Harmaline inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of NFKB1 protein]

PMID:12065299 PMID:12107048

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

prostaglandin-endoperoxide synthase 2

multiple interactions
decreases expression

Doxorubicin promotes the reaction [Harmaline results in decreased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Harmaline inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Harmaline inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of RELA protein]

PMID:12065299 PMID:12107048

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

vascular endothelial growth factor A

multiple interactions
decreases expression

Doxorubicin promotes the reaction [Harmaline results in decreased expression of VEGFA mRNA]
Harmaline results in decreased expression of VEGFA mRNA; Harmaline results in decreased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

harmalol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases activity
increases expression

harmalol results in increased activity of CASP3 protein
harmalol results in increased expression of CASP3 mRNA

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases stability
decreases activity

[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein]; harmalol inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; harmalol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of CYP1A1 protein]; harmalol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
harmalol results in decreased stability of CYP1A1 protein
harmalol results in decreased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

tumor protein p53

increases expression

harmalol results in increased expression of TP53 mRNA; harmalol results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

harman

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

AHR mutant form inhibits the reaction [harman results in increased activity of CYP1A1 protein]; AHR mutant form inhibits the reaction [harman results in increased expression of CYP1A1 protein]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

caspase 3

increases cleavage
increases expression

harman results in increased cleavage of CASP3 protein
harman results in increased expression of CASP3 mRNA

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases expression

harman results in increased expression of CASP7 mRNA

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 9

increases expression

harman results in increased expression of CASP9 mRNA

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

decreases activity

harman results in decreased activity of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression
increases activity

AHR mutant form inhibits the reaction [harman results in increased activity of CYP1A1 protein]; AHR mutant form inhibits the reaction [harman results in increased expression of CYP1A1 protein]; Dactinomycin inhibits the reaction [harman results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [harman results in increased activity of CYP1A1 protein]
harman results in increased expression of CYP1A1 mRNA; harman results in increased expression of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

heme oxygenase 1

increases expression

harman results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

monoamine oxidase A

decreases activity

harman results in decreased activity of MAOA protein

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

NFE2 like bZIP transcription factor 2

increases expression

harman results in increased expression of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NAD(P)H quinone dehydrogenase 1

increases expression

harman results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

poly (ADP-ribose) polymerase 1

increases cleavage

harman results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

solute carrier family 22 member 1

multiple interactions
decreases activity

harman inhibits the reaction [SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]
harman results in decreased activity of SLC22A1 protein

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 22 member 2

decreases activity
multiple interactions

harman results in decreased activity of SLC22A2 protein
harman inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

trace-amine-associated receptor 1

increases activity
multiple interactions

harman results in increased activity of TAAR1 protein
[harman results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

harmine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

decreases activity

Harmine results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

aryl hydrocarbon receptor

multiple interactions

Harmine inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

axin 2

multiple interactions

Harmine inhibits the reaction [WNT3A protein results in increased expression of AXIN2 mRNA]

NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231

G

Bcl2-like 11

multiple interactions

Harmine promotes the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L11 protein]

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

calcium/calmodulin-dependent protein kinase II delta

decreases expression

harmine decreases expression of camk2d protein after myocardial infarction in rat heart left ventricle

RGD

NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178

G

cyclin A1

increases expression

Harmine results in increased expression of CCNA1 mRNA; Harmine results in increased expression of CCNA1 protein

NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157

G

cyclin E2

increases expression

Harmine results in increased expression of CCNE2 mRNA; Harmine results in increased expression of CCNE2 protein

NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632

G

cell division cycle 25A

increases expression

Harmine results in increased expression of CDC25A mRNA

NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701

G

cell division cycle 25C

increases expression

Harmine results in increased expression of CDC25C mRNA

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

G

cyclin-dependent kinase 1

increases expression

Harmine results in increased expression of CDK1 mRNA; Harmine results in increased expression of CDK1 protein

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase inhibitor 1B

decreases phosphorylation

Harmine results in decreased phosphorylation of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 1C

decreases expression

Harmine results in decreased expression of CDKN1C mRNA; Harmine results in decreased expression of CDKN1C protein

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048

G

cyclin-dependent kinase inhibitor 2A

decreases expression

Harmine results in decreased expression of CDKN2A mRNA; Harmine results in decreased expression of CDKN2A protein

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cyclin-dependent kinase inhibitor 2B

decreases expression

Harmine results in decreased expression of CDKN2B mRNA

NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050

G

chromodomain helicase DNA binding protein 4

multiple interactions
increases phosphorylation

AZD 6244 inhibits the reaction [Harmine results in increased phosphorylation of CHD4 protein]; Harmine inhibits the reaction [CHD4 protein affects the expression of UCP1 mRNA]; Harmine inhibits the reaction [CHD4 protein binds to UCP1 promoter]

NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541

G

cell death-inducing DFFA-like effector a

multiple interactions
increases expression

Harmine affects the reaction [Dietary Fats affects the expression of CIDEA mRNA]
Harmine results in increased expression of CIDEA protein

NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases activity
decreases stability

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Harmine results in decreased stability of CYP1A1 protein]; Harmine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Harmine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
Harmine results in decreased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

iodothyronine deiodinase 2

increases expression

Harmine results in increased expression of DIO2 protein

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

dual specificity tyrosine phosphorylation regulated kinase 1A

multiple interactions
decreases expression
affects binding
decreases activity

Harmine inhibits the reaction [DYRK1A protein results in increased phosphorylation of MAPT protein]
harmine decreases expression of dyrk1a protein after myocardial infarction in rat heart left ventricle
Harmine binds to DYRK1A protein
Harmine results in decreased activity of DYRK1A protein

CTD
RGD

PMID:21573099 PMID:25751815 PMID:26067684

NCBI chr11:33,890,706...34,009,420
Ensembl chr11:33,890,490...34,009,420

G

E2F transcription factor 1

increases expression

Harmine results in increased expression of E2F1 mRNA; Harmine results in increased expression of E2F1 protein

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

E2F transcription factor 2

increases expression

Harmine results in increased expression of E2F2 mRNA; Harmine results in increased expression of E2F2 protein

NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217

G

E2F transcription factor 7

increases expression

Harmine results in increased expression of E2F7 mRNA

NCBI chr 7:46,150,533...46,192,739
Ensembl chr 7:46,151,293...46,192,734

G

E2F transcription factor 8

increases expression

Harmine results in increased expression of E2F8 mRNA

NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098

G

fatty acid binding protein 4

multiple interactions

[phenylamil co-treated with Harmine] results in increased expression of FABP4 mRNA

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

forkhead box M1

increases expression

Harmine results in increased expression of FOXM1 mRNA; Harmine results in increased expression of FOXM1 protein

NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684

G

inhibitor of DNA binding 2

multiple interactions

Harmine inhibits the reaction [WNT3A protein results in decreased expression of ID2 mRNA]

NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400

G

insulin 1

multiple interactions

Harmine affects the reaction [LEPR protein affects the susceptibility to INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

increases expression

Harmine results in increased expression of INS mRNA

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

leptin receptor

multiple interactions

Harmine affects the reaction [LEPR protein affects the susceptibility to INS1 protein]

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

MAF bZIP transcription factor A

increases expression

Harmine results in increased expression of MAFA mRNA; Harmine results in increased expression of MAFA protein

NCBI chr 7:107,432,292...107,435,084
Ensembl chr 7:107,433,605...107,434,690

G

monoamine oxidase A

decreases activity

Harmine results in decreased activity of MAOA protein

PMID:24373881 PMID:28302559

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

mitogen activated protein kinase 1

increases phosphorylation

Harmine results in increased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation

Harmine results in increased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

microtubule-associated protein tau

multiple interactions

Harmine inhibits the reaction [DYRK1A protein results in increased phosphorylation of MAPT protein]

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

MYC proto-oncogene, bHLH transcription factor

increases expression

Harmine results in increased expression of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

nuclear factor of activated T-cells 1

affects localization

Harmine affects the localization of NFATC1 protein

NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028

G

nuclear factor of activated T-cells 2

affects localization

Harmine affects the localization of NFATC2 protein

NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325

G

nuclear factor of activated T-cells 3

affects localization

Harmine affects the localization of NFATC3 protein

NCBI chr19:33,960,643...34,035,150
Ensembl chr19:33,960,852...34,035,150

G

nuclear factor of activated T-cells 4

affects localization

Harmine affects the localization of NFATC4 protein

NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610

G

poly (ADP-ribose) polymerase 1

multiple interactions

Harmine promotes the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

pancreatic and duodenal homeobox 1

increases expression

Harmine results in increased expression of PDX1 mRNA; Harmine results in increased expression of PDX1 protein

NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064

G

phospholamban

increases expression

harmine increases expression of Pln protein after myocardial infarction in rat heart left ventricle

RGD

NCBI chr20:32,629,537...32,639,559

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

[phenylamil co-treated with Harmine] results in increased expression of PPARG mRNA
Harmine results in increased expression of PPARG protein

PMID:20519739 PMID:27805061

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

increases expression
multiple interactions

Harmine results in increased expression of PPARGC1A protein
Harmine affects the reaction [Dietary Fats affects the expression of PPARGC1A mRNA]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

PR/SET domain 16

increases expression
multiple interactions

Harmine results in increased expression of PRDM16 protein
Harmine affects the reaction [Dietary Fats affects the expression of PRDM16 mRNA]

NCBI chr 5:164,879,864...165,203,986
Ensembl chr 5:164,880,587...165,203,601

G

uncoupling protein 1

increases expression
multiple interactions

Harmine results in increased expression of UCP1 mRNA; Harmine results in increased expression of UCP1 protein
2-chloro-5-nitrobenzanilide inhibits the reaction [Harmine results in increased expression of UCP1 mRNA]; AZD 6244 inhibits the reaction [Harmine results in increased expression of UCP1 mRNA]; Harmine affects the reaction [Dietary Fats affects the expression of UCP1 mRNA]; Harmine inhibits the reaction [CHD4 protein affects the expression of UCP1 mRNA]; Harmine inhibits the reaction [CHD4 protein binds to UCP1 promoter]; N4-(9-ethyl-9H-carbazol-3-yl)-N2-(3-morpholin-4-ylpropyl)-pyrimidine-2,4-diamine inhibits the reaction [Harmine results in increased expression of UCP1 mRNA]

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

Wnt family member 3A

multiple interactions

Harmine inhibits the reaction [WNT3A protein results in decreased expression of ID2 mRNA]; Harmine inhibits the reaction [WNT3A protein results in increased expression of AXIN2 mRNA]

NCBI chr10:44,034,174...44,078,366
Ensembl chr10:44,034,194...44,078,324

harmol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

harmol inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases activity
decreases stability

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [harmol results in decreased stability of CYP1A1 protein]; harmol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; harmol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
harmol results in decreased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

sulfotransferase family 1A member 1

multiple interactions

Mefenamic Acid inhibits the reaction [SULT1A1 protein results in increased sulfation of harmol]

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

ibogaine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Ibogaine results in decreased activity of KCNH2 protein

PMID:23707769 PMID:24307198

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

sodium voltage-gated channel alpha subunit 5

decreases activity

Ibogaine results in decreased activity of SCN5A protein

NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769

G

SEC24 homolog D, COPII coat complex component

increases response to substance

SEC24D protein results in increased susceptibility to Ibogaine

NCBI chr 2:211,418,557...211,526,588
Ensembl chr 2:211,418,623...211,526,587

G

solute carrier family 6 member 3

multiple interactions
increases expression

Ibogaine inhibits the reaction [SLC6A3 protein mutant form results in decreased import of Dopamine]; Ibogaine promotes the reaction [SLC6A3 protein results in increased import of Dopamine]
Ibogaine results in increased expression of SLC6A3 protein

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

icajine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

sodium voltage-gated channel alpha subunit 5

multiple interactions

icajine binds to and results in decreased activity of SCN5A protein

NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769

lisuride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor alpha 1A

multiple interactions

Lisuride binds to and results in decreased activity of ADRA1A protein; Lisuride promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein]

NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500

G

5-hydroxytryptamine receptor 7

multiple interactions

[Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Lisuride binds to and results in decreased activity of HTR7 protein

PMID:18996971 PMID:19509219

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

interferon gamma

increases expression

Lisuride results in increased expression of IFNG

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

prolactin

multiple interactions
decreases secretion

Lisuride inhibits the reaction [Metoclopramide results in increased secretion of PRL protein]; Lisuride results in decreased expression of and results in decreased secretion of PRL protein
Lisuride analog results in decreased secretion of PRL protein; Lisuride results in decreased secretion of PRL protein

PMID:386688 PMID:6492995

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

solute carrier family 22 member 2

multiple interactions

Lisuride inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

luzindole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

multiple interactions

luzindole inhibits the reaction [Melatonin results in increased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

gastrin

multiple interactions

luzindole inhibits the reaction [Melatonin results in increased expression of GAST]

NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496

G

glutathione-disulfide reductase

multiple interactions

luzindole inhibits the reaction [Melatonin results in increased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

H19 imprinted maternally expressed transcript

multiple interactions

luzindole inhibits the reaction [melatonin inhibits the reaction [hydrogen peroxide decreases expression of H19 RNA in C-kit+ cardiac progenitor cells]]

RGD

NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134

G

KRAS proto-oncogene, GTPase

multiple interactions

luzindole inhibits the reaction [melatonin inhibits the reaction [hydrogen peroxide increases expression of Kras protein in C-kit+ cardiac progenitor cells]]

RGD

NCBI chr 4:178,185,418...178,218,484

G

microRNA 675

multiple interactions

luzindole inhibits the reaction [melatonin inhibits the reaction [hydrogen peroxide decreases expression of Mir675 RNA in C-kit+ cardiac progenitor cells]]

RGD

NCBI chr 1:197,732,275...197,732,358
Ensembl chr 1:197,732,275...197,732,358

G

melatonin receptor 1A

multiple interactions

luzindole inhibits the reaction [Melatonin results in increased expression of MTNR1A protein]

NCBI chr16:47,144,461...47,163,919
Ensembl chr16:47,144,461...47,163,919

G

melatonin receptor 1B

multiple interactions

[luzindole binds to and results in decreased activity of MTNR1B protein] which results in decreased susceptibility to Melatonin; luzindole binds to and results in decreased activity of MTNR1B protein
luzindole inhibits the reaction [Melatonin results in increased expression of MTNR1B protein]

PMID:11270484 PMID:21473625 PMID:28238930

NCBI chr 8:12,638,219...12,652,737
Ensembl chr 8:12,638,219...12,652,737

G

NFKB inhibitor alpha

multiple interactions

luzindole inhibits the reaction [Melatonin inhibits the reaction [Methamphetamine results in increased degradation of NFKBIA protein]]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

peroxisome proliferator-activated receptor gamma

multiple interactions

luzindole inhibits the reaction [Melatonin results in increased expression of PPARG protein]; luzindole inhibits the reaction [Pioglitazone results in increased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions

luzindole inhibits the reaction [Melatonin inhibits the reaction [Cadmium Chloride results in increased acetylation of PPARGC1A protein]]; luzindole inhibits the reaction [Melatonin inhibits the reaction [Cadmium results in increased acetylation of PPARGC1A protein]]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

prion protein

multiple interactions

luzindole inhibits the reaction [Melatonin results in increased expression of PRNP protein]; luzindole inhibits the reaction [Pioglitazone results in increased expression of PRNP protein]

NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

luzindole inhibits the reaction [Melatonin inhibits the reaction [Methamphetamine affects the localization of RELA protein]]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

sirtuin 1

multiple interactions

luzindole inhibits the reaction [Melatonin inhibits the reaction [Cadmium Chloride results in decreased activity of SIRT1 protein]]; luzindole inhibits the reaction [Melatonin inhibits the reaction [Cadmium results in decreased activity of SIRT1 protein]]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

superoxide dismutase 1

multiple interactions

luzindole inhibits the reaction [Melatonin results in increased activity of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions

luzindole inhibits the reaction [Melatonin results in increased activity of SOD2 protein]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

tumor necrosis factor

multiple interactions

luzindole inhibits the reaction [Melatonin inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

luzindole inhibits the reaction [melatonin inhibits the reaction [hydrogen peroxide increases expression of Trp53 protein in C-kit+ cardiac progenitor cells]]

RGD

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

ubiquitin specific peptidase 10

multiple interactions

luzindole inhibits the reaction [melatonin inhibits the reaction [hydrogen peroxide increases expression of Usp10 protein in C-kit+ cardiac progenitor cells]]

RGD

NCBI chr19:47,972,858...48,014,900
Ensembl chr19:47,972,611...48,014,897

lysergic acid diethylamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

dopamine receptor D2

affects binding

LSD binds to Drd2 protein

RGD

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Lysergic Acid Diethylamide results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

5-hydroxytryptamine receptor 2B

multiple interactions
affects binding

2-aminoindan analog inhibits the reaction [Lysergic Acid Diethylamide binds to HTR2B protein]; Lysergic Acid Diethylamide analog binds to and results in increased activity of HTR2B protein; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Lysergic Acid Diethylamide binds to HTR2B protein]

PMID:14659797 PMID:29458138

NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108

G

5-hydroxytryptamine (serotonin) receptor 5B

multiple interactions

lysergic acid diethylamide binds to protein 5-Htr5b; inhibits the reaction[5-carboxamidotryptamine binds to 5-Htr5b]

RGD

NCBI chr13:32,686,911...32,699,835
Ensembl chr13:32,687,042...32,699,835

G

5-hydroxytryptamine receptor 6

affects binding

Lysergic Acid Diethylamide binds to HTR6 protein

NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912

melatonin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

Melatonin inhibits the reaction [Methamphetamine results in decreased expression of ABCB1 protein]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 6

multiple interactions
decreases metabolic processing

[ABCB6 gene mutant form results in decreased expression of CYP1A2 mRNA] inhibits the reaction [CYP1A2 protein results in increased metabolism of Melatonin]; [ABCB6 gene mutant form results in decreased expression of CYP1A2 protein] inhibits the reaction [CYP1A2 protein results in increased metabolism of Melatonin]
ABCB6 gene mutant form results in decreased metabolism of Melatonin

NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924

G

acyl-CoA dehydrogenase medium chain

multiple interactions

Melatonin inhibits the reaction [Cisplatin results in decreased expression of ACADM mRNA]

PMID:35367536 PMID:36006825

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

acyl-CoA dehydrogenase short chain

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA]

NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898

G

aggrecan

increases expression

Melatonin results in increased expression of ACAN mRNA

NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627

G

acetyl-CoA acetyltransferase 1

multiple interactions

Melatonin inhibits the reaction [Cisplatin results in decreased expression of ACAT1 mRNA]

PMID:35367536 PMID:36006825

NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855

G

angiotensin converting enzyme 2

multiple interactions

Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of ACE2 protein]

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acetylcholinesterase

multiple interactions

Melatonin inhibits the reaction [[Dietary Fats co-treated with Ethanol] results in increased expression of ACHE protein]; Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of ACHE protein]; Melatonin inhibits the reaction [Cadmium results in decreased expression of ACHE]; Melatonin inhibits the reaction [Dexamethasone results in decreased activity of ACHE protein]; Melatonin inhibits the reaction [Dexamethasone results in increased activity of ACHE protein]; Melatonin inhibits the reaction [Dietary Fats results in increased expression of ACHE protein]; Melatonin inhibits the reaction [Ethanol results in increased expression of ACHE protein]; Melatonin inhibits the reaction [Streptozocin results in increased activity of ACHE protein]; Melatonin promotes the reaction [Zinc Sulfate inhibits the reaction [Aluminum Chloride results in increased expression of ACHE protein]]; Zinc Sulfate promotes the reaction [Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of ACHE protein]]

PMID:19705549 PMID:21986892 PMID:22013727 PMID:30372842 PMID:35526705

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

Melatonin inhibits the reaction [Doxorubicin results in increased expression of ACSL4 protein]; Verteporfin inhibits the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased expression of ACSL4 protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased expression of ACSL4 protein]]

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

acyl-CoA synthetase medium-chain family member 2

multiple interactions

Melatonin inhibits the reaction [Cisplatin results in decreased expression of ACSM2 mRNA]

PMID:35367536 PMID:36006825

NCBI chr 1:173,916,368...173,955,116
Ensembl chr 1:173,916,368...173,955,116

G

acyl-CoA synthetase medium-chain family member 3

multiple interactions

Melatonin inhibits the reaction [Cisplatin results in decreased expression of ACSM3 mRNA]

NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184

G

actin alpha 2, smooth muscle

multiple interactions

Melatonin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adiponectin, C1Q and collagen domain containing

decreases expression

Melatonin results in decreased expression of ADIPOQ mRNA

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adenosine A2B receptor

multiple interactions
decreases expression

[Lipopolysaccharides co-treated with Melatonin] results in decreased expression of ADORA2B mRNA; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of ADORA2B mRNA]
Melatonin results in decreased expression of ADORA2B mRNA

NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772

G

advanced glycosylation end product-specific receptor

multiple interactions

Melatonin inhibits the reaction [sodium arsenite results in increased expression of AGER protein]

NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078

G

angiotensinogen

decreases expression
multiple interactions

Melatonin results in decreased expression of AGT protein
Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of AGT protein]

PMID:19018803 PMID:35844137

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

allograft inflammatory factor 1

multiple interactions

Melatonin inhibits the reaction [decabromobiphenyl ether results in increased expression of IBA1 protein]; Melatonin inhibits the reaction [Galactose results in increased expression of AIF1 protein]

PMID:34673010 PMID:36566971

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

absent in melanoma 2

decreases expression
multiple interactions

Melatonin results in decreased expression of AIM2 mRNA
Melatonin affects the reaction [Nickel affects the reaction [SELENOM protein affects the expression of AIM2 mRNA]]; Melatonin affects the reaction [SELENOM protein affects the expression of AIM2 mRNA]; Melatonin inhibits the reaction [Nickel results in increased expression of AIM2 mRNA]; Nickel affects the reaction [Melatonin affects the reaction [SELENOM protein affects the expression of AIM2 mRNA]]; Nickel inhibits the reaction [Melatonin results in decreased expression of AIM2 mRNA]

NCBI chr13:85,865,206...85,906,996
Ensembl chr13:85,866,284...85,906,975

G

aldo-keto reductase family 7 member A3

multiple interactions

Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of AKR7A3 mRNA]

NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

Melatonin results in increased phosphorylation of AKT1 protein
Melatonin inhibits the reaction [arsenite results in increased phosphorylation of AKT1 protein]; Melatonin inhibits the reaction [cyfluthrin results in increased expression of AKT1 mRNA]
[Melatonin co-treated with Folic Acid] inhibits the reaction [Carbon Tetrachloride results in increased expression of AKT1 mRNA]; Melatonin inhibits the reaction [Carbon Tetrachloride results in increased expression of AKT1 mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased expression of AKT1 mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of AKT1 protein]]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA]; Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased expression of AKT1 mRNA]; Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased phosphorylation of AKT1 protein]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein]; Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of AKT1 protein]; Wortmannin promotes the reaction [Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of AKT1 protein]]

PMID:18078454 PMID:21138475 PMID:22225513 PMID:23374533 PMID:23963992 More...

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

5'-aminolevulinate synthase 1

multiple interactions

Melatonin inhibits the reaction [Griseofulvin results in increased activity of ALAS1 protein]

NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917

G

albumin

multiple interactions

Melatonin inhibits the reaction [Doxorubicin results in decreased expression of ALB protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 5 family, member A1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA]

NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677

G

alkaline phosphatase, biomineralization associated

increases expression
multiple interactions

Melatonin results in increased expression of ALPL mRNA
Melatonin inhibits the reaction [Cadmium Chloride results in decreased activity of ALPL protein]; Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of ALPL mRNA]

PMID:20738756 PMID:31809235

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

anti-Mullerian hormone

increases expression
multiple interactions

Melatonin results in increased expression of AMH mRNA
bisphenol A inhibits the reaction [Melatonin results in increased expression of AMH mRNA]

NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282

G

aldehyde oxidase 1

multiple interactions

Melatonin inhibits the reaction [cyfluthrin results in increased expression of AOX1 mRNA]

NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770

G

apoptotic peptidase activating factor 1

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of APAF1 mRNA]

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

amyloid beta precursor protein

multiple interactions
decreases expression

Melatonin affects the reaction [APP protein binds to APP protein]; Melatonin inhibits the reaction [Mercuric Chloride results in increased secretion of APP protein modified form]
Melatonin inhibits the reaction [[Aluminum Chloride results in increased expression of APP protein] which results in increased abundance of amyloid beta-protein (1-42)]; Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of APP protein modified form]; Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of APP protein]; Melatonin promotes the reaction [Zinc Sulfate inhibits the reaction [Aluminum Chloride results in increased expression of APP protein modified form]]; Melatonin promotes the reaction [Zinc Sulfate inhibits the reaction [Aluminum Chloride results in increased expression of APP protein]]; Zinc Sulfate promotes the reaction [Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of APP protein modified form]]; Zinc Sulfate promotes the reaction [Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of APP protein]]
Melatonin analog results in decreased expression of APP protein; Melatonin results in decreased expression of APP protein

PMID:10617124 PMID:18231852 PMID:18537544 PMID:33130240 PMID:35526705

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

androgen receptor

multiple interactions
increases expression

[Melatonin co-treated with Ethanol] results in increased expression of AR protein; Ethanol inhibits the reaction [Melatonin results in increased expression of AR protein]

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

arginase 1

multiple interactions

Melatonin inhibits the reaction [decabromobiphenyl ether results in decreased expression of ARG1 mRNA]; Melatonin inhibits the reaction [decabromobiphenyl ether results in decreased secretion of ARG1 protein]

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of ARNT mRNA]

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

astacin like metalloendopeptidase

multiple interactions

Melatonin inhibits the reaction [bisphenol A results in decreased expression of and affects the localization of ASTL protein]; Melatonin inhibits the reaction [Ethinyl Estradiol results in decreased expression of and affects the localization of ASTL protein]

PMID:28178360 PMID:31931096

NCBI chr 3:114,563,135...114,580,295
Ensembl chr 3:114,563,135...114,578,868

G

activating transcription factor 2

multiple interactions

Melatonin inhibits the reaction [sodium arsenite results in increased expression of ATF2 mRNA]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of ATF2 protein modified form]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of ATF2 protein]

NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236

G

activating transcription factor 4

multiple interactions

Melatonin inhibits the reaction [sodium arsenite results in increased expression of ATF4 protein]
Melatonin inhibits the reaction [Atrazine results in increased expression of ATF4 protein]

PMID:17645694 PMID:25259610

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

multiple interactions

Melatonin inhibits the reaction [Methamphetamine results in increased expression of ATF6 protein]; Melatonin inhibits the reaction [sodium arsenite results in increased activity of ATF6 protein]
Melatonin inhibits the reaction [Atrazine results in increased cleavage of ATF6 protein]

PMID:18715270 PMID:25259610 PMID:28070110

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

autophagy related 5

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of ATG5 mRNA]]; Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of ATG5 mRNA]

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of ATG7 mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of ATG7 protein]]; Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of ATG7 mRNA]; Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of ATG7 protein]; Melatonin inhibits the reaction [nickel chloride results in increased expression of ATG7 mRNA]; Melatonin inhibits the reaction [nickel chloride results in increased expression of ATG7 protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of ATG7 mRNA]]

PMID:35568058 PMID:36421005

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

ATM serine/threonine kinase

multiple interactions

Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in increased phosphorylation of ATM protein]

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase H+ transporting V1 subunit C1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA]

NCBI chr 7:69,834,464...69,872,278
Ensembl chr 7:69,834,463...69,872,278

G

beta-secretase 1

multiple interactions

Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of BACE1 protein]

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

BCL2-associated agonist of cell death

multiple interactions
increases phosphorylation

Melatonin promotes the reaction [YWHAB protein binds to BAD protein]
Melatonin results in increased phosphorylation of BAD protein
Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of BAD protein]; Melatonin inhibits the reaction [sodium arsenite results in increased phosphorylation of BAD protein]

PMID:18078454 PMID:21138475 PMID:29763682

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2-antagonist/killer 1

multiple interactions

[Melatonin co-treated with Tretinoin] results in increased expression of BAK1 protein; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAK1 mRNA]
Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA]
Melatonin inhibits the reaction [Indomethacin results in increased expression of BAK1 mRNA]

PMID:10965999 PMID:19220725 PMID:23963992 PMID:33962019

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

decreases expression
increases expression
multiple interactions

Melatonin results in decreased expression of BAX protein
Melatonin results in increased expression of BAX mRNA
Melatonin inhibits the reaction [Cisplatin results in increased cleavage of BAX protein]; Melatonin inhibits the reaction [Doxorubicin results in increased expression of BAX protein]; Melatonin inhibits the reaction [Galactose results in increased expression of BAX protein]; Melatonin inhibits the reaction [Gentamicins results in increased expression of BAX protein]; Melatonin inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]; Melatonin inhibits the reaction [Indomethacin affects the localization of BAX protein]; Melatonin inhibits the reaction [Indomethacin results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [Methionine results in increased expression of BAX protein]; Verteporfin inhibits the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased expression of BAX protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased expression of BAX protein]]
Melatonin results in increased expression of BAX protein
Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein]; Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in increased expression of BAX protein]; Melatonin inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Melatonin inhibits the reaction [Diethylhexyl Phthalate results in increased expression of BAX protein]; Melatonin inhibits the reaction [nickel chloride results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [nickel chloride results in increased expression of BAX protein]; Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased expression of BAX protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of BAX mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of BAX protein]]
[Doxorubicin co-treated with Melatonin] results in increased expression of BAX protein; [Melatonin co-treated with Tretinoin] results in increased expression of BAX protein; [Tretinoin co-treated with Melatonin] results in increased expression of BAX protein; Doxorubicin promotes the reaction [Melatonin results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BAX protein]; Melatonin inhibits the reaction [BAX protein binds to BAX protein]; Melatonin inhibits the reaction [Cisplatin affects the expression of BAX protein]; Melatonin inhibits the reaction [cyfluthrin results in increased expression of BAX mRNA]; Melatonin promotes the reaction [BID protein binds to BAX protein]; Melatonin results in increased activity of and results in increased expression of BAX protein
Melatonin results in increased expression of BAX mRNA; Melatonin results in increased expression of BAX protein

PMID:9649124 PMID:10965999 PMID:14690559 PMID:15683462 PMID:15964511 More...

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BBC3 mRNA]
Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in increased expression of BBC3 mRNA]; Melatonin inhibits the reaction [Atrazine results in increased expression of BBC3 protein]

PMID:25259610 PMID:33962019 PMID:35643323

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

multiple interactions
decreases expression
increases expression
affects localization

[Doxorubicin co-treated with Melatonin] results in decreased expression of BCL2 protein; [Melatonin co-treated with Tretinoin] results in decreased expression of BCL2 protein; [Tretinoin co-treated with Melatonin] results in decreased expression of BCL2 protein; Doxorubicin promotes the reaction [Melatonin results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [Cisplatin affects the expression of BCL2 protein]; Melatonin promotes the reaction [Puromycin results in decreased expression of BCL2 protein]
Melatonin results in decreased expression of BCL2 mRNA; Melatonin results in decreased expression of BCL2 protein
[Puromycin Aminonucleoside co-treated with Melatonin] results in increased expression of BCL2 protein; Melatonin inhibits the reaction [decamethrin results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [Galactose results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [Indomethacin results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [Methionine results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [sodium arsenite results in increased activity of BCL2 protein]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]; Verteporfin inhibits the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]
Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [nickel chloride results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [nickel chloride results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of BCL2 protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in decreased expression of BCL2 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in decreased expression of BCL2 protein]]
Melatonin results in increased expression of BCL2 protein
Melatonin affects the localization of BCL2 protein

PMID:9649124 PMID:10965999 PMID:12220328 PMID:14690559 PMID:14993511 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

Melatonin inhibits the reaction [Indomethacin results in decreased expression of BCL2L1 mRNA]
Melatonin promotes the reaction [Puromycin results in decreased expression of BCL2L1 protein]

PMID:19220725 PMID:21244482

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

Bcl2-like 11

multiple interactions

Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in increased expression of BCL2L11 mRNA]

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

Bcl2-like 15

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BCL2L15 mRNA]

NCBI chr 2:191,338,959...191,344,078
Ensembl chr 2:191,338,959...191,344,078

G

3-hydroxybutyrate dehydrogenase 2

multiple interactions

Melatonin inhibits the reaction [Cisplatin results in decreased expression of BDH2 mRNA]

PMID:35367536 PMID:36006825

NCBI chr 2:223,702,410...223,723,076
Ensembl chr 2:223,702,412...223,723,072

G

brain-derived neurotrophic factor

multiple interactions

Melatonin inhibits the reaction [Scopolamine results in decreased expression of BDNF protein]
Melatonin inhibits the reaction [[Dietary Fats co-treated with Ethanol] results in decreased expression of BDNF mRNA]; Melatonin inhibits the reaction [Aluminum Chloride results in decreased expression of BDNF protein]; Melatonin inhibits the reaction [Dietary Fats results in decreased expression of BDNF mRNA]; Melatonin inhibits the reaction [Ethanol results in decreased expression of BDNF mRNA]; Melatonin promotes the reaction [Zinc Sulfate inhibits the reaction [Aluminum Chloride results in decreased expression of BDNF protein]]; Zinc Sulfate promotes the reaction [Melatonin inhibits the reaction [Aluminum Chloride results in decreased expression of BDNF protein]]

PMID:29476728 PMID:30372842 PMID:35526705

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

beclin 1

multiple interactions
increases expression

Cisplatin inhibits the reaction [Melatonin results in increased expression of BECN1 protein]
Melatonin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of BECN1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of BECN1 mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of BECN1 protein]]; Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of BECN1 mRNA]; Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of BECN1 protein]; Melatonin inhibits the reaction [Dibutyl Phthalate results in increased expression of BECN1 protein]; Melatonin inhibits the reaction [nickel chloride results in increased expression of BECN1 mRNA]; Melatonin inhibits the reaction [nickel chloride results in increased expression of BECN1 protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of BECN1 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of BECN1 protein]]

PMID:24799992 PMID:35568058 PMID:35598369 PMID:36421005 PMID:37277016

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

bone gamma-carboxyglutamate protein

increases expression
multiple interactions

Melatonin results in increased expression of BGLAP mRNA
Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of BGLAP mRNA]; Melatonin inhibits the reaction [Cadmium Chloride results in decreased secretion of BGLAP protein]

PMID:20738756 PMID:31809235

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

BH3 interacting domain death agonist

multiple interactions
increases expression

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BID mRNA]; Melatonin promotes the reaction [BID protein binds to BAX protein]
Melatonin results in increased expression of BID protein

PMID:19552762 PMID:33962019

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

baculoviral IAP repeat-containing 5

decreases expression
multiple interactions

Melatonin results in decreased expression of BIRC5 mRNA
[Doxorubicin co-treated with Melatonin] results in decreased expression of BIRC5 protein; Doxorubicin promotes the reaction [Melatonin results in decreased expression of BIRC5 mRNA]

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

basic helix-loop-helix ARNT like 1

multiple interactions

Melatonin affects the reaction [Rotenone affects the expression of BMAL1 mRNA]; Melatonin inhibits the reaction [Cadmium Chloride affects the expression of BMAL1]

PMID:23085516 PMID:25430725

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

BMI1 proto-oncogene, polycomb ring finger

multiple interactions
increases expression

Melatonin affects the reaction [Rotenone affects the phosphorylation of BMI1 protein]
Melatonin results in increased expression of BMI1 mRNA

NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690

G

BCL2 interacting protein 3

multiple interactions
increases expression

[PINK1 protein co-treated with BNIP3 protein] affects the reaction [Melatonin promotes the reaction [Paraquat results in increased expression of BNIP3 protein]]; [PINK1 protein co-treated with BNIP3 protein] affects the reaction [Melatonin promotes the reaction [Paraquat results in increased expression of PINK1 protein]]; [PINK1 protein co-treated with BNIP3 protein] affects the reaction [Melatonin results in increased expression of BNIP3 protein]; [PINK1 protein co-treated with BNIP3 protein] affects the reaction [Melatonin results in increased expression of PINK1 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3 mRNA]; Melatonin inhibits the reaction [cyfluthrin results in increased expression of BNIP3 mRNA]; Melatonin promotes the reaction [Paraquat results in increased expression of BNIP3 protein]
Melatonin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of BNIP3 protein]
[BNIP3 protein co-treated with PINK1 protein] affects the reaction [Melatonin inhibits the reaction [Paraquat results in increased secretion of IL1B protein]]; [BNIP3 protein co-treated with PINK1 protein] affects the reaction [Melatonin inhibits the reaction [Paraquat results in increased secretion of TNF protein]]; Melatonin promotes the reaction [Paraquat results in increased expression of BNIP3 protein]

PMID:31330490 PMID:33962019 PMID:35598369 PMID:37028639

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

BCL2 interacting protein 3 like

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of BNIP3L mRNA]

NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803

G

BTG anti-proliferation factor 2

decreases expression
multiple interactions

Melatonin results in decreased expression of BTG2 mRNA
Melatonin inhibits the reaction [Ethanol results in increased expression of BTG2 protein]; MIR497 mRNA affects the reaction [Melatonin results in decreased expression of BTG2 mRNA]

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

calcitonin-related polypeptide alpha

multiple interactions

Melatonin inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased expression of CALCA protein]]

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calmodulin 1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA]

NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227

G

calpain 1

multiple interactions

Melatonin inhibits the reaction [[Dietary Fats co-treated with Ethanol] results in increased expression of CAPN1 mRNA]
Melatonin inhibits the reaction [Atrazine results in increased cleavage of CAPN1 protein]

PMID:25259610 PMID:30372842

NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177

G

caspase 1

multiple interactions

[SELENOM protein affects the susceptibility to Melatonin] which affects the expression of CASP1 protein; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of CASP1 mRNA]; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of CASP1 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]; Melatonin inhibits the reaction [Nickel results in increased expression of CASP1 mRNA]
[essential 303 forte co-treated with Silymarin co-treated with Melatonin analog] affects the activity of CASP1 protein; Melatonin inhibits the reaction [arsenite results in increased expression of CASP1 protein]

PMID:23963992 PMID:25903262 PMID:36343453 PMID:36504304

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 12

multiple interactions

[Melatonin co-treated with Aluminum Chloride] results in decreased expression of CASP12 protein; Melatonin inhibits the reaction [Galactose results in increased expression of CASP12 protein]; Melatonin inhibits the reaction [Methamphetamine results in increased cleavage of CASP12 protein]; Melatonin inhibits the reaction [sodium arsenite results in decreased expression of CASP12 protein]; Melatonin inhibits the reaction [sodium arsenite results in increased activity of CASP12 protein]
Melatonin inhibits the reaction [Dibutyl Phthalate results in increased activity of CASP12 protein]

PMID:17645694 PMID:18715270 PMID:28070110 PMID:30910607 PMID:33130240 More...

NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037

G

caspase 3

multiple interactions
increases expression
decreases activity
increases activity
decreases expression

[Doxorubicin co-treated with Melatonin] results in increased expression of CASP3 protein; [essential 303 forte co-treated with Silymarin co-treated with Melatonin analog] affects the activity of CASP3 protein; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP3 protein]; Melatonin inhibits the reaction [cyfluthrin results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; Melatonin inhibits the reaction [linsidomine results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CASP3 protein]; Melatonin inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein]; Melatonin promotes the reaction [flavone results in increased activity of CASP3 protein]; Melatonin promotes the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; Melatonin promotes the reaction [Puromycin results in increased activity of CASP3 protein]
Melatonin results in increased expression of CASP3 protein
Melatonin results in decreased activity of CASP3 protein
Melatonin results in increased activity of CASP3 protein
Melatonin results in decreased expression of CASP3 protein
[Melatonin co-treated with Thioacetamide] results in increased expression of CASP3 protein; Melatonin inhibits the reaction [[Dietary Fats co-treated with Ethanol] results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of and results in increased cleavage of CASP3 protein]; Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of CASP3 protein]; Melatonin inhibits the reaction [bisphenol A results in increased activity of CASP3 protein]; Melatonin inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Melatonin inhibits the reaction [Dietary Fats results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [Ethanol results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [Galactose results in increased expression of CASP3 protein]; Melatonin inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]; Melatonin inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; Melatonin inhibits the reaction [Indomethacin results in increased activity of CASP3 protein]; Melatonin inhibits the reaction [Methotrexate results in increased expression of and results in increased cleavage of CASP3 protein]; Melatonin inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Melatonin promotes the reaction [Zinc Sulfate inhibits the reaction [Aluminum Chloride results in increased expression of CASP3 protein]]; Zinc Sulfate promotes the reaction [Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of CASP3 protein]]
Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; Melatonin inhibits the reaction [Atrazine results in increased cleavage of CASP3 protein]; Melatonin inhibits the reaction [Cisplatin results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [nickel chloride results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [nickel chloride results in increased expression of CASP3 protein]; Melatonin inhibits the reaction [Radon results in increased cleavage of CASP3 protein]; Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased activity of CASP3 protein]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of CASP3 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of CASP3 protein]]

PMID:12220328 PMID:12880480 PMID:15683462 PMID:15800915 PMID:15964511 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
increases activity

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CASP8 mRNA]; Melatonin promotes the reaction [Hydrogen Peroxide results in increased activity of CASP8 protein]
Melatonin inhibits the reaction [Atrazine results in increased cleavage of CASP8 protein]; Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of CASP8 protein]
Melatonin inhibits the reaction [bisphenol A results in increased activity of CASP8 protein]
Melatonin results in increased activity of CASP8 protein

PMID:19012662 PMID:21431366 PMID:25259610 PMID:25454643 PMID:33962019 More...

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases activity

Melatonin inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]; Melatonin inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased activity of CASP9 protein]; Melatonin inhibits the reaction [Thapsigargin results in increased activity of CASP9 protein]; Melatonin promotes the reaction [Hydrogen Peroxide results in increased activity of CASP9 protein]
Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein]; Melatonin inhibits the reaction [Cisplatin results in increased expression of CASP9 protein modified form]; Melatonin inhibits the reaction [Dibutyl Phthalate results in increased activity of CASP9 protein]; Melatonin inhibits the reaction [nickel chloride results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [nickel chloride results in increased expression of CASP9 protein]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of CASP9 protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of CASP9 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of CASP9 protein]]
Melatonin results in increased activity of CASP9 protein
Melatonin inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Melatonin inhibits the reaction [Doxorubicin results in decreased expression of and results in increased cleavage of CASP9 protein]; Melatonin inhibits the reaction [Indomethacin results in increased activity of CASP9 protein]; Verteporfin inhibits the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of and results in increased cleavage of CASP9 protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of and results in increased cleavage of CASP9 protein]]

PMID:19012662 PMID:19220725 PMID:19552762 PMID:20130848 PMID:20964710 More...

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions
increases activity
increases expression
decreases activity

[aluminum lactate co-treated with Melatonin] results in increased expression of CAT mRNA; [Melatonin co-treated with Pentoxifylline] inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; luzindole inhibits the reaction [Melatonin results in increased activity of CAT protein]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased activity of CAT protein]; Melatonin inhibits the reaction [Arsenic Trioxide results in decreased expression of CAT protein]; Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; Melatonin inhibits the reaction [Dibutyl Phthalate results in increased activity of CAT protein]; Melatonin inhibits the reaction [Ethinyl Estradiol results in decreased expression of CAT mRNA]; Melatonin inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Melatonin inhibits the reaction [Urethane results in increased expression of CAT protein]
Melatonin results in increased expression of CAT mRNA
[Melatonin co-treated with cyfluthrin] results in increased activity of CAT protein; Melatonin inhibits the reaction [cyfluthrin results in decreased activity of CAT protein]
Melatonin results in decreased activity of CAT protein
[aluminum lactate co-treated with Melatonin] results in increased activity of CAT mRNA; [aluminum lactate co-treated with Melatonin] results in increased activity of CAT protein; [Melatonin co-treated with aluminum lactate] results in increased expression of CAT mRNA; [Melatonin co-treated with Folic Acid] inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; Melatonin inhibits the reaction [aluminum lactate results in decreased activity of CAT protein]; Melatonin inhibits the reaction [aluminum lactate results in increased activity of CAT protein]; Melatonin inhibits the reaction [Cadmium results in decreased expression of CAT]; Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; Melatonin inhibits the reaction [Doxorubicin results in increased activity of CAT protein]; Melatonin inhibits the reaction [Gentamicins results in decreased activity of CAT protein]; Melatonin inhibits the reaction [Indomethacin results in decreased expression of CAT protein]; Melatonin inhibits the reaction [Ketorolac Tromethamine results in increased activity of CAT protein]; Melatonin inhibits the reaction [Potassium Dichromate results in decreased activity of CAT protein]; Melatonin inhibits the reaction [Propoxur results in decreased activity of CAT protein]; Melatonin inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Melatonin inhibits the reaction [Streptozocin results in decreased activity of CAT protein]

PMID:9194422 PMID:12500499 PMID:12823611 PMID:15589378 PMID:16098089 More...

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cholecystokinin

increases secretion

Melatonin results in increased secretion of CCK protein

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

C-C motif chemokine ligand 2

multiple interactions

Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

multiple interactions

Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]
Melatonin inhibits the reaction [cyfluthrin results in increased expression of CCL5 mRNA]

PMID:22225513 PMID:31330490

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cyclin B1

decreases expression
multiple interactions

Melatonin results in decreased expression of CCNB1 mRNA; Melatonin results in decreased expression of CCNB1 protein
Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in increased expression of CCNB1 protein]

PMID:21108658 PMID:35643323

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

decreases expression

Melatonin results in decreased expression of CCND1 mRNA; Melatonin results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

C-C motif chemokine receptor 7

multiple interactions

Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 protein]

NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309

G

CD14 molecule

multiple interactions

Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of CD14 protein]; Melatonin inhibits the reaction [TLR4 protein promotes the reaction [MYD88 protein binds to LY96 protein binds to CD14 protein]]

NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261

G

Cd200 molecule

decreases expression

Melatonin results in decreased expression of CD200 protein

NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648

G

CD36 molecule

multiple interactions

Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CD36 mRNA]

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cyclin-dependent kinase 1

decreases expression
multiple interactions

Melatonin results in decreased expression of CDK1 mRNA; Melatonin results in decreased expression of CDK1 protein
Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in decreased expression of CDK1 protein]

PMID:21108658 PMID:35643323

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA]; Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in decreased expression of CDK2 protein]

PMID:23963992 PMID:35643323

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression

Melatonin results in decreased expression of CDK4 mRNA; Melatonin results in decreased expression of CDK4 protein

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

Melatonin results in increased expression of CDKN1A protein
Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1A mRNA]; Melatonin inhibits the reaction [bisphenol A results in decreased expression of CDKN1A protein]; Melatonin inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]; Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]]; Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]]; PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]]]

PMID:12071473 PMID:18384530 PMID:29330934 PMID:29734669 PMID:33962019 More...

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1B mRNA]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2A

multiple interactions

Melatonin inhibits the reaction [Galactose results in increased expression of CDKN2A protein]

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

CCAAT/enhancer binding protein beta

multiple interactions

CEBPB protein inhibits the reaction [Melatonin results in decreased activity of HDAC3 protein]
Melatonin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of CEBPB protein]

PMID:34973135 PMID:38008054

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

cytokine inducible SH2-containing protein

multiple interactions
decreases expression

[Lipopolysaccharides co-treated with Melatonin] results in decreased expression of CISH mRNA; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CISH mRNA]
Melatonin results in decreased expression of CISH mRNA

NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250

G

creatine kinase B

multiple interactions

Melatonin inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased activity of CKB protein]

NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315

G

C-type lectin domain family 4, member A

multiple interactions
decreases expression

Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CLEC4N mRNA]
Melatonin results in decreased expression of CLEC4N mRNA

NCBI chr 4:156,340,439...156,434,212
Ensembl chr 4:156,414,688...156,432,402

G

C-type lectin domain family 4, member A3

increases expression
multiple interactions

Melatonin results in increased expression of CLEC4A3 mRNA
Melatonin inhibits the reaction [Lipopolysaccharides results in decreased expression of CLEC4A3 mRNA]

NCBI chr 4:156,214,030...156,224,818
Ensembl chr 4:156,214,718...156,224,817

G

clock circadian regulator

multiple interactions

Melatonin inhibits the reaction [Cadmium Chloride affects the expression of CLOCK]

NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400

G

collagen type I alpha 1 chain

multiple interactions

Melatonin inhibits the reaction [Glucose results in decreased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collectin sub-family member 12

multiple interactions

[Lipopolysaccharides co-treated with Melatonin] results in increased expression of COLEC12 mRNA

NCBI chr18:732,950...920,620
Ensembl chr18:732,950...920,618

G

cytochrome c oxidase subunit 4i1

multiple interactions

Melatonin inhibits the reaction [Dibutyl Phthalate results in decreased expression of COX4I1 protein]

NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921

G

cytochrome c oxidase subunit 6B1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA]

NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001
Ensembl chr 2:85,875,109...85,884,001

G

cAMP responsive element binding protein 1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cryptochrome circadian regulator 1

multiple interactions

Melatonin affects the reaction [Cadmium Chloride affects the expression of CRY1]; Melatonin affects the reaction [Rotenone affects the expression of CRY1 mRNA]

PMID:23085516 PMID:25430725

NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091

G

cryptochrome circadian regulator 2

affects expression
multiple interactions

Melatonin affects the expression of CRY2 mRNA
Melatonin affects the reaction [Cadmium Chloride affects the expression of CRY2]; Melatonin affects the reaction [Rotenone affects the expression of CRY2 mRNA]

PMID:21442002 PMID:23085516 PMID:25430725

NCBI chr 3:78,374,995...78,405,001
Ensembl chr 3:78,374,995...78,404,965

G

catenin beta 1

multiple interactions

Melatonin inhibits the reaction [Estradiol promotes the reaction [ESR1 protein binds to CTNNB1 promoter]]
Melatonin inhibits the reaction [Aluminum Chloride results in decreased expression of CTNNB1 protein]; Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of CTNNB1 protein]

PMID:26990689 PMID:31809235 PMID:35526705

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin B

multiple interactions

Melatonin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CTSB protein]

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin D

multiple interactions

Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of CTSD]

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

C-X-C motif chemokine ligand 10

multiple interactions
decreases expression

[Lipopolysaccharides co-treated with Melatonin] results in decreased expression of CXCL10 mRNA; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]
Melatonin results in decreased expression of CXCL10 mRNA

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

cytochrome b-245 beta chain

multiple interactions
decreases expression

Melatonin inhibits the reaction [cyfluthrin results in increased expression of CYBB mRNA]
[SELENOM protein affects the susceptibility to Melatonin] which affects the expression of CYBB mRNA; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of CYBB mRNA]
Melatonin results in decreased expression of CYBB mRNA
Melatonin inhibits the reaction [Galactose results in increased expression of CYBB protein]

PMID:31330490 PMID:34673010 PMID:36504304

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome c, somatic

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of CYCS mRNA]
Melatonin inhibits the reaction [nickel chloride results in increased expression of CYCS mRNA]; Melatonin inhibits the reaction [nickel chloride results in increased expression of CYCS protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of CYCS mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of CYCS protein]]

PMID:33962019 PMID:36421005

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases expression
decreases activity

Melatonin results in decreased expression of CYP19A1
Melatonin results in decreased activity of CYP19A1 protein

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases activity
increases hydroxylation

Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP1A1 mRNA]
Melatonin results in decreased activity of CYP1A1 protein
CYP1A1 protein results in increased hydroxylation of Melatonin

PMID:15616152 PMID:19919601 PMID:20033131

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases methylation
multiple interactions
increases metabolic processing
increases hydroxylation
affects metabolic processing
decreases activity

CYP1A2 protein results in decreased methylation of Melatonin
[ABCB6 gene mutant form results in decreased expression of CYP1A2 mRNA] inhibits the reaction [CYP1A2 protein results in increased metabolism of Melatonin]; [ABCB6 gene mutant form results in decreased expression of CYP1A2 protein] inhibits the reaction [CYP1A2 protein results in increased metabolism of Melatonin]
CYP1A2 protein results in increased hydroxylation of Melatonin
CYP1A2 protein affects the metabolism of Melatonin
[Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of CYP1A2 mRNA
Melatonin results in decreased activity of CYP1A2 protein
Melatonin inhibits the reaction [CYP1A2 protein results in increased hydrolysis of Benzo(a)pyrene]

PMID:15616152 PMID:15626586 PMID:15824912 PMID:17565714 PMID:19919601 More...

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions
decreases activity
increases hydroxylation

2,4,3',5'-tetramethoxystilbene inhibits the reaction [CYP1B1 protein results in increased hydroxylation of Melatonin]
Melatonin results in decreased activity of CYP1B1 protein

PMID:15616152 PMID:19919601

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions

Melatonin inhibits the reaction [Ethanol results in increased expression of CYP27A1 mRNA]

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily b, polypeptide 2

multiple interactions

Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA]

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases hydroxylation
decreases methylation

CYP2C19 protein results in increased hydroxylation of Melatonin
CYP2C19 protein results in decreased methylation of Melatonin

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Melatonin inhibits the reaction [Benzene results in increased activity of CYP2E1 protein]
Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]

PMID:20338863 PMID:20964710

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450 family 7 subfamily A member 1

decreases expression
multiple interactions

Melatonin results in decreased expression of CYP7A1 mRNA
Melatonin inhibits the reaction [Ethanol results in increased expression of CYP7A1 mRNA]; Melatonin inhibits the reaction [Ethanol results in increased expression of CYP7A1 protein]; MIR497 mRNA affects the reaction [Melatonin results in decreased expression of CYP7A1 mRNA]

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

Melatonin inhibits the reaction [Ethanol results in increased expression of CYP8B1 mRNA]

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

death associated protein 3

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA]

NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461

G

dimethylarginine dimethylaminohydrolase 1

multiple interactions

Melatonin inhibits the reaction [Methotrexate results in decreased expression of DDAH1 protein]

NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339

G

DDAH family member 2, ADMA-independent

multiple interactions

Melatonin inhibits the reaction [Methotrexate results in decreased expression of DDAH2 protein]

NCBI chr20:3,761,460...3,764,718
Ensembl chr20:3,761,465...3,764,511

G

DNA-damage inducible transcript 3

multiple interactions

Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of DDIT3 protein]; Melatonin inhibits the reaction [Galactose results in increased expression of DDIT3 protein]; Melatonin inhibits the reaction [Methamphetamine results in increased expression of DDIT3 protein]; Melatonin inhibits the reaction [sodium arsenite results in increased activity of DDIT3 protein]
Melatonin inhibits the reaction [Atrazine results in increased expression of DDIT3 protein]

PMID:18715270 PMID:25259610 PMID:28070110 PMID:33130240 PMID:34673010

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

diablo, IAP-binding mitochondrial protein

increases expression
multiple interactions

Melatonin results in increased expression of DIABLO mRNA; Melatonin results in increased expression of DIABLO protein
[Doxorubicin co-treated with Melatonin] results in increased expression of DIABLO protein; Doxorubicin promotes the reaction [Melatonin results in increased expression of DIABLO mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DIABLO mRNA]

PMID:33507000 PMID:33962019

NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387

G

dynamin 1-like

multiple interactions

Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of DNM1L protein]; Melatonin inhibits the reaction [Doxorubicin results in increased expression of DNM1L protein]
Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of DNM1L mRNA]; Melatonin inhibits the reaction [Rotenone results in increased expression of DNM1L protein]

PMID:26882442 PMID:29183837 PMID:29966675 PMID:33962019

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

dynamin 2

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA]

NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157

G

dopamine receptor D1

multiple interactions

Melatonin inhibits the reaction [manganese chloride results in decreased expression of DRD1 protein]

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

multiple interactions

Melatonin inhibits the reaction [Rotenone results in increased expression of DRD2 protein]
Melatonin promotes the reaction [manganese chloride results in decreased expression of DRD2 protein]

PMID:18289173 PMID:24969583

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

E2F transcription factor 1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA]; Melatonin inhibits the reaction [Atrazine results in increased expression of E2F1 protein]

PMID:23963992 PMID:25259610

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

enoyl-CoA hydratase, short chain 1

multiple interactions

Melatonin inhibits the reaction [Cisplatin results in decreased expression of ECHS1 mRNA]

PMID:35367536 PMID:36006825

NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884

G

eukaryotic translation elongation factor 1 gamma

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA]

NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382

G

epidermal growth factor

multiple interactions

Melatonin inhibits the reaction [arsenite results in increased expression of and results in increased secretion of EGF protein]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

Melatonin inhibits the reaction [Galactose results in increased phosphorylation of EIF2AK3 protein]; Melatonin inhibits the reaction [Methamphetamine results in increased expression of EIF2AK3 protein modified form]

PMID:28070110 PMID:34673010

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions

Melatonin inhibits the reaction [Methamphetamine results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

Melatonin promotes the reaction [MTOR protein results in increased phosphorylation of EIF4EBP1 protein]

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

eukaryotic translation initiation factor 4, gamma 2

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA]

NCBI chr 1:165,181,433...165,193,583
Ensembl chr 1:165,181,434...165,193,588

G

ETS transcription factor ELK1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA]

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

G

enolase 2

multiple interactions

Melatonin inhibits the reaction [manganese chloride results in decreased expression of ENO2 protein]

NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980

G

ERCC excision repair 1, endonuclease non-catalytic subunit

increases expression

Melatonin results in increased expression of ERCC1 protein

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

Melatonin inhibits the reaction [Methamphetamine results in increased expression of ERN1 protein modified form]; Melatonin promotes the reaction [Cyclosporine results in increased expression of ERN1 protein]

PMID:20136702 PMID:28070110

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

estrogen receptor 1

multiple interactions
decreases expression

Melatonin inhibits the reaction [bisphenol A promotes the reaction [ESR1 protein binds to POU5F1 promoter]]; Melatonin inhibits the reaction [bisphenol A promotes the reaction [ESR1 protein binds to TFF1 promoter]]; Melatonin inhibits the reaction [bisphenol A results in increased expression of ESR1 mRNA]; Melatonin inhibits the reaction [bisphenol A results in increased expression of ESR1 protein]; Melatonin inhibits the reaction [Cadmium results in increased activity of ESR1 protein]; Melatonin inhibits the reaction [Estradiol promotes the reaction [ESR1 protein binds to CTNNB1 promoter]]; Melatonin inhibits the reaction [Estradiol promotes the reaction [ESR1 protein binds to POU5F1 promoter]]; Melatonin inhibits the reaction [Estradiol promotes the reaction [ESR1 protein binds to TFF1 promoter]]; Melatonin inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; Melatonin inhibits the reaction [Estradiol results in increased expression of ESR1 mRNA]; Melatonin inhibits the reaction [Estradiol results in increased expression of ESR1 protein]; Pertussis Toxin inhibits the reaction [Melatonin inhibits the reaction [Estradiol results in increased activity of ESR1 protein]]
Melatonin results in decreased expression of ESR1 mRNA
Melatonin results in decreased expression of ESR1 mRNA; Melatonin results in decreased expression of ESR1 protein
[Ethanol co-treated with Melatonin] results in decreased expression of ESR1 protein; [Ethanol co-treated with Melatonin] results in increased expression of ESR1 protein; Melatonin promotes the reaction [alitretinoin results in decreased expression of ESR1 mRNA]

PMID:15813899 PMID:16030176 PMID:16051031 PMID:16635015 PMID:23591044 More...

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions
decreases expression

[Melatonin co-treated with Ethanol] results in increased expression of ESR2 protein; Ethanol inhibits the reaction [Melatonin results in decreased expression of ESR2 protein]; Melatonin inhibits the reaction [Ethanol results in decreased expression of ESR2 protein]

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

fatty acid binding protein 4

decreases expression

Melatonin results in decreased expression of FABP4 mRNA

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

Fas cell surface death receptor

multiple interactions
decreases expression

Melatonin inhibits the reaction [bisphenol A results in increased expression of FAS protein]; Melatonin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of FAS protein]
Melatonin results in decreased expression of FAS mRNA; Melatonin results in decreased expression of FAS protein
Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA]; Melatonin inhibits the reaction [Atrazine results in increased expression of FAS protein]

PMID:14993511 PMID:20181888 PMID:23963992 PMID:25259610 PMID:25454643

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions

Melatonin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of FASLG protein]
Melatonin inhibits the reaction [Atrazine results in increased expression of FASL protein]

PMID:14993511 PMID:25259610

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fatty acid synthase

multiple interactions

Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of FASN mRNA]

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

Fc gamma receptor 2B

multiple interactions
decreases expression

Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of FCGR2B mRNA]
Melatonin results in decreased expression of FCGR2B mRNA

NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778

G

fibroblast growth factor 9

multiple interactions

Melatonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FGF9 mRNA]; Melatonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FGF9 protein]

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309

G

fission, mitochondrial 1

multiple interactions

Melatonin inhibits the reaction [Doxorubicin results in increased expression of FIS1 protein]
Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of FIS1 mRNA]

PMID:29966675 PMID:33962019

NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377

G

fibronectin 1

multiple interactions

Melatonin inhibits the reaction [manganese chloride results in increased expression of and results in increased secretion of FN1 protein]; Melatonin inhibits the reaction [manganese chloride results in increased expression of FN1 mRNA]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Melatonin inhibits the reaction [Capsaicin results in increased expression of FOS protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of and affects the localization of FOS protein]

PMID:19172228 PMID:28238930

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

follicle stimulating hormone subunit beta

multiple interactions

Melatonin inhibits the reaction [Ethanol results in decreased expression of FSHB protein]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

FUN14 domain containing 1

multiple interactions

Melatonin inhibits the reaction [Doxorubicin results in increased expression of FUNDC1 protein]; Verteporfin inhibits the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased expression of FUNDC1 protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased expression of FUNDC1 protein]]

NCBI chr X:5,083,635...5,100,293
Ensembl chr X:5,083,617...5,100,284

G

glucose-6-phosphate dehydrogenase

increases activity
multiple interactions

Melatonin results in increased activity of G6PD protein
Melatonin inhibits the reaction [sodium arsenite results in decreased expression of G6PD protein]
[essential 303 forte co-treated with Silymarin co-treated with Melatonin analog] affects the activity of G6PD protein

PMID:16224550 PMID:25903262 PMID:29763682

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

growth associated protein 43

multiple interactions

Melatonin inhibits the reaction [Methamphetamine results in decreased expression of GAP43 protein]

NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045

G

gastrin

multiple interactions
increases expression

luzindole inhibits the reaction [Melatonin results in increased expression of GAST]

PMID:12074098 PMID:16207293

NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

4-phenyl-2-propionamidotetraline inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLC mRNA]]; Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLC mRNA]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLC mRNA]]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

multiple interactions

4-phenyl-2-propionamidotetraline inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLM mRNA]]; Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLM mRNA]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLM mRNA]]

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glial fibrillary acidic protein

multiple interactions

Melatonin inhibits the reaction [Carmustine results in decreased expression of GFAP protein]; Melatonin inhibits the reaction [Galactose results in increased expression of GFAP protein]
Melatonin inhibits the reaction [manganese chloride results in increased expression of GFAP protein]

PMID:17572393 PMID:25288107 PMID:34673010

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

gamma-glutamyltransferase 1

multiple interactions

Melatonin inhibits the reaction [Carbon Tetrachloride results in increased activity of GGT1 protein]

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

galactosidase, beta 1

multiple interactions

Melatonin inhibits the reaction [Glucose results in increased expression of GLB1 protein]

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

gonadotropin releasing hormone 1

multiple interactions

Melatonin promotes the reaction [bisphenol A results in increased expression of GNRH1 mRNA]

NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581
Ensembl chr15:41,972,905...41,973,581

G

gonadotropin releasing hormone receptor

increases expression
multiple interactions

Melatonin results in increased expression of GNRHR mRNA
[bisphenol A co-treated with Melatonin] results in increased expression of GNRHR mRNA

NCBI chr14:21,856,871...21,874,861
Ensembl chr14:21,856,871...21,874,861

G

glutamic--pyruvic transaminase

multiple interactions

[Melatonin co-treated with Thioacetamide] results in increased expression of GPT protein; Melatonin inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; Melatonin inhibits the reaction [Methotrexate results in increased expression of GPT protein]

PMID:15700767 PMID:26882442 PMID:31967703 PMID:36890697

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions
increases expression

[aluminum lactate co-treated with Melatonin] results in increased expression of GPX1 mRNA
Melatonin affects the reaction [manganese chloride results in decreased expression of GPX1 protein]
Melatonin results in increased expression of GPX1 mRNA

PMID:15589378 PMID:25288107

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 2

multiple interactions

[Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione peroxidase 4

multiple interactions

Melatonin inhibits the reaction [Doxorubicin results in decreased expression of GPX4 protein]; Verteporfin inhibits the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of GPX4 protein]]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

growth factor receptor bound protein 2

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]

NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309

G

glutamate ionotropic receptor NMDA type subunit 1

multiple interactions

Melatonin inhibits the reaction [Galactose results in increased expression of GRIN1 protein]

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

Melatonin inhibits the reaction [Galactose results in increased expression of GRIN2B protein]

NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279

G

glycogen synthase kinase 3 beta

multiple interactions

Melatonin inhibits the reaction [wortmannin results in decreased expression of GSK3B protein modified form]
Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of GSK3B protein modified form]; Melatonin inhibits the reaction [Cadmium Chloride results in decreased phosphorylation of GSK3B protein]; Melatonin promotes the reaction [Zinc Sulfate inhibits the reaction [Aluminum Chloride results in increased expression of GSK3B protein modified form]]; Zinc Sulfate promotes the reaction [Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of GSK3B protein modified form]]

PMID:15842767 PMID:31809235 PMID:35526705

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione-disulfide reductase

multiple interactions
increases activity
decreases expression

[Cadmium Chloride co-treated with Melatonin] results in decreased expression of GSR mRNA; aluminum lactate affects the reaction [Melatonin results in increased activity of GSR protein]; Melatonin inhibits the reaction [Gentamicins results in decreased activity of GSR protein]; Melatonin inhibits the reaction [sodium arsenite results in decreased activity of GSR protein]; Melatonin inhibits the reaction [sodium arsenite results in increased activity of GSR protein]; Melatonin promotes the reaction [aluminum lactate results in decreased activity of GSR protein]
[essential 303 forte co-treated with Silymarin co-treated with Melatonin analog] affects the activity of GSR protein
Melatonin results in decreased expression of GSR protein
[aluminum lactate co-treated with Melatonin] results in increased expression of GSR mRNA; aluminum lactate promotes the reaction [Melatonin results in decreased expression of GSR protein]; luzindole inhibits the reaction [Melatonin results in increased activity of GSR protein]; Melatonin affects the reaction [manganese chloride results in decreased expression of GSR protein]; Melatonin inhibits the reaction [bisphenol A results in decreased activity of GSR protein]; Melatonin inhibits the reaction [manganese chloride results in decreased expression of GSR protein]; Melatonin inhibits the reaction [sodium arsenite results in decreased activity of GSR protein]; Melatonin promotes the reaction [aluminum lactate results in decreased expression of GSR protein]
Melatonin results in decreased expression of GSR mRNA

PMID:12823611 PMID:16098089 PMID:16224550 PMID:16931443 PMID:19405147 More...

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 5

multiple interactions

[Melatonin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

glutathione S-transferase mu 1

multiple interactions

[Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of GSTM1 mRNA

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase pi 1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA]
Melatonin affects the reaction [Dexamethasone results in decreased expression of GSTP1 mRNA]

PMID:21986892 PMID:23963992

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

H19 imprinted maternally expressed transcript

increases expression

monocrotaline increases expression of H19 RNA in pulmonary artery smooth muscle cells

RGD

NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134

G

H2A.X variant histone

multiple interactions

Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in increased expression of H2AX protein]

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

hepatitis A virus cellular receptor 1

multiple interactions

Melatonin inhibits the reaction [sodium arsenite results in increased expression of HAVCR1 protein]

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

histone deacetylase 3

multiple interactions
decreases activity

CEBPB protein inhibits the reaction [Melatonin results in decreased activity of HDAC3 protein]; RELA protein inhibits the reaction [Melatonin results in decreased activity of HDAC3 protein]

NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of HIF1A mRNA]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

high mobility group box 1

multiple interactions

Melatonin inhibits the reaction [decabromobiphenyl ether affects the localization of HMGB1 protein]; Melatonin inhibits the reaction [decabromobiphenyl ether promotes the reaction [SIRT1 protein results in increased acetylation of HMGB1 protein]]; Melatonin inhibits the reaction [tetrachlorobenzoquinone affects the localization of HMGB1 protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased acetylation of and results in increased phosphorylation of HMGB1 protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of HMGB1 protein]
Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of HMGB1 mRNA]

PMID:27413111 PMID:35844137 PMID:36566971

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

heme oxygenase 1

multiple interactions
increases expression
decreases expression

Melatonin affects the reaction [Dexamethasone results in increased expression of HMOX1 mRNA]; Melatonin inhibits the reaction [[Dietary Fats co-treated with Ethanol] results in decreased expression of HMOX1 mRNA]; Melatonin inhibits the reaction [Ammonium Chloride results in increased expression of HMOX1 mRNA]; Melatonin inhibits the reaction [Cadmium affects the expression of HMOX1 mRNA]; Melatonin inhibits the reaction [Cadmium Chloride affects the expression of HMOX1 mRNA]; Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Melatonin inhibits the reaction [Ethanol results in decreased expression of HMOX1 mRNA]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of HMOX1 protein]; Melatonin promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of HMOX1 protein]
[Melatonin co-treated with diisodecyl phthalate co-treated with Fluorescein-5-isothiocyanate] results in increased expression of HMOX1 protein; Acetylcysteine inhibits the reaction [Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of HMOX1 mRNA]]; Acetylcysteine inhibits the reaction [Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of HMOX1 protein]]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of HMOX1 mRNA]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of HMOX1 protein]; Melatonin inhibits the reaction [manganese chloride results in increased expression of HMOX1 protein]; Melatonin inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in decreased expression of HMOX1 mRNA]]
Melatonin results in increased expression of HMOX1 protein
Melatonin inhibits the reaction [HMOX1 protein results in increased expression of SOD2 mRNA]
Melatonin results in decreased expression of HMOX1 mRNA

PMID:10942521 PMID:12420312 PMID:16948784 PMID:17645694 PMID:18715270 More...

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heme oxygenase 2

multiple interactions
decreases expression

[Cadmium Chloride co-treated with Melatonin] results in decreased expression of HMOX2 mRNA; Melatonin affects the reaction [Dexamethasone results in increased expression of HMOX2 mRNA]
Melatonin results in decreased expression of HMOX2 mRNA

PMID:21442002 PMID:21986892

NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148

G

heat shock transcription factor 1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

heat shock protein 90 alpha family class A member 1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA]

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

Melatonin inhibits the reaction [cyfluthrin results in increased expression of HSPA1A mRNA]

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 5

multiple interactions

Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of HSPA5 protein]; Melatonin inhibits the reaction [Galactose results in increased expression of HSPA5 protein]; Melatonin promotes the reaction [Cyclosporine results in increased expression of HSPA5 protein]; Melatonin promotes the reaction [Methamphetamine results in increased expression of HSPA5 mRNA]; Melatonin promotes the reaction [Methamphetamine results in increased expression of HSPA5 protein]

PMID:20136702 PMID:28070110 PMID:33130240 PMID:34673010

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 9

multiple interactions

Melatonin affects the reaction [Mercuric Chloride results in increased expression of HSPA9 protein]

NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292

G

interferon gamma

multiple interactions

Gonadal Steroid Hormones affects the reaction [Melatonin affects the expression of IFNG protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA]
[Melatonin co-treated with Folic Acid] inhibits the reaction [Carbon Tetrachloride results in increased expression of IFNG mRNA]

PMID:16373423 PMID:23374533 PMID:23963992

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA]

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 1 receptor

decreases expression

melatonin decreases expression of Igf1r RNA in pulmonary artery smooth muscle cells

RGD

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

interleukin 10

multiple interactions

[Melatonin co-treated with Fluorides] results in increased expression of IL10 mRNA; Gonadal Steroid Hormones affects the reaction [Melatonin affects the expression of IL10 protein]; IL17A protein affects the reaction [[Melatonin co-treated with Fluorides] results in increased expression of IL10 mRNA]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of IL10 mRNA]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of IL10 protein]
Melatonin inhibits the reaction [decabromobiphenyl ether results in decreased expression of IL10 mRNA]; Melatonin inhibits the reaction [decabromobiphenyl ether results in decreased secretion of IL10 protein]

PMID:16373423 PMID:36566971 PMID:37269891 PMID:37598416

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 11

multiple interactions

Melatonin inhibits the reaction [Dextran Sulfate results in decreased expression of IL11 protein]

NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129

G

interleukin 13

multiple interactions

Melatonin inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased expression of IL13 protein]]

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 17A

multiple interactions

IL17A protein affects the reaction [[Melatonin co-treated with Fluorides] results in increased expression of IL10 mRNA]; Melatonin inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased expression of IL17A protein]]

PMID:34146326 PMID:37269891

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 18

multiple interactions

Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of IL18 mRNA]; Melatonin inhibits the reaction [Nickel results in increased expression of IL18 mRNA]
Melatonin inhibits the reaction [arsenite results in increased expression of and results in increased secretion of IL18 protein]

PMID:36343453 PMID:36504304

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 alpha

multiple interactions
decreases expression

Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL1A protein]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]
Melatonin results in decreased expression of IL1A mRNA

PMID:21461237 PMID:36265525

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
decreases secretion
decreases expression

[BNIP3 protein co-treated with PINK1 protein] affects the reaction [Melatonin inhibits the reaction [Paraquat results in increased secretion of IL1B protein]]; Gonadal Steroid Hormones affects the reaction [Melatonin affects the expression of IL1B protein]; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of IL1B mRNA]; Melatonin affects the reaction [Nickel affects the reaction [SELENOM protein affects the expression of IL1B protein]]; Melatonin affects the reaction [SELENOM protein affects the expression of IL1B protein]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of IL1B protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [nickel chloride results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [nickel chloride results in increased expression of IL1B protein]; Melatonin inhibits the reaction [Nickel results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [Paraquat results in increased secretion of IL1B protein]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of IL1B protein]; Nickel affects the reaction [Melatonin affects the reaction [SELENOM protein affects the expression of IL1B protein]]; Nickel inhibits the reaction [Melatonin results in decreased expression of IL1B mRNA]; Nickel inhibits the reaction [Melatonin results in decreased expression of IL1B protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of IL1B mRNA]]
Melatonin inhibits the reaction [arsenite results in increased expression of and results in increased secretion of IL1B protein]
Melatonin results in decreased secretion of IL1B protein
Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein]; Melatonin inhibits the reaction [[Dietary Fats co-treated with Ethanol] results in increased expression of IL1B protein]; Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of IL1B protein]; Melatonin inhibits the reaction [Carbon Tetrachloride results in increased secretion of IL1B protein]; Melatonin inhibits the reaction [decabromobiphenyl ether results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [decabromobiphenyl ether results in increased expression of IL1B protein]; Melatonin inhibits the reaction [Dietary Fats results in increased expression of IL1B protein]; Melatonin inhibits the reaction [Ethanol results in increased expression of IL1B protein]; Melatonin inhibits the reaction [Methamphetamine results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of and results in increased secretion of IL1B protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of IL1B protein]; Melatonin promotes the reaction [Zinc Sulfate inhibits the reaction [Aluminum Chloride results in increased expression of IL1B protein]]; Zinc Sulfate promotes the reaction [Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of IL1B protein]]
Melatonin results in decreased expression of IL1B mRNA; Melatonin results in decreased expression of IL1B protein

PMID:15714805 PMID:16373423 PMID:19028472 PMID:20374443 PMID:21461237 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

increases activity
multiple interactions

Melatonin results in increased activity of IL2 protein
Gonadal Steroid Hormones affects the reaction [Melatonin affects the expression of IL2 protein]; Melatonin inhibits the reaction [nickel chloride results in increased expression of IL2 mRNA]; Melatonin inhibits the reaction [nickel chloride results in increased expression of IL2 protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of IL2 mRNA]]

PMID:9730580 PMID:16373423 PMID:36421005

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 23 subunit alpha

multiple interactions

Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL23A protein]

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 4

multiple interactions

Melatonin inhibits the reaction [diisodecyl phthalate promotes the reaction [Fluorescein-5-isothiocyanate results in increased expression of IL4 protein]]; Melatonin inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased expression of IL4 protein]]

PMID:27871981 PMID:34146326

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

multiple interactions

Melatonin inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased expression of IL5 protein]]

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

multiple interactions
decreases secretion

Melatonin inhibits the reaction [Methamphetamine results in increased expression of IL6 mRNA]; Melatonin inhibits the reaction [Streptozocin results in increased expression of IL6 protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of and results in increased secretion of IL6 protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of IL6 mRNA]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of IL6 protein]
Melatonin results in decreased secretion of IL6 protein
Gonadal Steroid Hormones affects the reaction [Melatonin affects the expression of IL6 protein]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of IL6 mRNA]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of IL6 protein]; Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of IL6 mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Melatonin inhibits the reaction [nickel chloride results in increased expression of IL6 mRNA]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of IL6 protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of IL6 mRNA]]

PMID:16373423 PMID:20374443 PMID:21158907 PMID:27413111 PMID:28238930 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 7

multiple interactions

Melatonin inhibits the reaction [nickel chloride results in increased expression of IL7 mRNA]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of IL7 mRNA]]

NCBI chr 2:94,235,219...94,280,075
Ensembl chr 2:94,234,766...94,280,075

G

insulin 1

multiple interactions

Melatonin affects the reaction [Streptozocin results in decreased expression of INS1 protein]; Melatonin inhibits the reaction [Colforsin results in increased secretion of INS1 protein]; Melatonin inhibits the reaction [Triiodothyronine, Reverse inhibits the reaction [INS1 protein results in increased uptake of Glucose]]

PMID:12153439 PMID:17198541 PMID:32554039

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin receptor

multiple interactions

Melatonin inhibits the reaction [Streptozocin results in decreased expression of INSR protein]

NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883

G

insulin receptor substrate 1

multiple interactions

Melatonin inhibits the reaction [sodium arsenite results in decreased expression of IRS1 protein]

NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122

G

insulin receptor substrate 2

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA]

NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482

G

inositol 1,4,5-trisphosphate receptor, type 1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA]

NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491

G

inositol 1,4,5-trisphosphate receptor, type 3

multiple interactions

Melatonin inhibits the reaction [Galactose results in increased expression of ITPR3 protein]

NCBI chr20:5,136,968...5,202,339
Ensembl chr20:5,136,441...5,202,337

G

IZUMO1 receptor, JUNO

multiple interactions

Melatonin inhibits the reaction [bisphenol A affects the expression of and affects the localization of IZUMO1R protein]; Melatonin inhibits the reaction [Ethinyl Estradiol affects the localization of IZUMO1R protein]

PMID:28178360 PMID:31931096

NCBI chr 8:11,744,384...11,748,131
Ensembl chr 8:11,725,863...11,748,465

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of and affects the localization of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

kinase insert domain receptor

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of KDR mRNA]

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

Kelch-like ECH-associated protein 1

decreases expression
multiple interactions

Melatonin results in decreased expression of KEAP1 protein
Melatonin affects the reaction [manganese chloride affects the expression of KEAP1 protein]

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

Klotho

multiple interactions

4-phenyl-2-propionamidotetraline inhibits the reaction [Melatonin inhibits the reaction [KL mutant form affects the localization of and results in decreased activity of NFE2L2 protein]]; 4-phenyl-2-propionamidotetraline inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLC mRNA]]; 4-phenyl-2-propionamidotetraline inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLM mRNA]]; 4-phenyl-2-propionamidotetraline inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK1 protein]]; 4-phenyl-2-propionamidotetraline inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK3 protein]]; Melatonin inhibits the reaction [KL mutant form affects the localization of and results in decreased activity of NFE2L2 protein]; Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLC mRNA]; Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLM mRNA]; Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK1 protein]; Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK3 protein]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form affects the localization of and results in decreased activity of NFE2L2 protein]]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLC mRNA]]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased expression of GCLM mRNA]]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK1 protein]]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK3 protein]]

NCBI chr12:490,402...531,417
Ensembl chr12:490,399...530,080

G

lysosomal-associated membrane protein 2

multiple interactions

Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of LAMP2 protein]

NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522

G

leptin

decreases expression

Melatonin results in decreased expression of LEP mRNA
Melatonin results in decreased expression of LEP protein

PMID:19028472 PMID:20738756

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

luteinizing hormone subunit beta

multiple interactions

[Melatonin co-treated with LHB protein] results in increased chemical synthesis of Testosterone; Melatonin inhibits the reaction [Cadmium Chloride affects the expression of LHB]

PMID:16054318 PMID:23085516

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

lipoprotein lipase

decreases expression

Melatonin results in decreased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

LDL receptor related protein 1

multiple interactions

Melatonin inhibits the reaction [Aluminum Chloride results in decreased expression of LRP1 protein]

NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910

G

lymphocyte antigen 96

multiple interactions

Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of LY96 protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased localization of LY96 protein]; Melatonin inhibits the reaction [TLR4 protein promotes the reaction [MYD88 protein binds to LY96 protein binds to CD14 protein]]

PMID:27413111 PMID:28238930

NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386

G

mitotic arrest deficient 1 like 1

multiple interactions

Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in decreased expression of MAD1L1 mRNA]; Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in decreased expression of MAD1L1 protein]

NCBI chr12:14,320,892...14,630,750
Ensembl chr12:14,320,892...14,630,703

G

mitotic arrest deficient 2 like 1

multiple interactions

Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in decreased expression of MAD2L1 mRNA]; Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in decreased expression of MAD2L1 protein]

NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470

G

monoamine oxidase A

multiple interactions

Melatonin inhibits the reaction [Ketorolac Tromethamine results in increased activity of MAOA protein]

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

microtubule-associated protein 1 light chain 3 alpha

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of MAP1LC3A mRNA]]; Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in increased expression of MAP1LC3A mRNA]

NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

Melatonin inhibits the reaction [Atrazine results in increased expression of MAP1LC3B protein]; Melatonin inhibits the reaction [nickel chloride results in increased expression of MAP1LC3B mRNA]; Melatonin inhibits the reaction [Radon results in increased expression of MAP1LC3B protein]; Melatonin promotes the reaction [Paraquat results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Melatonin results in increased expression of and results in increased lipidation of MAP1LC3B protein; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of MAP1LC3B mRNA]]

PMID:25259610 PMID:33107683 PMID:36421005 PMID:37028639

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

microtubule-associated protein 2

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA]

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen activated protein kinase kinase 1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen-activated protein kinase kinase 6

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA]

NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293

G

mitogen activated protein kinase 1

multiple interactions

Melatonin inhibits the reaction [Nicotine results in decreased expression of MAPK1 protein]; Melatonin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased phosphorylation of MAPK1 protein]
Melatonin inhibits the reaction [arsenite results in increased phosphorylation of MAPK1 protein]; Melatonin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]
4-phenyl-2-propionamidotetraline inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK1 protein]]; Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in increased phosphorylation of MAPK1 protein]; Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK1 protein]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK1 protein]]

PMID:20050989 PMID:25550330 PMID:28238930 PMID:29330934 PMID:35643323 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 10

increases expression

Melatonin results in increased expression of MAPK10 protein

NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201

G

mitogen activated protein kinase 3

multiple interactions

Melatonin inhibits the reaction [Nicotine results in decreased expression of MAPK3 protein]; Melatonin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased phosphorylation of MAPK3 protein]
Melatonin inhibits the reaction [arsenite results in increased phosphorylation of MAPK3 protein]; Melatonin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]
4-phenyl-2-propionamidotetraline inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK3 protein]]; Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in increased phosphorylation of MAPK3 protein]; Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK3 protein]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form results in decreased phosphorylation of MAPK3 protein]]

PMID:20050989 PMID:25550330 PMID:28238930 PMID:29330934 PMID:35643323 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

increases expression
multiple interactions

Melatonin results in increased expression of MAPK8 protein
Melatonin inhibits the reaction [arsenite results in increased phosphorylation of MAPK8 protein]

PMID:19012662 PMID:36343453

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

increases expression

Melatonin results in increased expression of MAPK9 protein

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

microtubule-associated protein tau

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA]; Melatonin inhibits the reaction [Wortmannin results in increased phosphorylation of MAPT protein]
Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of MAPT protein modified form]; Melatonin inhibits the reaction [Streptozocin results in increased phosphorylation of MAPT protein]; Melatonin metabolite inhibits the reaction [Streptozocin results in increased phosphorylation of MAPT protein]; Melatonin promotes the reaction [Zinc Sulfate inhibits the reaction [Aluminum Chloride results in increased expression of MAPT protein modified form]]; Zinc Sulfate promotes the reaction [Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of MAPT protein modified form]]
Melatonin inhibits the reaction [Mercuric Chloride results in increased phosphorylation of MAPT protein]

PMID:10617124 PMID:15842767 PMID:23963992 PMID:31833155 PMID:35526705

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

myelin basic protein

multiple interactions

Melatonin inhibits the reaction [Scopolamine results in decreased expression of MBP protein]

NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions

Melatonin inhibits the reaction [oxaliplatin results in decreased expression of MCL1 protein]

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

malic enzyme 1

multiple interactions

Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA]

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

mitochondrial fission factor

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of MFF mRNA]

NCBI chr 9:84,007,798...84,036,039
Ensembl chr 9:84,007,798...84,036,039

G

mitofusin 1

multiple interactions
increases expression

[Doxorubicin results in increased susceptibility to Melatonin] which results in increased expression of MFN1 protein; [Melatonin results in increased susceptibility to Doxorubicin] which results in increased expression of MFN1 protein
Melatonin results in increased expression of MFN1 mRNA

PMID:29966675 PMID:33962019

NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640

G

mitofusin 2

multiple interactions
increases expression

Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN2 protein]; Melatonin inhibits the reaction [Doxorubicin results in decreased expression of MFN2 protein]
Melatonin affects the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of MFN2 mRNA]
Melatonin results in increased expression of MFN2 mRNA

PMID:26882442 PMID:29966675 PMID:33962019

NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342

G

mitochondrial elongation factor 2

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of MIEF2 mRNA]

NCBI chr10:45,408,055...45,414,144
Ensembl chr10:45,408,082...45,414,144

G

microRNA 200a

decreases expression

melatonin decreases expression of Mir200a RNA in pulmonary artery smooth muscle cells

RGD

NCBI chr 5:166,648,494...166,648,582

G

microRNA 21

multiple interactions

Melatonin inhibits the reaction [Cisplatin results in increased expression of MIR21 mRNA]

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

microRNA 497

multiple interactions
increases expression

MIR497 mRNA affects the reaction [Melatonin results in decreased expression of BTG2 mRNA]; MIR497 mRNA affects the reaction [Melatonin results in decreased expression of CYP7A1 mRNA]; MIR497 mRNA affects the reaction [Melatonin results in decreased expression of YY1 mRNA]
Melatonin results in increased expression of MIR497 mRNA

NCBI chr10:54,951,514...54,951,582
Ensembl chr10:54,951,505...54,951,584

G

microRNA 675

increases expression

melatonin increases expression of Mir675 RNA in pulmonary artery smooth muscle cells

RGD

NCBI chr 1:197,732,275...197,732,358
Ensembl chr 1:197,732,275...197,732,358

G

marker of proliferation Ki-67

multiple interactions
decreases expression

Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein]
Melatonin results in decreased expression of MKI67 mRNA; Melatonin results in decreased expression of MKI67 protein

PMID:19028472 PMID:21062352

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

mixed lineage kinase domain like pseudokinase

multiple interactions

Melatonin inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MLKL protein]

NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502

G

membrane metallo-endopeptidase

multiple interactions

Melatonin inhibits the reaction [Aluminum Chloride results in decreased expression of MME protein]

NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792

G

matrix metallopeptidase 14

multiple interactions

Melatonin inhibits the reaction [Indomethacin results in decreased expression of MMP14 protein]

NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864

G

matrix metallopeptidase 2

multiple interactions
decreases expression

Melatonin inhibits the reaction [Hydrogen Peroxide results in decreased activity of MMP2 protein]; Melatonin inhibits the reaction [Indomethacin results in decreased expression of and results in decreased secretion of and results in decreased activity of MMP2 protein]; Melatonin inhibits the reaction [Indomethacin results in decreased expression of and results in decreased secretion of MMP2 protein]
Melatonin results in decreased expression of MMP2 mRNA; Melatonin results in decreased expression of MMP2 protein
[Doxorubicin co-treated with Melatonin] results in decreased expression of MMP2 protein; Doxorubicin promotes the reaction [Melatonin results in decreased expression of MMP2 mRNA]
Melatonin inhibits the reaction [sodium arsenite results in increased expression of MMP2 protein]

PMID:16150113 PMID:16934674 PMID:29763682 PMID:33507000

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

multiple interactions
decreases expression

Melatonin inhibits the reaction [Galactose results in decreased expression of MMP9 protein]; Melatonin inhibits the reaction [Indomethacin results in increased expression of and results in increased secretion of MMP9 protein]
Doxorubicin promotes the reaction [Melatonin results in decreased expression of MMP9 mRNA]; Doxorubicin promotes the reaction [Melatonin results in decreased expression of MMP9 protein]
Melatonin results in decreased expression of MMP9 mRNA; Melatonin results in decreased expression of MMP9 protein

PMID:16150113 PMID:33507000 PMID:34673010

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions

[Melatonin co-treated with coenzyme Q10 co-treated with vinpocetine] inhibits the reaction [Chlorpyrifos results in increased activity of MPO protein]; Melatonin inhibits the reaction [Chlorpyrifos results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mitochondrially encoded cytochrome c oxidase II

multiple interactions

Melatonin inhibits the reaction [Paraquat results in increased expression of COX2 protein]

NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689

G

metallothionein 1

multiple interactions

Melatonin promotes the reaction [lead acetate results in increased expression of MT1A mRNA]

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

metallothionein 2A

multiple interactions

Melatonin promotes the reaction [lead acetate results in increased expression of MT2A mRNA]

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

melatonin receptor 1A

affects binding
increases expression
multiple interactions

Melatonin analog binds to MTNR1A protein; Melatonin binds to MTNR1A protein
Melatonin results in increased expression of MTNR1A protein
Carbaryl inhibits the reaction [Melatonin binds to MTNR1A protein]; Carbofuran inhibits the reaction [Melatonin binds to MTNR1A protein]
[Ethanol co-treated with Melatonin] results in increased expression of MTNR1A protein; luzindole inhibits the reaction [Melatonin results in increased expression of MTNR1A protein]

PMID:11063602 PMID:17645693 PMID:20399199 PMID:23591044 PMID:28027439 More...

NCBI chr16:47,144,461...47,163,919
Ensembl chr16:47,144,461...47,163,919

G

melatonin receptor 1B

multiple interactions
increases expression
affects binding

[luzindole binds to and results in decreased activity of MTNR1B protein] which results in decreased susceptibility to Melatonin
luzindole inhibits the reaction [Melatonin results in increased expression of MTNR1B protein]
Carbaryl inhibits the reaction [Melatonin binds to MTNR1B protein]; Carbofuran inhibits the reaction [Melatonin binds to MTNR1B protein]; Guanosine Triphosphate inhibits the reaction [Carbaryl inhibits the reaction [Melatonin binds to MTNR1B protein]]; Guanosine Triphosphate inhibits the reaction [Carbofuran inhibits the reaction [Melatonin binds to MTNR1B protein]]; MTNR1B protein promotes the reaction [Melatonin inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]]
Melatonin analog binds to MTNR1B protein; Melatonin binds to MTNR1B protein

PMID:11063602 PMID:11270484 PMID:16030176 PMID:17645693 PMID:20399199 More...

NCBI chr 8:12,638,219...12,652,737
Ensembl chr 8:12,638,219...12,652,737

G

mechanistic target of rapamycin kinase

multiple interactions
increases phosphorylation
increases activity

Cisplatin affects the reaction [Melatonin results in increased phosphorylation of MTOR protein]; Melatonin promotes the reaction [MTOR protein results in increased phosphorylation of EIF4EBP1 protein]
Melatonin inhibits the reaction [Methotrexate results in increased phosphorylation of MTOR protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased expression of MTOR mRNA]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased phosphorylation of MTOR protein]]; Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased expression of MTOR mRNA]; Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased phosphorylation of MTOR protein]; Melatonin inhibits the reaction [nickel chloride results in decreased expression of MTOR mRNA]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in decreased expression of MTOR mRNA]]
Melatonin results in increased activity of MTOR protein

PMID:19054297 PMID:24799992 PMID:35568058 PMID:36421005 PMID:36890697

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

MYD88, innate immune signal transduction adaptor

multiple interactions

Melatonin inhibits the reaction [decabromobiphenyl ether results in increased expression of MYD88 protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of MYD88 mRNA]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of MYD88 protein]; Melatonin inhibits the reaction [TLR4 protein promotes the reaction [MYD88 protein binds to LY96 protein binds to CD14 protein]]

PMID:28238930 PMID:36566971

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

neural cell adhesion molecule 1

increases expression

melatonin increases expression of NCAM1 protein isoform 180 in hippocampus of ethanol treated rats

RGD

NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014

G

nuclear receptor coactivator 1

multiple interactions

Melatonin inhibits the reaction [bisphenol A results in increased expression of NCOA1 protein]

NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664

G

nuclear receptor coactivator 3

multiple interactions

Melatonin inhibits the reaction [bisphenol A results in increased expression of NCOA3 protein]

NCBI chr 3:154,738,566...154,821,395
Ensembl chr 3:154,738,581...154,818,594

G

NEDD4 E3 ubiquitin protein ligase

affects response to substance
multiple interactions
decreases expression

[NEDD4 protein affects the susceptibility to Oxygen deficiency] which affects the susceptibility to Melatonin
Melatonin inhibits the reaction [NPM1 protein binds to NEDD4 protein]; Melatonin inhibits the reaction [Oxygen deficiency results in increased expression of NEDD4 protein]; Melatonin inhibits the reaction [RPL23 protein binds to NEDD4 protein]; Melatonin inhibits the reaction [RPS19 protein binds to NEDD4 protein]; Melatonin promotes the reaction [Cycloheximide results in decreased expression of NEDD4 protein]; Melatonin promotes the reaction [RPS7 protein binds to NEDD4 protein]
Melatonin results in decreased expression of NEDD4 protein

NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951

G

neurofilament heavy chain

decreases phosphorylation

Melatonin analog results in decreased phosphorylation of NEFH protein; Melatonin results in decreased phosphorylation of NEFH protein

NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351

G

nestin

decreases expression
multiple interactions

Melatonin results in decreased expression of NES protein
Melatonin inhibits the reaction [Carmustine results in increased expression of NES protein]

PMID:16369854 PMID:17572393 PMID:21269327

NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases expression

Melatonin inhibits the reaction [[Dietary Fats co-treated with Ethanol] results in decreased expression of NFE2L2 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 protein]; Melatonin promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of NFE2L2 protein]
Melatonin results in increased expression of NFE2L2 mRNA
Melatonin inhibits the reaction [arsenite results in increased expression of NFE2L2 protein]; Melatonin inhibits the reaction [cyfluthrin results in increased expression of NFE2L2 mRNA]
4-phenyl-2-propionamidotetraline inhibits the reaction [Melatonin inhibits the reaction [KL mutant form affects the localization of and results in decreased activity of NFE2L2 protein]]; [Melatonin co-treated with diisodecyl phthalate co-treated with Fluorescein-5-isothiocyanate] results in increased expression of NFE2L2 protein; Acetylcysteine inhibits the reaction [Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of NFE2L2 mRNA]]; Acetylcysteine inhibits the reaction [Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of NFE2L2 protein]]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of NFE2L2 mRNA]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of NFE2L2 protein]; Melatonin inhibits the reaction [KL mutant form affects the localization of and results in decreased activity of NFE2L2 protein]; Melatonin inhibits the reaction [manganese chloride results in increased expression of NFE2L2 protein]; Melatonin inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in decreased expression of NFE2L2 mRNA]]; SL 327 inhibits the reaction [Melatonin inhibits the reaction [KL mutant form affects the localization of and results in decreased activity of NFE2L2 protein]]
Melatonin results in increased expression of NFE2L2 protein

PMID:20433640 PMID:25288107 PMID:25550330 PMID:27871981 PMID:30372842 More...

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NFKB1 protein]; Melatonin inhibits the reaction [[Dietary Fats co-treated with Ethanol] results in increased expression of NFKB1 mRNA]; Melatonin inhibits the reaction [Ethanol results in increased expression of NFKB1 mRNA]
Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased localization of and results in increased activity of NFKB1 protein]

PMID:19028472 PMID:21158907 PMID:23963992 PMID:30372842

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

luzindole inhibits the reaction [Melatonin inhibits the reaction [Methamphetamine results in increased degradation of NFKBIA protein]]; Melatonin inhibits the reaction [Methamphetamine results in increased degradation of NFKBIA protein]
Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of NFKBIA mRNA]; Melatonin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of and results in increased localization of NFKBIA protein]; Melatonin promotes the reaction [Zinc Sulfate inhibits the reaction [Aluminum Chloride results in increased expression of NFKBIA mRNA]]; Zinc Sulfate promotes the reaction [Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of NFKBIA mRNA]]

PMID:26283214 PMID:35526705 PMID:36566971

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NLR family, pyrin domain containing 3

multiple interactions
decreases expression

[Nickel co-treated with Melatonin] results in decreased expression of NLRP3 protein; [SELENOM protein affects the susceptibility to Melatonin] which affects the expression of NLRP3 protein; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of NLRP3 mRNA]; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of NLRP3 protein]; Nickel inhibits the reaction [Melatonin results in decreased expression of NLRP3 mRNA]
Melatonin inhibits the reaction [arsenite results in increased expression of NLRP3 protein]

PMID:36343453 PMID:36504304

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 1

multiple interactions
decreases expression

Melatonin affects the reaction [Dexamethasone results in increased expression of NOS1 mRNA]; Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of NOS1 mRNA]; Melatonin inhibits the reaction [Cadmium results in increased expression of NOS1 mRNA]
Melatonin results in decreased expression of NOS1 mRNA

PMID:16948784 PMID:21442002 PMID:21986892

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

nitric oxide synthase 2

multiple interactions
increases expression
decreases expression

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of NOS2 protein]
Melatonin inhibits the reaction [cyfluthrin results in increased expression of NOS2 mRNA]
Melatonin results in increased expression of NOS2 mRNA
Melatonin results in decreased expression of NOS2 mRNA
Melatonin affects the reaction [Dexamethasone results in increased expression of NOS2 mRNA]; Melatonin affects the reaction [Mercuric Chloride results in increased expression of NOS2 protein]; Melatonin inhibits the reaction [[Dietary Fats co-treated with Ethanol] results in increased expression of NOS2 mRNA]; Melatonin inhibits the reaction [Amphetamine results in increased expression of NOS2 mRNA]; Melatonin inhibits the reaction [Cadmium affects the expression of NOS2 mRNA]; Melatonin inhibits the reaction [Cadmium Chloride affects the expression of NOS2 mRNA]; Melatonin inhibits the reaction [Dietary Fats results in increased expression of NOS2 mRNA]; Melatonin inhibits the reaction [Ethanol results in increased expression of NOS2 mRNA]; Melatonin inhibits the reaction [Gentamicins results in increased expression of NOS2 protein]

PMID:12074098 PMID:16801527 PMID:16948784 PMID:18524487 PMID:21442002 More...

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions

Melatonin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NOS3 mRNA]; Melatonin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NOS3 protein]; Melatonin promotes the reaction [Atorvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NOS3 protein]]

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

notch receptor 2

multiple interactions

Melatonin inhibits the reaction [Dibutyl Phthalate results in decreased expression of NOTCH2 protein alternative form]

NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088

G

NADPH oxidase 4

multiple interactions

Melatonin inhibits the reaction [Galactose results in increased expression of NOX4 protein]

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

nucleophosmin 1

multiple interactions

Melatonin inhibits the reaction [NPM1 protein binds to NEDD4 protein]

NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645

G

natriuretic peptide B

multiple interactions

Melatonin inhibits the reaction [Doxorubicin results in increased expression of NPPB protein]; Melatonin inhibits the reaction [Triiodothyronine, Reverse results in increased expression of NPPB mRNA]; Verteporfin inhibits the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased expression of NPPB protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased expression of NPPB protein]]

PMID:17198541 PMID:35093381

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression

[Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of NQO1 mRNA; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]
Melatonin inhibits the reaction [cyfluthrin results in decreased activity of NQO1 protein]; Melatonin inhibits the reaction [cyfluthrin results in increased expression of NQO1 mRNA]
Acetylcysteine inhibits the reaction [Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of NQO1 mRNA]]; Acetylcysteine inhibits the reaction [Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of NQO1 protein]]; Melatonin affects the reaction [manganese chloride affects the expression of NQO1 protein]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of NQO1 mRNA]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of NQO1 protein]; Melatonin inhibits the reaction [diisodecyl phthalate inhibits the reaction [Fluorescein-5-isothiocyanate results in increased expression of NQO1 protein]]; Melatonin inhibits the reaction [manganese chloride results in decreased expression of NQO1 protein]; Melatonin inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in decreased expression of NQO1 mRNA]]
Melatonin results in increased expression of NQO1 protein

PMID:20033131 PMID:20433640 PMID:24969583 PMID:25288107 PMID:27871981 More...

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

multiple interactions
affects activity

Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of 1-benzyl-1,4-dihydronicotinamide] which results in increased reduction of Ubiquinone Q2]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of 1-benzyl-1,4-dihydronicotinamide] which results in increased reduction of Vitamin K 3]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]
Melatonin affects the activity of NQO2 protein

PMID:20399199 PMID:22289031

NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

Melatonin inhibits the reaction [Lipopolysaccharides results in decreased expression of NR1H3 protein]

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

Melatonin inhibits the reaction [Lipopolysaccharides results in decreased expression of NR1I2 mRNA]

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
affects localization

Melatonin inhibits the reaction [Dexamethasone results in increased activity of NR3C1 protein]; Melatonin promotes the reaction [Dexamethasone results in decreased expression of NR3C1 mRNA]; Pertussis Toxin inhibits the reaction [Melatonin inhibits the reaction [Dexamethasone results in increased activity of NR3C1 protein]]
Melatonin inhibits the reaction [Dexamethasone results in increased expression of NR3C1 mRNA]
Melatonin affects the localization of NR3C1 protein

PMID:10463946 PMID:15813899 PMID:18395440

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

nuclear respiratory factor 1

multiple interactions

Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of NRF1 protein]

NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328

G

neurotrophic receptor tyrosine kinase 2

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA]; Melatonin inhibits the reaction [Scopolamine results in decreased expression of NTRK2 protein]

PMID:23963992 PMID:29476728

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

occludin

multiple interactions

Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of OCLN mRNA]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of OCLN protein]

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

OPA1, mitochondrial dynamin like GTPase

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of OPA1 mRNA]
Melatonin inhibits the reaction [Doxorubicin results in decreased expression of OPA1 protein]; Verteporfin inhibits the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of OPA1 protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of OPA1 protein]]

PMID:33962019 PMID:35093381

NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109

G

pyrimidinergic receptor P2Y4

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA]

NCBI chr X:65,681,680...65,717,404
Ensembl chr X:65,683,232...65,721,748

G

poly (ADP-ribose) polymerase 1

multiple interactions

Melatonin inhibits the reaction [Doxorubicin results in increased expression of PARP1 protein modified form]
Melatonin inhibits the reaction [Atrazine results in increased cleavage of PARP1 protein]

PMID:25259610 PMID:29966675

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

pro-apoptotic WT1 regulator

decreases expression

Melatonin results in decreased expression of PAWR protein

NCBI chr 7:43,645,028...43,725,033
Ensembl chr 7:43,645,084...43,725,028

G

proliferating cell nuclear antigen

multiple interactions
decreases expression

Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein]
Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in decreased expression of PCNA protein]
Melatonin results in decreased expression of PCNA mRNA

PMID:19028472 PMID:21062352 PMID:35643323

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

programmed cell death 4

increases expression

melatonin increases expression of Pdcd4 mRNA in pulmonary artery smooth muscle cells

RGD

NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275

G

phosphodiesterase 1B

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA]

NCBI chr 7:134,627,378...134,654,581
Ensembl chr 7:134,627,322...134,654,580

G

platelet derived growth factor receptor alpha

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA]

NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335

G

peroxisomal trans-2-enoyl-CoA reductase

multiple interactions

Melatonin inhibits the reaction [Cisplatin results in decreased expression of PECR mRNA]

PMID:35367536 PMID:36006825

NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511

G

period circadian regulator 1

multiple interactions

Melatonin affects the reaction [Cadmium Chloride affects the expression of PER1]; Melatonin affects the reaction [Rotenone affects the expression of PER1 mRNA]; Melatonin inhibits the reaction [Cadmium Chloride affects the expression of PER1 mRNA]; Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of PER1 mRNA]

PMID:17590544 PMID:21442002 PMID:23085516 PMID:25430725

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

period circadian regulator 2

multiple interactions
affects expression

Melatonin affects the reaction [Rotenone affects the expression of PER2 mRNA]; Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of PER2 mRNA]
Melatonin affects the expression of PER2 mRNA

PMID:17590544 PMID:21442002 PMID:25430725

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

platelet factor 4

multiple interactions

[Lipopolysaccharides co-treated with Melatonin] results in increased expression of PF4 mRNA

NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365

G

progesterone receptor

multiple interactions
decreases expression

Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of PGR]
Melatonin results in decreased expression of PGR protein alternative form
[Ethanol co-treated with Melatonin] results in decreased expression of PGR protein alternative form; [Ethanol co-treated with Melatonin] results in increased expression of PGR protein alternative form; Ethanol inhibits the reaction [Melatonin results in decreased expression of PGR protein alternative form]; Melatonin inhibits the reaction [Ethanol results in decreased expression of PGR protein alternative form]

PMID:22041583 PMID:23591044

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased expression of PIK3R1 mRNA]]; Melatonin inhibits the reaction [[nickel chloride results in increased abundance of Nickel] which results in decreased expression of PIK3R1 mRNA]

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

PTEN induced kinase 1

multiple interactions
increases expression

Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of PINK1 protein]; Melatonin inhibits the reaction [Doxorubicin results in increased expression of PINK1 protein]
Melatonin results in increased expression of PINK1 protein
[BNIP3 protein co-treated with PINK1 protein] affects the reaction [Melatonin inhibits the reaction [Paraquat results in increased secretion of IL1B protein]]; [BNIP3 protein co-treated with PINK1 protein] affects the reaction [Melatonin inhibits the reaction [Paraquat results in increased secretion of TNF protein]]; Melatonin promotes the reaction [Paraquat results in increased expression of PINK1 protein]
[PINK1 protein co-treated with BNIP3 protein] affects the reaction [Melatonin promotes the reaction [Paraquat results in increased expression of BNIP3 protein]]; [PINK1 protein co-treated with BNIP3 protein] affects the reaction [Melatonin promotes the reaction [Paraquat results in increased expression of PINK1 protein]]; [PINK1 protein co-treated with BNIP3 protein] affects the reaction [Melatonin results in increased expression of BNIP3 protein]; [PINK1 protein co-treated with BNIP3 protein] affects the reaction [Melatonin results in increased expression of PINK1 protein]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of PINK1 mRNA]; Melatonin promotes the reaction [Paraquat results in increased expression of PINK1 protein]

PMID:26882442 PMID:29966675 PMID:33962019 PMID:37028639

NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of PMAIP1 mRNA]

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

proopiomelanocortin

multiple interactions
decreases response to substance

[Melatonin co-treated with p-Chloroamphetamine] results in increased expression of POMC protein
Melatonin inhibits the reaction [POMC protein results in increased abundance of Hydrocortisone]; Melatonin inhibits the reaction [POMC protein results in increased abundance of Progesterone]
Melatonin results in decreased susceptibility to POMC protein

PMID:11478929 PMID:19301769 PMID:21332028

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

POU class 5 homeobox 1

multiple interactions
decreases expression

Melatonin inhibits the reaction [bisphenol A promotes the reaction [ESR1 protein binds to POU5F1 promoter]]; Melatonin inhibits the reaction [bisphenol A results in increased expression of POU5F1 mRNA]; Melatonin inhibits the reaction [bisphenol A results in increased expression of POU5F1 protein]; Melatonin inhibits the reaction [Estradiol promotes the reaction [ESR1 protein binds to POU5F1 promoter]]; Melatonin inhibits the reaction [Estradiol results in increased expression of POU5F1 mRNA]; Melatonin inhibits the reaction [Estradiol results in increased expression of POU5F1 protein]
Melatonin results in decreased expression of POU5F1 mRNA; Melatonin results in decreased expression of POU5F1 protein

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

peroxisome proliferator activated receptor alpha

multiple interactions

Melatonin inhibits the reaction [Cisplatin results in decreased expression of PPARA mRNA]; Melatonin inhibits the reaction [Cisplatin results in decreased expression of PPARA protein]
Melatonin inhibits the reaction [Cisplatin results in decreased expression of and results in decreased activity of PPARA protein]; Melatonin inhibits the reaction [Cisplatin results in decreased expression of PPARA mRNA]

PMID:35367536 PMID:36006825

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

decreases expression
increases expression
multiple interactions

Melatonin results in decreased expression of PPARG mRNA
Melatonin results in increased expression of PPARG mRNA; Melatonin results in increased expression of PPARG protein
GW 1929 inhibits the reaction [Melatonin results in increased expression of PPARG protein]; luzindole inhibits the reaction [Melatonin results in increased expression of PPARG protein]; Melatonin promotes the reaction [Pioglitazone results in increased expression of PPARG protein]; Pioglitazone promotes the reaction [Melatonin results in increased expression of PPARG protein]

PMID:20738756 PMID:29734669 PMID:33962019

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions
increases expression

luzindole inhibits the reaction [Melatonin inhibits the reaction [Cadmium Chloride results in increased acetylation of PPARGC1A protein]]; luzindole inhibits the reaction [Melatonin inhibits the reaction [Cadmium results in increased acetylation of PPARGC1A protein]]; Melatonin inhibits the reaction [Cadmium Chloride results in increased acetylation of PPARGC1A protein]; Melatonin inhibits the reaction [Cadmium results in increased acetylation of PPARGC1A protein]; sirtinol inhibits the reaction [Melatonin inhibits the reaction [Cadmium Chloride results in increased acetylation of PPARGC1A protein]]; sirtinol inhibits the reaction [Melatonin inhibits the reaction [Cadmium results in increased acetylation of PPARGC1A protein]]
Melatonin inhibits the reaction [Cisplatin results in decreased expression of PPARGC1A mRNA]
Melatonin results in increased expression of PPARGC1A mRNA
Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of PPARGC1A protein]; Melatonin inhibits the reaction [Doxorubicin results in decreased expression of PPARGC1A protein]

PMID:25159133 PMID:26882442 PMID:29966675 PMID:33962019 PMID:35367536

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions

Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of PRKN protein]

NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555

G

prolactin

multiple interactions

Melatonin inhibits the reaction [Cadmium Chloride affects the expression of PRL mRNA]; Melatonin inhibits the reaction [Cadmium Chloride affects the expression of PRL protein]; Melatonin inhibits the reaction [Cadmium Chloride affects the expression of PRL]

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

protein arginine methyltransferase 1

multiple interactions

Melatonin inhibits the reaction [Methotrexate results in decreased expression of PRMT1 protein]

NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345

G

prion protein

increases expression
multiple interactions

Melatonin results in increased expression of PRNP protein
GW 1929 inhibits the reaction [Melatonin results in increased expression of PRNP protein]; luzindole inhibits the reaction [Melatonin results in increased expression of PRNP protein]; Melatonin promotes the reaction [Pioglitazone results in increased expression of PRNP protein]; Pioglitazone promotes the reaction [Melatonin results in increased expression of PRNP protein]; PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in decreased expression of RGN protein]]]; PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in increased expression of CDKN1A protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in decreased expression of RGN protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in increased expression of CDKN1A protein]]]

NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937

G

prominin 1

decreases expression
multiple interactions

Melatonin results in decreased expression of PROM1 mRNA; Melatonin results in decreased expression of PROM1 protein
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid affects the reaction [Melatonin results in decreased expression of PROM1 protein]; 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [Melatonin results in decreased expression of PROM1 mRNA]; 2,4,6-trimethyl-N-(meta-3-trifluoromethylphenyl)benzenesulfonamide affects the reaction [Melatonin results in decreased expression of PROM1 protein]; 2,4,6-trimethyl-N-(meta-3-trifluoromethylphenyl)benzenesulfonamide inhibits the reaction [Melatonin results in decreased expression of PROM1 mRNA]; 2-amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine affects the reaction [Melatonin results in decreased expression of PROM1 protein]; 2-amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine inhibits the reaction [Melatonin results in decreased expression of PROM1 mRNA]; N-caproylsphingosine affects the reaction [Melatonin results in decreased expression of PROM1 protein]; N-caproylsphingosine inhibits the reaction [Melatonin results in decreased expression of PROM1 mRNA]; TWIST1 protein affects the reaction [Melatonin results in decreased expression of PROM1 protein]

NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527

G

presenilin 1

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA]

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

proteasome 26S subunit, ATPase 4

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA]

NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494

G

proteasome 26S subunit, non-ATPase 3

multiple interactions

[Oxygen deficiency co-treated with Melatonin] results in decreased expression of PSMD3 protein

NCBI chr10:83,643,473...83,655,620
Ensembl chr10:83,643,647...83,655,618

G

prostaglandin-endoperoxide synthase 2

multiple interactions

Melatonin inhibits the reaction [arsenic trioxide results in increased expression of PTGS2 mRNA]; Melatonin inhibits the reaction [arsenic trioxide results in increased expression of PTGS2 protein]; Melatonin inhibits the reaction [monomethylarsonous acid results in increased expression of PTGS2 mRNA]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of PTGS2 mRNA]
Melatonin inhibits the reaction [nickel chloride results in increased expression of PTGS2 mRNA]; Melatonin inhibits the reaction [nickel chloride results in increased expression of PTGS2 protein]; Melatonin inhibits the reaction [Radon results in decreased expression of PTGS2 mRNA]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of PTGS2 mRNA]]

PMID:18588940 PMID:23376440 PMID:33107683 PMID:36421005

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

PYD and CARD domain containing

multiple interactions
decreases expression

Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of PYCARD mRNA]; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of PYCARD protein]; Melatonin inhibits the reaction [Nickel results in increased expression of PYCARD mRNA]; Nickel inhibits the reaction [Melatonin results in decreased expression of PYCARD protein]
Melatonin inhibits the reaction [arsenite results in increased expression of PYCARD protein]
Melatonin results in decreased expression of PYCARD mRNA; Melatonin results in decreased expression of PYCARD protein

PMID:36343453 PMID:36504304

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

RAB7A, member RAS oncogene family

multiple interactions

Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of RAB7A protein]

NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889

G

Raf-1 proto-oncogene, serine/threonine kinase

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA]

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

G

retinoic acid receptor, alpha

multiple interactions

[Melatonin co-treated with Tretinoin] results in increased activity of RARA protein; Melatonin promotes the reaction [Tretinoin results in increased activity of RARA protein]

PMID:10965999 PMID:15813899

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RELA protein]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of RELA mRNA]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of RELA protein]; Melatonin inhibits the reaction [[diisodecyl phthalate co-treated with Fluorescein-5-isothiocyanate] results in increased phosphorylation of RELA protein]; Melatonin inhibits the reaction [[Formaldehyde co-treated with diisononyl phthalate] promotes the reaction [OVAL protein results in increased phosphorylation of RELA protein]]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]
luzindole inhibits the reaction [Melatonin inhibits the reaction [Methamphetamine affects the localization of RELA protein]]; Melatonin inhibits the reaction [arsenite results in increased phosphorylation of RELA protein]; Melatonin inhibits the reaction [Methamphetamine affects the localization of RELA protein]; Melatonin inhibits the reaction [Paraquat results in increased phosphorylation of RELA protein]; RELA protein inhibits the reaction [Melatonin results in decreased activity of HDAC3 protein]
Melatonin inhibits the reaction [Cyclophosphamide results in increased expression of RELA protein]; Melatonin inhibits the reaction [decabromobiphenyl ether results in increased phosphorylation of RELA protein]; Melatonin inhibits the reaction [Gentamicins results in increased expression of RELA protein]; Melatonin inhibits the reaction [Tenofovir affects the localization of RELA protein]; Melatonin inhibits the reaction [Tenofovir results in increased expression of and results in increased activity of RELA protein]; Melatonin inhibits the reaction [Tenofovir results in increased expression of RELA mRNA]

PMID:20433640 PMID:22225513 PMID:22526374 PMID:26283214 PMID:27871981 More...

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

renin binding protein

multiple interactions

Melatonin inhibits the reaction [sodium arsenite results in increased expression of RENBP protein]

NCBI chr X:151,661,463...151,670,538
Ensembl chr X:151,661,458...151,670,516

G

regucalcin

multiple interactions

Melatonin inhibits the reaction [Indican results in decreased expression of RGN protein]; Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in decreased expression of RGN protein]]; Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in decreased expression of RGN protein]]; PRNP protein promotes the reaction [Melatonin promotes the reaction [Pioglitazone inhibits the reaction [Indican results in decreased expression of RGN protein]]]; PRNP protein promotes the reaction [Pioglitazone promotes the reaction [Melatonin inhibits the reaction [Indican results in decreased expression of RGN protein]]]

NCBI chr X:1,619,030...1,634,456
Ensembl chr X:1,619,032...1,634,450

G

receptor interacting serine/threonine kinase 1

multiple interactions

Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of RIPK1 protein]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of RIPK1 protein]

PMID:29763682 PMID:35844137

NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824

G

receptor-interacting serine-threonine kinase 3

multiple interactions

Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of RIPK3 protein]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of RIPK3 protein]
[Melatonin co-treated with Thioacetamide] results in increased expression of RIPK3 protein

PMID:29763682 PMID:31967703 PMID:35844137

NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121

G

RAR-related orphan receptor A

affects binding

Melatonin binds to RORA protein

NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931

G

ribosomal protein L19

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RPL19 mRNA]

NCBI chr10:83,022,503...83,026,030
Ensembl chr10:83,019,257...83,052,112

G

ribosomal protein L23

multiple interactions

Melatonin inhibits the reaction [RPL23 protein binds to NEDD4 protein]

NCBI chr10:82,771,878...82,775,840
Ensembl chr10:82,771,538...82,775,870

G

ribosomal protein L3

multiple interactions

Melatonin inhibits the reaction [Oxygen deficiency results in increased expression of RPL3 protein]

NCBI chr 7:111,622,255...111,627,640
Ensembl chr 7:111,621,610...111,636,468

G

ribosomal protein S19

multiple interactions

Melatonin inhibits the reaction [RPS19 protein binds to NEDD4 protein]

NCBI chr 1:80,480,718...80,486,511
Ensembl chr 1:80,480,951...80,486,508

G

ribosomal protein S7

multiple interactions

Melatonin promotes the reaction [RPS7 protein binds to NEDD4 protein]

NCBI chr 6:45,266,200...45,271,064
Ensembl chr 6:45,223,980...45,271,145

G

RUNX family transcription factor 2

increases expression
multiple interactions

Melatonin results in increased expression of RUNX2 mRNA
Melatonin inhibits the reaction [Glucose results in decreased expression of RUNX2 mRNA]; Melatonin inhibits the reaction [Glucose results in decreased expression of RUNX2 protein]
Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of RUNX2 mRNA]

PMID:20738756 PMID:31809235 PMID:38000455

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

S100 calcium binding protein G

increases expression
multiple interactions

Melatonin results in increased expression of S100G mRNA; Melatonin results in increased expression of S100G protein
Hydrogen Peroxide promotes the reaction [Melatonin results in increased expression of S100G protein]

NCBI chr X:31,705,853...31,708,422
Ensembl chr X:31,705,866...31,708,433

G

selenoprotein M

multiple interactions
affects response to substance

[SELENOM protein affects the susceptibility to Melatonin] which affects the abundance of Malondialdehyde; [SELENOM protein affects the susceptibility to Melatonin] which affects the expression of CASP1 protein; [SELENOM protein affects the susceptibility to Melatonin] which affects the expression of CYBB mRNA; [SELENOM protein affects the susceptibility to Melatonin] which affects the expression of NLRP3 protein; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of CASP1 mRNA]; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of CASP1 protein]; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of CYBB mRNA]; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of IL18 mRNA]; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of IL1B mRNA]; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of NLRP3 mRNA]; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of NLRP3 protein]; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of PYCARD mRNA]; Melatonin affects the reaction [[SELENOM protein affects the susceptibility to Nickel] which affects the expression of PYCARD protein]; Melatonin affects the reaction [Nickel affects the reaction [SELENOM protein affects the expression of AIM2 mRNA]]; Melatonin affects the reaction [Nickel affects the reaction [SELENOM protein affects the expression of IL1B protein]]; Melatonin affects the reaction [Nickel affects the reaction [SELENOM protein affects the expression of TXNIP mRNA]]; Melatonin affects the reaction [SELENOM protein affects the expression of AIM2 mRNA]; Melatonin affects the reaction [SELENOM protein affects the expression of IL1B protein]; Melatonin affects the reaction [SELENOM protein affects the expression of TXNIP mRNA]; Melatonin inhibits the reaction [SELENOM protein affects the susceptibility to Nickel]; Nickel affects the reaction [Melatonin affects the reaction [SELENOM protein affects the expression of AIM2 mRNA]]; Nickel affects the reaction [Melatonin affects the reaction [SELENOM protein affects the expression of IL1B protein]]

NCBI chr14:78,395,826...78,398,429
Ensembl chr14:78,395,826...78,398,429

G

SET domain bifurcated histone lysine methyltransferase 1

multiple interactions

Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in increased expression of SETDB1 protein]

NCBI chr 2:182,898,738...182,930,283
Ensembl chr 2:182,898,738...182,930,506

G

sirtuin 1

decreases expression
multiple interactions

Melatonin results in decreased expression of SIRT1 protein
Melatonin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SIRT1 protein]; Melatonin inhibits the reaction [decabromobiphenyl ether promotes the reaction [SIRT1 protein results in increased acetylation of HMGB1 protein]]; Melatonin inhibits the reaction [decabromobiphenyl ether results in decreased activity of SIRT1 protein]; Melatonin inhibits the reaction [decabromobiphenyl ether results in decreased expression of and results in decreased localization of SIRT1 protein]; Melatonin inhibits the reaction [Doxorubicin results in decreased expression of SIRT1 protein]
luzindole inhibits the reaction [Melatonin inhibits the reaction [Cadmium Chloride results in decreased activity of SIRT1 protein]]; luzindole inhibits the reaction [Melatonin inhibits the reaction [Cadmium results in decreased activity of SIRT1 protein]]; Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of and results in decreased activity of SIRT1 protein]; Melatonin inhibits the reaction [Cadmium results in decreased expression of and results in decreased activity of SIRT1 protein]; sirtinol inhibits the reaction [Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of and results in decreased activity of SIRT1 protein]]; sirtinol inhibits the reaction [Melatonin inhibits the reaction [Cadmium results in decreased expression of and results in decreased activity of SIRT1 protein]]

PMID:21062352 PMID:25159133 PMID:29966675 PMID:35598369 PMID:36566971

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 18 member A2

multiple interactions

Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA]

NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325

G

solute carrier family 22 member 2

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SLC22A2 mRNA]
Melatonin inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

PMID:21599003 PMID:23963992

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 2 member 4

multiple interactions

Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SLC2A4 mRNA]
Melatonin inhibits the reaction [sodium arsenite results in decreased expression of SLC2A4 protein]

PMID:17198541 PMID:29763682

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 6 member 3

multiple interactions

Melatonin inhibits the reaction [Rotenone results in decreased expression of SLC6A3 protein]
Melatonin inhibits the reaction [manganese chloride results in decreased expression of SLC6A3 protein]

PMID:18289173 PMID:24969583

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

synuclein alpha

multiple interactions

Melatonin inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Melatonin inhibits the reaction [sodium arsenite promotes the reaction [SNCA protein binds to SNCA protein]]
Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]

PMID:17645694 PMID:18289173 PMID:34808223

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

superoxide dismutase 1

multiple interactions
increases activity
increases expression

[aluminum lactate co-treated with Melatonin] results in increased expression of SOD1 mRNA; [Cadmium Chloride co-treated with Melatonin] results in increased expression of SOD1 mRNA; Melatonin inhibits the reaction [Indomethacin results in decreased activity of SOD1 protein]; Melatonin inhibits the reaction [isolevin results in increased expression of SOD1 protein]; Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein]; Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SOD1 mRNA]
Melatonin results in increased activity of SOD1 protein
Melatonin results in increased expression of SOD1 mRNA
[aluminum lactate co-treated with Melatonin] results in increased expression of SOD1 mRNA; luzindole inhibits the reaction [Melatonin results in increased activity of SOD1 protein]; Melatonin inhibits the reaction [Dibutyl Phthalate results in increased activity of SOD1 protein]

PMID:11523592 PMID:15589378 PMID:17198541 PMID:19405147 PMID:19680607 More...

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
increases activity
increases expression

Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of SOD2 protein]; Melatonin inhibits the reaction [Indomethacin results in decreased activity of SOD2 protein]; Melatonin inhibits the reaction [isolevin results in increased expression of SOD2 protein]
luzindole inhibits the reaction [Melatonin results in increased activity of SOD2 protein]; Melatonin affects the reaction [manganese chloride results in decreased expression of SOD2 protein]
Melatonin results in increased expression of SOD2 mRNA
Melatonin inhibits the reaction [HMOX1 protein results in increased expression of SOD2 mRNA]

PMID:10942521 PMID:11523592 PMID:15589378 PMID:16098089 PMID:20210856 More...

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

secreted phosphoprotein 1

multiple interactions

Melatonin inhibits the reaction [Glucose results in decreased expression of SPP1 mRNA]; Melatonin inhibits the reaction [Glucose results in decreased expression of SPP1 protein]

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

sequestosome 1

multiple interactions
increases expression

Melatonin inhibits the reaction [Carbon Tetrachloride results in increased expression of SQSTM1 protein]
Melatonin results in increased expression of SQSTM1 protein
Melatonin inhibits the reaction [Atrazine results in increased expression of SQSTM1 protein]; Melatonin inhibits the reaction [nickel chloride results in decreased expression of SQSTM1 mRNA]; Melatonin inhibits the reaction [nickel chloride results in decreased expression of SQSTM1 protein]; Melatonin inhibits the reaction [Radon results in increased expression of SQSTM1 protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in decreased expression of SQSTM1 mRNA]]
Melatonin inhibits the reaction [cyfluthrin results in increased expression of SQSTM1 mRNA]

PMID:25259610 PMID:26882442 PMID:31330490 PMID:33107683 PMID:36421005 More...

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

multiple interactions

Melatonin inhibits the reaction [Lipopolysaccharides affects the localization of SREBF1 protein]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

signal transducer and activator of transcription 1

multiple interactions

Melatonin inhibits the reaction [Lipopolysaccharides results in increased activity of STAT1 protein]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein]

PMID:21158907 PMID:22225513

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 3

multiple interactions
increases response to substance
increases phosphorylation

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA]; Melatonin inhibits the reaction [diisodecyl phthalate promotes the reaction [Fluorescein-5-isothiocyanate results in increased phosphorylation of STAT3 protein]]; Melatonin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein]
STAT3 protein results in increased susceptibility to Melatonin
Melatonin results in increased phosphorylation of STAT3 protein
Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STAT3 protein]

PMID:19028472 PMID:21342247 PMID:22225513 PMID:23963992 PMID:27871981

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

signal transducer and activator of transcription 4

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA]

NCBI chr 9:49,472,660...49,588,540
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 5A

multiple interactions

Melatonin inhibits the reaction [diisodecyl phthalate promotes the reaction [Fluorescein-5-isothiocyanate results in increased phosphorylation of STAT5 protein]]

NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866

G

signal transducer and activator of transcription 6

multiple interactions

Melatonin inhibits the reaction [diisodecyl phthalate promotes the reaction [Fluorescein-5-isothiocyanate results in increased phosphorylation of STAT6 protein]]

NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495

G

synaptophysin

multiple interactions

Melatonin inhibits the reaction [Carmustine results in decreased expression of SYP protein]; Melatonin inhibits the reaction [Methamphetamine results in decreased expression of SYP protein]

PMID:17572393 PMID:19409439

NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745

G

synaptotagmin 5

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA]

NCBI chr 1:69,277,351...69,285,071
Ensembl chr 1:69,277,351...69,285,067

G

tryptophan 2,3-dioxygenase

multiple interactions

[Tolmetin results in decreased activity of TDO2 protein] which results in increased abundance of Melatonin

NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511

G

transferrin

increases expression
multiple interactions

Melatonin results in increased expression of TF protein
[Melatonin results in increased expression of TF protein] which affects the abundance of Iron

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

transcription factor A, mitochondrial

multiple interactions
increases expression

Melatonin inhibits the reaction [nickel chloride results in decreased expression of TFAM protein]
Melatonin results in increased expression of TFAM mRNA
Melatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of TFAM protein]

PMID:21797922 PMID:26882442 PMID:33962019

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

trefoil factor 1

multiple interactions

Melatonin inhibits the reaction [bisphenol A promotes the reaction [ESR1 protein binds to TFF1 promoter]]; Melatonin inhibits the reaction [Estradiol promotes the reaction [ESR1 protein binds to TFF1 promoter]]

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

transferrin receptor

decreases expression

Melatonin results in decreased expression of TFRC mRNA; Melatonin results in decreased expression of TFRC protein

PMID:17091493 PMID:18571630

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

transforming growth factor alpha

multiple interactions

Melatonin inhibits the reaction [arsenite results in increased expression of and results in increased secretion of TGFA protein]

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

transforming growth factor, beta 1

multiple interactions

[Tretinoin co-treated with Melatonin] results in increased expression of TGFB1 mRNA
Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA]
Melatonin inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; Melatonin inhibits the reaction [Carmustine results in decreased expression of TGFB1 protein]

PMID:9649124 PMID:17572393 PMID:23963992 PMID:26882442

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tyrosine hydroxylase

multiple interactions

Melatonin inhibits the reaction [Methamphetamine results in decreased expression of TH protein]; Melatonin inhibits the reaction [Rotenone results in decreased expression of TH protein]
Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TH protein]; Melatonin inhibits the reaction [manganese chloride results in decreased expression of TH protein]

PMID:18289173 PMID:19409439 PMID:20964710 PMID:24969583 PMID:34808223

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

TIMP metallopeptidase inhibitor 2

multiple interactions

Melatonin inhibits the reaction [Indomethacin results in increased expression of TIMP2 protein]

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

G

tight junction protein 1

multiple interactions

Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of TJP1 mRNA]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

toll-like receptor 4

multiple interactions

Melatonin inhibits the reaction [decabromobiphenyl ether results in increased expression of TLR4 protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of TLR4 mRNA]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of TLR4 protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased localization of TLR4 protein]; Melatonin inhibits the reaction [TLR4 protein promotes the reaction [MYD88 protein binds to LY96 protein binds to CD14 protein]]
Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TLR4 protein]

PMID:27413111 PMID:28238930 PMID:34808223 PMID:36566971

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

toll-like receptor 9

multiple interactions

Melatonin inhibits the reaction [Paraquat results in increased expression of TLR9 protein]

NCBI chr 8:106,864,680...106,868,796
Ensembl chr 8:106,864,680...106,868,796

G

tumor necrosis factor

multiple interactions
decreases secretion

[BNIP3 protein co-treated with PINK1 protein] affects the reaction [Melatonin inhibits the reaction [Paraquat results in increased secretion of TNF protein]]; Gonadal Steroid Hormones affects the reaction [Melatonin affects the expression of TNF protein]; Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of TNF protein]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of TNF protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Melatonin inhibits the reaction [nickel chloride results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [nickel chloride results in increased expression of TNF protein]; Melatonin inhibits the reaction [Paraquat results in increased secretion of TNF protein]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of TNF protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of TNF mRNA]]
melatonin inhibits the reaction [liver reperfusion increases secretion of Tnf protein in plasma]
Melatonin results in decreased secretion of TNF protein
[Melatonin co-treated with coenzyme Q10 co-treated with vinpocetine] inhibits the reaction [Chlorpyrifos results in increased secretion of TNF protein]; luzindole inhibits the reaction [Melatonin inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]]; Melatonin inhibits the reaction [Chlorpyrifos results in increased secretion of TNF protein]; Melatonin inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]; MTNR1B protein promotes the reaction [Melatonin inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]]
[Melatonin co-treated with Folic Acid] inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein]; Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of TNF protein]; Melatonin inhibits the reaction [Carbon Tetrachloride results in increased secretion of TNF protein]; Melatonin inhibits the reaction [decabromobiphenyl ether results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [decabromobiphenyl ether results in increased expression of TNF protein]; Melatonin inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Melatonin inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of and results in increased secretion of TNF protein]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [tetrachlorobenzoquinone results in increased expression of TNF protein]; Melatonin promotes the reaction [Zinc Sulfate inhibits the reaction [Aluminum Chloride results in increased expression of TNF protein]]; Zinc Sulfate promotes the reaction [Melatonin inhibits the reaction [Aluminum Chloride results in increased expression of TNF protein]]

CTD
RGD

PMID:15714805 PMID:16373423 PMID:17602819 PMID:19028472 PMID:19080501 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 3

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNFAIP3 mRNA]

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

TNF receptor superfamily member 1B

increases response to substance

TNFRSF1B protein results in increased susceptibility to Melatonin

NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206

G

tumor protein p53

increases expression
multiple interactions

Melatonin results in increased expression of TP53 protein
Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of TP53 mRNA]; Melatonin inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased expression of TP53 protein]; Melatonin inhibits the reaction [Glucose results in increased expression of TP53 protein]
Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form]; Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in increased phosphorylation of TRP53 protein]; Melatonin inhibits the reaction [nickel chloride results in increased expression of TRP53 mRNA]; Melatonin inhibits the reaction [nickel chloride results in increased expression of TRP53 protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of TRP53 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of TRP53 protein]]
Melatonin inhibits the reaction [bisphenol A results in increased expression of TP53 protein]; Melatonin inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein]; Melatonin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TP53 protein]

PMID:12071473 PMID:14993511 PMID:19012662 PMID:20041988 PMID:20964710 More...

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

TNFRSF1A-associated via death domain

multiple interactions

Melatonin inhibits the reaction [Cadmium Chloride results in increased expression of TRADD protein]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of TRADD protein]

PMID:29763682 PMID:35844137

NCBI chr19:33,136,148...33,142,714
Ensembl chr19:33,136,138...33,142,638

G

trafficking protein particle complex subunit 6A

multiple interactions

Melatonin inhibits the reaction [cyfluthrin results in decreased expression of TRAPPC6A mRNA]

NCBI chr 1:79,158,587...79,165,502
Ensembl chr 1:79,158,529...79,165,493

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

Melatonin inhibits the reaction [[Ovalbumin co-treated with Ozone] results in increased expression of TRPV1 protein]

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

thyroid stimulating hormone subunit beta

multiple interactions

Melatonin inhibits the reaction [Cadmium Chloride affects the expression of TSHB]; Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of TSHB mRNA]; Melatonin inhibits the reaction [Cadmium results in decreased expression of TSHB mRNA]

PMID:16948784 PMID:23085516

NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559

G

thymic stromal lymphopoietin

multiple interactions

Melatonin inhibits the reaction [diisodecyl phthalate promotes the reaction [Fluorescein-5-isothiocyanate results in increased expression of TSLP protein]]

NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548

G

tubulin, beta 5 class I

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of TUBB5 mRNA]

NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940

G

twist family bHLH transcription factor 1

multiple interactions

TWIST1 protein affects the reaction [Melatonin results in decreased expression of PROM1 protein]

NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653

G

thioredoxin 1

decreases expression
multiple interactions

Melatonin results in decreased expression of TXN1 mRNA
Nickel inhibits the reaction [Melatonin results in decreased expression of TXN1 mRNA]

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

thioredoxin interacting protein

decreases expression
multiple interactions

Melatonin results in decreased expression of TXNIP mRNA
Melatonin inhibits the reaction [arsenite results in increased expression of TXNIP protein]
Melatonin affects the reaction [Nickel affects the reaction [SELENOM protein affects the expression of TXNIP mRNA]]; Melatonin affects the reaction [SELENOM protein affects the expression of TXNIP mRNA]; Nickel inhibits the reaction [Melatonin results in decreased expression of TXNIP mRNA]

PMID:36343453 PMID:36504304

NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886

G

thioredoxin reductase 3

multiple interactions
decreases response to substance

TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in decreased expression of BCL2 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in decreased expression of BCL2 protein]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in decreased expression of MTOR mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in decreased expression of SQSTM1 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of ATG1 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of ATG7 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of BAX mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of BAX protein]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of BECN1 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of BECN1 protein]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of CASP3 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of CASP3 protein]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of CASP9 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of CASP9 protein]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of CYCS mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of CYCS protein]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of IL1B mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of IL2 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of IL6 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of IL7 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of MAP1LC3B mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of PTGS2 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of TNF mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of TRP53 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in increased expression of TRP53 protein]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin results in decreased susceptibility to nickel chloride]
TXNRD3 gene mutant form results in decreased susceptibility to Melatonin

NCBI chr 4:122,072,548...122,112,493
Ensembl chr 4:122,072,548...122,112,491

G

ubiquitin B

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA]

NCBI chr10:47,247,630...47,249,335
Ensembl chr10:47,245,637...47,249,333

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions

Melatonin inhibits the reaction [ferric 8-hydroxyquinoline results in increased expression of UGT1A6 mRNA]; Melatonin inhibits the reaction [Paraquat results in increased expression of UGT1A6 mRNA]

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

vesicle-associated membrane protein 5

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA]

NCBI chr 4:104,423,813...104,435,059
Ensembl chr 4:104,423,820...104,426,212

G

vascular endothelial growth factor A

multiple interactions

Melatonin inhibits the reaction [Streptozocin results in increased expression of VEGFA protein]
Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in increased expression of VEGFA mRNA]

PMID:32554039 PMID:33962019

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vacuolar protein sorting 45 homolog

multiple interactions

Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VPS45 mRNA]

NCBI chr 2:183,555,919...183,616,312
Ensembl chr 2:183,555,921...183,616,295

G

Wnt family member 3

multiple interactions

Melatonin inhibits the reaction [Aluminum Chloride results in decreased expression of WNT3 protein]; Melatonin promotes the reaction [Zinc Sulfate inhibits the reaction [Aluminum Chloride results in decreased expression of WNT3 protein]]; Zinc Sulfate promotes the reaction [Melatonin inhibits the reaction [Aluminum Chloride results in decreased expression of WNT3 protein]]

NCBI chr10:88,680,198...88,724,170
Ensembl chr10:88,680,248...88,724,099

G

Wnt family member 3A

multiple interactions

Melatonin inhibits the reaction [Cadmium Chloride results in decreased expression of WNT3A protein]

NCBI chr10:44,034,174...44,078,366
Ensembl chr10:44,034,194...44,078,324

G

X-box binding protein 1

multiple interactions

Melatonin inhibits the reaction [Methamphetamine results in increased expression of XBP1 mRNA alternative form]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of XBP1 protein]
Melatonin inhibits the reaction [Atrazine affects the splicing of XBP1]

PMID:17645694 PMID:25259610 PMID:28070110

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

Yes1 associated transcriptional regulator

multiple interactions

Melatonin inhibits the reaction [Doxorubicin results in increased phosphorylation of YAP1 protein]; Verteporfin inhibits the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased phosphorylation of YAP1 protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of and results in increased cleavage of CASP9 protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of OPA1 protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased expression of ACSL4 protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased expression of BAX protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased expression of FUNDC1 protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in increased expression of NPPB protein]]

NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta

multiple interactions

Melatonin promotes the reaction [YWHAB protein binds to BAD protein]

NCBI chr 3:152,659,663...152,682,105
Ensembl chr 3:152,659,651...152,682,105

G

YY1 transcription factor

decreases expression
multiple interactions

Melatonin results in decreased expression of YY1 mRNA
Melatonin inhibits the reaction [Ethanol results in increased expression of YY1 mRNA]; Melatonin inhibits the reaction [Ethanol results in increased expression of YY1 protein]; MIR497 mRNA affects the reaction [Melatonin results in decreased expression of YY1 mRNA]

NCBI chr 6:127,706,739...127,736,499
Ensembl chr 6:127,707,596...127,732,747

G

zona pellucida glycoprotein 2

multiple interactions

Melatonin inhibits the reaction [bisphenol A results in increased cleavage of ZP2 protein]; Melatonin inhibits the reaction [Ethinyl Estradiol results in increased cleavage of ZP2 protein]

PMID:28178360 PMID:31931096

NCBI chr 1:174,513,507...174,525,288
Ensembl chr 1:174,513,511...174,525,288

mesulergine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

5-hydroxytryptamine receptor 2B

affects binding
multiple interactions

mesulergine binds to HTR2B protein
Fluoxetine promotes the reaction [mesulergine binds to HTR2B protein]

NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108

G

5-hydroxytryptamine receptor 2C

affects binding
multiple interactions

mesulergine binds to HTR2C protein
Carbamazepine inhibits the reaction [Pilocarpine affects the reaction [mesulergine binds to HTR2C protein]]; Carbamazepine inhibits the reaction [Pilocarpine inhibits the reaction [mesulergine binds to HTR2C protein]]; Pilocarpine affects the reaction [mesulergine binds to HTR2C protein]; Pilocarpine inhibits the reaction [mesulergine binds to HTR2C protein]; Plant Extracts inhibits the reaction [Pilocarpine affects the reaction [mesulergine binds to HTR2C protein]]; Plant Extracts inhibits the reaction [Pilocarpine inhibits the reaction [mesulergine binds to HTR2C protein]]
N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [mesulergine binds to HTR2C protein]

PMID:18083778 PMID:19439326 PMID:19700373 PMID:29458138

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

5-hydroxytryptamine receptor 7

affects binding
multiple interactions

mesulergine binds to HTR7 protein
[mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; mesulergine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]

PMID:14578406 PMID:20827463

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

prolactin

multiple interactions

mesulergine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein]

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

methysergide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 4

decreases activity

Methysergide results in decreased activity of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

adrenoceptor alpha 1A

multiple interactions

Methysergide promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein]

NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500

G

calcitonin-related polypeptide alpha

affects activity

Methysergide affects the activity of CALCA protein

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

5-hydroxytryptamine receptor 1B

affects binding

Methysergide binds to HTR1B protein

NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549

G

5-hydroxytryptamine (serotonin) receptor 5B

multiple interactions

methysergide binds to protein 5-Htr5b; inhibits the reaction[5-carboxamidotryptamine binds to 5-Htr5b]

RGD

NCBI chr13:32,686,911...32,699,835
Ensembl chr13:32,687,042...32,699,835

midostaurin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity

midostaurin results in decreased activity of ABCB1 protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

angiotensinogen

multiple interactions

midostaurin inhibits the reaction [AGT protein results in increased abundance of Epoprostenol]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

aldo-keto reductase family 1, member C3

multiple interactions
decreases activity

midostaurin inhibits the reaction [AKR1C3 protein results in decreased susceptibility to Daunorubicin]; midostaurin inhibits the reaction [AKR1C3 protein results in increased metabolism of Daunorubicin]
midostaurin results in decreased activity of AKR1C3 protein

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

caspase 3

multiple interactions

midostaurin promotes the reaction [Loratadine results in increased activity of CASP3 protein]; midostaurin promotes the reaction [Terfenadine results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

epidermal growth factor

multiple interactions

midostaurin inhibits the reaction [EGF protein inhibits the reaction [resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein]]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

fibroblast growth factor receptor 3

decreases activity

midostaurin results in decreased activity of FGFR3 protein

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

Fms related receptor tyrosine kinase 3

decreases response to substance
decreases activity

FLT3 protein results in decreased susceptibility to midostaurin
midostaurin results in decreased activity of FLT3 protein

NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474

G

glycophorin A

decreases expression

midostaurin results in decreased expression of GYPA protein

NCBI chr19:27,450,304...27,465,940
Ensembl chr19:27,450,308...27,465,822

G

heme oxygenase 1

multiple interactions

midostaurin inhibits the reaction [KIT protein polymorphism results in increased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

integrin subunit beta 3

multiple interactions

midostaurin results in increased expression of and results in increased localization of ITGB3 protein

NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679

G

KIT proto-oncogene receptor tyrosine kinase

multiple interactions

midostaurin inhibits the reaction [KIT protein polymorphism results in increased expression of HMOX1 protein]

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

mitogen activated protein kinase 1

multiple interactions

midostaurin affects the reaction [resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

midostaurin affects the reaction [resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MPL proto-oncogene, thrombopoietin receptor

increases expression

midostaurin results in increased expression of MPL protein

NCBI chr 5:131,973,895...131,987,472
Ensembl chr 5:131,973,895...131,986,797

G

prostaglandin-endoperoxide synthase 2

multiple interactions

midostaurin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

tumor protein p53

multiple interactions

midostaurin affects the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein]; midostaurin inhibits the reaction [EGF protein inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein]]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

Mitragynine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 2

affects activity

mitragynine affects the activity of ABCG2 protein

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

carboxylesterase 1D

increases hydrolysis
decreases activity
multiple interactions

CES1 protein results in increased hydrolysis of mitragynine
mitragynine results in decreased activity of CES1 protein
[mitragynine results in decreased activity of CES1 protein] which results in decreased metabolism of Oseltamivir

PMID:25445008 PMID:37716419

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases activity
increases expression

mitragynine results in increased activity of CYP1A2 protein
mitragynine results in increased expression of CYP1A2 mRNA; mitragynine results in increased expression of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases activity

mitragynine results in decreased activity of CYP2C19 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases expression
decreases activity

mitragynine results in increased expression of CYP2D6 protein
mitragynine results in decreased activity of CYP2D6 protein

PMID:23274770 PMID:31707106

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases activity
increases expression

mitragynine results in increased activity of CYP3A4 protein
mitragynine results in increased expression of CYP3A4 mRNA; mitragynine results in increased expression of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

potassium voltage-gated channel subfamily H member 2

decreases expression
multiple interactions

mitragynine results in decreased expression of KCNH2 protein
mitragynine binds to and results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

opioid receptor, delta 1

affects binding

mitragynine binds to OPRD1 protein

NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960

G

opioid receptor, kappa 1

affects binding
multiple interactions

mitragynine binds to OPRK1 protein
mitragynine inhibits the reaction [3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer binds to and results in increased activity of OPRK1 protein]

NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823

G

opioid receptor, mu 1

multiple interactions
increases activity
affects binding

mitragynine affects the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to and results in increased activity of OPRM1 protein]; mitragynine binds to and results in increased activity of OPRM1 protein; mitragynine inhibits the reaction [Tretinoin results in increased expression of OPRM1 mRNA]
mitragynine results in increased activity of OPRM1 protein
mitragynine inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to and results in increased activity of OPRM1 protein]
mitragynine binds to OPRM1 protein

PMID:23608241 PMID:27192616 PMID:32734307

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

G

prostaglandin-endoperoxide synthase 1

multiple interactions

mitragynine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of PTGS1 protein]

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

multiple interactions

mitragynine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; mitragynine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

N,N-dimethyltryptamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases metabolic processing

CYP1A2 protein results in increased metabolism of N,N-Dimethyltryptamine

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases metabolic processing

CYP2C19 protein results in increased metabolism of N,N-Dimethyltryptamine

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

flavin containing dimethylaniline monoxygenase 3

increases metabolic processing

FMO3 protein results in increased metabolism of N,N-Dimethyltryptamine

NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028

G

5-hydroxytryptamine receptor 2A

decreases response to substance
multiple interactions
affects response to substance

HTR2A gene SNP results in decreased susceptibility to N,N-Dimethyltryptamine
N,N-Dimethyltryptamine binds to and results in increased activity of HTR2A protein
HTR2A protein affects the susceptibility to N,N-Dimethyltryptamine

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

N-acetylserotonin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

multiple interactions

N-acetylserotonin inhibits the reaction [cyfluthrin results in decreased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions
increases glucuronidation

methyl 2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate inhibits the reaction [UGT1A6 protein results in increased glucuronidation of N-acetylserotonin]

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

paxilline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

cAMP responsive element binding protein 1

multiple interactions

paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

fatty acid synthase

multiple interactions
increases expression

[Bexarotene co-treated with paxilline] results in increased expression of FASN mRNA; [CD 3254 co-treated with paxilline] results in increased expression of FASN mRNA
paxilline results in increased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

Fms related receptor tyrosine kinase 1

multiple interactions

paxilline inhibits the reaction [NS 1619 inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

potassium calcium-activated channel subfamily M alpha 1

affects response to substance

KCNMA1 protein affects the susceptibility to paxilline

NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198

G

MLX interacting protein-like

increases expression

paxilline results in increased expression of MLXIPL mRNA

NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions
increases expression

[Bexarotene co-treated with paxilline] results in increased expression of NR0B2 mRNA; [CD 3254 co-treated with paxilline] results in increased expression of NR0B2 mRNA
paxilline results in increased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions
increases expression

[Bexarotene co-treated with paxilline] results in increased expression of NR1H3 mRNA; [CD 3254 co-treated with paxilline] results in increased expression of NR1H3 mRNA; NR1H3 protein promotes the reaction [paxilline results in increased abundance of Lipids]
paxilline results in increased expression of NR1H3 mRNA

PMID:20079722 PMID:32123961

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor interacting protein 1

multiple interactions
increases expression

[CD 3254 co-treated with paxilline] results in increased expression of NRIP1 mRNA
paxilline results in increased expression of NRIP1 mRNA

NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761

G

phosphatase and tensin homolog

multiple interactions

paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in increased phosphorylation of PTEN protein]]

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

stearoyl-CoA desaturase

multiple interactions
increases expression

[CD 3254 co-treated with paxilline] results in increased expression of SCD mRNA
paxilline results in increased expression of SCD mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

sterol regulatory element binding transcription factor 1

multiple interactions
increases expression

[Bexarotene co-treated with paxilline] results in increased expression of SREBF1 mRNA; [CD 3254 co-treated with paxilline] results in increased expression of SREBF1 mRNA
paxilline results in increased expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

tumor necrosis factor

multiple interactions

paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of AKT1 protein]]; paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in decreased phosphorylation of CREB1 protein]]; paxilline inhibits the reaction [cilostazol inhibits the reaction [TNF results in increased phosphorylation of PTEN protein]]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

physostigmine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arylacetamide deacetylase

multiple interactions

Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine]

NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734

G

acetylcholinesterase

decreases activity
affects expression
multiple interactions
increases expression

Physostigmine results in decreased activity of ACHE protein
Physostigmine affects the expression of ACHE mRNA
[Corticosterone co-treated with Physostigmine] results in decreased activity of ACHE protein; Physostigmine inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
[Physostigmine co-treated with Dichlorvos] results in decreased activity of ACHE protein; [Physostigmine inhibits the reaction [Soman results in decreased activity of ACHE protein]] which results in decreased carbamoylation of ACHE protein; ALB protein affects the reaction [Physostigmine results in decreased activity of ACHE protein]; Physostigmine inhibits the reaction [Soman results in decreased activity of ACHE protein]
asoxime chloride affects the reaction [Physostigmine results in decreased activity of ACHE protein]; asoxime chloride promotes the reaction [Physostigmine inhibits the reaction [Soman results in decreased activity of ACHE protein]]; Physostigmine affects the expression of and affects the activity of ACHE protein; Physostigmine affects the reaction [Sarin affects the expression of ACHE mRNA]; Physostigmine affects the reaction [Sarin affects the expression of and affects the activity of ACHE protein]; Physostigmine inhibits the reaction [Soman results in decreased activity of ACHE protein]
Physostigmine results in increased expression of ACHE protein

PMID:4859365 PMID:11740913 PMID:14644616 PMID:15586889 PMID:19283689 More...

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

albumin

multiple interactions

ALB protein affects the reaction [Physostigmine results in decreased activity of ACHE protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

amyloid beta precursor protein

increases secretion

Physostigmine results in increased secretion of APP protein modified form

PMID:7605915 PMID:8624119

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

butyrylcholinesterase

decreases activity
multiple interactions

Physostigmine results in decreased activity of BCHE protein
Physostigmine inhibits the reaction [Sarin results in decreased activity of BCHE protein]

PMID:19283689 PMID:32795450

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

C-C motif chemokine ligand 2

multiple interactions

Physostigmine inhibits the reaction [Corticosterone results in decreased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

carboxylesterase 2H

decreases activity

Physostigmine results in decreased activity of CES2 protein

NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830

G

choline O-acetyltransferase

decreases expression
increases expression

Physostigmine results in decreased expression of CHAT protein
Physostigmine results in increased expression of CHAT protein

NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093

G

cholinergic receptor nicotinic alpha 4 subunit

affects binding
multiple interactions

Physostigmine binds to [CHRNA4 protein binds to CHRNB2 protein]
Physostigmine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Physostigmine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Physostigmine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Physostigmine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]

PMID:14645658 PMID:15733544

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic beta 2 subunit

affects binding
multiple interactions

Physostigmine binds to [CHRNA4 protein binds to CHRNB2 protein]
Physostigmine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Physostigmine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Physostigmine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Physostigmine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]

PMID:14645658 PMID:15733544

NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

Physostigmine inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Physostigmine inhibits the reaction [Scopolamine promotes the reaction [SK&F 82958 results in increased expression of FOS mRNA]]; Physostigmine inhibits the reaction [SK&F 82958 results in increased expression of FOS mRNA]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glial fibrillary acidic protein

multiple interactions

Physostigmine inhibits the reaction [Streptozocin results in decreased expression of GFAP protein]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

heme oxygenase 1

affects expression

Physostigmine affects the expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

5-hydroxytryptamine receptor 1A

multiple interactions

[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine; [8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine]; tertatolol inhibits the reaction [[8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine]

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

interleukin 1 beta

multiple interactions

Physostigmine affects the reaction [Corticosterone affects the expression of IL1B mRNA]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

[Corticosterone co-treated with Physostigmine] results in decreased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Physostigmine inhibits the reaction [Scopolamine promotes the reaction [SK&F 82958 results in increased expression of JUN mRNA]]; Physostigmine inhibits the reaction [SK&F 82958 results in increased expression of JUN mRNA]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

LIF, interleukin 6 family cytokine

multiple interactions

[Corticosterone co-treated with Physostigmine] results in decreased expression of LIF mRNA

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

microtubule-associated protein 2

multiple interactions

Physostigmine inhibits the reaction [Streptozocin results in decreased expression of MAP2 protein]

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

neurotrophic receptor tyrosine kinase 2

multiple interactions

Physostigmine inhibits the reaction [Streptozocin results in decreased phosphorylation of NTRK2 protein]

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

oncostatin M

multiple interactions

[Corticosterone co-treated with Physostigmine] results in increased expression of OSM mRNA

PMID:28500787 PMID:29846716

NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313

G

solute carrier family 18 member A3

increases expression

Physostigmine results in increased expression of SLC18A3 protein

NCBI chr16:7,713,630...7,716,491

G

superoxide dismutase 2

multiple interactions

Physostigmine inhibits the reaction [Streptozocin results in decreased expression of SOD2 protein]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

signal transducer and activator of transcription 3

decreases phosphorylation

Physostigmine results in decreased phosphorylation of STAT3 protein

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

synaptophysin

multiple interactions

Physostigmine inhibits the reaction [Streptozocin results in decreased expression of SYP protein]

NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745

G

tumor necrosis factor

multiple interactions

[Corticosterone co-treated with Physostigmine] results in increased expression of TNF mRNA

PMID:28500787 PMID:29846716

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

physostigmine salicylate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

decreases activity

physostigmine salicylate results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

rescinnamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases expression

rescinnamine results in increased expression of ABCB1 mRNA

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

potassium voltage-gated channel subfamily H member 2

decreases activity

rescinnamine results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

reserpic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

reserpic acid inhibits the reaction [Calcitriol results in increased expression of CYP3A4 protein]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

reserpine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

Reserpine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Reserpine results in decreased activity of ABCB11 protein

PMID:20829430 PMID:23956101 PMID:24014644

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression
decreases activity

Cycloheximide promotes the reaction [Reserpine results in increased expression of ABCB1 mRNA]; Reserpine inhibits the reaction [ABCB1 protein affects the export of calcein AM]; Reserpine inhibits the reaction [ABCB1 protein results in increased secretion of fluorexon]; Reserpine inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine]
Reserpine inhibits the reaction [ABCB1A protein results in increased secretion of fluorexon]
Reserpine results in increased expression of ABCB1 mRNA; Reserpine results in increased expression of ABCB1 protein
Reserpine results in decreased activity of ABCB1 protein

PMID:7476894 PMID:8632764 PMID:10617675 PMID:12235267 PMID:19528478

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily G member 2

multiple interactions

Reserpine inhibits the reaction [ABCG2 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Reserpine inhibits the reaction [ABCG2 protein results in increased transport of Irinotecan]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

acetylcholinesterase

multiple interactions
affects activity

[Plant Extracts results in increased abundance of Dronabinol] inhibits the reaction [Reserpine affects the activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

adrenoceptor alpha 1D

increases response to substance
increases expression

ADRA1D protein results in increased susceptibility to Reserpine
Reserpine results in increased expression of ADRA1D mRNA

PMID:15159276 PMID:17676312

NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354

G

adrenoceptor alpha 2A

increases expression

Reserpine results in increased expression of ADRA2A mRNA

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor beta 1

increases expression
increases stability

Reserpine results in increased expression of ADRB1 mRNA; Reserpine results in increased expression of ADRB1 protein
Reserpine results in increased stability of ADRB1 mRNA

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

increases expression

Reserpine results in increased expression of ADRB2 mRNA

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

angiotensin II receptor, type 2

increases expression

Reserpine results in increased expression of AGTR2 mRNA; Reserpine results in increased expression of AGTR2 protein

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

aldo-keto reductase family 1 member B10

increases expression

Reserpine results in increased expression of AKR1B10 mRNA

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

Reserpine results in decreased phosphorylation of AKT1 protein
arsenic trioxide promotes the reaction [Reserpine results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

adenosylmethionine decarboxylase 1

multiple interactions

Reserpine inhibits the reaction [Folic Acid results in increased activity of AMD1 protein]

NCBI chr20:43,695,783...43,711,476
Ensembl chr20:43,697,237...43,711,476

G

androgen receptor

multiple interactions

Reserpine inhibits the reaction [Stanozolol binds to and results in increased activity of AR protein]

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

activity-regulated cytoskeleton-associated protein

multiple interactions

Reserpine inhibits the reaction [Cocaine results in increased expression of ARC mRNA]

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

IAPP protein inhibits the reaction [Reserpine results in increased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

IAPP protein inhibits the reaction [Reserpine results in decreased expression of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

brain-derived neurotrophic factor

decreases expression
multiple interactions

Reserpine results in decreased expression of BDNF protein
cerebrolysin inhibits the reaction [Reserpine results in decreased expression of BDNF protein]; Fluoxetine inhibits the reaction [Reserpine results in decreased expression of BDNF protein]
arsenic trioxide promotes the reaction [Reserpine results in decreased expression of BDNF protein]

PMID:26114099 PMID:33279466

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

baculoviral IAP repeat-containing 5

affects binding

Reserpine binds to BIRC5 promoter

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

complement C3

affects expression

Reserpine affects the expression of C3 mRNA

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

caspase 3

multiple interactions
increases activity

IAPP protein inhibits the reaction [Reserpine results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
increases activity

IAPP protein inhibits the reaction [Reserpine results in increased activity of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

catalase

multiple interactions
decreases expression
increases expression

Plant Extracts inhibits the reaction [Reserpine results in decreased expression of CAT protein]; Quercetin inhibits the reaction [Reserpine results in decreased expression of CAT protein]
Reserpine results in increased expression of CAT protein

PMID:14685008 PMID:16444668 PMID:19109989 PMID:19761039 PMID:20628966

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin D1

decreases expression

Reserpine results in decreased expression of CCND1 mRNA; Reserpine results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2A

multiple interactions

[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate affects the localization of CDKN2A protein]; [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA]

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

chromogranin A

multiple interactions
increases expression
increases activity

CHGA protein alternative form inhibits the reaction [Reserpine results in increased activity of CHGA promoter]; Chlorisondamine inhibits the reaction [Reserpine results in increased activity of CHGA promoter]
Reserpine results in increased expression of CHGA mRNA

PMID:1907749 PMID:8189248 PMID:12799369

NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398

G

chromogranin B

increases expression

Reserpine results in increased expression of CHGB mRNA; Reserpine results in increased expression of CHGB protein

PMID:1907749 PMID:8189248 PMID:8361347

NCBI chr 3:120,043,824...120,057,169
Ensembl chr 3:120,043,738...120,057,166

G

cholinergic receptor, muscarinic 1

increases expression
decreases expression

Reserpine results in increased expression of CHRM1 mRNA
Reserpine results in decreased expression of CHRM1 protein

NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356

G

cannabinoid receptor 1

decreases expression

Reserpine results in decreased expression of CNR1 mRNA

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

carboxypeptidase E

increases expression

Reserpine results in increased expression of CPE mRNA

NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233

G

cAMP responsive element modulator

multiple interactions
increases expression

Reserpine promotes the reaction [CREM protein binds to TH promoter]
Reserpine results in increased expression of CREM mRNA alternative form; Reserpine results in increased expression of CREM protein; Reserpine results in increased expression of CREM protein alternative form

PMID:8810303 PMID:11438978

NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989

G

corticotropin releasing hormone

increases expression

Reserpine results in increased expression of CRH mRNA; Reserpine results in increased expression of CRH protein

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Reserpine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Reserpine promotes the reaction [Benzo(a)pyrene results in increased expression of and results in increased activity of CYP1A1 protein]; Reserpine promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]

PMID:15627480 PMID:18493746

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Reserpine results in decreased abundance of Catecholamines] promotes the reaction [Benzo(a)pyrene results in increased expression of and results in increased activity of CYP1A2 protein]; [Reserpine results in decreased abundance of Catecholamines] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA]; Reserpine promotes the reaction [Benzo(a)pyrene results in increased expression of and results in increased activity of CYP1A2 protein]; Reserpine promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

[Reserpine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression
multiple interactions

Reserpine results in increased expression of CYP3A4 mRNA; Reserpine results in increased expression of CYP3A4 protein
[Reserpine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Reserpine inhibits the reaction [Calcitriol results in increased expression of CYP3A4 protein]

PMID:8632764 PMID:16837568 PMID:17041008 PMID:29782822

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

Reserpine results in increased expression of CYP3A5 protein

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cystatin S

multiple interactions

Reserpine inhibits the reaction [Isoproterenol results in increased expression of CYSS mRNA]

NCBI chr 3:137,432,049...137,436,654
Ensembl chr 3:137,432,049...137,436,610

G

dopamine beta-hydroxylase

decreases activity
increases expression
increases stability
increases activity

Reserpine results in decreased activity of DBH protein
Reserpine results in increased expression of DBH mRNA
Reserpine results in increased stability of DBH protein
Reserpine results in increased activity of DBH protein

PMID:1359376 PMID:2325165 PMID:7984052 PMID:8189248

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

dopa decarboxylase

increases expression

Reserpine results in increased expression of DDC mRNA

NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208

G

dopamine receptor D1

increases expression

Reserpine results in increased expression of DRD1 mRNA

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

multiple interactions
increases expression

DRD2 protein affects the susceptibility to [8-(3-chlorostyryl)caffeine co-treated with Reserpine]
Reserpine results in increased expression of DRD2 mRNA; Reserpine results in increased expression of DRD2 mRNA alternative form

PMID:1331675 PMID:8419537 PMID:11172060

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

early growth response 1

multiple interactions
increases expression

[Reserpine co-treated with Levodopa] results in increased expression of EGR1 mRNA; eticlopride inhibits the reaction [[Reserpine co-treated with Levodopa] results in increased expression of EGR1 mRNA]; Quinpirole inhibits the reaction [Reserpine results in increased expression of EGR1 mRNA]; Reserpine promotes the reaction [Dextroamphetamine results in increased expression of EGR1 mRNA]; SCH 23390 inhibits the reaction [[Reserpine co-treated with Levodopa] results in increased expression of EGR1 mRNA]; SCH 23390 inhibits the reaction [Reserpine promotes the reaction [Dextroamphetamine results in increased expression of EGR1 mRNA]]
Reserpine results in increased expression of EGR1 mRNA; Reserpine results in increased expression of EGR1 protein

PMID:1347779 PMID:8063705 PMID:9729266 PMID:9890435

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

erb-b2 receptor tyrosine kinase 2

increases response to substance

ERBB2 protein results in increased susceptibility to Reserpine

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

fatty acid binding protein 7

affects expression

Reserpine affects the expression of FABP7 mRNA

NCBI chr20:37,123,193...37,126,725
Ensembl chr20:37,123,193...37,126,880

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression
increases phosphorylation

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine promotes the reaction [Reserpine results in increased expression of FOS protein]; 3,7-dimethyl-1-propargylxanthine inhibits the reaction [Reserpine results in increased expression of FOS protein]; 8-(3-chlorostyryl)caffeine promotes the reaction [Quinpirole inhibits the reaction [Reserpine results in increased expression of FOS protein]]; Quinpirole inhibits the reaction [Reserpine results in increased expression of FOS protein]; Quinpirole promotes the reaction [Reserpine results in increased expression of FOS protein]; Reserpine inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Quinpirole] results in increased expression of FOS protein]; Reserpine inhibits the reaction [Cocaine results in increased expression of FOS protein]; Reserpine promotes the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of FOS protein]; Reserpine promotes the reaction [Amphetamine results in increased expression of FOS protein]; Reserpine promotes the reaction [Quinpirole results in increased expression of FOS protein]; Theophylline inhibits the reaction [Reserpine results in increased expression of FOS protein]
Reserpine results in increased expression of FOS mRNA; Reserpine results in increased expression of FOS protein
Reserpine results in increased phosphorylation of FOS protein

PMID:1359376 PMID:1686849 PMID:2118661 PMID:7845612 PMID:7914358 More...

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glutamate decarboxylase 1

increases expression
multiple interactions

Reserpine results in increased expression of GAD1 mRNA
Clenbuterol inhibits the reaction [Reserpine results in increased expression of GAD1 mRNA]

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

galanin and GMAP prepropeptide

decreases expression
increases expression
multiple interactions

Reserpine results in decreased expression of GAL mRNA
Reserpine results in increased expression of GAL mRNA
Desipramine inhibits the reaction [Reserpine results in increased expression of GAL mRNA]

PMID:1279347 PMID:1698642 PMID:1705056 PMID:1717808 PMID:9512271 More...

NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959

G

gastrin

multiple interactions

Reserpine inhibits the reaction [Levodopa results in decreased cleavage of GAST protein]

NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496

G

GTP cyclohydrolase 1

increases expression

Reserpine results in increased expression of GCH1 mRNA; Reserpine results in increased expression of GCH1 mRNA alternative form

NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698

G

glucosaminyl (N-acetyl) transferase 3, mucin type

increases expression

Reserpine results in increased expression of GCNT3 mRNA

NCBI chr 8:70,689,173...70,696,476
Ensembl chr 8:70,686,844...70,699,562

G

G protein subunit alpha i1

increases expression

Reserpine results in increased expression of GNAI1 protein

NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417

G

G protein subunit alpha i2

increases expression

Reserpine results in increased expression of GNAI2 mRNA; Reserpine results in increased expression of GNAI2 protein

PMID:8419537 PMID:11264240

NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979

G

G protein subunit alpha i3

increases expression

Reserpine results in increased expression of GNAI3 protein

NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742

G

G protein subunit alpha o1

increases expression

Reserpine results in increased expression of GNAO1 mRNA; Reserpine results in increased expression of GNAO1 protein

PMID:8419537 PMID:11264240

NCBI chr19:11,034,874...11,192,531
Ensembl chr19:11,035,956...11,192,493

G

GNAS complex locus

increases expression
decreases expression

Reserpine results in increased expression of GNAS mRNA; Reserpine results in increased expression of GNAS protein
Reserpine results in decreased expression of GNAS protein alternative form

PMID:1336118 PMID:8419537 PMID:11264240

NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262

G

glutamate metabotropic receptor 5

decreases expression
increases expression

Reserpine results in decreased expression of GRM5 mRNA
Reserpine results in increased expression of GRM5 protein

NCBI chr 1:141,310,069...141,884,980
Ensembl chr 1:141,312,368...141,882,274

G

hepatocyte growth factor

increases expression

Reserpine results in increased expression of HGF protein

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

heparan sulfate proteoglycan 2

multiple interactions

HSPG2 gene results in increased susceptibility to [Haloperidol co-treated with Reserpine]

NCBI chr 5:149,677,437...149,778,594
Ensembl chr 5:149,677,476...149,778,594

G

5-hydroxytryptamine receptor 1A

decreases expression

Reserpine results in decreased expression of HTR1A protein

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

islet amyloid polypeptide

multiple interactions

IAPP protein inhibits the reaction [Reserpine results in decreased expression of BCL2 protein]; IAPP protein inhibits the reaction [Reserpine results in increased activity of CASP3 protein]; IAPP protein inhibits the reaction [Reserpine results in increased activity of CASP8 protein]; IAPP protein inhibits the reaction [Reserpine results in increased expression of BAX protein]; IAPP protein inhibits the reaction [Reserpine results in increased expression of TNFSF10 protein]

NCBI chr 4:175,237,107...175,244,373
Ensembl chr 4:175,237,115...175,242,920

G

interleukin 10

decreases expression
multiple interactions

Reserpine results in decreased expression of IL10 mRNA; Reserpine results in decreased expression of IL10 protein
SCH 23390 inhibits the reaction [Reserpine results in decreased expression of IL10 mRNA]; SCH 23390 inhibits the reaction [Reserpine results in decreased expression of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 18

increases expression

Reserpine results in increased expression of IL18 mRNA

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

Reserpine results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Reserpine promotes the reaction [Dextroamphetamine results in increased expression of JUNB mRNA]; SCH 23390 inhibits the reaction [Reserpine promotes the reaction [Dextroamphetamine results in increased expression of JUNB mRNA]]

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

potassium voltage-gated channel subfamily A member 3

decreases activity
multiple interactions

Reserpine results in decreased activity of KCNA3 protein
[Reserpine results in decreased activity of KCNA3 protein] which results in decreased import of Thallium

NCBI chr 2:194,632,106...194,634,059
Ensembl chr 2:194,632,196...194,650,138

G

potassium voltage-gated channel subfamily A member 5

increases expression

Reserpine results in increased expression of KCNA5 mRNA

NCBI chr 4:159,354,689...159,358,173
Ensembl chr 4:159,350,097...159,357,697

G

potassium voltage-gated channel subfamily D member 2

decreases expression

Reserpine results in decreased expression of KCND2 mRNA

NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728

G

potassium voltage-gated channel subfamily D member 3

decreases expression

Reserpine results in decreased expression of KCND3 mRNA

NCBI chr 2:192,937,950...193,155,345
Ensembl chr 2:192,937,950...193,155,345

G

potassium voltage-gated channel subfamily H member 2

decreases activity
multiple interactions

Reserpine results in decreased activity of KCNH2 protein
[Reserpine results in decreased activity of KCNH2 protein] which results in decreased import of Thallium

PMID:21362439 PMID:28551711

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

leptin

increases expression

Reserpine results in increased expression of LEP mRNA

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

MYC proto-oncogene, bHLH transcription factor

increases response to substance
decreases expression

MYC protein results in increased susceptibility to Reserpine
Reserpine results in decreased expression of MYC protein

PMID:8093862 PMID:19607803

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

neutrophil cytosolic factor 1

increases expression

Reserpine results in increased expression of NCF1 mRNA; Reserpine results in increased expression of NCF1 protein

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

NFE2 like bZIP transcription factor 2

decreases activity

Reserpine results in decreased activity of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nerve growth factor

increases expression

Reserpine results in increased expression of NGF mRNA; Reserpine results in increased expression of NGF protein

PMID:1996081 PMID:8593794

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nitric oxide synthase 1

increases expression

Reserpine results in increased expression of NOS1 mRNA; Reserpine results in increased expression of NOS1 protein

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

neuropeptide Y

multiple interactions
increases expression
decreases expression

Chlorisondamine inhibits the reaction [Reserpine results in increased expression of NPY mRNA]; Chlorisondamine promotes the reaction [Reserpine results in increased expression of NPY mRNA]; Dexamethasone inhibits the reaction [Reserpine results in increased expression of NPY mRNA]
Reserpine results in increased expression of NPY mRNA; Reserpine results in increased expression of NPY protein
Reserpine results in decreased expression of NPY mRNA; Reserpine results in decreased expression of NPY protein

PMID:1671012 PMID:1676830 PMID:1687976 PMID:1698642 PMID:1713314 More...

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

[Reserpine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions
decreases activity

[Reserpine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA
Reserpine results in decreased activity of NR1I3 protein

PMID:17041008 PMID:30203046

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor subfamily 3, group C, member 1

increases expression

Reserpine results in increased expression of NR3C1 mRNA

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

neurotrophic receptor tyrosine kinase 2

multiple interactions
decreases expression

arsenic trioxide promotes the reaction [Reserpine results in decreased expression of NTRK2 protein]

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

neurotensin

increases expression

Reserpine results in increased expression of NTS mRNA

NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423

G

ornithine decarboxylase 1

decreases expression
multiple interactions

Reserpine results in decreased expression of ODC1 protein
Reserpine inhibits the reaction [CB 3717 results in increased activity of ODC1 protein]; Reserpine inhibits the reaction [CB 3717 results in increased expression of ODC1 mRNA]; Reserpine inhibits the reaction [Testosterone results in increased activity of ODC1 protein]; Reserpine inhibits the reaction [Testosterone results in increased expression of ODC1 mRNA]

PMID:6519379 PMID:9194572 PMID:10354516 PMID:17371283

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

peptidylglycine alpha-amidating monooxygenase

increases expression

Reserpine results in increased expression of PAM mRNA

NCBI chr 9:97,998,581...98,271,966
Ensembl chr 9:98,122,916...98,271,965

G

proliferating cell nuclear antigen

multiple interactions

[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of PCNA protein

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

proprotein convertase subtilisin/kexin type 2

increases expression

Reserpine results in increased expression of PCSK2 mRNA

NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127

G

proenkephalin

multiple interactions
increases expression
decreases expression

Apomorphine inhibits the reaction [Reserpine results in increased expression of PENK mRNA]
Reserpine results in increased expression of PENK mRNA; Reserpine results in increased expression of PENK protein
Reserpine results in decreased expression of PENK mRNA

PMID:1331675 PMID:1850078 PMID:3188958 PMID:3838946 PMID:4078631 More...

NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129

G

phenylethanolamine-N-methyltransferase

multiple interactions
increases expression
decreases expression

Chlorisondamine inhibits the reaction [Reserpine results in decreased expression of PNMT mRNA]; Dexamethasone inhibits the reaction [Reserpine results in decreased expression of PNMT mRNA]; POMC protein alternative form inhibits the reaction [Reserpine results in decreased expression of PNMT mRNA]; Reserpine results in increased expression of and results in increased activity of PNMT protein
Reserpine results in increased expression of PNMT mRNA

PMID:1359376 PMID:1687976 PMID:1714554 PMID:2903502 PMID:8063705 More...

NCBI chr10:83,383,019...83,386,557
Ensembl chr10:83,384,923...83,386,556

G

proopiomelanocortin

increases expression
multiple interactions

Reserpine results in increased expression of POMC mRNA; Reserpine results in increased expression of POMC protein alternative form
POMC protein alternative form inhibits the reaction [Reserpine results in decreased expression of PNMT mRNA]

PMID:8479280 PMID:20504635

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

protein kinase cAMP-activated catalytic subunit alpha

decreases expression

Reserpine results in decreased expression of PRKACA protein

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

prolactin

increases expression

Reserpine results in increased expression of PRL protein

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

serine protease 1

decreases expression
increases expression

Reserpine results in decreased expression of PRSS1 protein
Reserpine results in increased expression of PRSS1 protein

NCBI chr 4:70,364,589...70,367,792
Ensembl chr 4:70,364,586...70,367,792

G

prostaglandin-endoperoxide synthase 2

increases expression

Reserpine results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

6-pyruvoyl-tetrahydropterin synthase

increases expression

Reserpine results in increased expression of PTS mRNA

NCBI chr 8:50,870,838...50,877,869
Ensembl chr 8:50,870,841...50,877,869

G

RASD family, member 2

decreases expression

Reserpine results in decreased expression of RASD2 mRNA

NCBI chr19:13,594,291...13,605,016
Ensembl chr19:13,594,291...13,605,016

G

regulator of G-protein signaling 10

decreases expression

Reserpine results in decreased expression of RGS10 mRNA

NCBI chr 1:182,946,334...182,987,729
Ensembl chr 1:182,946,336...182,987,697

G

regulator of G-protein signaling 2

decreases expression

Reserpine results in decreased expression of RGS2 mRNA

NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385

G

regulator of G-protein signaling 4

decreases expression

Reserpine results in decreased expression of RGS4 mRNA

NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068

G

regulator of G-protein signaling 5

decreases expression

Reserpine results in decreased expression of RGS5 mRNA

NCBI chr13:81,848,254...81,885,053
Ensembl chr13:81,836,304...81,885,518

G

regulator of G-protein signaling 8

decreases expression

Reserpine results in decreased expression of RGS8 mRNA

NCBI chr13:65,804,703...65,848,955
Ensembl chr13:65,804,797...65,846,807

G

regulator of G-protein signaling 9

affects response to substance
decreases expression

RGS9 affects the susceptibility to Reserpine
Reserpine results in decreased expression of RGS9 mRNA

PMID:14505795 PMID:15728856

NCBI chr10:94,195,265...94,270,892
Ensembl chr10:94,197,054...94,270,892

G

secretogranin II

increases expression

Reserpine results in increased expression of SCG2 mRNA

PMID:1907749 PMID:8189248 PMID:8361347

NCBI chr 9:80,803,074...80,808,646
Ensembl chr 9:80,803,075...80,821,097

G

serpin family E member 1

multiple interactions

[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of SERPINE1 mRNA; [troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of SERPINE1 protein

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

siah E3 ubiquitin protein ligase 1

increases expression

Reserpine results in increased expression of SIAH1 mRNA

NCBI chr19:20,378,908...20,402,512
Ensembl chr19:20,378,439...20,403,808

G

solute carrier family 18 member A1

decreases activity
multiple interactions

Reserpine results in decreased activity of SLC18A1 protein
Reserpine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin]

PMID:8245983 PMID:21712771

NCBI chr16:20,653,268...20,687,051
Ensembl chr16:20,653,508...20,687,051

G

solute carrier family 18 member A2

affects binding
multiple interactions
decreases activity
increases expression
affects response to substance
decreases response to substance

Reserpine binds to SLC18A2 protein
Reserpine inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]
Reserpine results in decreased activity of SLC18A2 protein
SLC18A2 protein binds to Reserpine
Reserpine results in increased expression of SLC18A2 mRNA
SLC18A2 affects the susceptibility to Reserpine
Reserpine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin]; Serotonin inhibits the reaction [SLC18A2 protein binds to Reserpine]
SLC18A2 gene SNP results in decreased susceptibility to Reserpine

PMID:1438304 PMID:7912402 PMID:8189248 PMID:9038139 PMID:15475732 More...

NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325

G

solute carrier family 6 member 2

decreases expression

Reserpine results in decreased expression of SLC6A2 mRNA

PMID:7478180 PMID:7616203

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 6 member 3

decreases activity
affects response to substance

Reserpine results in decreased activity of SLC6A3 protein
SLC6A3 gene mutant form affects the susceptibility to Reserpine

PMID:17664021 PMID:19615345

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

solute carrier family 6 member 4

decreases expression

Reserpine results in decreased expression of SLC6A4 mRNA

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

synuclein alpha

affects response to substance

SNCA protein mutant form affects the susceptibility to Reserpine

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

sequestosome 1

increases expression

Reserpine results in increased expression of SQSTM1 mRNA

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

synaptotagmin 7

multiple interactions

[Reserpine co-treated with Apomorphine] results in increased expression of SYT7 mRNA

NCBI chr 1:207,031,359...207,093,787
Ensembl chr 1:207,031,592...207,089,026

G

tachykinin, precursor 1

multiple interactions
increases expression

[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Reserpine co-treated with Quinpirole] results in increased expression of TAC1 mRNA; [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Reserpine] results in increased expression of TAC1 mRNA; Apomorphine promotes the reaction [Reserpine results in increased expression of TAC1 mRNA]

PMID:9751140 PMID:17719177

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

trefoil factor 1

increases expression

Reserpine results in increased expression of TFF1 mRNA

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

tyrosine hydroxylase

increases expression
increases activity
decreases expression
affects activity
increases stability
multiple interactions

Reserpine results in increased expression of TH mRNA
Reserpine results in increased activity of TH protein
Reserpine results in increased expression of TH mRNA; Reserpine results in increased expression of TH protein
Reserpine results in decreased expression of TH mRNA
Reserpine affects the activity of TH protein
Reserpine results in increased stability of TH mRNA
Bicuculline promotes the reaction [Reserpine affects the activity of TH protein]; Bicuculline promotes the reaction [Reserpine results in increased expression of TH mRNA]; Chlorisondamine inhibits the reaction [Reserpine results in increased expression of TH mRNA]; Chlorisondamine promotes the reaction [Reserpine results in increased expression of TH mRNA]; Desipramine inhibits the reaction [Reserpine results in increased expression of TH mRNA]; Reserpine promotes the reaction [CREM protein binds to TH promoter]; Reserpine results in increased expression of and results in increased activity of TH protein

PMID:1350653 PMID:1359376 PMID:1676830 PMID:1687822 PMID:1687976 More...

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

tumor necrosis factor

increases expression
multiple interactions

Reserpine results in increased expression of TNF protein
cerebrolysin inhibits the reaction [Reserpine results in increased expression of TNF protein]; Fluoxetine inhibits the reaction [Reserpine results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 10

multiple interactions
increases expression

IAPP protein inhibits the reaction [Reserpine results in increased expression of TNFSF10 protein]

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

tryptophan hydroxylase 1

increases activity
decreases activity

Reserpine results in increased activity of TPH1 protein
Reserpine results in decreased activity of TPH1 protein

NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344

G

VGF nerve growth factor inducible

increases expression

Reserpine results in increased expression of VGF mRNA

NCBI chr12:19,637,313...19,645,123
Ensembl chr12:19,637,320...19,640,341

G

vasoactive intestinal peptide

increases expression

Reserpine results in increased expression of VIP mRNA

NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216

serotonin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA acetyltransferase 1

multiple interactions
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Serotonin results in increased expression of ACAT1 protein]; AG 1879 inhibits the reaction [Serotonin results in increased expression of ACAT1 protein]; guanosine 5'-O-(2-thiodiphosphate) inhibits the reaction [Serotonin results in increased expression of ACAT1 protein]; rottlerin inhibits the reaction [Serotonin results in increased expression of ACAT1 protein]; sarpogrelate inhibits the reaction [Serotonin results in increased expression of ACAT1 protein]; sarpogrelate metabolite inhibits the reaction [Serotonin results in increased expression of ACAT1 protein]; Serotonin results in increased expression of and results in increased activity of ACAT1 protein
Serotonin results in increased expression of ACAT1 mRNA alternative form

NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855

G

acetylcholinesterase

multiple interactions

Serotonin analog inhibits the reaction [Scopolamine results in increased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

AKT serine/threonine kinase 1

increases activity
multiple interactions

Serotonin results in increased activity of AKT1 protein
[[Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]] which results in increased ubiquitination of and results in increased degradation of IRS1 protein; [Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]; [sarpogrelate results in increased activity of AKT1 protein] inhibits the reaction [Serotonin results in increased ubiquitination of and results in increased degradation of IRS1 protein]; Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amyloid beta precursor protein

increases response to substance
multiple interactions

APP protein modified form results in increased susceptibility to Serotonin
Oils, Volatile inhibits the reaction [[APP protein modified form binds to APP protein modified form] which results in increased susceptibility to Serotonin]; Ursolic Acid inhibits the reaction [APP protein modified form results in increased susceptibility to Serotonin]

PMID:28915354 PMID:34902447

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aquaporin 3 (Gill blood group)

multiple interactions
increases expression

[Serotonin results in increased localization of and results in increased activity of PPARG protein] which results in increased expression of AQP3 mRNA; Fluoxetine inhibits the reaction [Serotonin results in increased expression of AQP3 mRNA]
Fluoxetine inhibits the reaction [Serotonin results in increased expression of AQP3 protein]

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

brain-derived neurotrophic factor

multiple interactions

[Butyrates co-treated with Serotonin] results in increased expression of BDNF mRNA; [trichostatin A co-treated with Serotonin] results in increased expression of BDNF mRNA; [Valproic Acid co-treated with Serotonin] results in increased expression of BDNF mRNA
Serotonin analog inhibits the reaction [Scopolamine results in decreased expression of BDNF protein]

PMID:19360904 PMID:26408985

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

calcitonin-related polypeptide alpha

multiple interactions
increases secretion

[KNG1 protein co-treated with Serotonin co-treated with Histamine] results in increased secretion of CALCA protein; [KNG1 protein co-treated with Serotonin] results in increased secretion of CALCA protein; Dinoprostone inhibits the reaction [Flurbiprofen inhibits the reaction [Serotonin results in increased secretion of CALCA protein]]; Flurbiprofen inhibits the reaction [[KNG1 protein co-treated with Serotonin co-treated with Histamine] results in increased secretion of CALCA protein]; Flurbiprofen inhibits the reaction [Histamine promotes the reaction [[KNG1 protein co-treated with Serotonin] results in increased secretion of CALCA protein]]; Flurbiprofen inhibits the reaction [Serotonin results in increased secretion of CALCA protein]; Histamine promotes the reaction [[KNG1 protein co-treated with Serotonin] results in increased secretion of CALCA protein]

PMID:11166334 PMID:12791437 PMID:14991081

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

caspase 3

multiple interactions

Serotonin inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

multiple interactions

Serotonin inhibits the reaction [7-ketocholesterol results in increased activity of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

catalase

multiple interactions

CAT protein inhibits the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in decreased abundance of Serotonin]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

CF transmembrane conductance regulator

multiple interactions
increases activity

Serotonin promotes the reaction [Isoproterenol results in increased activity of CFTR protein]
Serotonin results in increased activity of CFTR protein

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

choline O-acetyltransferase

multiple interactions

Serotonin analog inhibits the reaction [Scopolamine results in decreased activity of CHAT protein]

NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093

G

cannabinoid receptor 1

multiple interactions

Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cAMP responsive element binding protein 1

multiple interactions

Serotonin analog inhibits the reaction [Scopolamine results in decreased phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

corticotropin releasing hormone

multiple interactions
increases secretion

8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [CRH protein results in increased secretion of Serotonin]; corticotropin releasing hormone (9-41) inhibits the reaction [CRH protein results in increased secretion of Serotonin]

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

dopamine beta-hydroxylase

multiple interactions

DBH protein promotes the reaction [Citalopram results in increased abundance of Serotonin]; DBH protein promotes the reaction [Fluoxetine results in increased abundance of Serotonin]

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

dopa decarboxylase

multiple interactions

[DDC protein results in decreased carboxylation of 5-Hydroxytryptophan] which results in increased chemical synthesis of Serotonin

NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208

G

dopamine receptor D1

multiple interactions

Serotonin inhibits the reaction [Rotenone results in decreased expression of DRD1 mRNA]; Serotonin inhibits the reaction [Rotenone results in decreased expression of DRD1 protein]

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

multiple interactions

Serotonin inhibits the reaction [Rotenone results in increased expression of DRD2 mRNA]; Serotonin inhibits the reaction [Rotenone results in increased expression of DRD2 protein]

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

engrailed homeobox 2

affects abundance

EN2 protein affects the abundance of Serotonin; EN2 protein affects the abundance of Serotonin metabolite

NCBI chr 4:7,221,096...7,226,943
Ensembl chr 4:7,221,096...7,226,943

G

enamelin

decreases expression

Serotonin results in decreased expression of ENAM mRNA

NCBI chr14:19,556,729...19,581,433
Ensembl chr14:19,556,729...19,581,425

G

fatty acid amide hydrolase

multiple interactions

[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein

NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677

G

fibroblast growth factor 1

increases expression

Serotonin results in increased expression of FGF1 protein

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

fibroblast growth factor 5

affects uptake

FGF5 protein affects the uptake of Serotonin

NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Serotonin results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

[MPO protein co-treated with XDH protein co-treated with Acetaldehyde co-treated with Serotonin] affects the metabolism of and binds to GAPDH protein; [tryptamine-4,5-dione co-treated with Serotonin] affects the metabolism of and binds to GAPDH protein

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

ghrelin and obestatin prepropeptide

decreases export

GHRL protein results in decreased export of Serotonin

NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621

G

galactosidase, alpha

affects response to substance

GLA protein affects the susceptibility to Serotonin

NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664

G

G protein-coupled bile acid receptor 1

multiple interactions

[Bile Acids and Salts binds to and results in increased activity of GPBAR1 protein] which results in increased secretion of Serotonin

NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168

G

glycogen synthase kinase 3 beta

increases phosphorylation

Serotonin results in increased phosphorylation of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione-disulfide reductase

multiple interactions

Serotonin analog inhibits the reaction [Scopolamine results in decreased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

5-hydroxytryptamine receptor 1A

multiple interactions
increases activity
affects binding
increases uptake
increases expression
affects response to substance

[1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine binds to and results in decreased activity of HTR1A protein] which results in decreased susceptibility to Serotonin; [8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in increased susceptibility to Serotonin; Fluoxetine inhibits the reaction [HTR1A protein results in increased uptake of Serotonin]; Guanosine Diphosphate affects the reaction [Serotonin inhibits the reaction [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide binds to HTR1A protein]]; Guanosine Triphosphate affects the reaction [Serotonin binds to HTR1A protein]; Guanosine Triphosphate affects the reaction [Serotonin inhibits the reaction [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide binds to HTR1A protein]]; Magnesium affects the reaction [Serotonin inhibits the reaction [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide binds to HTR1A protein]]; Manganese affects the reaction [Serotonin inhibits the reaction [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide binds to HTR1A protein]]; Manganese inhibits the reaction [Guanosine Triphosphate affects the reaction [Serotonin binds to HTR1A protein]]; N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide promotes the reaction [Fluoxetine inhibits the reaction [HTR1A protein results in increased uptake of Serotonin]]; Serotonin inhibits the reaction [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide binds to HTR1A protein]
Serotonin results in increased activity of HTR1A protein
Endocannabinoids inhibits the reaction [Serotonin binds to and results in increased activity of HTR1A protein]; N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [Serotonin results in increased activity of HTR1A protein]; Serotonin binds to and results in increased activity of HTR1A protein
Serotonin results in increased expression of HTR1A mRNA
HTR1A protein affects the susceptibility to Serotonin

PMID:11106871 PMID:16528294 PMID:21083617 PMID:21126535 PMID:30102254 More...

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

5-hydroxytryptamine receptor 1B

affects binding
multiple interactions

Serotonin binds to HTR1B protein
Endocannabinoids inhibits the reaction [Serotonin binds to and results in increased activity of HTR1B protein]; Serotonin binds to and results in increased activity of HTR1B protein

PMID:11888550 PMID:30102254

NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549

G

5-hydroxytryptamine receptor 1D

affects abundance

HTR1D gene polymorphism affects the abundance of Serotonin

NCBI chr 5:148,656,252...148,676,532
Ensembl chr 5:148,674,495...148,675,619

G

5-hydroxytryptamine receptor 1F

multiple interactions

Endocannabinoids inhibits the reaction [Serotonin binds to and results in increased activity of HTR1F protein]; Serotonin binds to and results in increased activity of HTR1F protein

NCBI chr11:2,642,751...2,644,150
Ensembl chr11:2,642,751...2,644,150

G

5-hydroxytryptamine receptor 2A

decreases response to substance
affects response to substance
affects binding
increases expression
multiple interactions

HTR2A gene SNP results in decreased susceptibility to Serotonin
HTR2A protein affects the susceptibility to Serotonin
Serotonin binds to HTR2A protein
Serotonin results in increased expression of HTR2A mRNA
[Ketanserin binds to and results in decreased activity of HTR2A protein] inhibits the reaction [Methamphetamine results in decreased abundance of Serotonin]; [Ketanserin binds to and results in decreased activity of HTR2A protein] which results in decreased susceptibility to Serotonin; Phenoxybenzamine affects the reaction [Serotonin binds to HTR2A protein]
HTR2A protein affects the reaction [Serotonin affects the phosphorylation of PPP1R1B protein]
[Serotonin binds to and results in increased activity of HTR2A protein] which results in increased expression of and results in increased secretion of IL6 protein; Serotonin binds to and results in increased activity of HTR2A protein

PMID:8627522 PMID:11076827 PMID:11880652 PMID:16314884 PMID:16528294 More...

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

5-hydroxytryptamine receptor 2B

increases expression
affects binding
multiple interactions
affects response to substance

Serotonin results in increased expression of HTR2B mRNA
Serotonin binds to HTR2B protein
1-(5-fluoropentyl)-3-(1-naphthoyl)indole inhibits the reaction [Serotonin binds to and results in increased activity of HTR2B protein]; 1-(8-bromobenzo(1,2-b;4,5-b')difuran-4-yl)-2-aminopropane inhibits the reaction [Serotonin binds to HTR2B protein]; 1-pentyl-3-(1-naphthoyl)indole inhibits the reaction [Serotonin binds to and results in increased activity of HTR2B protein]; 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone inhibits the reaction [Serotonin binds to and results in increased activity of HTR2B protein]; JWH-073 inhibits the reaction [Serotonin binds to and results in increased activity of HTR2B protein]; Serotonin binds to and results in increased activity of HTR2B protein
HTR2B protein affects the susceptibility to Serotonin

PMID:8627522 PMID:9857084 PMID:21083617 PMID:27449567

NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108

G

5-hydroxytryptamine receptor 2C

affects expression
multiple interactions

Serotonin affects the expression of HTR2C mRNA
[Fluoxetine results in increased abundance of Serotonin] which results in decreased expression of HTR2C mRNA; Fluoxetine inhibits the reaction [Serotonin binds to and results in increased activity of HTR2C protein]; Serotonin binds to and results in increased activity of HTR2C protein

PMID:9050900 PMID:21083617 PMID:21554931

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

5-hydroxytryptamine receptor 3A

multiple interactions
increases activity
affects localization

1-Butanol promotes the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3A protein]]; 1-Butanol promotes the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]]; 1-Propanol promotes the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3A protein]]; 1-Propanol promotes the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]]; Ethanol promotes the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3A protein]]; Ethanol promotes the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]]; Hexanols inhibits the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3A protein]]; Hexanols inhibits the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]]; Octanols inhibits the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3A protein]]; Octanols inhibits the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]]; Pentanols promotes the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3A protein]]; Pentanols promotes the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]]; Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3A protein]; Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]
Cocaine inhibits the reaction [Serotonin results in increased activity of HTR3A protein]
Serotonin affects the localization of HTR3A protein alternative form
1,1,1-trichloroethane promotes the reaction [Serotonin results in increased activity of HTR3A protein]; Toluene promotes the reaction [Serotonin results in increased activity of HTR3A protein]; Trichloroethylene promotes the reaction [Serotonin results in increased activity of HTR3A protein]

PMID:12681521 PMID:17360702 PMID:17436349 PMID:32209479

NCBI chr 8:49,242,018...49,254,475
Ensembl chr 8:49,242,020...49,254,389

G

5-hydroxytryptamine receptor 3B

multiple interactions

1-Butanol promotes the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]]; 1-Propanol promotes the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]]; Ethanol promotes the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]]; Hexanols inhibits the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]]; Octanols inhibits the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]]; Pentanols promotes the reaction [Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]]; Serotonin binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]

NCBI chr 8:49,279,291...49,308,444
Ensembl chr 8:49,279,173...49,308,444

G

5-hydroxytryptamine receptor 4

multiple interactions

HTR4 protein affects the reaction [Serotonin affects the phosphorylation of PPP1R1B protein]

NCBI chr18:55,765,981...55,949,921
Ensembl chr18:55,766,725...55,949,321

G

5-hydroxytryptamine receptor 6

multiple interactions

HTR6 protein affects the reaction [Serotonin affects the phosphorylation of PPP1R1B protein]; Serotonin promotes the reaction [HTR6 protein results in increased abundance of Cyclic AMP]

PMID:11406289 PMID:11880652

NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912

G

5-hydroxytryptamine receptor 7

multiple interactions

[Serotonin binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

interleukin 12B

affects secretion

Serotonin affects the secretion of IL12B protein

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 13

affects response to substance

IL13 protein affects the susceptibility to Serotonin

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 1 beta

affects secretion
multiple interactions
increases expression

Serotonin affects the secretion of IL1B protein
anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]
Serotonin results in increased expression of IL1B

PMID:15302781 PMID:15802305 PMID:30611738

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 4

affects response to substance

IL4 protein affects the susceptibility to Serotonin

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

affects expression
multiple interactions
increases expression
affects secretion

Serotonin affects the expression of IL6 mRNA
anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]
Serotonin results in increased expression of IL6 mRNA
[Serotonin binds to and results in increased activity of HTR2A protein] which results in increased expression of and results in increased secretion of IL6 protein; calphostin C inhibits the reaction [Serotonin results in increased expression of and results in increased secretion of IL6 protein]; Ketanserin inhibits the reaction [Serotonin results in increased expression of and results in increased secretion of IL6 protein]; sarpogrelate inhibits the reaction [Serotonin results in increased expression of and results in increased secretion of IL6 protein]; Serotonin results in increased expression of and results in increased secretion of IL6 protein
Serotonin affects the secretion of IL6 protein

PMID:11076827 PMID:15302781 PMID:15802305 PMID:30611738

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin receptor substrate 1

multiple interactions

[[Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]] which results in increased ubiquitination of and results in increased degradation of IRS1 protein; [Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]; [sarpogrelate results in increased activity of AKT1 protein] inhibits the reaction [Serotonin results in increased ubiquitination of and results in increased degradation of IRS1 protein]; Serotonin affects the localization of and results in increased ubiquitination of and results in increased degradation of IRS1 protein; Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]

NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122

G

integrin subunit alpha 2

multiple interactions

ITGA2 protein promotes the reaction [[Dinoprostone co-treated with Serotonin] results in increased import of Calcium]; TRPV4 protein promotes the reaction [ITGA2 protein promotes the reaction [[Dinoprostone co-treated with Serotonin] results in increased import of Calcium]]
ITGA2 protein results in increased susceptibility to [KNG1 protein modified form co-treated with TAC1 protein modified form co-treated with Serotonin co-treated with Dinoprostone co-treated with Histamine]

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit alpha M

increases expression

Serotonin increases expression of Itgam protein on neutrophils

RGD

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 3

affects abundance

ITGB3 gene polymorphism affects the abundance of Serotonin

PMID:16724005 PMID:17203304

NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679

G

potassium two pore domain channel subfamily K member 3

multiple interactions

Serotonin inhibits the reaction [KCNK3 protein results in increased transport of Potassium]

NCBI chr 6:25,761,487...25,799,153
Ensembl chr 6:25,763,228...25,799,153

G

kininogen 1

multiple interactions

[KNG1 protein co-treated with Serotonin co-treated with Histamine] results in increased abundance of Dinoprostone; [KNG1 protein co-treated with Serotonin co-treated with Histamine] results in increased secretion of CALCA protein; [KNG1 protein co-treated with Serotonin] results in increased secretion of CALCA protein; [Serotonin co-treated with Histamine] promotes the reaction [KNG1 protein results in increased abundance of Dinoprostone]; Dinoprostone promotes the reaction [Histamine promotes the reaction [Serotonin promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]]]; Flurbiprofen inhibits the reaction [[KNG1 protein co-treated with Serotonin co-treated with Histamine] results in increased abundance of Dinoprostone]; Flurbiprofen inhibits the reaction [[KNG1 protein co-treated with Serotonin co-treated with Histamine] results in increased secretion of CALCA protein]; Flurbiprofen inhibits the reaction [[Serotonin co-treated with Histamine] promotes the reaction [KNG1 protein results in increased abundance of Dinoprostone]]; Flurbiprofen inhibits the reaction [Histamine promotes the reaction [[KNG1 protein co-treated with Serotonin] results in increased secretion of CALCA protein]]; Histamine promotes the reaction [[KNG1 protein co-treated with Serotonin] results in increased secretion of CALCA protein]; Histamine promotes the reaction [Serotonin promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]]; ITGA2 protein results in increased susceptibility to [KNG1 protein modified form co-treated with TAC1 protein modified form co-treated with Serotonin co-treated with Dinoprostone co-treated with Histamine]; Serotonin promotes the reaction [KNG1 protein results in increased abundance of Dinoprostone]; Serotonin promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]

PMID:11166334 PMID:12791437 PMID:18234883

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

monoamine oxidase A

increases metabolic processing
multiple interactions
increases degradation
decreases amination
increases abundance

MAOA protein results in increased metabolism of Serotonin
[MAOA protein results in increased hydroxylation of Serotonin] which results in increased chemical synthesis of Hydroxyindoleacetic Acid
MAOA protein results in increased degradation of Serotonin
[MAOA protein results in increased metabolism of Serotonin] which results in increased abundance of hydroxyindoleacetaldehyde; Luteolin inhibits the reaction [[MAOA protein results in increased metabolism of Serotonin] which results in increased abundance of hydroxyindoleacetaldehyde]; Luteolin inhibits the reaction [MAOA protein results in increased metabolism of Serotonin]; Quercetin inhibits the reaction [[MAOA protein results in increased metabolism of Serotonin] which results in increased abundance of hydroxyindoleacetaldehyde]; Quercetin inhibits the reaction [MAOA protein results in increased metabolism of Serotonin]
MAOA protein results in decreased amination of Serotonin
1-(8-bromobenzo(1,2-b;4,5-b')difuran-4-yl)-2-aminopropane inhibits the reaction [MAOA protein results in increased degradation of Serotonin]; 3,4-Methylenedioxyamphetamine inhibits the reaction [MAOA protein results in decreased amination of Serotonin]; Clorgyline inhibits the reaction [MAOA protein results in increased degradation of Serotonin]; Isocarboxazid inhibits the reaction [MAOA protein results in increased degradation of Serotonin]; Moclobemide inhibits the reaction [MAOA protein results in decreased amination of Serotonin]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [MAOA protein results in decreased amination of Serotonin]; Phenylpropanolamine inhibits the reaction [MAOA protein results in increased degradation of Serotonin]
MAOA mutant form results in increased abundance of Serotonin
MAOA gene polymorphism results in increased abundance of Serotonin

PMID:3961266 PMID:10647887 PMID:11834493 PMID:18405062 PMID:23009399 More...

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

monoamine oxidase B

increases abundance
decreases amination
multiple interactions

MAOB mutant form results in increased abundance of Serotonin
MAOB protein results in decreased amination of Serotonin
3,4-Methylenedioxyamphetamine inhibits the reaction [MAOB protein results in decreased amination of Serotonin]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [MAOB protein results in decreased amination of Serotonin]

PMID:11834493 PMID:26721607

NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003

G

mitogen activated protein kinase 1

increases phosphorylation

Serotonin results in increased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation

Serotonin results in increased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 20

decreases expression

Serotonin results in decreased expression of MMP20 mRNA

NCBI chr 8:4,789,415...4,830,035
Ensembl chr 8:4,789,415...4,830,035

G

myeloperoxidase

multiple interactions

[MPO protein co-treated with XDH protein co-treated with Acetaldehyde co-treated with Serotonin] affects the metabolism of and binds to GAPDH protein; [MPO protein co-treated with XDH protein co-treated with Acetaldehyde] promotes the reaction [Serotonin binds to Acetylcysteine]
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]; GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]; Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]

PMID:23009681 PMID:30611738

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

metallothionein 2A

multiple interactions

[MT1 gene mutant form co-treated with MT2 gene mutant form] results in increased abundance of Serotonin

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

mechanistic target of rapamycin kinase

multiple interactions
increases activity

sarpogrelate inhibits the reaction [Serotonin results in increased activity of MTOR protein]; Sirolimus inhibits the reaction [Serotonin results in increased activity of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

N-acyl phosphatidylethanolamine phospholipase D

multiple interactions

GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in decreased expression of NAPEPLD protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in decreased expression of NAPEPLD protein]]; Serotonin promotes the reaction [Dextran Sulfate results in decreased expression of NAPEPLD protein]

NCBI chr 4:13,360,532...13,398,815
Ensembl chr 4:13,361,006...13,398,748

G

nitric oxide synthase 2

multiple interactions

Serotonin analog inhibits the reaction [Scopolamine results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

Serotonin analog inhibits the reaction [Scopolamine results in decreased expression of NQO1 protein]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

opioid receptor, delta 1

multiple interactions

[dextrallorphan binds to OPRD1 protein] which results in decreased uptake of Serotonin; [Dextromethorphan binds to OPRD1 protein] which results in decreased uptake of Serotonin; [Dextropropoxyphene binds to OPRD1 protein] which results in decreased uptake of Serotonin; [Dextrorphan binds to OPRD1 protein] which results in decreased uptake of Serotonin; [Levallorphan binds to OPRD1 protein] which results in decreased uptake of Serotonin; [Levorphanol binds to OPRD1 protein] which results in decreased uptake of Serotonin; [Methadone binds to OPRD1 protein] which results in decreased uptake of Serotonin; [Methadyl Acetate binds to OPRD1 protein] which results in decreased uptake of Serotonin; [Tramadol binds to OPRD1 protein] which results in decreased uptake of Serotonin

NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960

G

opioid receptor, kappa 1

multiple interactions

[dextrallorphan binds to OPRK1 protein] which results in decreased uptake of Serotonin; [Dextromethorphan binds to OPRK1 protein] which results in decreased uptake of Serotonin; [Dextropropoxyphene binds to OPRK1 protein] which results in decreased uptake of Serotonin; [Dextrorphan binds to OPRK1 protein] which results in decreased uptake of Serotonin; [Levallorphan binds to OPRK1 protein] which results in decreased uptake of Serotonin; [Levorphanol binds to OPRK1 protein] which results in decreased uptake of Serotonin; [Methadone binds to OPRK1 protein] which results in decreased uptake of Serotonin; [Methadyl Acetate binds to OPRK1 protein] which results in decreased uptake of Serotonin; [Tramadol binds to OPRK1 protein] which results in decreased uptake of Serotonin

NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823

G

opioid receptor, mu 1

multiple interactions

[dextrallorphan binds to OPRM1 protein] which results in decreased uptake of Serotonin; [Dextromethorphan binds to OPRM1 protein] which results in decreased uptake of Serotonin; [Dextropropoxyphene binds to OPRM1 protein] which results in decreased uptake of Serotonin; [Dextrorphan binds to OPRM1 protein] which results in decreased uptake of Serotonin; [Levallorphan binds to OPRM1 protein] which results in decreased uptake of Serotonin; [Levorphanol binds to OPRM1 protein] which results in decreased uptake of Serotonin; [Methadone binds to OPRM1 protein] which results in decreased uptake of Serotonin; [Methadyl Acetate binds to OPRM1 protein] which results in decreased uptake of Serotonin; [Tramadol binds to OPRM1 protein] which results in decreased uptake of Serotonin

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

G

ornithine transcarbamylase

affects metabolic processing
multiple interactions

OTC gene mutant form affects the metabolism of Serotonin
Sodium Benzoate affects the reaction [OTC gene mutant form affects the metabolism of Serotonin]

NCBI chr X:12,453,834...12,529,954
Ensembl chr X:12,453,834...12,566,918

G

oxytocin/neurophysin I prepropeptide

increases secretion

OXT protein results in increased secretion of Serotonin

NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490

G

poly (ADP-ribose) polymerase 1

affects abundance

PARP1 affects the abundance of Serotonin

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

proenkephalin

multiple interactions

Serotonin inhibits the reaction [Isoproterenol results in increased expression of PENK mRNA]

NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129

G

peroxisome proliferator-activated receptor gamma

increases localization
multiple interactions

Serotonin results in increased localization of PPARG protein
[Serotonin results in increased localization of and results in increased activity of PPARG protein] which results in increased expression of AQP3 mRNA; Fluoxetine inhibits the reaction [Serotonin results in increased localization of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 1, regulatory (inhibitor) subunit 1B

multiple interactions
increases phosphorylation
decreases phosphorylation

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Serotonin results in increased phosphorylation of PPP1R1B protein]; 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester inhibits the reaction [Serotonin results in decreased phosphorylation of PPP1R1B protein]; 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester inhibits the reaction [Serotonin results in increased phosphorylation of PPP1R1B protein]; Clozapine inhibits the reaction [Serotonin results in decreased phosphorylation of PPP1R1B protein]; Clozapine inhibits the reaction [Serotonin results in increased phosphorylation of PPP1R1B protein]; HTR2A protein affects the reaction [Serotonin affects the phosphorylation of PPP1R1B protein]; HTR4 protein affects the reaction [Serotonin affects the phosphorylation of PPP1R1B protein]; HTR6 protein affects the reaction [Serotonin affects the phosphorylation of PPP1R1B protein]; Ketanserin inhibits the reaction [Serotonin results in increased phosphorylation of PPP1R1B protein]; Quinpirole affects the reaction [Serotonin results in decreased phosphorylation of PPP1R1B protein]; Quinpirole affects the reaction [Serotonin results in increased phosphorylation of PPP1R1B protein]; Ro 4-6790 inhibits the reaction [Serotonin results in decreased phosphorylation of PPP1R1B protein]; Ro 4-6790 inhibits the reaction [Serotonin results in increased phosphorylation of PPP1R1B protein]; SK&F 82958 promotes the reaction [Serotonin results in decreased phosphorylation of PPP1R1B protein]; SK&F 82958 promotes the reaction [Serotonin results in increased phosphorylation of PPP1R1B protein]

NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

Serotonin analog inhibits the reaction [Scopolamine results in increased expression of PTGS2 protein]
Serotonin results in increased expression of PTGS2 mRNA; Serotonin results in increased expression of PTGS2 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Serotonin results in increased expression of PTGS2 mRNA]; AG 1879 inhibits the reaction [Serotonin results in increased expression of PTGS2 mRNA]; bisindolylmaleimide I inhibits the reaction [Serotonin results in increased expression of PTGS2 mRNA]; Calcium deficiency inhibits the reaction [Serotonin results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [Serotonin results in increased expression of PTGS2 mRNA]; sarpogrelate inhibits the reaction [Serotonin results in increased expression of PTGS2 mRNA]; sarpogrelate inhibits the reaction [Serotonin results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Serotonin results in increased expression of PTGS2 mRNA]

PMID:21262218 PMID:26408985

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

increases activity

Serotonin results in increased activity of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

serpin family E member 2

multiple interactions

[TGFB1 protein co-treated with Serotonin] results in increased expression of SERPINE2 mRNA; [TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein; Rosuvastatin Calcium inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein]; sarpogrelate inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased expression of SERPINE2 mRNA]; sarpogrelate inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein]

PMID:24107419 PMID:27097221

NCBI chr 9:81,124,746...81,188,866
Ensembl chr 9:81,124,804...81,188,826

G

solute carrier family 18 member A1

multiple interactions
increases uptake

1-Methyl-4-phenylpyridinium inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin]; Dopamine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin]; Histamine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin]; Norepinephrine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin]; phenethylamine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin]; Reserpine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin]; Tetrabenazine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin]

NCBI chr16:20,653,268...20,687,051
Ensembl chr16:20,653,508...20,687,051

G

solute carrier family 18 member A2

affects binding
increases uptake
increases transport
multiple interactions
affects uptake

Serotonin binds to SLC18A2 protein
Serotonin binds to Slc8a2 protein
SLC18A2 protein binds to Serotonin
SLC18A2 protein results in increased uptake of Serotonin
SLC18A2 protein results in increased transport of Serotonin
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin]; Dopamine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin]; Norepinephrine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin]; Reserpine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin]; Serotonin inhibits the reaction [SLC18A2 protein binds to Reserpine]; Serotonin inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin]; Tetrabenazine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin]; tributyltin inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin]; Valinomycin promotes the reaction [SLC18A2 protein results in increased uptake of Serotonin]
SLC18A2 gene SNP affects the uptake of Serotonin

CTD
RGD

PMID:1438304 PMID:7912402 PMID:9038139 PMID:15475732 PMID:18287335 More...

NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325

G

solute carrier family 22 member 16

multiple interactions

Serotonin inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium]

NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019

G

solute carrier family 22 member 3

multiple interactions
increases uptake

Serotonin inhibits the reaction [SLC22A3 protein results in increased transport of Histamine]; Serotonin inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]
SLC22A3 protein results in increased uptake of Serotonin

PMID:9830022 PMID:16928864 PMID:20858707

NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612

G

solute carrier family 29 member 4

increases uptake

SLC29A4 protein results in increased uptake of Serotonin

NCBI chr12:11,853,540...11,884,660
Ensembl chr12:11,853,540...11,874,834

G

solute carrier family 47 member 1

multiple interactions

Serotonin inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637

G

solute carrier family 47 member 2

multiple interactions

Serotonin inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904

G

solute carrier family 6 member 2

multiple interactions

SLC6A2 protein promotes the reaction [Serotonin results in increased activity of TAAR1 protein]

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 6 member 3

multiple interactions
increases uptake

SLC6A3 protein promotes the reaction [Serotonin results in increased activity of TAAR1 protein]
SLC6A3 protein results in increased uptake of Serotonin

PMID:17234900 PMID:17250655

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

solute carrier family 6 member 4

multiple interactions
increases activity
decreases activity
increases uptake
affects binding
increases expression
affects abundance

4-methylaminorex inhibits the reaction [SLC6A4 protein results in increased uptake of Serotonin]; [SLC6A4 gene polymorphism results in decreased uptake of Serotonin] which results in decreased susceptibility to Clozapine; Cocaine inhibits the reaction [Serotonin results in increased activity of SLC6A4 protein]; Lamivudine promotes the reaction [SLC6A4 protein results in increased uptake of Serotonin]; Monensin promotes the reaction [para-methyl-4-methylaminorex inhibits the reaction [SLC6A4 protein results in increased uptake of Serotonin]]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A4 protein results in increased uptake of Serotonin]; para-methyl-4-methylaminorex inhibits the reaction [SLC6A4 protein results in increased uptake of Serotonin]; Ribavirin promotes the reaction [SLC6A4 protein results in increased uptake of Serotonin]; SLC6A4 protein promotes the reaction [Serotonin results in increased activity of TAAR1 protein]
serotonin decreases activity of Slc6a4 protein in epithelial colorectal adenocarcinoma cells
Serotonin binds to SLC6A4 protein
4-methylaminorex inhibits the reaction [SLC6A4 protein results in increased uptake of Serotonin]; [Fluoxetine results in decreased expression of SLC6A4 mRNA] which results in decreased abundance of Serotonin; Aminorex inhibits the reaction [SLC6A4 protein results in increased uptake of Serotonin]; Dextroamphetamine inhibits the reaction [SLC6A4 protein results in increased uptake of Serotonin]; para-methyl-4-methylaminorex inhibits the reaction [SLC6A4 protein results in increased uptake of Serotonin]
Serotonin results in increased expression of SLC6A4 mRNA
SLC6A4 gene polymorphism affects the abundance of Serotonin

CTD
RGD

PMID:15972295 PMID:16272152 PMID:16476009 PMID:16982082 PMID:17203304 More...

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

sortilin related receptor 1

multiple interactions
increases expression

sarpogrelate inhibits the reaction [Serotonin results in increased expression of SORL1 mRNA]

NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513

G

syntaxin binding protein 3

affects secretion

STXBP3 protein affects the secretion of Serotonin

NCBI chr 2:196,442,738...196,485,733
Ensembl chr 2:196,442,634...196,485,671

G

sulfotransferase family 1A member 1

increases sulfation

SULT1A1 protein results in increased sulfation of Serotonin

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

G

trace-amine-associated receptor 1

multiple interactions

SLC6A2 protein promotes the reaction [Serotonin results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [Serotonin results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [Serotonin results in increased activity of TAAR1 protein]

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

G

tachykinin, precursor 1

multiple interactions

Dinoprostone promotes the reaction [Histamine promotes the reaction [Serotonin promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]]]; Histamine promotes the reaction [Serotonin promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]]; ITGA2 protein results in increased susceptibility to [KNG1 protein modified form co-treated with TAC1 protein modified form co-treated with Serotonin co-treated with Dinoprostone co-treated with Histamine]; Serotonin promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]

PMID:11166334 PMID:18234883

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

tryptophan 2,3-dioxygenase

multiple interactions

[Sulindac results in decreased activity of TDO2 protein] which results in increased abundance of Serotonin; [Tolmetin results in decreased activity of TDO2 protein] which results in increased abundance of Serotonin

NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511

G

transforming growth factor, beta 1

multiple interactions

[TGFB1 protein co-treated with Serotonin] results in increased expression of SERPINE2 mRNA; [TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein; Rosuvastatin Calcium inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein]; sarpogrelate inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased expression of SERPINE2 mRNA]; sarpogrelate inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein]

PMID:24107419 PMID:27097221

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

affects secretion
multiple interactions
increases expression

Serotonin affects the secretion of TNF protein
[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein; anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]
Serotonin results in increased expression of TNF

PMID:15302781 PMID:15802305 PMID:30611738

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tryptophan hydroxylase 1

affects abundance
multiple interactions
increases chemical synthesis
increases abundance

TPH1 gene polymorphism affects the abundance of Serotonin
Granisetron inhibits the reaction [Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of TPH1 protein]]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of TPH1 protein]
TPH1 protein results in increased chemical synthesis of Serotonin
TPH1 gene polymorphism results in increased abundance of Serotonin

PMID:17203304 PMID:18405062 PMID:18506000 PMID:30611738

NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344

G

tryptophan hydroxylase 2

affects abundance

TPH2 protein affects the abundance of Serotonin

NCBI chr 7:50,685,694...50,789,424
Ensembl chr 7:50,685,694...50,789,424

G

transient receptor potential cation channel, subfamily A, member 1

multiple interactions

TRPA1 mRNA affects the reaction [Acrolein results in increased secretion of Serotonin]; TRPA1 mRNA affects the reaction [allyl isothiocyanate results in increased secretion of Serotonin]; TRPA1 mRNA affects the reaction [cinnamaldehyde results in increased secretion of Serotonin]

NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

Serotonin promotes the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased transport of Calcium]

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

transient receptor potential cation channel, subfamily V, member 4

multiple interactions

TRPV4 protein promotes the reaction [ITGA2 protein promotes the reaction [[Dinoprostone co-treated with Serotonin] results in increased import of Calcium]]

NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517

G

UDP glucuronosyltransferase family 1 member A6

increases glucuronidation
affects glucuronidation
multiple interactions

UGT1A6 protein results in increased glucuronidation of Serotonin; UGT1A6 protein results in increased glucuronidation of Serotonin metabolite
UGT1A6 gene polymorphism affects the glucuronidation of Serotonin; UGT1A6 gene polymorphism affects the glucuronidation of Serotonin metabolite
bisphenol A inhibits the reaction [UGT1A6 protein results in increased glucuronidation of Serotonin]

PMID:15761113 PMID:15761114 PMID:18214896

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

vascular cell adhesion molecule 1

multiple interactions

[Glucose co-treated with Serotonin] results in increased expression of VCAM1 protein; sarpogrelate inhibits the reaction [[Glucose co-treated with Serotonin] results in increased expression of VCAM1 protein]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

xanthine dehydrogenase

multiple interactions

[MPO protein co-treated with XDH protein co-treated with Acetaldehyde co-treated with Serotonin] affects the metabolism of and binds to GAPDH protein; [MPO protein co-treated with XDH protein co-treated with Acetaldehyde] promotes the reaction [Serotonin binds to Acetylcysteine]

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta

multiple interactions

[[Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]] which results in increased ubiquitination of and results in increased degradation of IRS1 protein; [Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]; Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]

NCBI chr 3:152,659,663...152,682,105
Ensembl chr 3:152,659,651...152,682,105

serpentine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily d, polypeptide 4

decreases activity
multiple interactions

serpentine (alkaloid) results in decreased activity of CYP2D6 protein
serpentine (alkaloid) inhibits the reaction [CYP2D6 protein affects the metabolism of Dextromethorphan]

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

staurosporine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

Staurosporine results in decreased activity of ABCB11 protein

PMID:20829430 PMID:23956101

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

acetylcholinesterase

multiple interactions
increases expression
increases activity

ACHE protein affects the susceptibility to [Staurosporine results in increased activity of CASP9 protein]
Staurosporine results in increased expression of ACHE protein alternative form
Staurosporine results in increased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

adrenomedullin

decreases expression

Staurosporine results in decreased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

Staurosporine inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]
Staurosporine results in increased phosphorylation of AKT1 protein
Staurosporine promotes the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]

PMID:11306697 PMID:15177934

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amyloid beta precursor protein

multiple interactions

Staurosporine inhibits the reaction [Ginkgo biloba extract inhibits the reaction [APP protein results in decreased phosphorylation of CREB1 protein]]; Staurosporine promotes the reaction [PSEN2 protein mutant form results in increased expression of APP protein]

PMID:12556443 PMID:18001288

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

androgen receptor

multiple interactions

Staurosporine binds to and results in decreased activity of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

autophagy related 12

affects response to substance

ATG12 protein affects the susceptibility to Staurosporine

NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418

G

autophagy related 7

affects response to substance

ATG7 protein affects the susceptibility to Staurosporine

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

decreases expression

Staurosporine results in decreased expression of ATP2A2 mRNA

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

BAG cochaperone 3

decreases response to substance
decreases expression
multiple interactions

BAG3 protein results in decreased susceptibility to Staurosporine
Staurosporine results in decreased expression of BAG3 protein
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Staurosporine results in increased degradation of BAG3 protein]; Staurosporine results in increased degradation of and results in increased ubiquitination of BAG3 protein

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

BAG cochaperone 4

decreases expression

Staurosporine results in decreased expression of BAG4 protein

NCBI chr16:66,288,678...66,305,893
Ensembl chr16:66,288,678...66,308,663

G

BAG cochaperone 6

decreases expression

Staurosporine results in decreased expression of BAG6 protein

NCBI chr20:3,675,938...3,690,414
Ensembl chr20:3,675,938...3,688,657

G

BCL2 associated X, apoptosis regulator

multiple interactions
affects localization
affects expression
increases expression

Silybin inhibits the reaction [Staurosporine promotes the reaction [Acetaldehyde results in increased expression of BAX protein]]; Staurosporine affects the folding of and results in increased activity of BAX protein; Staurosporine promotes the reaction [Acetaldehyde results in increased expression of BAX protein]; Staurosporine promotes the reaction [BID protein binds to BAX protein]; Staurosporine results in increased activity of and results in increased expression of BAX protein
Staurosporine affects the localization of BAX protein
Staurosporine affects the expression of BAX mRNA
Tacrine inhibits the reaction [Staurosporine results in increased expression of BAX protein]

PMID:11296547 PMID:12579951 PMID:15961378 PMID:16007140 PMID:19552762 More...

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

Silybin inhibits the reaction [Staurosporine promotes the reaction [Acetaldehyde results in decreased expression of BCL2 protein]]; Staurosporine inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Staurosporine promotes the reaction [Acetaldehyde results in decreased expression of BCL2 protein]

PMID:15907805 PMID:35158046

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases response to substance
increases expression
affects expression

BCL2L1 protein results in decreased susceptibility to Staurosporine
Staurosporine results in increased expression of BCL2L1 protein alternative form
Staurosporine affects the expression of BCL2L1 mRNA
BCL2L1 gene mutant form results in decreased susceptibility to Staurosporine

PMID:10679475 PMID:10970895 PMID:11296547 PMID:11468182 PMID:21256112

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

beclin 1

multiple interactions
decreases response to substance

3-methyladenine inhibits the reaction [BECN1 protein results in decreased susceptibility to Staurosporine]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

BH3 interacting domain death agonist

increases expression
multiple interactions

Staurosporine results in increased expression of BID protein
Staurosporine promotes the reaction [BID protein binds to BAX protein]

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

baculoviral IAP repeat-containing 3

decreases response to substance

BIRC3 protein results in decreased susceptibility to Staurosporine

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 5

decreases expression

Staurosporine results in decreased expression of BIRC5 protein

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

BUB1 mitotic checkpoint serine/threonine kinase B

affects expression

Staurosporine affects the expression of BUB1B mRNA

NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547

G

caspase 1

multiple interactions
increases activity
affects localization

Nicotine affects the reaction [Staurosporine affects the localization of CASP1 protein]; Nicotine inhibits the reaction [Staurosporine results in increased activity of CASP1 protein]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 2

increases cleavage

Staurosporine results in increased cleavage of CASP2 protein

PMID:10663630 PMID:26124276

NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379

G

caspase 3

multiple interactions
increases expression
increases cleavage
increases secretion
increases activity

Acetaminophen promotes the reaction [Staurosporine results in increased activity of CASP3 protein]; DOCK1 protein inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; ELMO1 protein inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; EOMES protein inhibits the reaction [Staurosporine results in increased expression of CASP3 protein modified form]; ginkgolide B inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Lithium Chloride inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; Memantine inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; pifithrin inhibits the reaction [PSEN2 protein mutant form promotes the reaction [Staurosporine results in increased activity of CASP3 protein]]; PSEN2 protein mutant form promotes the reaction [Staurosporine results in increased activity of CASP3 protein]; quinoline-val-asp(OMe)-CH2-OPH inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Staurosporine results in increased cleavage of and results in increased activity of CASP3 protein; Thiopental inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; Valproic Acid inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]
Staurosporine results in increased secretion of CASP3 protein
3-methyladenine promotes the reaction [Staurosporine results in increased cleavage of CASP3 protein]; EGF protein inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; HR protein inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; Ibuprofen inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; IGF1 protein inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; nimesulide inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]
HR protein affects the reaction [Staurosporine results in increased activity of CASP3 protein]; Staurosporine promotes the reaction [CASP3 protein results in increased cleavage of SPTAN1 protein]; TRP53 protein affects the reaction [HR protein affects the reaction [Staurosporine results in increased activity of CASP3 protein]]; VASP mutant form promotes the reaction [Staurosporine promotes the reaction [CASP3 protein results in increased cleavage of SPTAN1 protein]]

PMID:10663630 PMID:11296547 PMID:12556443 PMID:12871656 PMID:15909127 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 6

increases cleavage

Staurosporine results in increased cleavage of CASP6 protein

NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502

G

caspase 7

multiple interactions
increases expression
increases cleavage
increases activity

EGF protein inhibits the reaction [Staurosporine results in increased activity of CASP7 protein]; IGF1 protein inhibits the reaction [Staurosporine results in increased activity of CASP7 protein]
Staurosporine results in increased expression of CASP7 protein modified form
Staurosporine results in increased cleavage of CASP7 protein
DOCK1 protein inhibits the reaction [Staurosporine results in increased activity of CASP7 protein]; ELMO1 protein inhibits the reaction [Staurosporine results in increased activity of CASP7 protein]; EOMES protein inhibits the reaction [Staurosporine results in increased expression of CASP7 protein modified form]

PMID:16402917 PMID:18832097 PMID:19352495 PMID:19406941 PMID:21864672 More...

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

multiple interactions
increases cleavage
increases activity

benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Staurosporine results in increased cleavage of CASP8 protein]; Staurosporine results in increased cleavage of and results in increased activity of CASP8 protein
Staurosporine results in increased activity of CASP8 protein

PMID:16007152 PMID:19352495 PMID:24658017 PMID:29458164 PMID:31926150

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases cleavage
increases activity

ACHE protein affects the susceptibility to [Staurosporine results in increased activity of CASP9 protein]; Staurosporine results in increased cleavage of and results in increased activity of CASP9 protein
Staurosporine results in increased cleavage of CASP9 protein
3-methyladenine promotes the reaction [Staurosporine results in increased cleavage of CASP9 protein]; Sirolimus inhibits the reaction [Staurosporine results in increased cleavage of CASP9 protein]

PMID:16007152 PMID:16497721 PMID:19352495 PMID:20338155 PMID:26124276 More...

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine receptor 5

multiple interactions

Staurosporine inhibits the reaction [[CXCL8 protein binds to and results in increased activity of CXCR1 protein] which results in increased phosphorylation of and affects the localization of CCR5 protein]

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

Cd28 molecule

multiple interactions

Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD28 protein]

NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685

G

cell division cycle 42

multiple interactions

Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]

NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

Staurosporine inhibits the reaction [Tretinoin results in increased phosphorylation of CDKN1B protein]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cholinergic receptor, muscarinic 1

multiple interactions
affects binding

Staurosporine affects the reaction [KT 5720 promotes the reaction [N-Methylscopolamine binds to CHRM1 protein]]; Staurosporine affects the reaction [muscarinic toxin 7 binds to CHRM1 protein]; Staurosporine promotes the reaction [N-Methylscopolamine binds to CHRM1 protein]
Staurosporine binds to CHRM1 protein

PMID:10860942 PMID:16439611

NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356

G

cholinergic receptor, muscarinic 2

multiple interactions

Staurosporine promotes the reaction [N-Methylscopolamine binds to CHRM2 protein]

NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103

G

cholinergic receptor, muscarinic 3

affects binding

Staurosporine binds to CHRM3 protein

NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278

G

cAMP responsive element binding protein 1

multiple interactions

Staurosporine inhibits the reaction [Ginkgo biloba extract inhibits the reaction [APP protein results in decreased phosphorylation of CREB1 protein]]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

corticotropin releasing hormone

multiple interactions

Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

colony stimulating factor 2

multiple interactions

CSF2 protein affects the susceptibility to [Nitroblue Tetrazolium co-treated with Staurosporine]

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

casein beta

multiple interactions

Staurosporine inhibits the reaction [[INS1 protein co-treated with PRL protein] results in increased expression of CSN2 mRNA]

NCBI chr14:20,322,581...20,329,818
Ensembl chr14:20,322,581...20,329,817

G

casein kinase 2 alpha 1

multiple interactions

Staurosporine affects the reaction [Formaldehyde affects the phosphorylation of CSNK2A1 protein]

NCBI chr 3:140,709,984...140,756,757
Ensembl chr 3:140,709,991...140,756,696

G

casein kinase 2 alpha 2

affects expression

Staurosporine affects the expression of CSNK2A2 mRNA

NCBI chr19:9,556,443...9,596,080
Ensembl chr19:9,556,260...9,596,080

G

catenin beta 1

increases phosphorylation

Staurosporine results in increased phosphorylation of CTNNB1 protein

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

C-X-C motif chemokine receptor 1

multiple interactions

Staurosporine inhibits the reaction [[CXCL8 protein binds to and results in increased activity of CXCR1 protein] which results in increased phosphorylation of and affects the localization of CCR5 protein]; Staurosporine inhibits the reaction [[CXCL8 protein binds to and results in increased activity of CXCR1 protein] which results in increased phosphorylation of CXCR4 protein]

NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084

G

C-X-C motif chemokine receptor 4

multiple interactions

Staurosporine inhibits the reaction [[CXCL8 protein binds to and results in increased activity of CXCR1 protein] which results in increased phosphorylation of CXCR4 protein]

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome b-245 beta chain

multiple interactions

Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of CYBB protein]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Staurosporine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
Staurosporine inhibits the reaction [benz(a)anthracene results in increased activity of CYP1A1 protein]; Staurosporine inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; Staurosporine inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]

PMID:1312672 PMID:7587946 PMID:9395520 PMID:10696073 PMID:15947024

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
increases expression

Staurosporine inhibits the reaction [INS1 protein results in decreased expression of CYP2E1 mRNA]
Staurosporine results in increased expression of CYP2E1 mRNA

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

Staurosporine inhibits the reaction [Calcitriol results in increased expression of CYP3A4 mRNA]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

DNA-damage inducible transcript 3

increases expression

Staurosporine results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

death effector domain-containing

affects expression

Staurosporine affects the expression of DEDD mRNA

NCBI chr13:83,755,874...83,769,982
Ensembl chr13:83,756,108...83,769,332

G

dedicator of cyto-kinesis 1

multiple interactions

DOCK1 protein inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; DOCK1 protein inhibits the reaction [Staurosporine results in increased activity of CASP7 protein]

NCBI chr 1:189,467,143...189,983,777
Ensembl chr 1:189,467,143...189,983,768

G

endothelial differentiation-related factor 1

multiple interactions
decreases expression

Staurosporine inhibits the reaction [MBF1 protein results in increased secretion of NPPA protein]
Staurosporine results in decreased expression of MBF1 protein

NCBI chr 3:8,377,058...8,381,363
Ensembl chr 3:8,366,613...8,381,363

G

endothelin 1

decreases activity

Staurosporine results in decreased activity of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type B

multiple interactions

Staurosporine inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]; Staurosporine inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

epidermal growth factor

multiple interactions

Staurosporine inhibits the reaction [EGF protein inhibits the reaction [resveratrol inhibits the reaction [TP53 protein binds to MDM2 protein]]]; Staurosporine inhibits the reaction [EGF protein inhibits the reaction [resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of MAPK1 protein]]; Staurosporine inhibits the reaction [EGF protein inhibits the reaction [resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of MAPK3 protein]]; Staurosporine inhibits the reaction [EGF protein inhibits the reaction [resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein]]
EGF protein inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; EGF protein inhibits the reaction [Staurosporine results in increased activity of CASP7 protein]

PMID:15542774 PMID:19406941

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions

Staurosporine inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 2-alpha kinase 2

decreases activity

Staurosporine results in decreased activity of EIF2AK2 protein

NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation

Staurosporine results in increased phosphorylation of EIF2S1 protein

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

engulfment and cell motility 1

multiple interactions

ELMO1 protein inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; ELMO1 protein inhibits the reaction [Staurosporine results in increased activity of CASP7 protein]

NCBI chr17:44,286,495...44,822,668
Ensembl chr17:44,286,485...44,822,788

G

eomesodermin

multiple interactions

EOMES protein inhibits the reaction [Staurosporine results in increased cleavage of PARP1 protein]; EOMES protein inhibits the reaction [Staurosporine results in increased expression of CASP3 protein modified form]; EOMES protein inhibits the reaction [Staurosporine results in increased expression of CASP7 protein modified form]

NCBI chr 8:118,181,340...118,189,186
Ensembl chr 8:118,181,777...118,188,316

G

erythropoietin

decreases response to substance
multiple interactions

EPO protein results in decreased susceptibility to Staurosporine
tin mesoporphyrin inhibits the reaction [EPO protein results in decreased susceptibility to Staurosporine]

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

ERCC excision repair 5, endonuclease

affects expression

Staurosporine affects the expression of ERCC5 mRNA

NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472

G

estrogen receptor 1

multiple interactions

Staurosporine binds to and results in decreased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

Staurosporine binds to and results in decreased activity of ESR2 protein

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

coagulation factor III, tissue factor

multiple interactions

Staurosporine inhibits the reaction [Asbestos, Crocidolite results in increased expression of F3 mRNA]

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

FERM domain containing kindlin 2

affects expression

Staurosporine affects the expression of FERMT2 mRNA

NCBI chr15:18,682,927...18,751,959
Ensembl chr15:18,682,927...18,751,811

G

fibronectin 1

multiple interactions

Staurosporine inhibits the reaction [Acetaldehyde results in increased expression of FN1 mRNA]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Staurosporine inhibits the reaction [Acetaldehyde results in increased expression of FOS mRNA]; Staurosporine inhibits the reaction [Cadmium Chloride results in increased expression of FOS mRNA]

PMID:7945571 PMID:9417049

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

Staurosporine promotes the reaction [MYC protein binds to GCLC promoter]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

multiple interactions

Staurosporine promotes the reaction [MYC protein binds to GCLM promoter]

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glial fibrillary acidic protein

multiple interactions

Staurosporine inhibits the reaction [diphenylditelluride results in increased phosphorylation of GFAP protein]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

gastrin releasing peptide

multiple interactions

Staurosporine promotes the reaction [GRP protein modified form results in increased chemical synthesis of Inositol Phosphates]

NCBI chr18:59,388,679...59,402,061
Ensembl chr18:59,388,274...59,402,061

G

glutathione S-transferase alpha 2

multiple interactions

Staurosporine inhibits the reaction [benz(a)anthracene results in increased activity of GSTA2 protein]

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

heme oxygenase 1

multiple interactions
increases expression

Staurosporine inhibits the reaction [Acrolein results in increased expression of HMOX1 mRNA]; Staurosporine inhibits the reaction [Smoke analog results in increased expression of HMOX1 protein]; Staurosporine inhibits the reaction [VEGFA protein results in increased expression of HMOX1 protein]
Staurosporine results in increased expression of HMOX1 protein
SOD2 mutant form inhibits the reaction [Staurosporine results in increased expression of HMOX1 protein]; Staurosporine inhibits the reaction [hydroquinone results in increased expression of HMOX1 mRNA]; Staurosporine inhibits the reaction [hydroquinone results in increased expression of HMOX1 protein]

PMID:12788823 PMID:18048804 PMID:23290930 PMID:24740755 PMID:28108387

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

HR, lysine demethylase and nuclear receptor corepressor

multiple interactions
affects response to substance

HR protein affects the reaction [Staurosporine results in increased activity of CASP3 protein]; TRP53 protein affects the reaction [HR protein affects the reaction [Staurosporine results in increased activity of CASP3 protein]]
HR protein inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; HR protein inhibits the reaction [Staurosporine results in increased expression of TP53 protein]
HR protein affects the susceptibility to Staurosporine

NCBI chr15:45,626,835...45,646,313
Ensembl chr15:45,626,835...45,646,313

G

insulin-like growth factor 1

multiple interactions
affects activity

IGF1 protein inhibits the reaction [Staurosporine results in increased activity of CASP3 protein]; IGF1 protein inhibits the reaction [Staurosporine results in increased activity of CASP7 protein]
Staurosporine affects the activity of IGF1 protein

PMID:11548882 PMID:19406941

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 33

multiple interactions
increases expression

N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Staurosporine results in increased expression of IL33 protein]

NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373

G

interleukin 4

multiple interactions

Staurosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [IL4 protein results in increased expression of TNFRSF4 protein]]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

decreases activity

Staurosporine results in decreased activity of IL5 protein

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

insulin 1

multiple interactions

Staurosporine inhibits the reaction [[INS1 protein co-treated with PRL protein] results in increased expression of CSN2 mRNA]
Staurosporine inhibits the reaction [INS1 protein results in decreased expression of CYP2E1 mRNA]; Staurosporine promotes the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]

PMID:7648427 PMID:11306697

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

Staurosporine inhibits the reaction [INS protein results in increased uptake of cobaltous chloride]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

integrin subunit alpha L

multiple interactions

Staurosporine inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAL mRNA]; Staurosporine inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAL protein]; Staurosporine inhibits the reaction [TNF protein results in increased expression of ITGAL mRNA]; Staurosporine inhibits the reaction [TNF protein results in increased expression of ITGAL protein]

NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732

G

integrin subunit alpha M

multiple interactions

Staurosporine inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ITGAM protein]

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 2

multiple interactions

Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ITGB2 protein]

NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases phosphorylation

Staurosporine inhibits the reaction [Acetaldehyde results in increased expression of JUN mRNA]
Staurosporine results in increased phosphorylation of JUN protein

PMID:7945571 PMID:9751194

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

kininogen 1

decreases activity

Staurosporine results in decreased activity of KNG1

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

lamin A/C

increases cleavage

Staurosporine results in increased cleavage of LMNA protein

NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423

G

mitogen activated protein kinase 1

multiple interactions

Staurosporine inhibits the reaction [EGF protein inhibits the reaction [resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of MAPK1 protein]]; Staurosporine inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; Staurosporine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; Staurosporine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Staurosporine inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Staurosporine promotes the reaction [resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of MAPK1 protein]
Staurosporine inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]
Staurosporine inhibits the reaction [diphenylditelluride results in increased phosphorylation of MAPK1 protein]

PMID:11035063 PMID:15177934 PMID:15542774 PMID:16251475 PMID:17003101 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Staurosporine inhibits the reaction [EGF protein inhibits the reaction [resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of MAPK3 protein]]; Staurosporine inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; Staurosporine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; Staurosporine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Staurosporine inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Staurosporine promotes the reaction [resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of MAPK3 protein]
Staurosporine inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein]
Staurosporine inhibits the reaction [diphenylditelluride results in increased phosphorylation of MAPK3 protein]

PMID:11035063 PMID:15177934 PMID:15542774 PMID:16251475 PMID:17003101 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

microtubule-associated protein tau

multiple interactions

Staurosporine inhibits the reaction [oxophenylarsine results in increased phosphorylation of MAPT protein]

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

microtubule affinity regulating kinase 1

multiple interactions

Staurosporine inhibits the reaction [oxophenylarsine results in increased activity of MARK1 protein]

NCBI chr13:96,450,189...96,555,304
Ensembl chr13:96,451,487...96,555,173

G

MCL1 apoptosis regulator, BCL2 family member

increases cleavage
decreases response to substance

Staurosporine results in increased cleavage of MCL1 protein
MCL1 results in decreased susceptibility to Staurosporine

PMID:15217956 PMID:16007152

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

MDM2 proto-oncogene

multiple interactions

Staurosporine inhibits the reaction [EGF protein inhibits the reaction [resveratrol inhibits the reaction [TP53 protein binds to MDM2 protein]]]

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

matrix metallopeptidase 9

multiple interactions

Staurosporine inhibits the reaction [Homocysteine results in increased activity of MMP9 protein]; Staurosporine inhibits the reaction [Homocysteine results in increased expression of MMP9 protein]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
decreases response to substance

MYC protein inhibits the reaction [Staurosporine results in increased abundance of Reactive Oxygen Species]; Staurosporine promotes the reaction [MYC protein binds to GCLC promoter]; Staurosporine promotes the reaction [MYC protein binds to GCLM promoter]
MYC protein results in decreased susceptibility to Staurosporine

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

neurofilament light chain

multiple interactions

Staurosporine inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFL protein]

NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793

G

neurofilament medium chain

multiple interactions

Staurosporine inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFM protein]

NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases expression

Staurosporine inhibits the reaction [Ethanol affects the localization of NFE2L2 protein]; Staurosporine inhibits the reaction [sulforaphane results in increased expression of NFE2L2 protein]
Staurosporine results in decreased expression of NFE2L2 protein modified form

PMID:22530035 PMID:30703377

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

Staurosporine inhibits the reaction [bisphenol A results in increased expression of NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nerve growth factor

multiple interactions

Staurosporine inhibits the reaction [NGF results in increased susceptibility to Capsaicin]
Staurosporine inhibits the reaction [NGF protein results in increased uptake of Calcium]

PMID:1374475 PMID:12815188

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nitric oxide synthase 2

multiple interactions

Staurosporine inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

natriuretic peptide A

multiple interactions

Staurosporine inhibits the reaction [MBF1 protein results in increased secretion of NPPA protein]

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

Staurosporine inhibits the reaction [benz(a)anthracene results in increased activity of NQO1 protein]
Staurosporine inhibits the reaction [Smoke analog results in increased expression of NQO1 protein]

PMID:7587946 PMID:28108387

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

neurotrophin 3

multiple interactions

Staurosporine inhibits the reaction [Histamine results in increased expression of NTF3 protein]; Staurosporine inhibits the reaction [imetit results in increased expression of NTF3 protein]; Staurosporine inhibits the reaction [methylhistaprodifen results in increased expression of NTF3 protein]; Staurosporine inhibits the reaction [Neurotransmitter Agents results in increased expression of NTF3 protein]

PMID:19854260 PMID:21276809

NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596

G

neurotensin

multiple interactions
increases activity

Staurosporine inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; Staurosporine inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Staurosporine inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Staurosporine inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased activity of NTS protein]; Staurosporine promotes the reaction [NTS protein results in increased chemical synthesis of Inositol Phosphates]; Tetradecanoylphorbol Acetate inhibits the reaction [Staurosporine results in increased activity of NTS protein]

PMID:15177934 PMID:18313772

NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases expression
increases cleavage

SOD2 mutant form inhibits the reaction [Staurosporine results in increased cleavage of PARP1 protein]; Staurosporine affects the reaction [sodium arsenite results in increased cleavage of PARP1 protein]
Staurosporine results in increased expression of PARP1 protein modified form
EOMES protein inhibits the reaction [Staurosporine results in increased cleavage of PARP1 protein]; Silybin inhibits the reaction [Staurosporine promotes the reaction [Acetaldehyde results in increased cleavage of PARP1 protein]]; Staurosporine promotes the reaction [Acetaldehyde results in increased cleavage of PARP1 protein]

PMID:10704466 PMID:11035063 PMID:18451153 PMID:21447800 PMID:22639866 More...

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

progesterone receptor

multiple interactions

Staurosporine binds to and results in decreased activity of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

PPARG coactivator 1 alpha

multiple interactions

[Hydrogen Peroxide co-treated with Staurosporine] results in increased acetylation of PPARGC1A protein; resveratrol inhibits the reaction [[Hydrogen Peroxide co-treated with Staurosporine] results in increased acetylation of PPARGC1A protein]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein phosphatase 2, regulatory subunit B, beta

affects localization

Staurosporine affects the localization of PPP2R2B protein

NCBI chr18:34,653,716...35,080,889
Ensembl chr18:34,653,721...35,081,025

G

protein phosphatase 3 catalytic subunit alpha

decreases response to substance
increases cleavage

PPP3CA protein results in decreased susceptibility to Staurosporine
Staurosporine results in increased cleavage of PPP3CA protein

PMID:10679475 PMID:10898953

NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974

G

peroxiredoxin 1

multiple interactions

Staurosporine inhibits the reaction [sodium arsenate results in increased expression of PRDX1 protein]

NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856

G

protein kinase C, alpha

multiple interactions

Staurosporine affects the localization of and affects the activity of PRKCA protein
[linsidomine co-treated with Staurosporine] results in decreased expression of PRKCA protein; Staurosporine inhibits the reaction [Heptachlor affects the localization of PRKCA protein]; Staurosporine inhibits the reaction [linsidomine results in increased phosphorylation of PRKCA protein]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCA protein]

PMID:11994256 PMID:14678745 PMID:16225760

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

G

protein kinase C, delta

multiple interactions

Staurosporine inhibits the reaction [Curcumin results in increased phosphorylation of PRKCD protein]
Staurosporine inhibits the reaction [Heptachlor affects the localization of PRKCD protein]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCD protein]

PMID:14678745 PMID:17171638

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

prolactin

multiple interactions

Staurosporine inhibits the reaction [[INS1 protein co-treated with PRL protein] results in increased expression of CSN2 mRNA]

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

presenilin 2

multiple interactions

pifithrin inhibits the reaction [PSEN2 protein mutant form promotes the reaction [Staurosporine results in increased activity of CASP3 protein]]; PSEN2 protein mutant form promotes the reaction [Staurosporine results in increased activity of CASP3 protein]; Staurosporine promotes the reaction [PSEN2 protein mutant form results in increased expression of APP protein]

NCBI chr13:91,967,506...91,993,240
Ensembl chr13:91,967,983...91,993,174

G

prostaglandin E receptor 3

multiple interactions
decreases phosphorylation

Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of PTGER3 protein alternative form]
Staurosporine results in decreased phosphorylation of PTGER3 protein alternative form

NCBI chr 2:246,606,131...246,750,970
Ensembl chr 2:246,606,183...246,684,434

G

prostaglandin E synthase 3

increases cleavage

Staurosporine results in increased cleavage of PTGES3 protein

NCBI chr 7:490,698...507,759
Ensembl chr 7:490,656...508,084

G

prostaglandin-endoperoxide synthase 2

multiple interactions

Staurosporine inhibits the reaction [Nicotine results in increased expression of PTGS2]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Staurosporine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]; Staurosporine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein]
Staurosporine inhibits the reaction [bisphenol A results in increased expression of RELA protein]

PMID:20499049 PMID:24021941

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ret proto-oncogene

decreases expression

Staurosporine results in decreased expression of RET protein

NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176

G

succinate dehydrogenase complex iron sulfur subunit B

multiple interactions

[Hydrogen Peroxide co-treated with Staurosporine] results in decreased expression of SDHB protein; resveratrol inhibits the reaction [[Hydrogen Peroxide co-treated with Staurosporine] results in decreased expression of SDHB protein]

NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293

G

Set nuclear proto-oncogene

multiple interactions

Staurosporine affects the reaction [Formaldehyde affects the localization of SET protein alternative form]

NCBI chr 3:13,334,564...13,345,598
Ensembl chr 3:13,335,041...13,363,567

G

sirtuin 1

multiple interactions

[Hydrogen Peroxide co-treated with Staurosporine] results in decreased expression of SIRT1 protein; resveratrol inhibits the reaction [[Hydrogen Peroxide co-treated with Staurosporine] results in decreased expression of SIRT1 protein]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 11 member 2

multiple interactions
decreases phosphorylation

[Staurosporine results in decreased phosphorylation of SLC11A2 protein] which results in decreased uptake of Iron

NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145

G

solute carrier family 12 member 5

increases activity
multiple interactions

Staurosporine results in increased activity of SLC12A5 protein
Staurosporine inhibits the reaction [SLC12A5 protein results in increased import of Thallium]

NCBI chr 3:153,696,517...153,735,801
Ensembl chr 3:153,696,517...153,735,765

G

solute carrier family 1 member 1

multiple interactions
decreases activity

Staurosporine inhibits the reaction [Pregabalin results in increased activity of SLC1A1 protein]; Staurosporine inhibits the reaction [Progesterone results in increased activity of SLC1A1 protein]
Staurosporine results in decreased activity of SLC1A1 protein

PMID:17382927 PMID:22511482 PMID:23262392 PMID:23602688 PMID:24355585

NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402

G

solute carrier family 1 member 2

multiple interactions

Staurosporine inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SLC1A2 protein]

NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498

G

solute carrier family 22, member 25

multiple interactions

Staurosporine inhibits the reaction [Phorbol 12,13-Dibutyrate affects the localization of SLC22A9 protein]; Staurosporine inhibits the reaction [Phorbol 12,13-Dibutyrate results in decreased activity of SLC22A9 protein]

NCBI chr 1:205,338,698...205,498,486
Ensembl chr 1:205,338,699...205,433,085

G

solute carrier family 30 member 1

multiple interactions

Staurosporine inhibits the reaction [Zinc Sulfate results in increased expression of SLC30A1 mRNA]

NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910

G

solute carrier family 5 member 6

multiple interactions

Staurosporine inhibits the reaction [SLC5A6 protein results in increased transport of Biotin]

NCBI chr 6:25,319,187...25,331,713
Ensembl chr 6:25,320,442...25,331,712

G

solute carrier family 6 member 3

multiple interactions
increases activity

SNCA protein affects the reaction [Staurosporine results in increased activity of SLC6A3 protein]

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

solute carrier family 6 member 4

increases activity

staurosporine increases activity of SLC6A4 protein in placental choriocarcinoma cells

RGD

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

synuclein alpha

multiple interactions

[Staurosporine co-treated with Rotenone] promotes the reaction [SNCA protein binds to SNCA protein]; SNCA protein affects the reaction [Staurosporine results in increased activity of SLC6A3 protein]

PMID:19032594 PMID:19114014

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

superoxide dismutase 2

multiple interactions

[Hydrogen Peroxide co-treated with Staurosporine] results in decreased expression of SOD2 protein; resveratrol inhibits the reaction [[Hydrogen Peroxide co-treated with Staurosporine] results in decreased expression of SOD2 protein]; SOD2 mutant form inhibits the reaction [Staurosporine results in increased cleavage of PARP1 protein]; SOD2 mutant form inhibits the reaction [Staurosporine results in increased expression of HMOX1 protein]

PMID:23293585 PMID:24740755

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

spectrin, alpha, non-erythrocytic 1

multiple interactions
increases cleavage

Staurosporine promotes the reaction [CASP3 protein results in increased cleavage of SPTAN1 protein]; VASP mutant form promotes the reaction [Staurosporine promotes the reaction [CASP3 protein results in increased cleavage of SPTAN1 protein]]
Staurosporine results in increased cleavage of SPTAN1 protein

PMID:18182247 PMID:21683092 PMID:26124276

NCBI chr 3:13,241,164...13,306,047
Ensembl chr 3:13,241,217...13,306,046

G

signal transducer and activator of transcription 3

multiple interactions

Staurosporine inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

synaptotagmin binding, cytoplasmic RNA interacting protein

multiple interactions

Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of SYNCRIP protein]

NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515

G

telomerase reverse transcriptase

decreases activity

Staurosporine results in decreased activity of TERT protein

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

thyroid hormone receptor alpha

multiple interactions

Staurosporine binds to and results in decreased activity of THRA protein

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

thyroid hormone receptor beta

multiple interactions

Staurosporine binds to and results in decreased activity of THRB protein

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

G

tight junction protein 1

multiple interactions

Staurosporine inhibits the reaction [tert-Butylhydroperoxide affects the localization of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tumor necrosis factor

multiple interactions

Staurosporine inhibits the reaction [TNF protein results in increased expression of ITGAL mRNA]; Staurosporine inhibits the reaction [TNF protein results in increased expression of ITGAL protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 4

multiple interactions
increases expression

Staurosporine inhibits the reaction [IL4 protein promotes the reaction [Ionomycin results in increased expression of TNFRSF4 protein]]; Staurosporine inhibits the reaction [Ionomycin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [IL4 protein results in increased expression of TNFRSF4 protein]]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNFRSF4 protein]; Staurosporine promotes the reaction [Mercuric Chloride results in increased expression of TNFRSF4 protein]
Staurosporine results in increased expression of TNFRSF4 protein

NCBI chr 5:166,606,909...166,609,599
Ensembl chr 5:166,606,909...166,609,599

G

tumor protein p53

multiple interactions

Staurosporine inhibits the reaction [EGF protein inhibits the reaction [resveratrol inhibits the reaction [TP53 protein binds to MDM2 protein]]]; Staurosporine inhibits the reaction [EGF protein inhibits the reaction [resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein]]; Staurosporine promotes the reaction [resveratrol results in increased phosphorylation of and results in increased activity of and results in increased localization of TP53 protein]
TRP53 protein affects the reaction [HR protein affects the reaction [Staurosporine results in increased activity of CASP3 protein]]
HR protein inhibits the reaction [Staurosporine results in increased expression of TP53 protein]

PMID:15542774 PMID:20886113

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

vasodilator-stimulated phosphoprotein

multiple interactions

VASP mutant form promotes the reaction [Staurosporine promotes the reaction [CASP3 protein results in increased cleavage of SPTAN1 protein]]

NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061

G

voltage-dependent anion channel 1

multiple interactions

4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid inhibits the reaction [Staurosporine promotes the reaction [VDAC1 protein binds to VDAC1 protein]]; Staurosporine promotes the reaction [VDAC1 protein binds to VDAC1 protein]

NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640

G

vitamin D receptor

increases cleavage

Staurosporine results in increased cleavage of VDR protein

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

G

vascular endothelial growth factor A

multiple interactions

Staurosporine inhibits the reaction [VEGFA protein results in increased abundance of phosphatidylbutanol]; Staurosporine inhibits the reaction [VEGFA protein results in increased expression of HMOX1 protein]

PMID:12788823 PMID:14704231

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

multiple interactions

Staurosporine inhibits the reaction [diphenylditelluride results in increased phosphorylation of VIM protein]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

WT1 transcription factor

increases expression

Staurosporine results in increased expression of WT1 protein

NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643

strychnine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases expression

Strychnine results in increased expression of CASP3 mRNA

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cholinergic receptor, muscarinic 2

affects binding
multiple interactions

Strychnine binds to CHRM2 protein
Strychnine promotes the reaction [N-Methylscopolamine binds to CHRM2 protein]

PMID:9495826 PMID:15647330

NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103

G

cholinergic receptor, muscarinic 3

affects binding

Strychnine binds to CHRM3 protein

PMID:12435818 PMID:15647330

NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278

G

cholinergic receptor, muscarinic 4

multiple interactions

Strychnine promotes the reaction [N-Methylscopolamine binds to CHRM4 protein]

NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159

G

cytochrome P450, family 2, subfamily b, polypeptide 1

multiple interactions

Strychnine results in increased expression of and results in increased degradation of CYP2B1 protein

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 2

increases expression

Strychnine results in increased expression of CYP2B2 protein

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions

[Strychnine co-treated with Ketoconazole] results in decreased expression of CYP3A23-3A1 protein; [Strychnine co-treated with Phenobarbital] results in increased expression of CYP3A23-3A1 mRNA

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

glial fibrillary acidic protein

increases expression

Strychnine results in increased expression of GFAP mRNA

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

glycine receptor, alpha 1

multiple interactions
decreases activity

Strychnine analog binds to and results in decreased activity of GLRA1 protein; Strychnine binds to and results in decreased activity of GLRA1 protein; Strychnine promotes the reaction [Genistein results in decreased activity of GLRA1 protein]; Strychnine promotes the reaction [Quercetin results in decreased activity of GLRA1 protein]
Strychnine results in decreased activity of GLRA1 protein
Genistein promotes the reaction [Strychnine results in decreased activity of GLRA1 protein]; Quercetin promotes the reaction [Strychnine results in decreased activity of GLRA1 protein]

PMID:7752562 PMID:15081878 PMID:16687139 PMID:20719748

NCBI chr10:39,625,853...39,727,897
Ensembl chr10:39,629,459...39,727,162

G

glycine receptor, alpha 2

decreases activity

Strychnine results in decreased activity of GLRA2 protein

NCBI chr X:29,020,377...29,241,666
Ensembl chr X:29,020,557...29,241,666

G

interleukin 1 beta

multiple interactions

Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Strychnine results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

sodium voltage-gated channel alpha subunit 5

multiple interactions

Strychnine binds to and results in decreased activity of SCN5A protein

NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769

G

solute carrier family 22 member 2

multiple interactions

Strychnine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

sumatriptan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

brain-derived neurotrophic factor

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of BDNF protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of BDNF protein]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

calcitonin-related polypeptide alpha

multiple interactions
decreases expression

Sumatriptan results in decreased expression of and results in decreased secretion of CALCA protein
Sumatriptan results in decreased expression of CALCA mRNA
3-(3-(dimethylamino)propyl)-4-hydroxy-N-(4-(4-pyridinyl)phenyl)benzamide inhibits the reaction [Sumatriptan results in decreased expression of CALCA mRNA]; [Sumatriptan results in increased abundance of Calcium] inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]; GR 127935 inhibits the reaction [Sumatriptan results in decreased expression of CALCA mRNA]; isamoltane inhibits the reaction [Sumatriptan results in decreased expression of CALCA mRNA]; Sumatriptan inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]; Sumatriptan inhibits the reaction [NGF protein results in increased expression of CALCA mRNA]

PMID:12574409 PMID:14715155 PMID:15689192

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

caspase 3

multiple interactions

Sumatriptan inhibits the reaction [Vincristine results in increased expression of CASP3 mRNA]; Sumatriptan inhibits the reaction [Vincristine results in increased expression of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

C-C motif chemokine ligand 2

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CCL2 protein]; Sumatriptan affects the reaction [Capsaicin results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CCL20 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CCL20 protein]

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 22

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CCL22 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CCL22 protein]

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

C-C motif chemokine ligand 3

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CCL3 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine receptor 4

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CCR4 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CCR4 protein]

NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056

G

Cd80 molecule

multiple interactions

[Naproxen co-treated with Sumatriptan] affects the reaction [Capsaicin results in increased expression of CD80 protein]; Sumatriptan affects the reaction [Capsaicin results in increased expression of CD80 protein]

NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030

G

ciliogenesis associated kinase 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CILK1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CILK1 protein]

NCBI chr 8:78,984,075...79,042,695
Ensembl chr 8:78,984,258...79,042,691

G

ciliary neurotrophic factor

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CNTF protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CNTF protein]

NCBI chr 1:209,887,854...209,889,877
Ensembl chr 1:209,887,854...209,889,877

G

ciliary neurotrophic factor receptor

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CNTFR protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CNTFR protein]

NCBI chr 5:56,823,448...56,861,049
Ensembl chr 5:56,823,965...56,841,392

G

colony stimulating factor 2

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CSF2 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CSF2 protein]

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

catenin beta 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CTNNB1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CTNNB1 protein]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

C-X3-C motif chemokine ligand 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of CX3CL1 protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of CX3CL1 protein]

NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833

G

C-X-C motif chemokine ligand 10

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CXCL10 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CXCL10 protein]

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 2

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CXCL2 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CXCL2 protein]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine receptor 4

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CXCR4 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CXCR4 protein]

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

ERBB receptor feedback inhibitor 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of ERRFI1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of ERRFI1 protein]

NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282

G

Fas associated via death domain

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of FADD protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of FADD protein]

NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653

G

Fas cell surface death receptor

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of FAS protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of FAS protein]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of FASLG protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of FASLG protein]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fibroblast growth factor binding protein 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of FGFBP1 protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of FGFBP1 protein]

NCBI chr14:67,103,686...67,107,492
Ensembl chr14:67,104,545...67,107,496

G

fibrinogen-like 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of FGL1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of FGL1 protein]

NCBI chr16:51,120,652...51,150,907
Ensembl chr16:51,120,694...51,151,093

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Sumatriptan inhibits the reaction [Capsaicin results in increased expression of FOS protein]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

follistatin-like 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of FSTL1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of FSTL1 protein]

NCBI chr11:62,895,391...62,948,581
Ensembl chr11:62,779,783...62,948,677

G

GDNF family receptor alpha 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of GFRA1 protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of GFRA1 protein]

NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473

G

GDNF family receptor alpha 2

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of GFRA2 protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of GFRA2 protein]

NCBI chr15:45,941,841...46,033,715
Ensembl chr15:45,941,828...46,033,714

G

growth hormone 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of GH1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of GH1 protein]

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

growth hormone receptor

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of GHR protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of GHR protein]

NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735

G

hypocretin neuropeptide precursor

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of HCRT protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of HCRT protein]

NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210

G

5-hydroxytryptamine receptor 1B

multiple interactions
affects binding

Sumatriptan binds to and results in increased activity of HTR1B protein
Sumatriptan binds to HTR1B protein

PMID:11301495 PMID:11888550

NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549

G

5-hydroxytryptamine receptor 1D

multiple interactions

Sumatriptan binds to and results in increased activity of HTR1D protein

NCBI chr 5:148,656,252...148,676,532
Ensembl chr 5:148,674,495...148,675,619

G

insulin degrading enzyme

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of IDE protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of IDE protein]

NCBI chr 1:235,002,984...235,102,448
Ensembl chr 1:234,995,351...235,102,440

G

interferon gamma

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in decreased expression of IFNG protein]; Sumatriptan inhibits the reaction [Capsaicin results in decreased expression of IFNG protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of IL10 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of IL13 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of IL13 protein]

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 1 alpha

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in decreased expression of IL1A protein]; Sumatriptan inhibits the reaction [Capsaicin results in decreased expression of IL1A protein]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of IL1B protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of IL1B protein]; Sumatriptan inhibits the reaction [Vincristine results in increased expression of IL1B mRNA]

PMID:22150557 PMID:29958920

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of IL2 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of IL2 protein]

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 3

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of IL3 protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of IL3 protein]

NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066

G

interleukin 4

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of IL4 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of IL4 protein]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of IL5 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of IL5 protein]

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of IL6 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit beta A

multiple interactions

Sumatriptan inhibits the reaction [Capsaicin results in increased expression of INHBA protein]

NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982

G

insulin 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of INS1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

leptin

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of LEP protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of LEP protein]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

mitogen activated protein kinase kinase 1

multiple interactions

[Sumatriptan results in increased abundance of Calcium] inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]; Sumatriptan inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

macrophage migration inhibitory factor

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of MIF protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of MIF protein]

NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504

G

matrix metallopeptidase 13

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of MMP13 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of MMP13 protein]

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 2

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of MMP2 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of MMP2 protein]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

muscle associated receptor tyrosine kinase

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of MUSK protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of MUSK protein]

NCBI chr 5:73,058,427...73,169,696
Ensembl chr 5:73,058,121...73,171,932

G

nerve growth factor

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of NGF protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of NGF protein]; Sumatriptan inhibits the reaction [NGF protein results in increased expression of CALCA mRNA]

PMID:12574409 PMID:22150557

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nerve growth factor receptor

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of NGFR protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of NGFR protein]

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

nitric oxide synthase 1

multiple interactions

Sumatriptan inhibits the reaction [Nitroglycerin results in increased expression of NOS1 protein]

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

nuclear receptor subfamily 0, group B, member 2

decreases expression

Sumatriptan results in decreased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

neuropilin 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of NRP1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of NRP1 protein]

NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633

G

platelet derived growth factor subunit A

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of PDGFA protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of PDGFA protein]

NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497

G

perilipin 2

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of PLIN2 protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of PLIN2 protein]

NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319

G

proopiomelanocortin

decreases expression
multiple interactions

Sumatriptan results in decreased expression of POMC protein modified form
[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of POMC protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of POMC protein]

PMID:7640145 PMID:22150557

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

protein kinase AMP-activated catalytic subunit alpha 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of PRKAA1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of PRKAA1 protein]

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

prolactin receptor

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of PRLR protein]; Sumatriptan affects the reaction [Capsaicin results in increased expression of PRLR protein]

NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718

G

prokineticin 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of PROK1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of PROK1 protein]

NCBI chr 2:194,850,539...194,859,343
Ensembl chr 2:194,853,991...194,859,250

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Sumatriptan inhibits the reaction [Vincristine results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

resistin

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of RETN protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of RETN protein]

NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620

G

resistin like beta

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of RETNLB protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of RETNLB protein]

NCBI chr11:51,983,482...51,985,368
Ensembl chr11:51,983,483...51,985,368

G

selectin E

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of SELE protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of SELE protein]

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

selectin L

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of SELL protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of SELL protein]

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

secreted phosphoprotein 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of SPP1 protein]; Sumatriptan promotes the reaction [Capsaicin results in increased expression of SPP1 protein]

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

TAL bHLH transcription factor 1, erythroid differentiation factor

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TAL1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TAL1 protein]

NCBI chr 5:128,586,776...128,600,976
Ensembl chr 5:128,587,701...128,600,976

G

TEK receptor tyrosine kinase

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TEK protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TEK protein]

NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804

G

transforming growth factor, beta 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TGFB1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta 2

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TGFB2 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TGFB2 protein]

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

transforming growth factor, beta 3

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TGFB3 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TGFB3 protein]

NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564

G

TIMP metallopeptidase inhibitor 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TIMP1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TIMP1 protein]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

TIMP metallopeptidase inhibitor 2

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TIMP2 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TIMP2 protein]

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

G

TIMP metallopeptidase inhibitor 3

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TIMP3 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TIMP3 protein]

NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839

G

toll-like receptor 4

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TLR4 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TLR4 protein]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TNF protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TNF protein]; Sumatriptan inhibits the reaction [Vincristine results in increased expression of TNF mRNA]

PMID:22150557 PMID:29958920

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 19

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin affects the expression of TNFRSF19 protein]; Sumatriptan inhibits the reaction [Capsaicin affects the expression of TNFRSF19 protein]

NCBI chr15:35,092,206...35,158,472
Ensembl chr15:35,092,206...35,180,795

G

TNF superfamily member 10

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TNFSF10 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TNFSF10 protein]

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

vascular cell adhesion molecule 1

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of VCAM1 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of VCAM1 protein]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vascular endothelial growth factor A

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of VEGFA protein]; Sumatriptan affects the reaction [Capsaicin results in increased expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

zinc finger protein 866

multiple interactions

[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of CXCL5 protein]; Sumatriptan inhibits the reaction [Capsaicin results in increased expression of CXCL5 protein]

NCBI chr16:19,653,966...19,675,968
Ensembl chr16:19,668,258...19,675,932

Syrosingopine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

syrosingopine results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

tryptamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

gastrin

decreases cleavage

tryptamine results in decreased cleavage of GAST protein

NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496

G

5-hydroxytryptamine receptor 2A

decreases response to substance
affects response to substance
multiple interactions

HTR2A gene SNP results in decreased susceptibility to tryptamine
HTR2A protein affects the susceptibility to tryptamine
tryptamine binds to and results in increased activity of HTR2A protein

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

monoamine oxidase A

decreases amination
multiple interactions

MAOA protein results in decreased amination of tryptamine
[[MAOA protein results in decreased amination of tryptamine] which results in increased chemical synthesis of indole-3-acetaldehyde] which results in increased chemical synthesis of 6-formylindolo(3,2-b)carbazole; [MAOA protein results in decreased amination of tryptamine] which results in increased chemical synthesis of indole-3-acetaldehyde

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

monoamine oxidase B

multiple interactions
decreases amination

[[MAOB protein results in decreased amination of tryptamine] which results in increased chemical synthesis of indole-3-acetaldehyde] which results in increased chemical synthesis of 6-formylindolo(3,2-b)carbazole; [MAOB protein results in decreased amination of tryptamine] which results in increased chemical synthesis of indole-3-acetaldehyde

NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003

G

nuclear receptor subfamily 1, group I, member 2

increases activity

tryptamine results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

solute carrier family 6 member 2

multiple interactions

Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 6 member 3

multiple interactions

indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

solute carrier family 6 member 4

multiple interactions

Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; SLC6A4 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

trace-amine-associated receptor 1

multiple interactions
increases activity

[tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]

PMID:17234900 PMID:19725810

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

tryptamine alkaloid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

5-hydroxytryptamine (serotonin) receptor 5B

multiple interactions

5-hydroxytryptamine binds to protein 5-Htr5b; inhibits the reaction[5-carboxamidotryptamine binds to 5-Htr5b]

RGD

NCBI chr13:32,686,911...32,699,835
Ensembl chr13:32,687,042...32,699,835

vincaleukoblastine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 2

decreases response to substance
increases expression

ABCA2 mRNA results in decreased susceptibility to Vinblastine
Vinblastine results in increased expression of ABCA2 mRNA

NCBI chr 3:8,244,515...8,264,545
Ensembl chr 3:8,244,639...8,264,537

G

ATP binding cassette subfamily A member 3

decreases response to substance
increases expression

ABCA3 mRNA results in decreased susceptibility to Vinblastine
Vinblastine results in increased expression of ABCA3 mRNA

NCBI chr10:13,382,439...13,439,748
Ensembl chr10:13,382,540...13,439,745

G

ATP binding cassette subfamily B member 11

decreases uptake
decreases activity
multiple interactions
increases export

ABCB11 protein results in decreased uptake of Vinblastine
Vinblastine results in decreased activity of ABCB11 protein
Vinblastine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
ABCB11 protein results in increased export of Vinblastine

PMID:10617675 PMID:24014644

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

decreases response to substance
increases secretion
increases activity
increases expression
affects binding
multiple interactions
affects uptake
increases transport

ABCB1 protein results in decreased susceptibility to Vinblastine
ABCB1A protein results in increased secretion of Vinblastine
Vinblastine results in increased activity of ABCB1 protein mutant form
Vinblastine results in increased expression of ABCB1 protein
Vinblastine binds to ABCB1 protein
[Carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Vinblastine]] which results in decreased susceptibility to Vinblastine; [Elacridar binds to and results in decreased activity of ABCB1 protein] which results in decreased export of Vinblastine; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which affects the susceptibility to Vinblastine; [sodium arsenite results in increased expression of ABCB1 protein] which results in decreased susceptibility to Vinblastine; [Vinblastine results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; Amiodarone inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine]; Carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Vinblastine]; Clotrimazole inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine]; cnidiadin inhibits the reaction [ABCB1 protein results in increased export of Vinblastine]; Curcumin analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vinblastine]; Curcumin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vinblastine]; Cyclosporine inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine]; Diazinon affects the reaction [ABCB1 protein results in increased transport of Vinblastine]; Erythromycin inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine]; Ketoconazole inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine]; Miconazole inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine]; NR1I2 protein promotes the reaction [Vinblastine results in increased expression of ABCB1 protein]; Reserpine inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine]; Sesquiterpenes analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vinblastine]; Troleandomycin inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine]; Verapamil inhibits the reaction [ABCB1 protein affects the uptake of Vinblastine]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Vinblastine]; Vinblastine inhibits the reaction [Verapamil analog results in increased activity of ABCB1 protein mutant form]

PMID:1967174 PMID:8917702 PMID:9148857 PMID:11355955 PMID:11455017 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

increases secretion

ABCB1B protein results in increased secretion of Vinblastine

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily C member 1

affects response to substance
decreases response to substance

ABCC1 protein affects the susceptibility to Vinblastine
ABCC1 protein results in decreased susceptibility to Vinblastine

PMID:9334814 PMID:11455017 PMID:16156793

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

affects transport
decreases response to substance
multiple interactions

ABCC2 protein affects the transport of Vinblastine
ABCC2 protein results in decreased susceptibility to Vinblastine
[isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate results in decreased activity of ABCC2 protein] which results in increased uptake of Vinblastine; [verlukast results in decreased activity of ABCC2 protein] which results in increased uptake of Vinblastine; Probenecid promotes the reaction [ABCC2 protein affects the transport of Vinblastine]

PMID:9525973 PMID:11455017 PMID:15849751 PMID:25844889

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

actin-binding LIM protein 1

affects response to substance

ABLIM1 protein affects the susceptibility to Vinblastine

NCBI chr 1:256,083,747...256,372,075
Ensembl chr 1:256,084,297...256,371,969

G

acetyl-CoA acetyltransferase 2

affects response to substance

ACAT2 protein affects the susceptibility to Vinblastine

NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821

G

acyl-CoA thioesterase 13

affects response to substance

ACOT13 protein affects the susceptibility to Vinblastine

NCBI chr17:40,240,378...40,252,851
Ensembl chr17:40,240,378...40,252,851

G

acid phosphatase 1

affects response to substance

ACP1 protein affects the susceptibility to Vinblastine

NCBI chr 6:47,506,380...47,522,021
Ensembl chr 6:47,506,380...47,522,021

G

adducin 3

affects response to substance

ADD3 protein affects the susceptibility to Vinblastine

NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124

G

allograft inflammatory factor 1

decreases expression

Vinblastine results in decreased expression of AIF1 mRNA

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

adenylate kinase 1

decreases expression

Vinblastine results in decreased expression of AK1 mRNA

NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041

G

aldehyde oxidase 1

affects response to substance

AOX1 protein affects the susceptibility to Vinblastine

NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770

G

apelin

decreases expression

Vinblastine results in decreased expression of APLN mRNA

NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391

G

ATP synthase membrane subunit e

affects response to substance

ATP5ME protein affects the susceptibility to Vinblastine

NCBI chr14:1,319,868...1,320,996
Ensembl chr14:1,319,868...1,321,013

G

ATP synthase membrane subunit f

affects response to substance

ATP5MF protein affects the susceptibility to Vinblastine

NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236

G

aurora kinase B

affects response to substance

AURKB protein affects the susceptibility to Vinblastine

NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837

G

Axl receptor tyrosine kinase

affects response to substance

AXL protein affects the susceptibility to Vinblastine

NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265

G

baculoviral IAP repeat-containing 2

affects response to substance

BIRC2 protein affects the susceptibility to Vinblastine

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

affects response to substance

BIRC3 protein affects the susceptibility to Vinblastine

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 7

decreases response to substance

BIRC7 protein results in decreased susceptibility to Vinblastine

NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606

G

BUB1 mitotic checkpoint serine/threonine kinase

affects response to substance

BUB1 protein affects the susceptibility to Vinblastine

NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650

G

similar to human chromosome 5 open reading frame 15

affects response to substance

C5ORF15 protein affects the susceptibility to Vinblastine

NCBI chr10:36,563,989...36,576,593
Ensembl chr10:36,563,958...36,576,590

G

caspase 3

increases cleavage
multiple interactions

Vinblastine results in increased cleavage of CASP3 protein
CD40LG protein inhibits the reaction [Vinblastine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; Vinblastine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]

PMID:16545138 PMID:20624997

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

affects response to substance

CAT protein affects the susceptibility to Vinblastine

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

increases expression

Vinblastine results in increased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cellular communication network factor 2

affects response to substance

CCN2 protein affects the susceptibility to Vinblastine

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin B1

affects response to substance
increases response to substance

CCNB1 protein affects the susceptibility to Vinblastine
CCNB1 protein results in increased susceptibility to Vinblastine

PMID:16217747 PMID:16849574

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin B2

affects response to substance

CCNB2 protein affects the susceptibility to Vinblastine

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

CD14 molecule

increases expression

Vinblastine results in increased expression of CD14 mRNA

NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261

G

CD40 ligand

decreases response to substance
multiple interactions

CD40LG protein results in decreased susceptibility to Vinblastine
CD40LG protein inhibits the reaction [Vinblastine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]

NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306

G

CD44 molecule

increases expression

Vinblastine results in increased expression of CD44 mRNA

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

cell division cycle associated 8

affects response to substance

CDCA8 protein affects the susceptibility to Vinblastine

NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629

G

cyclin-dependent kinase 1

affects response to substance

CDK1 protein affects the susceptibility to Vinblastine

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

affects response to substance

CDK2 protein affects the susceptibility to Vinblastine

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

increases expression

Vinblastine results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2C

affects response to substance

CDKN2C protein affects the susceptibility to Vinblastine

NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278

G

cyclin-dependent kinase inhibitor 3

decreases expression

Vinblastine results in decreased expression of CDKN3 mRNA

NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945

G

centromere protein A

affects response to substance

CENPA protein affects the susceptibility to Vinblastine

NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675

G

cytoskeleton associated protein 2

affects response to substance

CKAP2 protein affects the susceptibility to Vinblastine

NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913

G

cytochrome c oxidase copper chaperone COX17

affects response to substance

COX17 protein affects the susceptibility to Vinblastine

NCBI chr11:62,400,733...62,406,507

G

cytochrome c oxidase subunit 5A

affects response to substance

COX5A protein affects the susceptibility to Vinblastine

NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781

G

cytochrome c oxidase subunit 6B1

affects response to substance

COX6B1 protein affects the susceptibility to Vinblastine

NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001
Ensembl chr 2:85,875,109...85,884,001

G

ceruloplasmin

increases expression

Vinblastine results in increased expression of CP mRNA

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

cellular repressor of E1A-stimulated genes 1

affects response to substance

CREG1 protein affects the susceptibility to Vinblastine

NCBI chr13:78,019,814...78,032,310
Ensembl chr13:78,019,843...78,032,308

G

CXXC repeat containing interactor of PDZ3 domain

affects response to substance

CRIPT protein affects the susceptibility to Vinblastine

NCBI chr 6:7,581,428...7,589,384
Ensembl chr 6:7,580,703...7,589,399

G

cathepsin S

increases expression

Vinblastine results in increased expression of CTSS mRNA

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Vinblastine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

decapping enzyme, scavenger

affects response to substance

DCPS protein affects the susceptibility to Vinblastine

NCBI chr 8:33,468,669...33,524,407
Ensembl chr 8:33,415,671...33,524,389

G

DEAD-box helicase 23

affects response to substance

DDX23 protein affects the susceptibility to Vinblastine

NCBI chr 7:129,797,620...129,814,909
Ensembl chr 7:129,797,614...129,814,949

G

deoxyribose-phosphate aldolase

affects response to substance

DERA protein affects the susceptibility to Vinblastine

NCBI chr 4:170,663,689...170,742,469
Ensembl chr 4:170,663,665...170,758,865

G

DNA fragmentation factor subunit beta

affects response to substance

DFFB protein affects the susceptibility to Vinblastine

NCBI chr 5:164,522,446...164,534,733
Ensembl chr 5:164,522,463...164,534,628

G

divergent protein kinase domain 1A

affects response to substance

DIPK1A protein affects the susceptibility to Vinblastine

NCBI chr14:1,772,412...1,843,508
Ensembl chr14:1,772,422...1,843,743

G

dickkopf WNT signaling pathway inhibitor 1

affects response to substance

DKK1 protein affects the susceptibility to Vinblastine

NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202

G

dickkopf WNT signaling pathway inhibitor 3

affects response to substance

DKK3 protein affects the susceptibility to Vinblastine

NCBI chr 1:166,237,969...166,281,271
Ensembl chr 1:166,238,238...166,280,590

G

DNA replication fork stabilization factor DONSON

affects response to substance

DONSON protein affects the susceptibility to Vinblastine

NCBI chr11:30,919,834...30,933,150
Ensembl chr11:30,923,239...30,932,889

G

DNA replication and sister chromatid cohesion 1

affects response to substance

DSCC1 protein affects the susceptibility to Vinblastine

NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212

G

E2F transcription factor 1

increases response to substance

E2F1 protein results in increased susceptibility to Vinblastine

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

endothelin receptor type B

increases expression

Vinblastine results in increased expression of EDNRB mRNA

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

EF-hand calcium binding domain 7

affects response to substance

EFCAB7 protein affects the susceptibility to Vinblastine

NCBI chr 5:114,525,403...114,576,130
Ensembl chr 5:114,525,167...114,576,129

G

epithelial membrane protein 2

affects response to substance

EMP2 protein affects the susceptibility to Vinblastine

NCBI chr10:5,360,073...5,394,734
Ensembl chr10:5,360,073...5,394,733

G

epithelial cell adhesion molecule

affects response to substance

EPCAM protein affects the susceptibility to Vinblastine

NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127

G

glutamyl-prolyl-tRNA synthetase 1

increases expression

Vinblastine results in increased expression of EPRS1 mRNA

NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966

G

erb-b2 receptor tyrosine kinase 2

affects response to substance

ERBB2 protein affects the susceptibility to Vinblastine

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

epiregulin

affects response to substance

EREG protein affects the susceptibility to Vinblastine

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

endothelial cell-specific molecule 1

decreases expression

Vinblastine results in decreased expression of ESM1 mRNA

NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804

G

electron transfer flavoprotein subunit beta

affects response to substance

ETFB protein affects the susceptibility to Vinblastine

NCBI chr 1:93,851,908...93,866,072
Ensembl chr 1:93,851,858...93,866,068

G

exosome component 9

affects response to substance

EXOSC9 protein affects the susceptibility to Vinblastine

NCBI chr 2:119,416,028...119,426,981
Ensembl chr 2:119,388,715...119,427,051

G

coagulation factor III, tissue factor

increases expression

Vinblastine results in increased expression of F3 mRNA

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

FAM3 metabolism regulating signaling molecule C

affects response to substance

FAM3C protein affects the susceptibility to Vinblastine

NCBI chr 4:50,839,929...50,887,276
Ensembl chr 4:50,838,818...50,888,078

G

FA complementation group L

affects response to substance

FANCL protein affects the susceptibility to Vinblastine

NCBI chr14:100,249,733...100,317,958
Ensembl chr14:100,248,875...100,314,255

G

Fas ligand

increases expression

Vinblastine results in increased expression of FASLG protein

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

Fc gamma receptor 2B

increases expression

Vinblastine results in increased expression of FCGR2B mRNA

NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778

G

flap structure-specific endonuclease 1

affects response to substance

FEN1 protein affects the susceptibility to Vinblastine

NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003

G

FKBP prolyl isomerase 1A

affects response to substance

FKBP1A protein affects the susceptibility to Vinblastine

NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743

G

Fli-1 proto-oncogene, ETS transcription factor

affects response to substance

FLI1 protein affects the susceptibility to Vinblastine

NCBI chr 8:30,831,422...30,950,468
Ensembl chr 8:30,832,753...30,950,433

G

fibronectin 1

affects response to substance

FN1 protein affects the susceptibility to Vinblastine

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

FOS like 1, AP-1 transcription factor subunit

affects response to substance

FOSL1 protein affects the susceptibility to Vinblastine

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

G0/G1switch 2

affects response to substance

G0S2 protein affects the susceptibility to Vinblastine

NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451

G

growth arrest and DNA-damage-inducible, alpha

increases expression

Vinblastine results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest and DNA-damage-inducible, beta

increases expression

Vinblastine results in increased expression of GADD45B mRNA

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

growth arrest and DNA-damage-inducible, gamma

increases expression

Vinblastine results in increased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

growth arrest specific 7

decreases expression

Vinblastine results in decreased expression of GAS7 mRNA

NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276

G

gamma-glutamyl cyclotransferase

affects response to substance

GGCT protein affects the susceptibility to Vinblastine

NCBI chr 4:84,122,921...84,129,327
Ensembl chr 4:84,123,118...84,129,277

G

gamma-glutamyl carboxylase

affects response to substance

GGCX protein affects the susceptibility to Vinblastine

NCBI chr 4:104,469,737...104,485,631
Ensembl chr 4:104,469,765...104,487,063

G

geminin, DNA replication inhibitor

affects response to substance

GMNN protein affects the susceptibility to Vinblastine

NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054

G

N-acetylglucosamine-1-phosphate transferase subunits alpha and beta

affects response to substance

GNPTAB protein affects the susceptibility to Vinblastine

NCBI chr 7:22,800,502...22,866,336
Ensembl chr 7:22,800,485...22,866,933

G

G protein-coupled receptor 176

affects response to substance

GPR176 protein affects the susceptibility to Vinblastine

NCBI chr 3:105,236,794...105,337,664
Ensembl chr 3:105,236,795...105,337,226

G

G-protein signaling modulator 2

affects response to substance

GPSM2 protein affects the susceptibility to Vinblastine

NCBI chr 2:196,327,149...196,375,322
Ensembl chr 2:196,327,149...196,375,154

G

glutathione S-transferase pi 1

decreases response to substance

GSTP1 protein results in decreased susceptibility to Vinblastine

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

general transcription factor II I

affects response to substance

GTF2I protein affects the susceptibility to Vinblastine

NCBI chr12:22,400,933...22,476,243
Ensembl chr12:22,401,431...22,476,243

G

general transcription factor III A

affects response to substance

GTF3A protein affects the susceptibility to Vinblastine

NCBI chr12:8,136,746...8,144,690
Ensembl chr12:8,136,747...8,144,690

G

G-2 and S-phase expressed 1

affects response to substance

GTSE1 protein affects the susceptibility to Vinblastine

NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806

G

glucuronidase, beta

affects response to substance

GUSB protein affects the susceptibility to Vinblastine

NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905

G

H1.2 linker histone, cluster member

affects response to substance

H1-2 protein affects the susceptibility to Vinblastine

NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635

G

hydroxyacyl-CoA dehydrogenase

affects response to substance

HADH protein affects the susceptibility to Vinblastine

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

hematopoietic cell specific Lyn substrate 1

affects response to substance

HCLS1 protein affects the susceptibility to Vinblastine

NCBI chr11:63,817,482...63,840,943
Ensembl chr11:63,817,476...63,841,014

G

high mobility group box 1

affects response to substance

HMGB1 protein affects the susceptibility to Vinblastine

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

high mobility group box 2

affects response to substance

HMGB2 protein affects the susceptibility to Vinblastine

NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140

G

high mobility group nucleosomal binding domain 3

affects response to substance

HMGN3 protein affects the susceptibility to Vinblastine

NCBI chr 8:84,022,493...84,059,329
Ensembl chr 8:84,022,495...84,062,976

G

hyaluronan-mediated motility receptor

affects response to substance

HMMR protein affects the susceptibility to Vinblastine

NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060

G

heme oxygenase 1

increases expression

Vinblastine results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

homer scaffold protein 1

affects response to substance

HOMER1 protein affects the susceptibility to Vinblastine

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

intercellular adhesion molecule 1

increases expression
decreases expression

Vinblastine results in increased expression of ICAM1 mRNA
Vinblastine results in decreased expression of ICAM1 mRNA; Vinblastine results in decreased expression of ICAM1 protein

PMID:12649748 PMID:20624997

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inhibitor of DNA binding 2

affects response to substance

ID2 protein affects the susceptibility to Vinblastine

NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400

G

isocitrate dehydrogenase (NADP(+)) 2

affects response to substance

IDH2 protein affects the susceptibility to Vinblastine

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

insulin-like growth factor 2 mRNA binding protein 3

affects response to substance

IGF2BP3 protein affects the susceptibility to Vinblastine

NCBI chr 4:78,060,494...78,195,007
Ensembl chr 4:78,060,494...78,194,865

G

inhibitor of nuclear factor kappa B kinase subunit beta

increases phosphorylation
multiple interactions

Vinblastine results in increased phosphorylation of IKBKB protein
Vinblastine results in decreased localization of [IKBKB protein binds to NFKBIA protein]

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

interleukin 13 receptor subunit alpha 2

affects response to substance

IL13RA2 protein affects the susceptibility to Vinblastine

NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381

G

interleukin 1 beta

affects response to substance
increases expression

IL1B protein affects the susceptibility to Vinblastine
Vinblastine results in increased expression of IL1B mRNA

PMID:16217747 PMID:20624997

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

decreases chemical synthesis
increases stability

Vinblastine results in decreased chemical synthesis of IL6 protein
Vinblastine results in increased stability of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit alpha

decreases expression

Vinblastine results in decreased expression of INHA mRNA

NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248

G

inhibin subunit beta A

affects response to substance

INHBA protein affects the susceptibility to Vinblastine

NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982

G

integrin subunit alpha L

decreases expression

Vinblastine results in decreased expression of ITGAL mRNA; Vinblastine results in decreased expression of ITGAL protein

NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732

G

integrin subunit beta 1 binding protein 1

affects response to substance

ITGB1BP1 protein affects the susceptibility to Vinblastine

NCBI chr 6:40,820,693...40,836,074
Ensembl chr 6:40,821,339...40,836,037

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases phosphorylation

TP53 protein affects the reaction [Vinblastine results in increased phosphorylation of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

KN motif and ankyrin repeat domains 1

affects response to substance

KANK1 protein affects the susceptibility to Vinblastine

NCBI chr 1:222,877,962...223,074,514
Ensembl chr 1:222,877,622...223,074,514

G

kazrin, periplakin interacting protein

affects response to substance

KAZN protein affects the susceptibility to Vinblastine

NCBI chr 5:154,392,793...155,381,567
Ensembl chr 5:154,392,793...154,779,074

G

kinesin family member 11

affects response to substance

KIF11 protein affects the susceptibility to Vinblastine

NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766

G

kinesin family member 15

affects response to substance

KIF15 protein affects the susceptibility to Vinblastine

NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750

G

kinesin family member 1B

affects response to substance

KIF1B protein affects the susceptibility to Vinblastine

NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778

G

kinesin family member 20A

affects response to substance

KIF20A protein affects the susceptibility to Vinblastine

NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780

G

kinesin family member 23

affects response to substance

KIF23 protein affects the susceptibility to Vinblastine

NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072

G

kinesin family member 4A

affects response to substance

KIF4A protein affects the susceptibility to Vinblastine

NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139

G

karyopherin subunit alpha 2

affects response to substance

KPNA2 protein affects the susceptibility to Vinblastine

NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150

G

lamin B1

affects response to substance

LMNB1 protein affects the susceptibility to Vinblastine

NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502

G

lysophosphatidic acid receptor 1

affects response to substance

LPAR1 protein affects the susceptibility to Vinblastine

NCBI chr 5:73,229,047...73,347,874
Ensembl chr 5:73,229,625...73,369,895

G

leucine rich repeat containing 1

affects response to substance

LRRC1 protein affects the susceptibility to Vinblastine

NCBI chr 8:78,239,897...78,407,347
Ensembl chr 8:78,239,900...78,406,490

G

LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated

affects response to substance

LSM7 protein affects the susceptibility to Vinblastine

NCBI chr 7:8,856,698...8,859,113
Ensembl chr 7:8,856,489...8,859,119

G

latent transforming growth factor beta binding protein 2

affects response to substance

LTBP2 protein affects the susceptibility to Vinblastine

NCBI chr 6:104,429,947...104,530,498
Ensembl chr 6:104,429,947...104,526,208

G

mitotic arrest deficient 2 like 1

affects response to substance

MAD2L1 protein affects the susceptibility to Vinblastine

NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470

G

mitogen-activated protein kinase 8

increases phosphorylation
multiple interactions

Vinblastine results in increased phosphorylation of MAPK8 protein
TP53 protein affects the reaction [Vinblastine results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

multiple interactions
increases phosphorylation

TP53 protein affects the reaction [Vinblastine results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

MAPK activated protein kinase 5

affects response to substance

MAPKAPK5 protein affects the susceptibility to Vinblastine

NCBI chr12:34,993,520...35,013,059
Ensembl chr12:34,994,092...35,013,052

G

maternal embryonic leucine zipper kinase

affects response to substance

MELK protein affects the susceptibility to Vinblastine

NCBI chr 5:58,540,393...58,600,562
Ensembl chr 5:58,540,449...58,600,937

G

membrane metallo-endopeptidase

affects response to substance

MME protein affects the susceptibility to Vinblastine

NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792

G

matrix metallopeptidase 1

affects response to substance

MMP1 protein affects the susceptibility to Vinblastine

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

MOK protein kinase

affects response to substance

MOK protein affects the susceptibility to Vinblastine

NCBI chr 6:129,823,794...129,854,669
Ensembl chr 6:129,823,795...129,854,700

G

mitochondrial ribosomal protein L57

affects response to substance

MRPL57 protein affects the susceptibility to Vinblastine

NCBI chr15:31,970,904...31,971,766
Ensembl chr15:31,970,860...31,973,993

G

MYC proto-oncogene, bHLH transcription factor

affects response to substance
increases expression

MYC protein affects the susceptibility to Vinblastine
Vinblastine results in increased expression of MYC mRNA

PMID:18802399 PMID:20624997

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

Myc binding protein

affects response to substance

MYCBP protein affects the susceptibility to Vinblastine

NCBI chr 5:136,135,955...136,143,163
Ensembl chr 5:136,135,931...136,145,616

G

nibrin

increases expression

Vinblastine results in increased expression of NBN mRNA

NCBI chr 5:29,459,574...29,494,152
Ensembl chr 5:29,459,457...29,494,150

G

non-SMC condensin I complex, subunit G

affects response to substance

NCAPG protein affects the susceptibility to Vinblastine

NCBI chr14:65,403,930...65,432,902
Ensembl chr14:65,404,163...65,432,902

G

non-SMC condensin I complex, subunit H

affects response to substance

NCAPH protein affects the susceptibility to Vinblastine

NCBI chr 3:114,371,937...114,399,178
Ensembl chr 3:114,371,941...114,399,180

G

NDC80 kinetochore complex component

affects response to substance

NDC80 protein affects the susceptibility to Vinblastine

NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924

G

NADH:ubiquinone oxidoreductase subunit A1

affects response to substance

NDUFA1 protein affects the susceptibility to Vinblastine

NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633

G

NADH:ubiquinone oxidoreductase subunit A13

affects response to substance

NDUFA13 protein affects the susceptibility to Vinblastine

NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726

G

NADH:ubiquinone oxidoreductase subunit A3

affects response to substance

NDUFA3 protein affects the susceptibility to Vinblastine

NCBI chr 1:65,597,567...65,600,197
Ensembl chr 1:65,597,578...65,600,235

G

NADH:ubiquinone oxidoreductase subunit A7

affects response to substance

NDUFA7 protein affects the susceptibility to Vinblastine

NCBI chr 7:14,609,283...14,622,064
Ensembl chr 7:14,609,146...14,631,976

G

NADH:ubiquinone oxidoreductase subunit B2

affects response to substance

NDUFB2 protein affects the susceptibility to Vinblastine

NCBI chr 4:68,367,526...68,374,609
Ensembl chr15:46,536,062...46,536,851
Ensembl chr 4:46,536,062...46,536,851

G

NADH:ubiquinone oxidoreductase subunit C1

affects response to substance

NDUFC1 protein affects the susceptibility to Vinblastine

NCBI chr 2:135,447,067...135,450,950
Ensembl chr 2:135,447,119...135,450,874

G

NADH:ubiquinone oxidoreductase subunit C2

affects response to substance

NDUFC2 protein affects the susceptibility to Vinblastine

NCBI chr 1:151,711,965...151,718,188
Ensembl chr 1:151,711,901...151,718,189

G

NADH:ubiquinone oxidoreductase subunit S6

affects response to substance

NDUFS6 protein affects the susceptibility to Vinblastine

NCBI chr 1:29,968,833...29,977,423
Ensembl chr 1:29,968,842...29,977,467

G

NADH:ubiquinone oxidoreductase core subunit V2

affects response to substance

NDUFV2 protein affects the susceptibility to Vinblastine

NCBI chr 9:105,690,454...105,710,669
Ensembl chr 9:105,690,455...105,710,713

G

nuclear factor of activated T-cells 4

decreases localization

Vinblastine results in decreased localization of NFATC4 protein

NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610

G

NFKB inhibitor alpha

increases phosphorylation
multiple interactions

Vinblastine results in increased phosphorylation of NFKBIA protein
Vinblastine results in decreased localization of [IKBKB protein binds to NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nerve growth factor

decreases response to substance

Vinblastine results in decreased susceptibility to NGF protein

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

neuropeptide Y

decreases expression

Vinblastine results in decreased expression of NPY mRNA

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

Vinblastine inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
increases activity

[Vinblastine results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; NR1I2 protein promotes the reaction [Vinblastine results in increased expression of ABCB1 protein]

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

neutral sphingomyelinase activation associated factor

affects response to substance

NSMAF protein affects the susceptibility to Vinblastine

NCBI chr 5:19,517,795...19,578,773
Ensembl chr 5:19,518,348...19,577,627

G

nudix hydrolase 15

affects response to substance

NUDT15 protein affects the susceptibility to Vinblastine

NCBI chr15:48,707,776...48,713,847
Ensembl chr15:48,709,700...48,747,363

G

nudix hydrolase 4

affects response to substance

NUDT4 protein affects the susceptibility to Vinblastine

NCBI chr 7:30,188,100...30,204,615
Ensembl chr 7:30,188,100...30,204,615

G

nucleolar and spindle associated protein 1

affects response to substance

NUSAP1 protein affects the susceptibility to Vinblastine

NCBI chr 3:106,603,273...106,633,428
Ensembl chr 3:106,603,289...106,633,624

G

ornithine decarboxylase antizyme 1

affects response to substance

OAZ1 protein affects the susceptibility to Vinblastine

NCBI chr 7:8,883,855...8,886,315
Ensembl chr 7:8,883,851...8,886,310

G

ornithine decarboxylase 1

multiple interactions

Vinblastine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of ODC1 protein]

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

Opa interacting protein 5

affects response to substance

OIP5 protein affects the susceptibility to Vinblastine

NCBI chr 3:106,593,746...106,603,281
Ensembl chr 3:106,593,760...106,603,250

G

olfactory receptor family 1 subfamily I member 2

affects response to substance

OR1I1 protein affects the susceptibility to Vinblastine

NCBI chr 7:10,985,938...10,986,879
Ensembl chr 7:10,980,344...10,987,036

G

origin recognition complex, subunit 6

affects response to substance

ORC6 protein affects the susceptibility to Vinblastine

NCBI chr19:21,757,867...21,765,638
Ensembl chr19:21,757,866...21,765,662

G

oxysterol binding protein-like 10

affects response to substance

OSBPL10 protein affects the susceptibility to Vinblastine

NCBI chr 8:114,661,050...114,918,664
Ensembl chr 8:114,660,743...114,918,625

G

poly (ADP-ribose) polymerase 1

multiple interactions

CD40LG protein inhibits the reaction [Vinblastine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; Vinblastine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

pyruvate dehydrogenase E1 subunit beta

affects response to substance

PDHB protein affects the susceptibility to Vinblastine

NCBI chr15:16,752,561...16,758,503
Ensembl chr15:16,750,980...16,758,500

G

pelota mRNA surveillance and ribosome rescue factor

affects response to substance

PELO protein affects the susceptibility to Vinblastine

NCBI chr 2:46,797,853...46,799,621
Ensembl chr 2:46,797,853...46,799,746

G

progesterone receptor membrane component 1

affects response to substance

PGRMC1 protein affects the susceptibility to Vinblastine

NCBI chr X:115,832,865...115,841,060
Ensembl chr X:115,832,884...115,888,682

G

pirin

affects response to substance

PIR protein affects the susceptibility to Vinblastine

NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218

G

PLAG1 like zinc finger 1

increases expression

Vinblastine results in increased expression of PLAGL1 mRNA

NCBI chr 1:7,477,295...7,517,229
Ensembl chr 1:7,477,177...7,517,228

G

plasminogen activator, tissue type

increases expression

Vinblastine results in increased expression of PLAT mRNA

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

plasminogen activator, urokinase

affects response to substance

PLAU protein affects the susceptibility to Vinblastine

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

plasminogen activator, urokinase receptor

increases expression

Vinblastine results in increased expression of PLAUR mRNA

NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595

G

protein phosphatase 1, regulatory subunit 15A

increases expression

Vinblastine results in increased expression of PPP1R15A mRNA

NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171

G

protein regulator of cytokinesis 1

affects response to substance

PRC1 protein affects the susceptibility to Vinblastine

NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765

G

protein kinase C, delta

affects localization

Vinblastine affects the localization of PRKCD protein

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

proteasome 20S subunit beta 1

affects response to substance

PSMB1 protein affects the susceptibility to Vinblastine

NCBI chr 1:56,442,432...56,463,544
Ensembl chr 1:56,420,618...56,463,560

G

proteasome activator subunit 4

affects response to substance

PSME4 protein affects the susceptibility to Vinblastine

NCBI chr14:104,505,716...104,609,410
Ensembl chr14:104,505,716...104,609,408

G

prostaglandin E synthase 3

affects response to substance

PTGES3 protein affects the susceptibility to Vinblastine

NCBI chr 7:490,698...507,759
Ensembl chr 7:490,656...508,084

G

PTTG1 regulator of sister chromatid separation, securin

affects response to substance

PTTG1 protein affects the susceptibility to Vinblastine

NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837

G

pentraxin 3

affects response to substance

PTX3 protein affects the susceptibility to Vinblastine

NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323

G

glutamine-rich 1

increases phosphorylation

Vinblastine results in increased phosphorylation of QRICH1 protein

NCBI chr 8:109,216,900...109,256,472
Ensembl chr 8:109,217,376...109,261,359

G

RAB11 family interacting protein 1

affects response to substance

RAB11FIP1 protein affects the susceptibility to Vinblastine

NCBI chr16:64,886,902...64,917,491
Ensembl chr16:64,884,676...64,917,491

G

Rac GTPase-activating protein 1

affects response to substance

RACGAP1 protein affects the susceptibility to Vinblastine

NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831

G

RAN binding protein 1

affects response to substance

RANBP1 protein affects the susceptibility to Vinblastine

NCBI chr11:82,742,603...82,750,836
Ensembl chr11:82,742,600...82,750,838

G

Ras association domain family member 1

increases expression

Vinblastine results in increased expression of RASSF1 mRNA

NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164

G

REV3 like, DNA directed polymerase zeta catalytic subunit

affects response to substance

REV3L protein affects the susceptibility to Vinblastine

NCBI chr20:43,131,841...43,290,102
Ensembl chr20:43,132,363...43,290,099

G

replication factor C subunit 5

affects response to substance

RFC5 protein affects the susceptibility to Vinblastine

NCBI chr12:39,207,484...39,217,041
Ensembl chr12:39,207,484...39,217,312

G

replication protein A3

affects response to substance

RPA3 protein affects the susceptibility to Vinblastine

NCBI chr 4:36,304,649...36,307,755
Ensembl chr 4:36,304,651...36,307,709

G

ribonucleotide reductase regulatory subunit M2

affects response to substance

RRM2 protein affects the susceptibility to Vinblastine

NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773

G

S100 calcium binding protein A8

increases expression

Vinblastine results in increased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

increases expression

Vinblastine results in increased expression of S100A9 mRNA

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

selectin E

increases expression

Vinblastine results in increased expression of SELE mRNA

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

serpin family B member 2

affects response to substance

SERPINB2 protein affects the susceptibility to Vinblastine

NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408

G

serpin family E member 1

increases expression
affects response to substance

Vinblastine results in increased expression of SERPINE1 mRNA
SERPINE1 protein affects the susceptibility to Vinblastine

PMID:16217747 PMID:20624997

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

sideroflexin 1

affects response to substance

SFXN1 protein affects the susceptibility to Vinblastine

NCBI chr17:10,486,250...10,522,640
Ensembl chr17:10,486,271...10,522,529

G

shootin 1

affects response to substance

SHTN1 protein affects the susceptibility to Vinblastine

NCBI chr 1:258,121,966...258,225,861
Ensembl chr 1:258,121,968...258,228,265

G

SKI8 subunit of superkiller complex

affects response to substance

SKIC8 protein affects the susceptibility to Vinblastine

NCBI chr 8:55,103,542...55,120,837
Ensembl chr 8:55,103,545...55,120,813

G

S-phase kinase associated protein 2

affects response to substance

SKP2 protein affects the susceptibility to Vinblastine

NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338

G

solute carrier family 22 member 3

affects response to substance

SLC22A3 protein affects the susceptibility to Vinblastine

NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612

G

small nuclear ribonucleoprotein U11/U12 subunit 25

affects response to substance

SNRNP25 protein affects the susceptibility to Vinblastine

NCBI chr10:15,420,482...15,423,806
Ensembl chr10:15,420,486...15,423,804

G

sorting nexin 10

affects response to substance

SNX10 protein affects the susceptibility to Vinblastine

NCBI chr 4:80,612,648...80,677,005
Ensembl chr 4:80,612,669...80,676,996

G

superoxide dismutase 1

affects response to substance

SOD1 protein affects the susceptibility to Vinblastine

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
increases expression

bisindolylmaleimide I inhibits the reaction [Vinblastine results in increased expression of SOD2 mRNA]; calphostin C inhibits the reaction [Vinblastine results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vinblastine results in increased expression of SOD2 mRNA]; Dactinomycin inhibits the reaction [Vinblastine results in increased expression of SOD2 mRNA]; Tetradecanoylphorbol Acetate inhibits the reaction [Vinblastine results in increased expression of SOD2 mRNA]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sortilin 1

affects response to substance

SORT1 protein affects the susceptibility to Vinblastine

NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354

G

spondin 1

increases expression

Vinblastine results in increased expression of SPON1 mRNA

NCBI chr 1:167,929,049...168,228,239
Ensembl chr 1:167,928,972...168,228,226

G

steroid 5 alpha-reductase 1

affects response to substance

SRD5A1 protein affects the susceptibility to Vinblastine

NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461

G

serglycin

affects response to substance

SRGN protein affects the susceptibility to Vinblastine

NCBI chr20:30,442,810...30,479,549
Ensembl chr20:30,442,813...30,457,406

G

signal transducer and activator of transcription 1

multiple interactions

Vinblastine deficiency results in decreased activity of and affects the localization of STAT1 protein

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 3

multiple interactions

Vinblastine deficiency results in decreased activity of and affects the localization of STAT3 protein

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

stanniocalcin 2

affects response to substance

STC2 protein affects the susceptibility to Vinblastine

NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973

G

serine/threonine kinase 26

affects response to substance

STK26 protein affects the susceptibility to Vinblastine

NCBI chr X:130,325,064...130,375,674
Ensembl chr X:130,310,885...130,374,291

G

striatin

affects response to substance

STRN protein affects the susceptibility to Vinblastine

NCBI chr 6:16,335,265...16,422,159
Ensembl chr 6:16,335,358...16,417,083

G

succinate-CoA ligase ADP-forming subunit beta

affects response to substance

SUCLA2 protein affects the susceptibility to Vinblastine

NCBI chr15:48,752,356...48,805,495
Ensembl chr15:48,752,312...48,805,138

G

succinate-CoA ligase GDP/ADP-forming subunit alpha

affects response to substance

SUCLG1 protein affects the susceptibility to Vinblastine

NCBI chr 4:105,308,236...105,337,595
Ensembl chr 4:105,308,039...105,337,600

G

sulfotransferase family 1A member 1

affects response to substance

SULT1A1 protein affects the susceptibility to Vinblastine

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

G

synapse defective Rho GTPase homolog 1

affects response to substance

SYDE1 protein affects the susceptibility to Vinblastine

NCBI chr 7:11,032,931...11,038,917
Ensembl chr 7:11,032,898...11,039,869

G

TBC1 domain family, member 4

affects response to substance

TBC1D4 protein affects the susceptibility to Vinblastine

NCBI chr15:78,256,030...78,434,168
Ensembl chr15:78,257,121...78,434,265

G

thymine-DNA glycosylase

affects response to substance

TDG protein affects the susceptibility to Vinblastine

NCBI chr 7:21,077,853...21,097,617
Ensembl chr 7:21,077,853...21,097,567

G

tissue factor pathway inhibitor 2

affects response to substance
increases expression

TFPI2 protein affects the susceptibility to Vinblastine
Vinblastine results in increased expression of TFPI2 mRNA

PMID:16217747 PMID:20624997

NCBI chr 4:31,981,786...31,986,707
Ensembl chr 4:31,982,178...31,986,600

G

thrombomodulin

increases expression

Vinblastine results in increased expression of THBD mRNA

NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193

G

thrombospondin 1

increases expression

Vinblastine results in increased expression of THBS1 mRNA

NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440

G

TIMP metallopeptidase inhibitor 1

increases expression

Vinblastine results in increased expression of TIMP1 mRNA

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

transmembrane protein 134

affects response to substance

TMEM134 protein affects the susceptibility to Vinblastine

NCBI chr 1:201,419,225...201,424,778
Ensembl chr 1:201,419,264...201,431,411

G

transmembrane protein 14A

affects response to substance

TMEM14A protein affects the susceptibility to Vinblastine

NCBI chr 9:23,640,594...23,652,379
Ensembl chr 9:23,733,039...23,734,463
Ensembl chr 9:23,733,039...23,734,463

G

transmembrane protein 156

affects response to substance

TMEM156 protein affects the susceptibility to Vinblastine

NCBI chr14:43,221,464...43,252,453
Ensembl chr14:43,223,381...43,252,449

G

transmembrane protein 97

affects response to substance

TMEM97 protein affects the susceptibility to Vinblastine

NCBI chr10:63,438,228...63,447,311
Ensembl chr10:63,438,222...63,589,730

G

thymopoietin

affects response to substance

TMPO protein affects the susceptibility to Vinblastine

NCBI chr 7:25,642,752...25,667,756
Ensembl chr 7:25,586,725...25,667,727

G

DNA topoisomerase II alpha

affects response to substance

TOP2A protein affects the susceptibility to Vinblastine

NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874

G

tumor protein p53

multiple interactions

TP53 protein affects the reaction [Vinblastine results in increased phosphorylation of JUN protein]; TP53 protein affects the reaction [Vinblastine results in increased phosphorylation of MAPK8 protein]; TP53 protein affects the reaction [Vinblastine results in increased phosphorylation of MAPK9 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

TPD52 like 1

increases expression
affects response to substance

Vinblastine results in increased expression of TPD52L1 mRNA
TPD52L1 protein affects the susceptibility to Vinblastine

PMID:16217747 PMID:20624997

NCBI chr 1:26,172,038...26,290,704
Ensembl chr 1:26,172,170...26,291,109

G

tripartite motif-containing 2

affects response to substance

TRIM2 protein affects the susceptibility to Vinblastine

NCBI chr 2:169,500,628...169,652,855
Ensembl chr 2:169,500,634...169,652,927

G

tRNA methyltransferase 5

affects response to substance

TRMT5 protein affects the susceptibility to Vinblastine

NCBI chr 6:91,963,558...91,987,660
Ensembl chr 6:91,943,724...91,987,555

G

tetraspanin 13

affects response to substance

TSPAN13 protein affects the susceptibility to Vinblastine

NCBI chr 6:52,738,748...52,765,503
Ensembl chr 6:52,738,758...52,765,547

G

transcription termination factor 2

affects response to substance

TTF2 protein affects the susceptibility to Vinblastine

NCBI chr 2:188,366,321...188,397,750
Ensembl chr 2:188,366,331...188,397,689

G

Ttk protein kinase

affects response to substance

TTK protein affects the susceptibility to Vinblastine

NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651

G

tubulin, alpha 1B

decreases expression

Vinblastine results in decreased expression of TUBA1B mRNA

NCBI chr 7:130,090,663...130,093,644
Ensembl chr 7:130,081,032...130,196,186

G

tubulin, alpha 4A

decreases expression

Vinblastine results in decreased expression of TUBA4A mRNA

NCBI chr 9:76,709,617...76,714,327
Ensembl chr 9:76,709,614...76,713,918

G

tubulin, beta 4B class IVb

decreases expression

Vinblastine results in decreased expression of TUBB4B mRNA

NCBI chr 3:8,037,838...8,040,294
Ensembl chr 3:8,037,799...8,040,296

G

tubulin, beta 5 class I

decreases expression

Vinblastine results in decreased expression of TUBB5 mRNA

NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940

G

tubulin, gamma 1

decreases expression

Vinblastine results in decreased expression of TUBG1 mRNA

NCBI chr10:86,052,845...86,059,436
Ensembl chr10:86,052,743...86,059,433

G

ubiquinol-cytochrome c reductase, complex III subunit X

affects response to substance

UQCR10 protein affects the susceptibility to Vinblastine

NCBI chr14:79,566,151...79,569,017
Ensembl chr14:79,566,157...79,569,003

G

vascular cell adhesion molecule 1

increases expression

Vinblastine results in increased expression of VCAM1 mRNA

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vascular endothelial growth factor A

decreases expression

Vinblastine results in decreased expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vascular endothelial growth factor C

affects response to substance

VEGFC protein affects the susceptibility to Vinblastine

NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848

G

von Willebrand factor

increases expression

Vinblastine results in increased expression of VWF mRNA

NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539

G

WD repeat and SOCS box-containing 2

affects response to substance

WSB2 protein affects the susceptibility to Vinblastine

NCBI chr12:39,217,645...39,238,634
Ensembl chr12:39,217,648...39,238,640

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta

affects response to substance

YWHAQ protein affects the susceptibility to Vinblastine

NCBI chr 6:40,935,714...40,966,240
Ensembl chr 6:40,935,949...40,966,273

G

zinc finger, DHHC-type containing 11

affects response to substance

ZDHHC11 protein affects the susceptibility to Vinblastine

NCBI chr 1:29,296,334...29,327,227
Ensembl chr 1:29,296,334...29,326,898

G

zinc finger protein 36, C3H type-like 2

affects response to substance

ZFP36L2 protein affects the susceptibility to Vinblastine

NCBI chr 6:10,490,032...10,494,073
Ensembl chr 6:10,490,032...10,494,064

G

ZW10 interacting kinetochore protein

affects response to substance

ZWINT protein affects the susceptibility to Vinblastine

NCBI chr20:15,938,157...15,953,997
Ensembl chr20:15,938,157...15,953,957

vincamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Vincamine results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

vincristine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adipogenesis associated, Mth938 domain containing

increases expression

Vincristine results in increased expression of AAMDC mRNA

NCBI chr 1:151,861,990...151,893,621
Ensembl chr 1:151,845,255...151,892,398

G

ATP binding cassette subfamily A member 1

multiple interactions

[Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily A member 12

increases expression
multiple interactions

Vincristine results in increased expression of ABCA12 mRNA
[Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCA12 mRNA

PMID:19944135 PMID:23649840

NCBI chr 9:72,822,661...72,995,748
Ensembl chr 9:72,823,350...72,996,049

G

ATP binding cassette subfamily A member 4

multiple interactions

[Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCA4 mRNA

NCBI chr 2:210,164,813...210,302,069
Ensembl chr 2:210,164,813...210,302,069

G

ATP binding cassette subfamily A member 5

multiple interactions

[Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCA5 mRNA

NCBI chr10:95,240,159...95,309,195
Ensembl chr10:95,240,154...95,308,976

G

ATP binding cassette subfamily A member 8

multiple interactions

[Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCA8 mRNA

NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988

G

ATP binding cassette subfamily B member 1A

affects response to substance
increases expression
multiple interactions
increases transport
decreases uptake
decreases response to substance
affects uptake

ABCB1 protein affects the susceptibility to Vincristine
Vincristine results in increased expression of ABCB1A mRNA
Vincristine results in increased expression of ABCB1 protein
[Estradiol results in decreased expression of ABCB1 protein] which results in increased uptake of and results in increased susceptibility to Vincristine; [MGMT protein co-treated with ABCB1 protein] results in decreased susceptibility to Vincristine; [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Vincristine; [Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCB1 mRNA; [Vincristine results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; CEP 33779 inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine]; Cyclosporine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine]; Fenofibrate inhibits the reaction [ABCB1 protein results in increased transport of Vincristine]; Flupenthixol analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine]; NR1I2 protein promotes the reaction [Vincristine results in increased expression of ABCB1 protein]; pinostrobin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine]; tectochrysin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine]; Verapamil inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine]; zosuquidar trihydrochloride inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine]
ABCB1 protein results in decreased uptake of Vincristine
ABCB1 protein affects the uptake of Vincristine

PMID:7905786 PMID:10617675 PMID:11792417 PMID:11934808 PMID:15239124 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

affects uptake

ABCB1B protein affects the uptake of Vincristine

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily B member 4

multiple interactions

[Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily B member 6

multiple interactions
decreases response to substance

[Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCB6 mRNA
ABCB6 protein results in decreased susceptibility to Vincristine

PMID:19944135 PMID:25202056

NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924

G

ATP binding cassette subfamily C member 1

increases response to substance
increases expression
multiple interactions
decreases response to substance
affects transport
affects response to substance
affects export

ABCC1 gene SNP results in increased susceptibility to Vincristine
Vincristine results in increased expression of ABCC1 mRNA
[Genistein results in decreased activity of ABCC1 protein] which results in increased uptake of Vincristine; [Indomethacin results in decreased activity of ABCC1 protein] which results in increased uptake of Vincristine; [Probenecid results in decreased activity of ABCC1 protein] which results in increased uptake of Vincristine; [Sulfinpyrazone results in decreased activity of ABCC1 protein] which results in increased uptake of Vincristine; [verlukast results in decreased activity of ABCC1 protein] which results in increased uptake of Vincristine
ABCC1 protein results in decreased susceptibility to Vincristine; ABCC1 results in decreased susceptibility to Vincristine
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Vincristine; [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCC1 mRNA; ABCC1 protein affects the export of and results in decreased susceptibility to Vincristine; Buthionine Sulfoximine inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Cyclosporine inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Doxorubicin inhibits the reaction [ABCC1 protein affects the transport of Vincristine]; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; myricetin inhibits the reaction [ABCC1 protein affects the export of and results in decreased susceptibility to Vincristine]; myricetin inhibits the reaction [ABCC1 protein affects the export of Vincristine]; myricetin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Quercetin promotes the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Verapamil inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Vincristine inhibits the reaction [ABCC1 protein affects the transport of fluorexon]; Vincristine inhibits the reaction [Glutathione promotes the reaction [ABCC1 results in increased transport of methylarsine analog]]; zafirlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]
ABCC1 protein affects the transport of Vincristine; ABCC1 protein mutant form affects the transport of Vincristine
ABCC1 protein affects the susceptibility to Vincristine

PMID:7954421 PMID:8649356 PMID:8968083 PMID:10348353 PMID:10685512 More...

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 10

multiple interactions
decreases response to substance

Imatinib Mesylate inhibits the reaction [ABCC10 protein results in decreased susceptibility to Vincristine]; nilotinib inhibits the reaction [ABCC10 protein results in decreased susceptibility to Vincristine]

NCBI chr 9:14,657,242...14,677,178
Ensembl chr 9:14,657,264...14,677,178

G

ATP binding cassette subfamily C member 2

affects export
multiple interactions
decreases response to substance

ABCC2 protein affects the export of Vincristine
[Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCC2 mRNA; ABCC2 protein affects the export of and results in decreased susceptibility to Vincristine; myricetin inhibits the reaction [ABCC2 protein affects the export of and results in decreased susceptibility to Vincristine]; myricetin inhibits the reaction [ABCC2 protein affects the export of Vincristine]; myricetin inhibits the reaction [ABCC2 protein results in decreased susceptibility to Vincristine]

PMID:15896345 PMID:19944135 PMID:22095822

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

multiple interactions

[Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCC4 mRNA

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily C member 5

multiple interactions

[Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCC5 mRNA

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ATP binding cassette subfamily C member 6

multiple interactions

[Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCC6 mRNA

NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464

G

ATP binding cassette subfamily D member 3

multiple interactions

[Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCD3 mRNA

NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020

G

ATP binding cassette subfamily G member 1

multiple interactions

[Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 2

multiple interactions

[Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Vincristine; [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCG2 mRNA

PMID:19944135 PMID:21833476

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 4

multiple interactions

[Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCG4 mRNA

NCBI chr 8:44,611,187...44,629,818
Ensembl chr 8:44,611,187...44,626,881

G

abhydrolase domain containing 11

decreases expression

Vincristine results in decreased expression of ABHD11 mRNA

NCBI chr12:21,682,206...21,685,331
Ensembl chr12:21,682,202...21,685,398

G

ankyrin repeat and BTB domain containing 2

increases expression

Vincristine results in increased expression of ABTB2 mRNA

NCBI chr 3:89,954,726...90,108,549
Ensembl chr 3:89,954,713...90,108,548

G

acyl-CoA dehydrogenase family, member 9

decreases expression

Vincristine results in decreased expression of ACAD9 mRNA

NCBI chr 2:118,943,170...118,966,150
Ensembl chr 2:118,943,174...118,966,547

G

acetylcholinesterase

decreases expression
multiple interactions

Vincristine results in decreased expression of ACHE protein
xaliproden inhibits the reaction [Vincristine results in decreased expression of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

atypical chemokine receptor 3

increases expression

Vincristine results in increased expression of ACKR3 mRNA

NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237

G

actin related protein 2

increases expression

Vincristine results in increased expression of ACTR2 mRNA

NCBI chr14:94,296,443...94,333,735
Ensembl chr14:94,296,443...94,340,524

G

adenosine deaminase, tRNA-specific 2

decreases expression

Vincristine results in decreased expression of ADAT2 mRNA

NCBI chr 1:7,954,520...7,975,254
Ensembl chr 1:7,954,631...7,975,251

G

adhesion G protein-coupled receptor F4

increases expression

Vincristine results in increased expression of ADGRF4 mRNA

NCBI chr 9:18,272,050...18,303,219
Ensembl chr 9:18,272,050...18,303,217

G

adrenoceptor beta 1

decreases expression

Vincristine results in decreased expression of ADRB1 mRNA

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

increases response to substance

ADRB2 gene SNP results in increased susceptibility to Vincristine

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

AGBL carboxypeptidase 3

decreases expression

Vincristine results in decreased expression of AGBL3 mRNA

NCBI chr 4:63,448,789...63,535,538
Ensembl chr 4:63,453,940...63,531,188

G

activator of HSP90 ATPase homolog 2

decreases expression

Vincristine results in decreased expression of AHSA2P mRNA

NCBI chr14:97,476,304...97,485,725
Ensembl chr14:97,476,817...97,485,657

G

absent in melanoma 2

increases expression

Vincristine results in increased expression of AIM2 mRNA

NCBI chr13:85,865,206...85,906,996
Ensembl chr13:85,866,284...85,906,975

G

adenylate kinase 1

decreases expression

Vincristine results in decreased expression of AK1 mRNA

NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041

G

adenylate kinase 3

decreases expression

Vincristine results in decreased expression of AK3 mRNA

NCBI chr 1:226,737,472...226,764,647
Ensembl chr 1:226,739,318...226,764,625

G

A-kinase anchoring protein 10

increases expression

Vincristine results in increased expression of AKAP10 mRNA

NCBI chr10:46,545,371...46,608,730
Ensembl chr10:46,551,532...46,608,769

G

AKT serine/threonine kinase 1

multiple interactions
decreases expression

Vincristine inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT1 protein]
Vincristine results in decreased expression of AKT1 mRNA
Quercetin inhibits the reaction [Vincristine results in decreased expression of AKT1 mRNA]
Vincristine promotes the reaction [NVP ADW742 inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]]

PMID:16740780 PMID:18590705 PMID:33038355

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

AKT serine/threonine kinase 2

decreases expression
multiple interactions

Vincristine results in decreased expression of AKT2 mRNA
Quercetin inhibits the reaction [Vincristine results in decreased expression of AKT2 mRNA]

NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817

G

aldolase, fructose-bisphosphate C

decreases expression

Vincristine results in decreased expression of ALDOC mRNA

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

ALMS1, centrosome and basal body associated protein

decreases expression

Vincristine results in decreased expression of ALMS1 mRNA

NCBI chr 4:118,125,581...118,226,005
Ensembl chr 4:118,125,607...118,226,005

G

alpha-kinase 2

increases expression

Vincristine results in increased expression of ALPK2 mRNA

NCBI chr18:58,775,603...58,906,150
Ensembl chr18:58,775,605...58,906,258

G

anti-Mullerian hormone

decreases secretion

Vincristine results in decreased secretion of AMH protein

NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282

G

anaphase-promoting complex subunit 5

increases expression

Vincristine results in increased expression of ANAPC5 mRNA

NCBI chr12:33,748,709...33,781,709
Ensembl chr12:33,748,735...33,781,781

G

ankyrin repeat and death domain containing 1A

decreases expression

Vincristine results in decreased expression of ANKDD1A mRNA

NCBI chr 8:66,017,571...66,043,738
Ensembl chr 8:66,017,773...66,042,651

G

ankyrin repeat and KH domain containing 1

increases expression

Vincristine results in increased expression of ANKHD1 mRNA

NCBI chr18:28,161,882...28,260,917
Ensembl chr18:28,162,311...28,268,024

G

ankyrin repeat family A member 2

increases expression

Vincristine results in increased expression of ANKRA2 mRNA

NCBI chr 2:29,612,867...29,623,748
Ensembl chr 2:29,612,925...29,623,730

G

ankyrin repeat domain 13C

decreases expression

Vincristine results in decreased expression of ANKRD13C mRNA

NCBI chr 2:247,023,040...247,070,433
Ensembl chr 2:247,022,286...247,070,433

G

ankyrin repeat domain 33B

increases expression

Vincristine results in increased expression of ANKRD33B mRNA

NCBI chr 2:82,277,604...82,359,420
Ensembl chr 2:82,283,108...82,358,872

G

ankyrin repeat domain 37

decreases expression

Vincristine results in decreased expression of ANKRD37 mRNA

NCBI chr16:46,268,933...46,271,971
Ensembl chr16:46,268,443...46,271,963

G

acidic nuclear phosphoprotein 32 family member E

decreases expression

Vincristine results in decreased expression of ANP32E mRNA

NCBI chr 2:183,472,600...183,489,057
Ensembl chr 2:183,472,609...183,489,054

G

annexin A1

increases expression

Vincristine results in increased expression of ANXA1 mRNA

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

annexin A2

increases expression

Vincristine results in increased expression of ANXA2 mRNA

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

adaptor related protein complex 1 subunit sigma 2

decreases expression

Vincristine results in decreased expression of AP1S2 mRNA

NCBI chr X:30,572,746...30,598,961
Ensembl chr X:30,572,751...30,597,262

G

apurinic/apyrimidinic endodeoxyribonuclease 2

decreases expression

Vincristine results in decreased expression of APEX2 mRNA

NCBI chr X:19,425,684...19,508,459
Ensembl chr X:19,487,419...19,508,439

G

apelin

decreases expression

Vincristine results in decreased expression of APLN mRNA

NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391

G

apolipoprotein D

increases expression

Vincristine results in increased expression of APOD mRNA

NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305

G

apolipoprotein L domain containing 1

increases expression

Vincristine results in increased expression of APOLD1 mRNA

NCBI chr 4:167,768,437...167,825,706
Ensembl chr 4:167,818,271...167,825,706

G

aquaporin 9

increases expression

Vincristine results in increased expression of AQP9 mRNA

NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2

decreases expression

Vincristine results in decreased expression of ARAP2 mRNA

NCBI chr14:46,717,657...46,917,326
Ensembl chr14:46,718,760...46,917,154

G

ADP-ribosylation factor 1

increases expression

Vincristine results in increased expression of ARF1 mRNA

NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434

G

Rho GTPase activating protein 15

increases expression

Vincristine results in increased expression of ARHGAP15 mRNA

NCBI chr 3:27,989,368...28,592,722
Ensembl chr 3:27,989,633...28,600,265

G

Rho GTPase activating protein 18

decreases expression

Vincristine results in decreased expression of ARHGAP18 mRNA

NCBI chr 1:18,403,531...18,637,306
Ensembl chr 1:18,403,537...18,637,256

G

Rho GTPase activating protein 5

decreases expression

Vincristine results in decreased expression of ARHGAP5 mRNA

NCBI chr 6:69,975,904...70,039,299
Ensembl chr 6:69,976,214...70,037,660

G

Rac/Cdc42 guanine nucleotide exchange factor 6

increases expression

Vincristine results in increased expression of ARHGEF6 mRNA

NCBI chr X:135,145,447...135,264,636
Ensembl chr X:135,146,786...135,275,304

G

Rho guanine nucleotide exchange factor 7

increases expression

Vincristine results in increased expression of ARHGEF7 mRNA

NCBI chr16:77,671,021...77,782,593
Ensembl chr16:77,671,023...77,782,697

G

AT-rich interaction domain 2

increases expression

Vincristine results in increased expression of ARID2 mRNA

NCBI chr 7:127,447,192...127,565,987
Ensembl chr 7:127,447,278...127,563,512

G

AT-rich interaction domain 4B

increases expression

Vincristine results in increased expression of ARID4B mRNA

NCBI chr17:51,138,419...51,262,894
Ensembl chr17:51,138,535...51,262,906

G

ADP-ribosylation factor like GTPase 5A

decreases expression

Vincristine results in decreased expression of ARL5A mRNA

NCBI chr 3:36,878,461...36,903,362
Ensembl chr 3:36,880,712...36,903,211

G

ADP-ribosylation factor like GTPase 5B

increases expression

Vincristine results in increased expression of ARL5B mRNA

NCBI chr17:77,955,864...77,979,895
Ensembl chr17:77,955,818...77,979,854

G

ADP-ribosylation factor like GTPase 6 interacting protein 1

decreases expression

Vincristine results in decreased expression of ARL6IP1 mRNA

NCBI chr 1:172,430,475...172,439,990
Ensembl chr 1:172,430,489...172,439,994

G

armadillo repeat containing 8

decreases expression

Vincristine results in decreased expression of ARMC8 mRNA

NCBI chr 8:100,036,946...100,131,544
Ensembl chr 8:100,036,946...100,131,520

G

assembly factor for spindle microtubules

increases expression

Vincristine results in increased expression of ASPM mRNA

NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755

G

ASXL transcriptional regulator 1

increases expression

Vincristine results in increased expression of ASXL1 mRNA

NCBI chr 3:141,814,012...141,881,526
Ensembl chr 3:141,813,433...141,881,538

G

ATPase family, AAA domain containing 2

decreases expression

Vincristine results in decreased expression of ATAD2 mRNA

NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738

G

activating transcription factor 3

increases expression

Vincristine results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 5

increases expression

Vincristine results in increased expression of ATF5 mRNA

NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707

G

activating transcription factor 6

multiple interactions
increases expression

Quercetin inhibits the reaction [Vincristine results in increased expression of ATF6 mRNA]

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

ATPase plasma membrane Ca2+ transporting 4

increases expression

Vincristine results in increased expression of ATP2B4 mRNA

NCBI chr13:45,156,137...45,255,292
Ensembl chr13:45,156,146...45,255,246

G

ATP synthase F1 subunit gamma

decreases expression

Vincristine results in decreased expression of ATP5F1C mRNA

NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367

G

ATPase H+ transporting V0 subunit e1

increases expression

Vincristine results in increased expression of ATP6V0E1 mRNA

NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434

G

ATPase copper transporting alpha

decreases response to substance

ATP7A protein results in decreased susceptibility to Vincristine

NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354

G

ATPase phospholipid transporting 8A1

decreases expression

Vincristine results in decreased expression of ATP8A1 mRNA

NCBI chr14:40,315,013...40,557,572
Ensembl chr14:40,315,049...40,554,611

G

aurora kinase A

increases response to substance
increases expression

AURKA gene SNP results in increased susceptibility to Vincristine
Vincristine results in increased expression of AURKA mRNA

PMID:17374387 PMID:20864405

NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390

G

aurora kinase B

decreases expression

Vincristine results in decreased expression of AURKB mRNA

NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837

G

arginine vasopressin

increases expression

Vincristine results in increased expression of AVP protein

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

Beta-1,3-galactosyltransferase 6

decreases expression

Vincristine results in decreased expression of B3GALT6 mRNA

NCBI chr 5:166,584,202...166,586,338
Ensembl chr 5:166,584,202...166,586,338

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5

increases expression

Vincristine results in increased expression of B3GNT5 mRNA

NCBI chr11:81,141,102...81,153,206
Ensembl chr11:81,140,599...81,156,166

G

BCL2-antagonist/killer 1

affects response to substance

BAK1 protein affects the susceptibility to Vincristine

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BMP and activin membrane-bound inhibitor

increases expression

Vincristine results in increased expression of BAMBI mRNA

NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060

G

BRCA1 associated RING domain 1

decreases expression

Vincristine results in decreased expression of BARD1 mRNA

NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265

G

brain abundant, membrane attached signal protein 1

increases expression

Vincristine results in increased expression of BASP1 mRNA

NCBI chr 2:75,816,130...75,863,801
Ensembl chr 2:75,816,122...75,864,043

G

basic leucine zipper ATF-like transcription factor

increases expression

Vincristine results in increased expression of BATF mRNA

NCBI chr 6:105,353,715...105,376,051
Ensembl chr 6:105,353,715...105,376,051

G

BCL2 associated X, apoptosis regulator

decreases expression
multiple interactions
increases expression
affects response to substance

Vincristine results in decreased expression of BAX mRNA
KN 93 inhibits the reaction [Vincristine results in increased expression of BAX mRNA]; KN 93 inhibits the reaction [Vincristine results in increased expression of BAX protein]
Vincristine results in increased expression of BAX mRNA; Vincristine results in increased expression of BAX protein
Quercetin inhibits the reaction [Vincristine results in increased expression of BAX mRNA]
BAX protein affects the susceptibility to Vincristine
[Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BAX protein; Vincristine results in increased cleavage of and results in increased expression of BAX protein

PMID:9815696 PMID:15131059 PMID:16001973 PMID:22178383 PMID:33038355 More...

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

branched chain amino acid transaminase 1

increases expression

Vincristine results in increased expression of BCAT1 mRNA

NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597

G

BCL2, apoptosis regulator

decreases response to substance
multiple interactions
decreases expression
increases phosphorylation

BCL2 protein results in decreased susceptibility to Vincristine
KN 93 inhibits the reaction [Vincristine results in decreased expression of BCL2 mRNA]; KN 93 inhibits the reaction [Vincristine results in decreased expression of BCL2 protein]
Vincristine results in decreased expression of BCL2 mRNA; Vincristine results in decreased expression of BCL2 protein
Quercetin inhibits the reaction [Vincristine results in decreased expression of BCL2 mRNA]
Vincristine results in increased phosphorylation of BCL2 protein
[Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BCL2 protein; [MIR497 results in decreased expression of BCL2 protein] which results in increased susceptibility to Vincristine; TYMP inhibits the reaction [Vincristine results in increased phosphorylation of BCL2 protein]

PMID:9815696 PMID:15907805 PMID:20162574 PMID:21182165 PMID:21258880 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL2-related protein A1

increases expression

Vincristine results in increased expression of BCL2A1 mRNA

NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998

G

Bcl2-like 1

increases expression
affects response to substance

Vincristine results in increased expression of BCL2L1 mRNA
BCL2L1 protein affects the susceptibility to Vincristine

PMID:22178383 PMID:23649840

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

BCL2-associated transcription factor 1

decreases expression

Vincristine results in decreased expression of BCLAF1 mRNA

NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:15,070,894...15,148,832

G

BCL6 co-repressor

increases expression

Vincristine results in increased expression of BCOR mRNA

NCBI chr X:10,609,756...10,729,613
Ensembl chr X:10,687,732...10,729,613

G

bradykinin receptor B1

multiple interactions

[HOE 140, desArg(10)- binds to and results in decreased activity of BDKRB1 protein] which results in decreased susceptibility to Vincristine

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

bradykinin receptor B2

multiple interactions

[icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Vincristine

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

baculoviral IAP repeat-containing 2

increases expression

Vincristine results in increased expression of BIRC2 mRNA

NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732

G

baculoviral IAP repeat-containing 3

increases expression

Vincristine results in increased expression of BIRC3 mRNA

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

BLM RecQ like helicase

decreases expression

Vincristine results in decreased expression of BLM mRNA

NCBI chr 1:134,409,832...134,496,073
Ensembl chr 1:134,409,857...134,484,312

G

bone morphogenetic protein 2

increases expression

Vincristine results in increased expression of BMP2 mRNA

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

BCL2 interacting protein 3

decreases expression
multiple interactions

Vincristine results in decreased expression of BNIP3 mRNA
Vincristine affects the reaction [Valproic Acid affects the localization of BNIP3 protein]

PMID:23649840 PMID:25446377

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

BCL2 interacting protein 3 like

decreases expression

Vincristine results in decreased expression of BNIP3L mRNA

NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803

G

BLOC-1 related complex subunit 7

increases expression

Vincristine results in increased expression of BORCS7 mRNA

NCBI chr 1:245,564,347...245,578,182
Ensembl chr 1:245,564,369...245,579,343

G

BRCA1 interacting helicase 1

decreases expression

Vincristine results in decreased expression of BRIP1 mRNA

NCBI chr10:70,907,266...71,031,502
Ensembl chr10:70,907,371...71,030,324

G

bromodomain and WD repeat domain containing 1

decreases expression

Vincristine results in decreased expression of BRWD1 mRNA

NCBI chr11:35,286,364...35,378,768
Ensembl chr11:35,288,313...35,378,768

G

BTG anti-proliferation factor 1

increases expression

Vincristine results in increased expression of BTG1 mRNA

NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649

G

BTG anti-proliferation factor 2

increases expression

Vincristine results in increased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

BTG anti-proliferation factor 4

increases expression

Vincristine results in increased expression of BTG4 mRNA

NCBI chr 8:51,410,774...51,425,802
Ensembl chr 8:51,422,061...51,425,796

G

BUB3 mitotic checkpoint protein

decreases expression

Vincristine results in decreased expression of BUB3 mRNA

NCBI chr 1:186,330,358...186,340,969
Ensembl chr 1:186,327,931...186,395,036

G

similar to human chromosome 1 open reading frame 74

decreases expression

Vincristine results in decreased expression of C1ORF74 mRNA

NCBI chr13:104,692,769...104,695,368
Ensembl chr13:104,692,824...104,695,470

G

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1

decreases expression

Vincristine results in decreased expression of C1GALT1 mRNA

NCBI chr 4:35,930,981...35,966,100
Ensembl chr 4:35,928,104...35,961,831

G

similar to human chromosome 12 open reading frame 54

increases expression

Vincristine results in increased expression of C12ORF54 mRNA

NCBI chr 7:129,529,811...129,548,676

G

similar to human chromosome 15 open reading frame 39

decreases expression

Vincristine results in decreased expression of C15ORF39 mRNA

NCBI chr 8:57,646,324...57,655,896
Ensembl chr 8:57,645,756...57,655,941

G

Cdk5 and Abl enzyme substrate 2

decreases expression

Vincristine results in decreased expression of CABLES2 mRNA

NCBI chr 3:167,347,527...167,362,274
Ensembl chr 3:167,347,461...167,362,279

G

calcium voltage-gated channel subunit alpha1 H

increases expression
multiple interactions

Vincristine results in increased expression of CACNA1H mRNA; Vincristine results in increased expression of CACNA1H protein
Ascorbic Acid inhibits the reaction [Vincristine results in increased expression of CACNA1H mRNA]; Ascorbic Acid inhibits the reaction [Vincristine results in increased expression of CACNA1H protein]; KN 62 inhibits the reaction [Vincristine results in increased expression of CACNA1H protein]; KN 93 inhibits the reaction [Vincristine results in increased expression of CACNA1H mRNA]; KN 93 inhibits the reaction [Vincristine results in increased expression of CACNA1H protein]; zinc chloride inhibits the reaction [Vincristine results in increased expression of CACNA1H protein]

NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376

G

calcium voltage-gated channel auxiliary subunit beta 2

increases expression

Vincristine results in increased expression of CACNB2 mRNA

NCBI chr17:77,564,630...77,910,000
Ensembl chr17:77,564,460...77,909,106

G

caldesmon 1

increases expression

Vincristine results in increased expression of CALD1 mRNA

NCBI chr 4:63,265,781...63,446,938
Ensembl chr 4:63,265,942...63,446,932

G

calmodulin 2

decreases expression

Vincristine results in decreased expression of CALM2 mRNA

NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
Ensembl chr15:7,091,567...7,104,287

G

calumenin

increases expression

Vincristine results in increased expression of CALU mRNA

NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593

G

calcium/calmodulin-dependent protein kinase II delta

decreases expression

Vincristine results in decreased expression of CAMK2D mRNA

NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178

G

calcium/calmodulin-dependent protein kinase kinase 1

increases response to substance

CAMKK1 gene SNP results in increased susceptibility to Vincristine

NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498

G

capping actin protein, gelsolin like

increases expression

Vincristine results in increased expression of CAPG mRNA

NCBI chr 4:104,594,743...104,611,856
Ensembl chr 4:104,594,753...104,611,856

G

calcium regulated heat stable protein 1

decreases expression

Vincristine results in decreased expression of CARHSP1 mRNA

NCBI chr10:6,946,036...6,960,556
Ensembl chr10:6,946,959...7,020,019

G

caspase 1

increases expression

Vincristine results in increased expression of CASP1 mRNA

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

increases cleavage
multiple interactions
increases expression

Vincristine results in increased cleavage of CASP3 protein
KN 93 inhibits the reaction [Vincristine results in increased cleavage of CASP3 protein]
coenzyme Q10 inhibits the reaction [Vincristine results in increased expression of CASP3 protein]; Quercetin inhibits the reaction [Vincristine results in increased expression of CASP3 mRNA]; Quercetin inhibits the reaction [Vincristine results in increased expression of CASP3 protein]; Sumatriptan inhibits the reaction [Vincristine results in increased expression of CASP3 mRNA]; Sumatriptan inhibits the reaction [Vincristine results in increased expression of CASP3 protein]
Vincristine results in increased expression of CASP3 mRNA; Vincristine results in increased expression of CASP3 protein

PMID:20624997 PMID:29958920 PMID:33038355 PMID:34286406 PMID:34939713 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 6

increases expression

Vincristine results in increased expression of CASP6 mRNA

NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502

G

caspase 8

increases expression
increases response to substance
multiple interactions

Vincristine results in increased expression of CASP8 mRNA
CASP8 protein results in increased susceptibility to Vincristine
Vincristine results in increased expression of and results in increased cleavage of CASP8 protein

PMID:16001973 PMID:22010212

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

catalase

affects response to substance
decreases activity
decreases expression
multiple interactions

CAT protein affects the susceptibility to Vincristine
Vincristine results in decreased activity of CAT protein
Vincristine results in decreased expression of CAT protein
Quercetin inhibits the reaction [Vincristine results in decreased activity of CAT protein]; tetrahydrocurcumin inhibits the reaction [Vincristine results in decreased expression of CAT protein]; Vincristine inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]; Vincristine inhibits the reaction [Isoproterenol results in decreased expression of CAT protein]

PMID:11178967 PMID:24201307 PMID:25537132 PMID:26102012 PMID:36808657

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

chromobox 3

decreases expression

Vincristine results in decreased expression of CBX3 mRNA

NCBI chr 4:80,545,450...80,559,284
Ensembl chr 4:80,546,010...80,559,283

G

chromobox 5

decreases expression

Vincristine results in decreased expression of CBX5 mRNA

NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022

G

cell division cycle and apoptosis regulator 1

decreases expression

Vincristine results in decreased expression of CCAR1 mRNA

NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526

G

coiled-coil domain containing 12

decreases expression

Vincristine results in decreased expression of CCDC12 mRNA

NCBI chr 8:110,635,276...110,686,417
Ensembl chr 8:110,635,710...110,686,417

G

coiled-coil domain containing 186

decreases expression

Vincristine results in decreased expression of CCDC186 mRNA

NCBI chr 1:255,831,663...255,871,954
Ensembl chr 1:255,839,595...255,871,935

G

coiled-coil domain containing 198

decreases expression

Vincristine results in decreased expression of CCDC198 mRNA

NCBI chr15:22,500,181...22,527,011
Ensembl chr15:22,502,687...22,526,992

G

coiled-coil domain containing 32

decreases expression

Vincristine results in decreased expression of CCDC32 mRNA

NCBI chr 3:105,998,429...106,010,985
Ensembl chr 3:105,998,430...106,010,975

G

coiled-coil domain containing 82

increases expression

Vincristine results in increased expression of CCDC82 mRNA

NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963

G

coiled-coil alpha-helical rod protein 1

decreases expression

Vincristine results in decreased expression of CCHCR1 mRNA

NCBI chr20:3,205,675...3,218,437
Ensembl chr20:3,205,676...3,218,308

G

C-C motif chemokine ligand 1

increases expression

Vincristine results in increased expression of CCL1 mRNA

NCBI chr10:67,128,331...67,131,109
Ensembl chr10:67,128,331...67,131,159

G

C-C motif chemokine ligand 2

increases expression

Vincristine results in increased expression of CCL2 mRNA

PMID:20624997 PMID:23649840

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

increases expression

Vincristine results in increased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 22

increases expression

Vincristine results in increased expression of CCL22 mRNA

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

C-C motif chemokine ligand 4

increases expression

Vincristine results in increased expression of CCL4 mRNA

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

increases expression

Vincristine results in increased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cellular communication network factor 2

decreases response to substance

CCN2 mRNA results in decreased susceptibility to Vincristine

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin B1

affects response to substance
increases expression

CCNB1 protein affects the susceptibility to Vincristine
Vincristine results in increased expression of CCNB1 mRNA

PMID:22178383 PMID:23649840

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin B2

increases expression

Vincristine results in increased expression of CCNB2 mRNA

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

cyclin E1

decreases expression

Vincristine results in decreased expression of CCNE1 mRNA

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin E2

decreases expression

Vincristine results in decreased expression of CCNE2 mRNA

NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632

G

cyclin L1

decreases expression

Vincristine results in decreased expression of CCNL1 mRNA

NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368

G

CD109 molecule

increases expression

Vincristine results in increased expression of CD109 mRNA

NCBI chr 8:79,454,480...79,569,195
Ensembl chr 8:79,454,480...79,569,194

G

CD14 molecule

increases expression

Vincristine results in increased expression of CD14 mRNA

NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261

G

Cd200 molecule

increases expression

Vincristine results in increased expression of CD200 mRNA

NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648

G

CD274 molecule

increases expression

Vincristine results in increased expression of CD274 mRNA

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

CD36 molecule

increases expression

Vincristine results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

CD40 molecule

increases expression

Vincristine results in increased expression of CD40 mRNA

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

CD44 molecule

increases expression

Vincristine results in increased expression of CD44 mRNA

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

Cd48 molecule

increases expression

Vincristine results in increased expression of CD48 mRNA

NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142

G

CD55 molecule (Cromer blood group)

increases expression

Vincristine results in increased expression of CD55 mRNA

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

Cd69 molecule

increases expression

Vincristine results in increased expression of CD69 mRNA

NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542

G

Cd80 molecule

increases expression

Vincristine results in increased expression of CD80 mRNA

NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030

G

CD83 molecule

increases expression

Vincristine results in increased expression of CD83 mRNA

NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083

G

CD86 molecule

increases expression

Vincristine results in increased expression of CD86 mRNA

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

CDC42 effector protein 3

increases expression

Vincristine results in increased expression of CDC42EP3 mRNA

NCBI chr 6:15,710,894...15,731,366
Ensembl chr 6:15,708,730...15,732,721

G

CDC42 effector protein 4

increases expression

Vincristine results in increased expression of CDC42EP4 mRNA

NCBI chr10:98,772,613...98,797,924
Ensembl chr10:98,772,495...98,797,695

G

CDC42 small effector 1

increases expression

Vincristine results in increased expression of CDC42SE1 mRNA

NCBI chr 2:182,805,691...182,813,520
Ensembl chr 2:182,804,925...182,814,028

G

cell division cycle 6

decreases expression

Vincristine results in decreased expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cell division cycle associated 3

decreases expression

Vincristine results in decreased expression of CDCA3 mRNA

NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799

G

cell division cycle associated 7

decreases expression

Vincristine results in decreased expression of CDCA7 mRNA

NCBI chr 3:57,322,718...57,333,353
Ensembl chr 3:57,322,708...57,333,353

G

cadherin 1

increases expression

Vincristine results in increased expression of CDH1 mRNA

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cyclin-dependent kinase 1

decreases expression

Vincristine results in decreased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase 10

decreases expression

Vincristine results in decreased expression of CDK10 mRNA

NCBI chr19:51,260,012...51,273,009
Ensembl chr19:51,261,356...51,269,078

G

cyclin-dependent kinase 19

decreases expression

Vincristine results in decreased expression of CDK19 mRNA

NCBI chr20:43,770,409...43,910,629
Ensembl chr20:43,770,409...43,910,628

G

cyclin dependent kinase 2

decreases expression

Vincristine results in decreased expression of CDK2 mRNA

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

Vincristine results in increased expression of CDKN1A mRNA
[XL019 compound co-treated with Vincristine] results in increased expression of CDKN1A protein; Resveratrol inhibits the reaction [Vincristine results in increased expression of CDKN1A mRNA]

PMID:20624997 PMID:23649840 PMID:26055805 PMID:29187454

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2A

increases response to substance

CDKN2A protein results in increased susceptibility to Vincristine

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cyclin-dependent kinase inhibitor 2C

decreases expression

Vincristine results in decreased expression of CDKN2C mRNA

NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278

G

CEA cell adhesion molecule 1

increases expression

Vincristine results in increased expression of CEACAM1 mRNA

NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992

G

CCAAT/enhancer binding protein beta

increases expression

Vincristine results in increased expression of CEBPB mRNA

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

CUGBP, Elav-like family member 1

decreases expression

Vincristine results in decreased expression of CELF1 mRNA

NCBI chr 3:76,924,591...76,999,429
Ensembl chr 3:76,924,613...76,999,426

G

centromere protein C

decreases expression

Vincristine results in decreased expression of CENPC1 mRNA

NCBI chr14:21,988,067...22,046,732
Ensembl chr14:21,988,144...22,055,476

G

centromere protein F

decreases expression

Vincristine results in decreased expression of CENPF mRNA

NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669

G

centromere protein I

decreases expression

Vincristine results in decreased expression of CENPI mRNA

NCBI chr X:97,515,919...97,567,671
Ensembl chr X:97,515,972...97,567,657

G

centromere protein U

decreases expression

Vincristine results in decreased expression of CENPU mRNA

NCBI chr16:45,715,821...45,739,038
Ensembl chr16:45,714,294...45,738,823

G

centrosomal protein 135

increases expression

Vincristine results in increased expression of CEP135 mRNA

NCBI chr14:31,530,538...31,595,812
Ensembl chr14:31,531,482...31,595,772

G

carboxylesterase 5A

increases expression

Vincristine results in increased expression of CES5A mRNA

NCBI chr19:11,469,431...11,499,007
Ensembl chr19:11,469,469...11,499,006

G

CASP8 and FADD-like apoptosis regulator

increases expression

Vincristine results in increased expression of CFLAR mRNA

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

chromodomain helicase DNA binding protein 1-like

increases expression

Vincristine results in increased expression of CHD1L mRNA

NCBI chr 2:185,138,526...185,217,498
Ensembl chr 2:185,139,308...185,217,595

G

checkpoint kinase 2

decreases expression

Vincristine results in decreased expression of CHEK2 mRNA

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

CHM Rab escort protein

increases expression

Vincristine results in increased expression of CHM mRNA

NCBI chr X:78,203,200...78,361,996
Ensembl chr X:78,203,204...78,361,943

G

CHM like Rab escort protein

decreases expression

Vincristine results in decreased expression of CHML mRNA

NCBI chr13:87,609,647...87,619,868
Ensembl chr13:87,589,298...87,619,862

G

chromosome transmission fidelity factor 18

decreases expression

Vincristine results in decreased expression of CHTF18 mRNA

NCBI chr10:14,743,006...14,751,044
Ensembl chr10:14,742,621...14,751,050

G

cytokine induced apoptosis inhibitor 1

decreases response to substance

CIAPIN1 protein results in decreased susceptibility to Vincristine

NCBI chr19:10,179,963...10,195,511
Ensembl chr19:10,180,100...10,195,503

G

cold inducible RNA binding protein

decreases expression

Vincristine results in decreased expression of CIRBP mRNA

NCBI chr 7:9,533,857...9,538,899
Ensembl chr 7:9,424,178...9,538,818

G

cytoplasmic linker associated protein 2

increases expression

Vincristine results in increased expression of CLASP2 mRNA

NCBI chr 8:113,677,345...113,859,957
Ensembl chr 8:113,677,284...113,858,731

G

C-type lectin domain family 2, member D

decreases expression

Vincristine results in decreased expression of CLEC2D mRNA

NCBI chr 4:162,216,052...162,239,530
Ensembl chr 4:162,216,572...162,239,527

G

chloride intracellular channel 2

increases expression

Vincristine results in increased expression of CLIC2 mRNA

NCBI chr20:149,337...164,375
Ensembl chr20:148,907...164,355

G

claspin

decreases expression

Vincristine results in decreased expression of CLSPN mRNA

NCBI chr 5:138,850,119...138,885,037
Ensembl chr 5:138,850,128...138,885,034

G

connector enhancer of kinase suppressor of Ras 2

decreases expression

Vincristine results in decreased expression of CNKSR2 mRNA

NCBI chr X:36,908,135...37,148,337
Ensembl chr X:36,907,850...37,150,555

G

CCR4-NOT transcription complex, subunit 3

decreases expression

Vincristine results in decreased expression of CNOT3 mRNA

NCBI chr 1:65,555,924...65,572,167
Ensembl chr 1:65,555,924...65,572,167

G

CCR4-NOT transcription complex, subunit 6-like

decreases expression

Vincristine results in decreased expression of CNOT6L mRNA

NCBI chr14:13,410,499...13,502,511
Ensembl chr14:13,411,281...13,498,203

G

centlein

decreases expression

Vincristine results in decreased expression of CNTLN mRNA

NCBI chr 5:99,295,865...99,576,402
Ensembl chr 5:99,296,000...99,576,396

G

collagen type XV alpha 1 chain

decreases response to substance

COL15A1 mRNA results in decreased susceptibility to Vincristine

NCBI chr 5:61,501,963...61,607,591
Ensembl chr 5:61,501,963...61,607,591

G

collagen type I alpha 2 chain

increases response to substance

COL1A2 mRNA results in increased susceptibility to Vincristine

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type III alpha 1 chain

decreases response to substance

COL3A1 mRNA results in decreased susceptibility to Vincristine

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type V alpha 2 chain

decreases response to substance

COL5A2 mRNA results in decreased susceptibility to Vincristine

NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154

G

catechol-O-methyltransferase domain containing 1

decreases expression

Vincristine results in decreased expression of COMTD1 mRNA

NCBI chr15:2,459,783...2,462,895
Ensembl chr15:2,459,783...2,462,895

G

ceruloplasmin

increases expression

Vincristine results in increased expression of CP mRNA

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

cytoplasmic polyadenylation element binding protein 2

increases expression

Vincristine results in increased expression of CPEB2 mRNA

NCBI chr14:67,787,503...67,839,973
Ensembl chr14:67,787,507...67,840,743

G

copine 3

decreases expression

Vincristine results in decreased expression of CPNE3 mRNA

NCBI chr 5:33,014,658...33,063,934
Ensembl chr 5:33,016,307...33,063,934

G

cleavage and polyadenylation specific factor 6

decreases expression

Vincristine results in decreased expression of CPSF6 mRNA

NCBI chr 7:52,956,589...53,001,783
Ensembl chr 7:52,956,589...52,988,122

G

CREB binding protein

increases expression

Vincristine results in increased expression of CREBBP mRNA

NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888

G

CREB3 regulatory factor

increases expression

Vincristine results in increased expression of CREBRF mRNA

NCBI chr10:16,399,170...16,479,650
Ensembl chr10:16,404,596...16,461,999

G

CREB/ATF bZIP transcription factor

decreases expression

Vincristine results in decreased expression of CREBZF mRNA

NCBI chr 1:144,416,864...144,423,540
Ensembl chr 1:144,417,446...144,428,553

G

cartilage associated protein

decreases expression

Vincristine results in decreased expression of CRTAP mRNA

NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631

G

CREB regulated transcription coactivator 3

increases expression

Vincristine results in increased expression of CRTC3 mRNA

NCBI chr 1:134,552,830...134,655,929
Ensembl chr 1:134,554,696...134,655,500

G

cysteine sulfinic acid decarboxylase

decreases expression

Vincristine results in decreased expression of CSAD mRNA

NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615

G

colony stimulating factor 2

increases expression

Vincristine results in increased expression of CSF2 mRNA

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

casein kinase 1, alpha 1

increases expression

Vincristine results in increased expression of CSNK1A1 mRNA

NCBI chr18:55,017,049...55,050,184
Ensembl chr18:55,017,055...55,049,271

G

casein kinase 1, gamma 1

increases expression

Vincristine results in increased expression of CSNK1G1 mRNA

NCBI chr 8:66,439,760...66,577,247
Ensembl chr 8:66,439,864...66,572,826

G

cystatin A

increases expression

Vincristine results in increased expression of CSTA mRNA

NCBI chr11:64,620,483...64,631,488
Ensembl chr11:64,620,483...64,631,488

G

cleavage stimulation factor subunit 1

decreases expression

Vincristine results in decreased expression of CSTF1 mRNA

NCBI chr 3:161,144,522...161,156,294
Ensembl chr 3:161,144,548...161,156,300

G

CST telomere replication complex component 1

decreases expression

Vincristine results in decreased expression of CTC1 mRNA

NCBI chr10:53,714,614...53,735,298
Ensembl chr10:53,714,644...53,735,298

G

cystathionine gamma-lyase

increases expression

Vincristine results in increased expression of CTH mRNA

NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234

G

catenin alpha-like 1

decreases expression

Vincristine results in decreased expression of CTNNAL1 mRNA

NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431

G

catenin beta 1

increases expression
decreases response to substance

Vincristine results in increased expression of CTNNB1 mRNA
CTNNB1 results in decreased susceptibility to Vincristine

PMID:22000491 PMID:23649840

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cullin 4A

increases expression

Vincristine results in increased expression of CUL4A mRNA

NCBI chr16:76,385,298...76,422,316
Ensembl chr16:76,384,546...76,422,330

G

C-X-C motif chemokine ligand 10

increases expression

Vincristine results in increased expression of CXCL10 mRNA

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 11

increases expression

Vincristine results in increased expression of CXCL11 mRNA

NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271

G

C-X-C motif chemokine ligand 12

increases expression
multiple interactions

Vincristine results in increased expression of CXCL12 mRNA
KN 93 inhibits the reaction [Vincristine results in increased expression of CXCL12 mRNA]

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 9

increases expression

Vincristine results in increased expression of CXCL9 mRNA

NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435

G

CYLD lysine 63 deubiquitinase

increases expression

Vincristine results in increased expression of CYLD mRNA

NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658

G

cytochrome P450, family 2, subfamily c, polypeptide 79

increases response to substance

CYP2C8 gene SNP results in increased susceptibility to Vincristine

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases metabolic processing

CYP3A4 protein results in increased metabolism of Vincristine

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions
increases metabolic processing

[CYP3A5 gene polymorphism results in increased activity of CYP3A5 protein] which results in increased metabolism of Vincristine
CYP3A5 protein results in increased metabolism of Vincristine

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450, family 4, subfamily f, polypeptide 18

increases expression

Vincristine results in increased expression of CYP4F3 mRNA

NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940

G

cytochrome P450, family 4, subfamily v, polypeptide 3

decreases expression

Vincristine results in decreased expression of CYP4V2 mRNA

NCBI chr16:46,917,929...46,958,735
Ensembl chr16:46,918,401...46,943,395

G

cysteinyl leukotriene receptor 1

decreases expression

Vincristine results in decreased expression of CYSLTR1 mRNA

NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121

G

dishevelled associated activator of morphogenesis 1

increases expression

Vincristine results in increased expression of DAAM1 mRNA

NCBI chr 6:90,389,544...90,550,114
Ensembl chr 6:90,389,688...90,550,114

G

DDB1 and CUL4 associated factor 8

increases expression

Vincristine results in increased expression of DCAF8 mRNA

NCBI chr13:84,609,838...84,667,025
Ensembl chr13:84,610,248...84,669,726

G

decorin

decreases response to substance

DCN mRNA results in decreased susceptibility to Vincristine

NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270

G

defective in cullin neddylation 1 domain containing 1

increases expression

Vincristine results in increased expression of DCUN1D1 mRNA

NCBI chr 2:118,721,275...118,772,606
Ensembl chr 2:118,721,822...118,772,602

G

defective in cullin neddylation 1 domain containing 4

decreases expression

Vincristine results in decreased expression of DCUN1D4 mRNA

NCBI chr14:34,652,723...34,733,122
Ensembl chr14:34,652,723...34,733,207

G

DNA-damage inducible transcript 3

increases expression

Vincristine results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DExD-box helicase 50

increases expression

Vincristine results in increased expression of DDX50 mRNA

NCBI chr20:30,561,623...30,591,324
Ensembl chr20:30,560,544...30,591,152

G

DExD-box helicase 52

increases expression

Vincristine results in increased expression of DDX52 mRNA

NCBI chr10:68,824,594...68,847,400
Ensembl chr10:68,824,645...68,848,266

G

DEXD/H-box helicase 60

increases expression

Vincristine results in increased expression of DDX60 mRNA

NCBI chr16:28,077,000...28,197,903
Ensembl chr16:28,076,999...28,179,526

G

DENN domain containing 5A

increases expression

Vincristine results in increased expression of DENND5A mRNA

NCBI chr 1:163,928,183...163,994,207
Ensembl chr 1:163,928,183...163,994,316

G

DGCR8 microprocessor complex subunit

decreases expression

Vincristine results in decreased expression of DGCR8 mRNA

NCBI chr11:82,704,673...82,737,251
Ensembl chr11:82,704,729...82,737,242

G

dihydrofolate reductase

decreases expression

Vincristine results in decreased expression of DHFR mRNA

NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713

G

dehydrogenase/reductase 11

decreases expression

Vincristine results in decreased expression of DHRS11 mRNA

NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295

G

dehydrogenase/reductase 2

increases expression

Vincristine results in increased expression of DHRS2 mRNA

NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644

G

dehydrogenase/reductase 7

increases expression

Vincristine results in increased expression of DHRS7 mRNA

NCBI chr 6:91,332,259...91,347,856
Ensembl chr 6:91,251,323...91,347,892

G

diablo, IAP-binding mitochondrial protein

decreases expression

Vincristine results in decreased expression of DIABLO mRNA

NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387

G

death inducer-obliterator 1

decreases expression

Vincristine results in decreased expression of DIDO1 mRNA

NCBI chr 3:167,772,535...167,825,894
Ensembl chr 3:167,772,770...167,817,218

G

disco-interacting protein 2 homolog A

increases expression

Vincristine results in increased expression of DIP2A mRNA

NCBI chr20:12,284,566...12,371,068
Ensembl chr20:12,284,654...12,370,217

G

dystrophin

increases expression

Vincristine results in increased expression of DMD mRNA

NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207

G

DnaJ heat shock protein family (Hsp40) member B1

decreases expression

Vincristine results in decreased expression of DNAJB1 mRNA

NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458

G

DnaJ heat shock protein family (Hsp40) member C7

increases expression

Vincristine results in increased expression of DNAJC7 mRNA

NCBI chr10:85,518,637...85,555,079
Ensembl chr10:85,518,621...85,555,575

G

deoxyribonuclease 1L3

decreases expression

Vincristine results in decreased expression of DNASE1L3 mRNA

NCBI chr15:16,922,335...16,948,322
Ensembl chr15:16,922,335...16,948,317

G

dynamin binding protein

decreases expression

Vincristine results in decreased expression of DNMBP mRNA

NCBI chr 1:242,736,189...242,829,431
Ensembl chr 1:242,736,189...242,802,604

G

dedicator of cytokinesis 4

increases expression

Vincristine results in increased expression of DOCK4 mRNA

NCBI chr 6:57,512,929...57,902,597
Ensembl chr 6:57,512,908...57,901,855

G

dedicator of cytokinesis 8

decreases expression

Vincristine results in decreased expression of DOCK8 mRNA

NCBI chr 1:222,649,309...222,842,474
Ensembl chr 1:222,649,309...222,842,474

G

docking protein 4

increases expression

Vincristine results in increased expression of DOK4 mRNA

NCBI chr19:10,146,520...10,157,187
Ensembl chr19:10,146,474...10,158,203

G

DNA replication fork stabilization factor DONSON

decreases expression

Vincristine results in decreased expression of DONSON mRNA

NCBI chr11:30,919,834...30,933,150
Ensembl chr11:30,923,239...30,932,889

G

dipeptidylpeptidase 4

decreases expression

Vincristine results in decreased expression of DPP4 mRNA

NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901

G

dihydropyrimidine dehydrogenase

increases response to substance

DPYD gene SNP results in increased susceptibility to Vincristine

NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982

G

DNA-damage regulated autophagy modulator 1

increases expression

Vincristine results in increased expression of DRAM1 mRNA

NCBI chr 7:22,742,794...22,776,888
Ensembl chr 7:22,742,849...22,776,765

G

denticleless E3 ubiquitin protein ligase homolog

decreases expression

Vincristine results in decreased expression of DTL mRNA

NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890

G

dual specificity phosphatase 1

increases expression

Vincristine results in increased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 10

increases expression

Vincristine results in increased expression of DUSP10 mRNA

NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716

G

dual specificity phosphatase 16

increases expression

Vincristine results in increased expression of DUSP16 mRNA

NCBI chr 4:167,546,780...167,630,173
Ensembl chr 4:167,548,155...167,629,980

G

dual specificity phosphatase 2

increases expression

Vincristine results in increased expression of DUSP2 mRNA

NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499

G

dual specificity phosphatase 4

increases expression

Vincristine results in increased expression of DUSP4 mRNA

NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138

G

dynein light chain Tctex-type 2

decreases expression

Vincristine results in decreased expression of DYNLT2 mRNA

NCBI chr 1:55,971,285...55,983,249
Ensembl chr 1:55,971,283...55,983,307

G

E2F transcription factor 8

decreases expression

Vincristine results in decreased expression of E2F8 mRNA

NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098

G

EBF transcription factor 1

increases expression

Vincristine results in increased expression of EBF1 mRNA

NCBI chr10:29,095,858...29,489,142
Ensembl chr10:29,099,933...29,487,665

G

endothelin receptor type B

increases expression

Vincristine results in increased expression of EDNRB mRNA

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

ephrin A4

decreases expression

Vincristine results in decreased expression of EFNA4 mRNA

NCBI chr 2:174,748,729...174,752,979
Ensembl chr 2:174,748,724...174,752,979

G

EGF-like-domain, multiple 6

decreases response to substance

EGFL6 mRNA results in decreased susceptibility to Vincristine

NCBI chr X:27,884,087...27,942,044
Ensembl chr X:27,884,125...27,942,044

G

early growth response 1

increases expression

Vincristine results in increased expression of EGR1 mRNA

PMID:12706485 PMID:23649840

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 3

increases expression

Vincristine results in increased expression of EGR3 mRNA

NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627

G

EH domain binding protein 1-like 1

decreases expression

Vincristine results in decreased expression of EHBP1L1 mRNA

NCBI chr 1:202,994,115...203,014,320
Ensembl chr 1:202,994,118...203,014,270

G

eukaryotic translation initiation factor 1

decreases expression

Vincristine results in decreased expression of EIF1 mRNA

NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327

G

eukaryotic translation initiation factor 1A domain containing

decreases expression

Vincristine results in decreased expression of EIF1AD mRNA

NCBI chr 1:202,674,362...202,679,662
Ensembl chr 1:202,674,185...202,679,658

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases expression
multiple interactions

Vincristine results in increased expression of EIF2AK3 mRNA
Quercetin inhibits the reaction [Vincristine results in increased expression of EIF2AK3 mRNA]

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 3, subunit B

decreases expression

Vincristine results in decreased expression of EIF3B mRNA

NCBI chr12:14,196,403...14,220,865
Ensembl chr12:14,196,403...14,220,886

G

eukaryotic translation initiation factor 3, subunit M

increases expression

Vincristine results in increased expression of EIF3M mRNA

NCBI chr 3:91,424,754...91,442,358
Ensembl chr 3:91,416,325...91,442,392

G

eukaryotic translation initiation factor 4A1

increases expression

Vincristine results in increased expression of EIF4A1 mRNA

NCBI chr10:54,384,345...54,389,855
Ensembl chr10:54,384,347...54,389,858

G

eukaryotic translation initiation factor 4A2

decreases expression

Vincristine results in decreased expression of EIF4A2 mRNA

NCBI chr11:77,764,126...77,770,810
Ensembl chr11:77,764,124...77,770,781

G

E74 like ETS transcription factor 3

increases expression

Vincristine results in increased expression of ELF3 mRNA

NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481

G

ETS transcription factor ELK3

increases expression

Vincristine results in increased expression of ELK3 mRNA

NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084

G

essential meiotic structure-specific endonuclease subunit 2

decreases expression

Vincristine results in decreased expression of EME2 mRNA

NCBI chr10:13,913,216...13,915,991
Ensembl chr10:13,913,221...13,915,968

G

EMAP like 6

decreases expression

Vincristine results in decreased expression of EML6 mRNA

NCBI chr14:103,471,537...103,806,120
Ensembl chr14:103,476,372...103,805,849

G

ecto-NOX disulfide-thiol exchanger 1

increases expression

Vincristine results in increased expression of ENOX1 mRNA

NCBI chr15:52,517,833...53,079,752
Ensembl chr15:52,515,178...53,079,749

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

increases expression

Vincristine results in increased expression of ENPP2 mRNA

NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827

G

endosulfine alpha

decreases expression

Vincristine results in decreased expression of ENSA mRNA

NCBI chr 2:183,185,552...183,192,888
Ensembl chr 2:183,185,552...183,194,847

G

ectonucleoside triphosphate diphosphohydrolase 2

increases expression

Vincristine results in increased expression of ENTPD2 mRNA

NCBI chr 3:8,213,575...8,219,094
Ensembl chr 3:8,213,663...8,226,866

G

eomesodermin

decreases expression

Vincristine results in decreased expression of EOMES mRNA

NCBI chr 8:118,181,340...118,189,186
Ensembl chr 8:118,181,777...118,188,316

G

ectopic P-granules 5 autophagy tethering factor

increases expression

Vincristine results in increased expression of EPG5 mRNA

NCBI chr18:71,403,990...71,502,079
Ensembl chr18:71,404,010...71,501,502

G

Eph receptor B1

decreases expression

Vincristine results in decreased expression of EPHB1 mRNA

NCBI chr 8:102,507,549...102,944,839
Ensembl chr 8:102,507,549...102,944,839

G

epoxide hydrolase 1

decreases expression

Vincristine results in decreased expression of EPHX1 mRNA

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

EPM2A interacting protein 1

decreases expression

Vincristine results in decreased expression of EPM2AIP1 mRNA

NCBI chr 8:111,233,871...111,241,219
Ensembl chr 8:111,233,826...111,241,871

G

erythropoietin receptor

decreases expression

Vincristine results in decreased expression of EPOR mRNA

NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257

G

glutamyl-prolyl-tRNA synthetase 1

increases expression

Vincristine results in increased expression of EPRS1 mRNA

NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966

G

epithelial stromal interaction 1

increases expression

Vincristine results in increased expression of EPSTI1 mRNA

NCBI chr15:53,283,964...53,382,192
Ensembl chr15:53,284,216...53,382,191

G

glutamate-rich 3

decreases expression

Vincristine results in decreased expression of ERICH3 mRNA

NCBI chr 2:243,615,777...243,717,973
Ensembl chr 2:243,615,872...243,715,317

G

endoplasmic reticulum to nucleus signaling 1

increases expression
multiple interactions

Vincristine results in increased expression of ERN1 mRNA
Quercetin inhibits the reaction [Vincristine results in increased expression of ERN1 mRNA]

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

establishment of sister chromatid cohesion N-acetyltransferase 2

decreases expression

Vincristine results in decreased expression of ESCO2 mRNA

NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306

G

esterase D

decreases expression

Vincristine results in decreased expression of ESD mRNA

NCBI chr15:50,043,634...50,063,134
Ensembl chr15:50,043,632...50,063,144

G

endothelial cell-specific molecule 1

decreases expression

Vincristine results in decreased expression of ESM1 mRNA

NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804

G

estrogen receptor 1

multiple interactions
decreases expression

bisphenol A inhibits the reaction [Vincristine results in decreased expression of ESR1 mRNA]; bisphenol A inhibits the reaction [Vincristine results in decreased expression of ESR1 protein]; Diethylhexyl Phthalate inhibits the reaction [Vincristine results in decreased expression of ESR1 mRNA]; Diethylhexyl Phthalate inhibits the reaction [Vincristine results in decreased expression of ESR1 protein]; Vincristine binds to and results in decreased activity of ESR1 protein
Vincristine results in decreased expression of ESR1 mRNA; Vincristine results in decreased expression of ESR1 protein

PMID:25752796 PMID:35263089

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions
decreases expression

bisphenol A inhibits the reaction [Vincristine results in decreased expression of ESR2 mRNA]; bisphenol A inhibits the reaction [Vincristine results in decreased expression of ESR2 protein]; Diethylhexyl Phthalate inhibits the reaction [Vincristine results in decreased expression of ESR2 mRNA]; Diethylhexyl Phthalate inhibits the reaction [Vincristine results in decreased expression of ESR2 protein]
Vincristine results in decreased expression of ESR2 mRNA; Vincristine results in decreased expression of ESR2 protein

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

EvC ciliary complex subunit 1

increases expression

Vincristine results in increased expression of EVC mRNA

NCBI chr14:73,456,181...73,498,955
Ensembl chr14:73,456,222...73,498,099

G

exonuclease 1

decreases expression

Vincristine results in decreased expression of EXO1 mRNA

NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654

G

exo/endonuclease G

decreases expression

Vincristine results in decreased expression of EXOG mRNA

NCBI chr 8:119,184,974...119,204,819
Ensembl chr 8:119,185,136...119,204,672

G

exostosin glycosyltransferase 1

increases expression

Vincristine results in increased expression of EXT1 mRNA

NCBI chr 7:84,375,769...84,654,625
Ensembl chr 7:84,375,784...84,655,357

G

coagulation factor II, thrombin

affects expression

Vincristine affects the expression of F2 protein

NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486

G

coagulation factor III, tissue factor

increases expression

Vincristine results in increased expression of F3 mRNA; Vincristine results in increased expression of F3 protein

PMID:12542493 PMID:20624997

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

family with sequence similarity 13, member B

increases expression

Vincristine results in increased expression of FAM13B mRNA

NCBI chr18:26,040,285...26,107,112
Ensembl chr18:26,040,285...26,106,587

G

family with sequence similarity 13, member C

increases expression

Vincristine results in increased expression of FAM13C mRNA

NCBI chr20:18,065,625...18,187,792
Ensembl chr20:18,065,628...18,187,592

G

family with sequence similarity 171, member B

decreases expression

Vincristine results in decreased expression of FAM171B mRNA

NCBI chr 3:68,930,755...68,986,113
Ensembl chr 3:68,930,822...68,986,127

G

family with sequence similarity 174, member A

increases expression

Vincristine results in increased expression of FAM174A mRNA

NCBI chr 9:95,742,815...95,761,083
Ensembl chr 9:95,742,927...95,761,081

G

family with sequence similarity 76, member B

decreases expression

Vincristine results in decreased expression of FAM76B mRNA

NCBI chr 8:10,689,396...10,711,847
Ensembl chr 8:10,688,963...10,711,861

G

family with sequence similarity 81, member A

decreases expression

Vincristine results in decreased expression of FAM81A mRNA

NCBI chr 8:70,762,852...70,821,898
Ensembl chr 8:70,763,614...70,821,875

G

family with sequence similarity 83, member D

decreases expression

Vincristine results in decreased expression of FAM83D mRNA

NCBI chr 3:147,421,941...147,441,211
Ensembl chr 3:147,421,908...147,441,192

G

FA complementation group F

decreases expression

Vincristine results in decreased expression of FANCF mRNA

NCBI chr 1:101,449,120...101,451,936
Ensembl chr 1:101,450,389...101,451,923

G

FA complementation group G

decreases expression

Vincristine results in decreased expression of FANCG mRNA

NCBI chr 5:57,230,287...57,240,067
Ensembl chr 5:57,231,685...57,240,029

G

Fas cell surface death receptor

increases expression

Vincristine results in increased expression of FAS mRNA

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

increases expression

Vincristine results in increased expression of FASLG protein

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

FAST kinase domains 2

decreases expression

Vincristine results in decreased expression of FASTKD2 mRNA

NCBI chr 9:65,166,148...65,188,184
Ensembl chr 9:65,168,228...65,188,174

G

F-box and leucine-rich repeat protein 20

decreases expression

Vincristine results in decreased expression of FBXL20 mRNA

NCBI chr10:83,080,568...83,143,680
Ensembl chr10:83,086,551...83,144,162

G

F-box and leucine-rich repeat protein 4

decreases expression

Vincristine results in decreased expression of FBXL4 mRNA

NCBI chr 5:35,955,801...36,029,446
Ensembl chr 5:35,955,812...36,029,443

G

F-box protein 33

decreases expression

Vincristine results in decreased expression of FBXO33 mRNA

NCBI chr 6:76,900,619...76,934,232
Ensembl chr 6:76,900,631...76,932,669

G

F-box protein 5

decreases expression

Vincristine results in decreased expression of FBXO5 mRNA

NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437

G

f-box protein 9

decreases expression

Vincristine results in decreased expression of FBXO9 mRNA

NCBI chr 8:78,958,482...78,984,015
Ensembl chr 8:78,958,483...78,983,949

G

Fc gamma receptor 2B

increases expression

Vincristine results in increased expression of FCGR2B mRNA

NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778

G

farnesyl diphosphate farnesyl transferase 1

increases expression

Vincristine results in increased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

FERM domain containing kindlin 2

increases expression

Vincristine results in increased expression of FERMT2 mRNA

NCBI chr15:18,682,927...18,751,959
Ensembl chr15:18,682,927...18,751,811

G

free fatty acid receptor 2

decreases expression

Vincristine results in decreased expression of FFAR2 mRNA

NCBI chr 1:86,071,855...86,075,049
Ensembl chr 1:86,072,184...86,075,033

G

FGR proto-oncogene, Src family tyrosine kinase

decreases expression

Vincristine results in decreased expression of FGR mRNA

NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326

G

flotillin 2

decreases expression

Vincristine results in decreased expression of FLOT2 mRNA

NCBI chr10:62,926,047...62,947,759
Ensembl chr10:62,920,665...62,947,756

G

Fms related receptor tyrosine kinase 1

decreases expression

Vincristine results in decreased expression of FLT1 mRNA

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

formin-like 3

increases expression

Vincristine results in increased expression of FMNL3 mRNA

NCBI chr 7:130,454,270...130,505,626
Ensembl chr 7:130,454,275...130,505,626

G

formin binding protein 1

increases expression

Vincristine results in increased expression of FNBP1 mRNA

NCBI chr 3:14,309,067...14,424,378
Ensembl chr 3:14,309,640...14,424,881

G

formin binding protein 4

increases expression

Vincristine results in increased expression of FNBP4 mRNA

NCBI chr 3:76,733,012...76,763,077
Ensembl chr 3:76,733,027...76,763,079

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Vincristine results in increased expression of FOS protein

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 2, AP-1 transcription factor subunit

increases expression

Vincristine results in increased expression of FOSL2 mRNA

NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034

G

forkhead box K2

decreases expression

Vincristine results in decreased expression of FOXK2 mRNA

NCBI chr10:106,542,643...106,592,569
Ensembl chr10:106,542,566...106,592,563

G

forkhead box O1

multiple interactions
decreases expression

Quercetin inhibits the reaction [Vincristine results in decreased expression of FOXO1 mRNA]

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

forkhead box P1

increases expression

Vincristine results in increased expression of FOXP1 mRNA

NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258

G

FRY microtubule binding protein

decreases expression

Vincristine results in decreased expression of FRY mRNA

NCBI chr12:4,493,890...4,887,118
Ensembl chr12:4,493,891...4,799,116

G

fascin actin-bundling protein 1

increases expression

Vincristine results in increased expression of FSCN1 mRNA

NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211

G

fibronectin type III and SPRY domain containing 1-like

increases expression

Vincristine results in increased expression of FSD1L mRNA

NCBI chr 5:68,258,877...68,334,931
Ensembl chr 5:68,258,932...68,334,928

G

far upstream element binding protein 1

decreases expression

Vincristine results in decreased expression of FUBP1 mRNA

NCBI chr 2:241,159,481...241,186,591
Ensembl chr 2:241,159,512...241,186,602

G

fucosyltransferase 11

decreases expression

Vincristine results in decreased expression of FUT11 mRNA

NCBI chr15:3,598,768...3,602,328
Ensembl chr15:3,598,758...3,602,356

G

G3BP stress granule assembly factor 1

increases expression

Vincristine results in increased expression of G3BP1 mRNA

NCBI chr10:39,586,864...39,620,268
Ensembl chr10:39,586,864...39,620,268

G

growth arrest and DNA-damage-inducible, alpha

increases expression

Vincristine results in increased expression of GADD45A mRNA

PMID:20624997 PMID:23649840

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest and DNA-damage-inducible, beta

increases expression

Vincristine results in increased expression of GADD45B mRNA

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

growth arrest and DNA-damage-inducible, gamma

increases expression

Vincristine results in increased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

golgi associated RAB2 interactor 1B

increases expression

Vincristine results in increased expression of GARIN1B mRNA

NCBI chr 4:57,915,184...57,938,593
Ensembl chr 4:57,920,790...57,938,591

G

phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase

decreases expression

Vincristine results in decreased expression of GART mRNA

NCBI chr11:30,864,896...30,891,125
Ensembl chr11:30,865,889...30,891,125

G

growth arrest specific 7

decreases expression

Vincristine results in decreased expression of GAS7 mRNA

NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276

G

guanylate binding protein 1

increases expression

Vincristine results in increased expression of GBP1 mRNA

NCBI chr 2:231,398,136...231,432,773
Ensembl chr 2:231,398,163...231,432,131
Ensembl chr 2:231,398,163...231,432,131

G

guanylate binding protein 2

increases expression

Vincristine results in increased expression of GBP2 mRNA

NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571

G

guanylate binding protein family member 6

decreases expression

Vincristine results in decreased expression of GBP6 mRNA

NCBI chr14:4,730,286...4,756,508
Ensembl chr14:4,730,453...4,839,062
Ensembl chr14:4,730,453...4,839,062

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Vincristine

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

multiple interactions
decreases expression

[GCLC protein co-treated with GCLM protein] results in decreased susceptibility to Vincristine
Vincristine results in decreased expression of GCLM mRNA

PMID:10900222 PMID:23649840

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

growth differentiation factor 15

increases expression

Vincristine results in increased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

glial fibrillary acidic protein

increases expression
multiple interactions

Vincristine results in increased expression of GFAP protein
Ascorbic Acid inhibits the reaction [Vincristine results in increased expression of GFAP protein]; KN 93 inhibits the reaction [Vincristine results in increased expression of GFAP protein]
Quercetin inhibits the reaction [Vincristine results in increased expression of GFAP protein]

PMID:33038355 PMID:34286406

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

growth factor independent 1 transcriptional repressor

decreases expression

Vincristine results in decreased expression of GFI1 mRNA

NCBI chr14:2,040,576...2,056,874
Ensembl chr14:2,042,434...2,051,814

G

G elongation factor, mitochondrial 1

increases expression

Vincristine results in increased expression of GFM1 mRNA

NCBI chr 2:151,700,573...151,745,477
Ensembl chr 2:151,700,564...151,745,471

G

gap junction protein, alpha 1

increases expression
multiple interactions

Vincristine results in increased expression of GJA1 mRNA; Vincristine results in increased expression of GJA1 protein
Ascorbic Acid inhibits the reaction [Vincristine results in increased expression of GJA1 mRNA]; Ascorbic Acid inhibits the reaction [Vincristine results in increased expression of GJA1 protein]; gap 27 peptide inhibits the reaction [Vincristine results in increased expression of GJA1 mRNA]; gap 27 peptide inhibits the reaction [Vincristine results in increased expression of GJA1 protein]; GJA1 protein promotes the reaction [Vincristine results in increased secretion of IL1B protein]; GJA1 protein promotes the reaction [Vincristine results in increased secretion of IL6 protein]; KN 62 inhibits the reaction [Vincristine results in increased expression of GJA1 protein]; KN 93 inhibits the reaction [Vincristine results in increased expression of GJA1 mRNA]; KN 93 inhibits the reaction [Vincristine results in increased expression of GJA1 protein]; zinc chloride inhibits the reaction [Vincristine results in increased expression of GJA1 protein]

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

gap junction protein, gamma 1

decreases expression

Vincristine results in decreased expression of GJC1 mRNA

NCBI chr10:87,758,192...87,785,443
Ensembl chr10:87,760,528...87,785,867

G

GLI family zinc finger 1

increases response to substance

GLI1 gene SNP results in increased susceptibility to Vincristine

NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251

G

GLI pathogenesis-related 1

increases expression

Vincristine results in increased expression of GLIPR1 mRNA

NCBI chr 7:47,487,342...47,498,974
Ensembl chr 7:47,487,345...47,498,429

G

glia maturation factor, beta

increases expression

Vincristine results in increased expression of GMFB mRNA

NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331

G

GDP-mannose pyrophosphorylase B

decreases expression

Vincristine results in decreased expression of GMPPB mRNA

NCBI chr 8:108,737,429...108,740,437
Ensembl chr 8:108,693,060...108,767,286

G

G protein subunit alpha 15

increases expression

Vincristine results in increased expression of GNA15 mRNA

NCBI chr 7:8,184,632...8,205,508
Ensembl chr 7:8,184,861...8,205,508

G

G protein subunit gamma 2

increases expression

Vincristine results in increased expression of GNG2 mRNA

NCBI chr15:4,316,038...4,416,918
Ensembl chr15:4,316,059...4,417,183

G

gon-4 like

increases expression

Vincristine results in increased expression of GON4L mRNA

NCBI chr 2:174,233,461...174,306,636
Ensembl chr 2:174,233,461...174,306,634

G

golgi associated PDZ and coiled-coil motif containing

decreases expression

Vincristine results in decreased expression of GOPC mRNA

NCBI chr20:31,727,617...31,776,904
Ensembl chr20:31,727,620...31,776,903

G

G patch domain containing 11

decreases expression

Vincristine results in decreased expression of GPATCH11 mRNA

NCBI chr 6:16,229,933...16,243,305
Ensembl chr 6:16,233,059...16,243,238

G

G patch domain containing 2

increases expression

Vincristine results in increased expression of GPATCH2 mRNA

NCBI chr13:98,784,993...98,925,696
Ensembl chr13:98,784,969...98,925,661

G

G patch domain containing 2-like

increases expression

Vincristine results in increased expression of GPATCH2L mRNA

NCBI chr 6:105,883,383...105,935,644
Ensembl chr 6:105,883,460...105,934,888

G

GC-rich promoter binding protein 1-like 1

increases expression

Vincristine results in increased expression of GPBP1L1 mRNA

NCBI chr 5:130,009,768...130,050,636
Ensembl chr 5:130,023,137...130,050,459

G

glypican 3

increases response to substance

GPC3 mRNA results in increased susceptibility to Vincristine

NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798

G

glycerol-3-phosphate dehydrogenase 2

decreases expression

Vincristine results in decreased expression of GPD2 mRNA

NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901

G

glycoprotein nmb

increases expression

Vincristine results in increased expression of GPNMB mRNA

NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367

G

G protein-coupled receptor 132

increases expression

Vincristine results in increased expression of GPR132 mRNA

NCBI chr 6:131,924,061...131,943,327
Ensembl chr 6:131,924,160...131,942,168

G

G protein-coupled receptor 137B

increases expression

Vincristine results in increased expression of GPR137B mRNA

NCBI chr17:86,003,635...86,041,841
Ensembl chr17:85,966,921...86,041,835

G

G protein-coupled receptor 180

decreases expression

Vincristine results in decreased expression of GPR180 mRNA

NCBI chr15:95,195,782...95,224,955
Ensembl chr15:95,199,777...95,228,373

G

G protein-coupled receptor 55

increases expression

Vincristine results in increased expression of GPR55 mRNA

NCBI chr 9:86,584,906...86,640,601
Ensembl chr 9:86,590,885...86,640,613

G

G protein-coupled receptor 63

decreases expression

Vincristine results in decreased expression of GPR63 mRNA

NCBI chr 5:38,672,548...38,727,224
Ensembl chr 5:38,635,472...38,727,677

G

G protein-coupled receptor 84

increases expression

Vincristine results in increased expression of GPR84 mRNA

NCBI chr 7:134,443,904...134,446,173
Ensembl chr 7:134,443,936...134,446,178

G

glutamic--pyruvic transaminase

multiple interactions
increases activity

Quercetin inhibits the reaction [Vincristine results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

GRAM domain containing 2B

increases expression

Vincristine results in increased expression of GRAMD2B mRNA

NCBI chr18:49,884,014...49,981,955
Ensembl chr18:49,884,014...49,981,953

G

GRB2-related adaptor protein 2

decreases expression

Vincristine results in decreased expression of GRAP2 mRNA

NCBI chr 7:112,117,142...112,190,880
Ensembl chr 7:112,117,142...112,190,877

G

G1 to S phase transition 1

increases expression

Vincristine results in increased expression of GSPT1 mRNA

NCBI chr10:4,362,528...4,397,215
Ensembl chr10:4,362,510...4,397,198

G

glutathione S-transferase mu 1

affects response to substance
decreases response to substance
multiple interactions

GSTM1 gene polymorphism affects the susceptibility to Vincristine
GSTM1 protein results in decreased susceptibility to Vincristine
Sulfinpyrazone inhibits the reaction [GSTM1 protein results in decreased susceptibility to Vincristine]

PMID:15044619 PMID:15713801

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase pi 1

decreases response to substance
multiple interactions

GSTP1 protein results in decreased susceptibility to Vincristine
GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

general transcription factor IIIC subunit 3

increases expression

Vincristine results in increased expression of GTF3C3 mRNA

NCBI chr 9:55,882,252...55,943,037
Ensembl chr 9:55,883,721...55,942,967

G

GTP binding protein 3

decreases expression

Vincristine results in decreased expression of GTPBP3 mRNA

NCBI chr16:18,175,766...18,180,857
Ensembl chr16:18,175,766...18,180,857

G

H2A.X variant histone

multiple interactions

[CEP 33779 results in increased susceptibility to Vincristine] which results in increased phosphorylation of H2AX protein; [NVP-BSK805 results in increased susceptibility to Vincristine] which results in increased phosphorylation of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

H2B clustered histone 12

increases expression

Vincristine results in increased expression of H2BC12 mRNA

NCBI chr17:42,485,699...42,486,162

G

H2B clustered histone 6

increases expression

Vincristine results in increased expression of H2BC6 mRNA

NCBI chr17:41,520,775...41,521,238

G

hepcidin antimicrobial peptide

decreases expression

Vincristine results in decreased expression of HAMP mRNA

NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891

G

HAUS augmin like complex subunit 2

decreases expression

Vincristine results in decreased expression of HAUS2 mRNA

NCBI chr 3:107,553,146...107,565,982
Ensembl chr 3:107,553,161...107,565,157

G

hemoglobin subunit beta

decreases expression

Vincristine results in decreased expression of HBB mRNA

NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012

G

hemoglobin, beta adult major chain

decreases expression

Vincristine results in decreased expression of HBD mRNA

NCBI chr 1:158,224,175...158,231,675
Ensembl chr 1:158,120,200...158,252,012

G

histone deacetylase 1

decreases expression

Vincristine results in decreased expression of HDAC1 protein

NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111

G

histone deacetylase 4

decreases expression

Vincristine results in decreased expression of HDAC4 protein

NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164

G

histone deacetylase 9

decreases expression

Vincristine results in decreased expression of HDAC9 mRNA

NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333

G

haloacid dehalogenase-like hydrolase domain containing 3

decreases expression

Vincristine results in decreased expression of HDHD3 mRNA

NCBI chr 5:75,951,308...75,954,775
Ensembl chr 5:75,946,013...75,955,266

G

HECT domain E3 ubiquitin protein ligase 4

increases expression

Vincristine results in increased expression of HECTD4 mRNA

NCBI chr12:35,182,165...35,330,935
Ensembl chr12:35,182,154...35,330,987

G

helicase, lymphoid specific

decreases expression

Vincristine results in decreased expression of HELLS mRNA

NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844

G

hephaestin

increases expression

Vincristine results in increased expression of HEPH mRNA

NCBI chr X:61,151,131...61,402,980
Ensembl chr X:61,296,345...61,402,980

G

hedgehog acyltransferase

increases expression

Vincristine results in increased expression of HHAT mRNA

NCBI chr13:104,024,507...104,283,580
Ensembl chr13:104,010,916...104,282,893

G

HIC ZBTB transcriptional repressor 1

decreases expression

Vincristine results in decreased expression of HIC1 mRNA

NCBI chr10:60,014,520...60,019,475
Ensembl chr10:60,011,528...60,019,475

G

hypoxia inducible lipid droplet-associated

decreases expression

Vincristine results in decreased expression of HILPDA mRNA

NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557

G

histidine triad nucleotide binding protein 1

decreases expression

Vincristine results in decreased expression of HINT1 mRNA

NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568

G

histidine triad nucleotide binding protein 3

increases expression

Vincristine results in increased expression of HINT3 mRNA

NCBI chr 1:27,035,936...27,045,799
Ensembl chr 1:27,035,905...27,047,721

G

histone cluster 1 H2A family like 1

increases expression

Vincristine results in increased expression of H2AC6 mRNA

NCBI chr17:42,707,954...42,708,420

G

histone cluster 1, H2bc

increases expression

Vincristine results in increased expression of H2BC21 mRNA

NCBI chr17:42,692,335...42,696,601
Ensembl chr17:42,694,723...42,696,642

G

histone cluster 1 H2B family member D

increases expression

Vincristine results in increased expression of H2BC5 mRNA

NCBI chr17:42,792,887...42,793,268

G

histone cluster 1 H2B family member Q

increases expression

Vincristine results in increased expression of H2BC7 mRNA

NCBI chr17:41,432,100...41,441,487
Ensembl chr17:41,429,164...41,442,153

G

HIVEP zinc finger 3

increases expression

Vincristine results in increased expression of HIVEP3 mRNA

NCBI chr 5:133,325,327...133,727,797
Ensembl chr 5:133,658,052...133,727,795

G

HLF transcription factor, PAR bZIP family member

increases expression

Vincristine results in increased expression of HLF mRNA

NCBI chr10:75,154,244...75,211,884
Ensembl chr10:75,154,507...75,211,935

G

hemicentin 1

increases response to substance

HMCN1 mRNA results in increased susceptibility to Vincristine

NCBI chr13:62,615,461...63,084,524
Ensembl chr13:62,615,461...63,084,524

G

high mobility group AT-hook 2

decreases expression

Vincristine results in decreased expression of HMGA2 mRNA

NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784

G

high mobility group box 1

decreases expression
increases secretion
decreases response to substance

Vincristine results in decreased expression of HMGB1 protein
Vincristine results in increased secretion of HMGB1 protein
HMGB1 protein results in decreased susceptibility to Vincristine

PMID:27474498 PMID:27807322

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

high mobility group nucleosome binding domain 5

decreases expression

Vincristine results in decreased expression of HMGN5 mRNA

NCBI chr X:74,085,871...74,094,488
Ensembl chr X:74,085,875...74,094,441

G

heme oxygenase 1

decreases expression
decreases activity
multiple interactions
increases expression

Vincristine results in decreased expression of HMOX1 mRNA
Vincristine results in decreased expression of HMOX1 protein
Vincristine results in decreased activity of HMOX1 protein
Quercetin inhibits the reaction [Vincristine results in decreased activity of HMOX1 protein]; Quercetin inhibits the reaction [Vincristine results in decreased expression of HMOX1 protein]
Vincristine results in increased expression of HMOX1 mRNA

PMID:20624997 PMID:23649840 PMID:33038355 PMID:36808657

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heterogeneous nuclear ribonucleoprotein A2/B1

decreases expression

Vincristine results in decreased expression of HNRNPA2B1 mRNA

NCBI chr 4:80,534,659...80,545,297
Ensembl chr 4:80,534,651...80,545,249

G

heterogeneous nuclear ribonucleoprotein D

decreases expression

Vincristine results in decreased expression of HNRNPD mRNA

NCBI chr14:9,615,375...9,638,975
Ensembl chr14:9,615,479...9,633,786

G

heterogeneous nuclear ribonucleoprotein D-like

decreases expression

Vincristine results in decreased expression of HNRNPDL mRNA

NCBI chr14:9,557,430...9,563,659
Ensembl chr14:9,557,425...9,562,506

G

heterogeneous nuclear ribonucleoprotein R

decreases expression

Vincristine results in decreased expression of HNRNPR mRNA

NCBI chr 5:148,542,999...148,574,888
Ensembl chr 5:148,543,044...148,574,867

G

heterogeneous nuclear ribonucleoprotein U

decreases expression

Vincristine results in decreased expression of HNRNPU mRNA

NCBI chr13:90,069,058...90,086,905
Ensembl chr13:90,074,181...90,086,588

G

hook microtubule-tethering protein 1

decreases expression

Vincristine results in decreased expression of HOOK1 mRNA

NCBI chr 5:110,824,501...110,887,791
Ensembl chr 5:110,824,501...110,887,787

G

hook microtubule-tethering protein 3

decreases expression

Vincristine results in decreased expression of HOOK3 mRNA

NCBI chr16:65,954,293...66,058,812
Ensembl chr16:65,954,350...66,061,338

G

homeo box B7

decreases expression

Vincristine results in decreased expression of HOXB7 mRNA

NCBI chr10:81,252,616...81,256,034
Ensembl chr10:81,252,553...81,256,034

G

4-hydroxyphenylpyruvate dioxygenase-like

decreases expression

Vincristine results in decreased expression of HPDL mRNA

NCBI chr 5:130,286,627...130,288,233
Ensembl chr 5:130,286,631...130,288,233

G

HRas proto-oncogene, GTPase

increases expression

Vincristine results in increased expression of HRAS mRNA

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

heparan sulfate 2-O-sulfotransferase 1

decreases expression

Vincristine results in decreased expression of HS2ST1 mRNA

NCBI chr 2:233,508,018...233,641,769
Ensembl chr 2:233,508,021...233,641,769

G

heat shock protein family A (Hsp70) member 14

decreases expression

Vincristine results in decreased expression of HSPA14 mRNA

NCBI chr17:74,728,945...74,749,727
Ensembl chr17:74,728,899...74,749,727

G

heat shock protein family A (Hsp70) member 5

increases expression
multiple interactions

Vincristine results in increased expression of HSPA5 mRNA
Quercetin inhibits the reaction [Vincristine results in increased expression of HSPA5 mRNA]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family B (small) member 2

decreases response to substance

HSPB2 protein results in decreased susceptibility to Vincristine

NCBI chr 8:51,093,267...51,094,528
Ensembl chr 8:51,081,342...51,094,533

G

heat shock protein family D (Hsp60) member 1

decreases expression

Vincristine results in decreased expression of HSPD1 mRNA

NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662

G

5-hydroxytryptamine receptor 2A

multiple interactions
increases expression

[alpha-phenyl-1-(2-phenylethyl)-4-piperidinemethanol binds to and results in decreased activity of HTR2A protein] which results in decreased susceptibility to Vincristine
Vincristine results in increased expression of HTR2A protein

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

HYLS1, centriolar and ciliogenesis associated

decreases expression

Vincristine results in decreased expression of HYLS1 mRNA

NCBI chr 8:33,912,692...33,921,760
Ensembl chr 8:33,912,692...33,921,760

G

intercellular adhesion molecule 1

increases expression

Vincristine results in increased expression of ICAM1 mRNA

PMID:20624997 PMID:23649840

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

intercellular adhesion molecule 4, Landsteiner-Wiener blood group

increases expression

Vincristine results in increased expression of ICAM4 mRNA

NCBI chr 8:19,566,075...19,567,171
Ensembl chr 8:19,566,075...19,567,171

G

inhibitor of DNA binding 2

increases expression

Vincristine results in increased expression of ID2 mRNA

NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400

G

inhibitor of DNA binding 3

increases response to substance

ID3 gene SNP results in increased susceptibility to Vincristine

NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349

G

immediate early response 3

increases expression

Vincristine results in increased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

interferon-induced protein 44

increases expression

Vincristine results in increased expression of IFI44 mRNA

NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844

G

interferon-induced protein 44-like

increases expression

Vincristine results in increased expression of IFI44L mRNA

NCBI chr 2:240,668,742...240,706,425
Ensembl chr 2:240,668,713...240,706,359

G

interferon induced with helicase C domain 1

increases expression

Vincristine results in increased expression of IFIH1 mRNA

NCBI chr 3:47,228,980...47,275,403
Ensembl chr 3:47,227,364...47,275,456

G

interferon-induced protein with tetratricopeptide repeats 2

increases expression

Vincristine results in increased expression of IFIT2 mRNA

NCBI chr 1:232,102,570...232,108,638
Ensembl chr 1:232,102,570...232,108,635

G

interferon gamma

increases expression

Vincristine results in increased expression of IFNG mRNA

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interferon-related developmental regulator 1

decreases expression

Vincristine results in decreased expression of IFRD1 mRNA

NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990

G

intraflagellar transport 20

increases expression

Vincristine results in increased expression of IFT20 mRNA

NCBI chr10:63,432,597...63,438,125
Ensembl chr10:63,432,633...63,438,124

G

intraflagellar transport 25

decreases expression

Vincristine results in decreased expression of IFT25 mRNA

NCBI chr 5:122,035,588...122,062,421
Ensembl chr 5:122,035,581...122,062,421

G

intraflagellar transport 43

increases expression

Vincristine results in increased expression of IFT43 mRNA

NCBI chr 6:105,729,734...105,806,257
Ensembl chr 6:105,729,792...105,806,257

G

insulin-like growth factor 1

multiple interactions
decreases response to substance

Vincristine promotes the reaction [NVP ADW742 inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]]
IGF1 protein results in decreased susceptibility to Vincristine

PMID:9452187 PMID:16740780

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

immunoglobulin heavy constant gamma 1

decreases expression

Vincristine results in decreased expression of IGHG1 mRNA

Ensembl chr 6:132,389,370...132,393,397

G

immunoglobulin kappa constant

decreases expression

Vincristine results in decreased expression of IGKC mRNA

G

immunoglobulin kappa chain variable 8-30 like 1

decreases expression

Vincristine results in decreased expression of IGKV4-1 mRNA

NCBI chr 4:101,838,285...101,839,132

G

IKAROS family zinc finger 2

decreases expression

Vincristine results in decreased expression of IKZF2 mRNA

NCBI chr 9:71,046,038...71,191,296
Ensembl chr 9:71,042,440...71,190,867

G

interleukin 10 receptor subunit alpha

increases expression

Vincristine results in increased expression of IL10RA mRNA

NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061

G

interleukin 15

increases expression

Vincristine results in increased expression of IL15 mRNA

NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820

G

interleukin 17 receptor B

decreases expression

Vincristine results in decreased expression of IL17RB mRNA

NCBI chr16:5,180,431...5,194,125
Ensembl chr16:5,180,432...5,194,125

G

interleukin 1 beta

increases expression
multiple interactions
increases secretion

Vincristine results in increased expression of IL1B mRNA; Vincristine results in increased expression of IL1B protein
gap 27 peptide inhibits the reaction [Vincristine results in increased secretion of IL1B protein]; GJA1 protein promotes the reaction [Vincristine results in increased secretion of IL1B protein]; KN 93 inhibits the reaction [Vincristine results in increased expression of IL1B mRNA]
coenzyme Q10 inhibits the reaction [Vincristine results in increased expression of IL1B protein]; Sumatriptan inhibits the reaction [Vincristine results in increased expression of IL1B mRNA]

PMID:20624997 PMID:29958920 PMID:34286406 PMID:34939713

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 1

increases expression

Vincristine results in increased expression of IL1R1 mRNA

NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937

G

interleukin 2

multiple interactions
increases expression

tropisetron inhibits the reaction [Vincristine results in increased expression of IL2 protein]

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 23 subunit alpha

increases expression

Vincristine results in increased expression of IL23A mRNA

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 36, gamma

increases expression

Vincristine results in increased expression of IL36G mRNA

NCBI chr 3:6,948,323...6,954,485
Ensembl chr 3:6,948,297...6,954,480

G

interleukin 6

affects response to substance
multiple interactions
increases secretion
increases expression

IL6 protein affects the susceptibility to Vincristine
gap 27 peptide inhibits the reaction [Vincristine results in increased secretion of IL6 protein]; GJA1 protein promotes the reaction [Vincristine results in increased secretion of IL6 protein]; KN 93 inhibits the reaction [Vincristine results in increased expression of IL6 mRNA]
Vincristine results in increased expression of IL6 mRNA; Vincristine results in increased expression of IL6 protein

PMID:16001973 PMID:18270703 PMID:18652822 PMID:23649840 PMID:34286406

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 7

increases expression

Vincristine results in increased expression of IL7 mRNA

NCBI chr 2:94,235,219...94,280,075
Ensembl chr 2:94,234,766...94,280,075

G

immunoglobulin-like domain containing receptor 1

increases expression

Vincristine results in increased expression of ILDR1 mRNA

NCBI chr11:64,085,774...64,118,760
Ensembl chr11:64,008,566...64,118,760

G

immunoglobulin-like domain containing receptor 2

decreases expression

Vincristine results in decreased expression of ILDR2 mRNA

NCBI chr13:78,518,770...78,580,627
Ensembl chr13:78,518,802...78,576,924

G

inositol monophosphatase 2

decreases expression

Vincristine results in decreased expression of IMPA2 mRNA

NCBI chr18:60,834,206...60,867,575
Ensembl chr18:60,834,246...60,865,641

G

internexin neuronal intermediate filament protein, alpha

multiple interactions

INA affects the susceptibility to [Procarbazine co-treated with Lomustine co-treated with Vincristine]

NCBI chr 1:245,896,775...245,908,330
Ensembl chr 1:245,896,775...245,908,330

G

inhibitor of growth family, member 2

decreases expression

Vincristine results in decreased expression of ING2 mRNA

NCBI chr16:44,573,592...44,584,180
Ensembl chr16:44,575,597...44,583,482

G

inhibin subunit alpha

decreases expression

Vincristine results in decreased expression of INHA mRNA

NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248

G

inhibin subunit beta E

increases expression

Vincristine results in increased expression of INHBE mRNA

NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172

G

inositol polyphosphate-1-phosphatase

increases expression

Vincristine results in increased expression of INPP1 mRNA

NCBI chr 9:48,688,037...48,717,793
Ensembl chr 9:48,669,901...48,717,793

G

inositol polyphosphate-4-phosphatase type II B

increases expression

Vincristine results in increased expression of INPP4B mRNA

NCBI chr19:25,920,189...26,670,085
Ensembl chr19:25,925,358...26,280,634

G

integrator complex subunit 11

decreases expression

Vincristine results in decreased expression of INTS11 mRNA

NCBI chr 5:166,479,134...166,497,956
Ensembl chr 5:166,479,155...166,497,651

G

integrator complex subunit 5

decreases expression

Vincristine results in decreased expression of INTS5 mRNA

NCBI chr 1:205,788,906...205,793,685
Ensembl chr 1:205,788,906...205,793,685

G

importin 5

decreases expression

Vincristine results in decreased expression of IPO5 mRNA

NCBI chr15:97,990,755...98,041,074
Ensembl chr15:98,005,299...98,041,126

G

IQ motif containing GTPase activating protein 2

decreases expression

Vincristine results in decreased expression of IQGAP2 mRNA

NCBI chr 2:26,894,836...27,170,270
Ensembl chr 2:26,894,825...27,170,279

G

interleukin-1 receptor-associated kinase 2

increases expression

Vincristine results in increased expression of IRAK2 mRNA

NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602

G

iron responsive element binding protein 2

increases expression

Vincristine results in increased expression of IREB2 mRNA

NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611

G

interferon regulatory factor 1

increases expression

Vincristine results in increased expression of IRF1 mRNA

NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166

G

interferon stimulated exonuclease gene 20

increases expression

Vincristine results in increased expression of ISG20 mRNA

NCBI chr 1:132,829,303...132,837,027
Ensembl chr 1:132,815,123...132,837,027

G

immunoglobulin superfamily containing leucine-rich repeat

increases expression

Vincristine results in increased expression of ISLR mRNA

NCBI chr 8:58,571,155...58,574,128
Ensembl chr 8:58,570,777...58,574,130

G

integrin subunit alpha 1

increases response to substance

ITGA1 mRNA results in increased susceptibility to Vincristine

NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238

G

integrin subunit alpha 4

decreases expression

Vincristine results in decreased expression of ITGA4 mRNA

NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715

G

integrin subunit alpha M

increases expression

Vincristine results in increased expression of ITGAM mRNA

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 1 binding protein 2

decreases expression

Vincristine results in decreased expression of ITGB1BP2 mRNA

NCBI chr X:66,572,537...66,577,174
Ensembl chr X:66,572,537...66,577,174

G

integrin subunit beta 7

decreases expression

Vincristine results in decreased expression of ITGB7 mRNA

NCBI chr 7:133,347,927...133,364,955
Ensembl chr 7:133,347,960...133,364,876

G

integrin subunit beta 8

increases expression

Vincristine results in increased expression of ITGB8 mRNA

NCBI chr 6:140,125,002...140,208,261
Ensembl chr 6:140,127,203...140,208,476

G

inositol-trisphosphate 3-kinase B

decreases expression

Vincristine results in decreased expression of ITPKB mRNA

NCBI chr13:92,069,160...92,164,281
Ensembl chr13:92,069,216...92,162,004

G

inositol 1,4,5-trisphosphate receptor, type 1

increases expression

Vincristine results in increased expression of ITPR1 mRNA

NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491

G

ITPR interacting domain containing 2

decreases expression

Vincristine results in decreased expression of ITPRID2 mRNA

NCBI chr 3:64,536,707...64,573,978
Ensembl chr 3:64,536,707...64,573,978

G

ITPRIP like 1

decreases expression

Vincristine results in decreased expression of ITPRIPL1 mRNA

NCBI chr 3:114,403,123...114,407,917
Ensembl chr 3:114,402,270...114,414,497

G

involucrin

increases expression

Vincristine results in increased expression of IVL mRNA

NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100

G

influenza virus NS1A binding protein

decreases expression

Vincristine results in decreased expression of IVNS1ABP mRNA

NCBI chr13:63,427,040...63,446,701
Ensembl chr13:63,427,041...63,446,701

G

jade family PHD finger 2

increases expression

Vincristine results in increased expression of JADE2 mRNA

NCBI chr10:36,075,239...36,124,210
Ensembl chr10:36,078,917...36,116,984

G

joining chain of multimeric IgA and IgM

decreases expression

Vincristine results in decreased expression of JCHAIN mRNA

NCBI chr14:19,538,927...19,547,023
Ensembl chr14:19,538,952...19,546,298

G

jumonji domain containing 1C

increases expression

Vincristine results in increased expression of JMJD1C mRNA

NCBI chr20:21,332,147...21,494,220
Ensembl chr20:21,332,147...21,463,122

G

Jupiter microtubule associated homolog 1

decreases expression

Vincristine results in decreased expression of JPT1 mRNA

NCBI chr10:100,744,468...100,762,504
Ensembl chr10:100,686,797...100,784,513

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

Vincristine results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

lysine acetyltransferase 2B

increases expression

Vincristine results in increased expression of KAT2B mRNA

NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064

G

potassium channel modulatory factor 1

decreases expression

Vincristine results in decreased expression of KCMF1 mRNA

NCBI chr 4:104,888,452...104,950,234
Ensembl chr 4:104,889,847...104,950,234

G

potassium voltage-gated channel subfamily A member 5

increases response to substance

KCNA5 protein results in increased susceptibility to Vincristine

NCBI chr 4:159,354,689...159,358,173
Ensembl chr 4:159,350,097...159,357,697

G

potassium calcium-activated channel subfamily M regulatory beta subunit 1

increases expression

Vincristine results in increased expression of KCNMB1 mRNA

NCBI chr10:18,557,510...18,614,824
Ensembl chr10:18,557,904...18,565,798

G

potassium calcium-activated channel subfamily N member 2

increases expression

Vincristine results in increased expression of KCNN2 mRNA

NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347

G

lysine demethylase 2B

increases expression

Vincristine results in increased expression of KDM2B mRNA

NCBI chr12:33,566,530...33,701,366
Ensembl chr12:33,574,657...33,701,355

G

3-ketodihydrosphingosine reductase

decreases expression

Vincristine results in decreased expression of KDSR mRNA

NCBI chr13:22,862,117...22,894,118
Ensembl chr13:22,862,117...22,894,108

G

KLF transcription factor 12

decreases expression

Vincristine results in decreased expression of KLF12 mRNA

NCBI chr15:76,628,778...77,062,000
Ensembl chr15:76,637,654...77,062,056

G

KLF transcription factor 6

increases expression

Vincristine results in increased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

kelch-like family member 14

decreases expression

Vincristine results in decreased expression of KLHL14 mRNA

NCBI chr18:12,804,253...12,917,828
Ensembl chr18:12,804,253...12,917,828

G

kelch-like family member 28

increases expression

Vincristine results in increased expression of KLHL28 mRNA

NCBI chr 6:82,987,360...83,018,971
Ensembl chr 6:82,990,945...83,016,164

G

lysine methyltransferase 5B

increases expression

Vincristine results in increased expression of KMT5B mRNA

NCBI chr 1:201,000,444...201,049,819
Ensembl chr 1:201,000,444...201,049,819

G

karyopherin subunit alpha 2

decreases expression

Vincristine results in decreased expression of KPNA2 mRNA

NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150

G

keratin 23

increases response to substance

KRT23 mRNA results in increased susceptibility to Vincristine

NCBI chr10:84,434,445...84,450,773
Ensembl chr10:84,434,380...84,450,983

G

keratin 7

increases expression

Vincristine results in increased expression of KRT7 mRNA

NCBI chr 7:132,528,881...132,545,052
Ensembl chr 7:132,528,895...132,545,052

G

kynureninase

increases expression

Vincristine results in increased expression of KYNU mRNA

NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488

G

lactamase, beta 2

decreases expression

Vincristine results in decreased expression of LACTB2 mRNA

NCBI chr 5:5,569,080...5,591,843
Ensembl chr 5:5,569,067...5,596,429

G

laminin subunit alpha 2

increases response to substance

LAMA2 mRNA results in increased susceptibility to Vincristine

NCBI chr 1:17,672,675...18,320,641
Ensembl chr 1:17,672,536...18,320,530

G

lysosomal-associated membrane protein 3

increases expression

Vincristine results in increased expression of LAMP3 mRNA

NCBI chr11:81,153,491...81,224,643
Ensembl chr11:81,193,649...81,221,784

G

La ribonucleoprotein 1B

decreases expression

Vincristine results in decreased expression of LARP1B mRNA

NCBI chr 2:123,936,057...123,969,254
Ensembl chr 2:123,935,983...123,968,896

G

LBH regulator of WNT signaling pathway

decreases expression

Vincristine results in decreased expression of LBH mRNA

NCBI chr 6:22,569,238...22,593,056
Ensembl chr 6:22,568,834...22,593,079

G

late cornified envelope 1B

increases expression

Vincristine results in increased expression of LCE1B mRNA

NCBI chr 2:178,255,351...178,257,533
Ensembl chr 2:178,256,213...178,257,985

G

ligand dependent nuclear receptor corepressor

increases expression

Vincristine results in increased expression of LCOR mRNA

NCBI chr 1:240,298,565...240,405,627
Ensembl chr 1:240,298,563...240,402,448

G

ligand dependent nuclear receptor corepressor-like

decreases expression

Vincristine results in decreased expression of LCORL mRNA

NCBI chr14:65,271,339...65,407,732
Ensembl chr14:65,271,135...65,404,174

G

lymphocyte cytosolic protein 2

increases expression

Vincristine results in increased expression of LCP2 mRNA

NCBI chr10:18,642,600...18,689,562
Ensembl chr10:18,642,658...18,689,559

G

low density lipoprotein receptor class A domain containing 4

increases expression

Vincristine results in increased expression of LDLRAD4 mRNA

NCBI chr18:61,519,253...61,848,403
Ensembl chr18:61,521,428...61,843,238

G

low density lipoprotein receptor adaptor protein 1

decreases expression

Vincristine results in decreased expression of LDLRAP1 mRNA

NCBI chr 5:146,955,607...146,978,601
Ensembl chr 5:146,955,607...146,978,601

G

liver enriched gene 1

increases expression

Vincristine results in increased expression of C6ORF58 mRNA

NCBI chr 1:28,799,902...28,816,230
Ensembl chr 1:28,799,902...28,815,993

G

leukocyte receptor cluster member 8

decreases expression

Vincristine results in decreased expression of LENG8 mRNA

NCBI chr 1:70,040,785...70,052,662
Ensembl chr 1:70,040,785...70,052,488

G

LIF, interleukin 6 family cytokine

increases expression

Vincristine results in increased expression of LIF mRNA

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

LIM domain and actin binding 1

increases expression

Vincristine results in increased expression of LIMA1 mRNA

NCBI chr 7:130,901,717...131,001,512
Ensembl chr 7:130,901,717...131,001,473

G

LIM zinc finger domain containing 1

increases expression

Vincristine results in increased expression of LIMS1 mRNA

NCBI chr20:26,309,833...26,418,511
Ensembl chr20:26,309,895...26,418,500

G

lamin A/C

increases expression

Vincristine results in increased expression of LMNA mRNA

NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423

G

leucyl and cystinyl aminopeptidase

increases expression

Vincristine results in increased expression of LNPEP mRNA

NCBI chr 1:58,258,642...58,355,532
Ensembl chr 1:58,258,642...58,354,544

G

histone H2B type 1-N-like

increases expression

Vincristine results in increased expression of H2BC3 mRNA

NCBI chr17:41,380,056...41,380,686

G

LPS responsive beige-like anchor protein

decreases expression

Vincristine results in decreased expression of LRBA mRNA

NCBI chr 2:171,623,668...172,202,576
Ensembl chr 2:171,621,507...172,202,724

G

leucine rich repeats and calponin homology domain containing 3

increases expression

Vincristine results in increased expression of LRCH3 mRNA

NCBI chr11:67,772,499...67,872,269
Ensembl chr11:67,772,506...67,872,264

G

LDL receptor related protein 8

decreases expression

Vincristine results in decreased expression of LRP8 mRNA

NCBI chr 5:122,563,468...122,635,434
Ensembl chr 5:122,563,453...122,631,352

G

leucine rich repeat containing 8 VRAC subunit C

decreases expression

Vincristine results in decreased expression of LRRC8C mRNA

NCBI chr14:4,223,901...4,315,590
Ensembl chr14:4,227,832...4,315,249

G

leucine rich repeat and coiled-coil centrosomal protein 1

decreases expression

Vincristine results in decreased expression of LRRCC1 mRNA

NCBI chr 2:87,025,671...87,060,313
Ensembl chr 2:87,025,598...87,060,294

G

LRR binding FLII interacting protein 1

decreases expression

Vincristine results in decreased expression of LRRFIP1 mRNA

NCBI chr 9:91,592,032...91,720,250
Ensembl chr 9:91,643,197...91,720,250

G

lymphotoxin alpha

increases expression

Vincristine results in increased expression of LTA mRNA

NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859

G

LTO1 maturation factor of ABCE1

decreases expression

Vincristine results in decreased expression of LTO1 mRNA

NCBI chr 1:200,074,247...200,080,951
Ensembl chr 1:200,074,253...200,088,061

G

lumican

decreases response to substance

LUM mRNA results in decreased susceptibility to Vincristine

NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793

G

lymphocyte antigen 96

increases expression

Vincristine results in increased expression of LY96 mRNA

NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386

G

leucine zipper transcription factor-like 1

decreases expression

Vincristine results in decreased expression of LZTFL1 mRNA

NCBI chr 8:123,344,085...123,360,245
Ensembl chr 8:123,344,925...123,360,192

G

leucine zipper tumor suppressor 2

decreases expression

Vincristine results in decreased expression of LZTS2 mRNA

NCBI chr 1:243,876,665...243,888,489
Ensembl chr 1:243,880,022...243,888,423

G

microtubule-actin crosslinking factor 1

increases expression

Vincristine results in increased expression of MACF1 mRNA

NCBI chr 5:135,623,734...135,949,097
Ensembl chr 5:135,623,742...135,945,905

G

macrophage immunometabolism regulator

decreases expression

Vincristine results in decreased expression of MACIR mRNA

NCBI chr 9:98,420,760...98,440,818
Ensembl chr 9:98,420,376...98,441,733

G

MAF bZIP transcription factor F

increases expression

Vincristine results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

magnesium transporter 1

decreases expression

Vincristine results in decreased expression of MAGT1 mRNA

NCBI chr X:71,038,489...71,079,704
Ensembl chr X:71,038,489...71,079,699

G

mannosidase, alpha, class 2A, member 1

decreases expression

Vincristine results in decreased expression of MAN2A1 mRNA

NCBI chr 9:104,252,001...104,408,349
Ensembl chr 9:104,252,001...104,408,349

G

mannosidase, endo-alpha

decreases expression

Vincristine results in decreased expression of MANEA mRNA

NCBI chr 5:40,196,373...40,218,540
Ensembl chr 5:40,196,396...40,218,459

G

microtubule-associated protein 1 light chain 3 beta

increases expression
multiple interactions

Vincristine results in increased expression of MAP1LC3B mRNA
Quercetin inhibits the reaction [Vincristine results in increased expression of MAP1LC3B protein]

PMID:23649840 PMID:36808657

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen-activated protein kinase kinase kinase 1

decreases expression

Vincristine results in decreased expression of MAP3K1 mRNA

NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463

G

mitogen activated protein kinase kinase kinase 7

decreases expression

Vincristine results in decreased expression of MAP3K7 mRNA

NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597

G

mitogen-activated protein kinase kinase kinase 8

increases expression

Vincristine results in increased expression of MAP3K8 mRNA

NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216

G

mitogen-activated protein kinase kinase kinase kinase 4

increases expression

Vincristine results in increased expression of MAP4K4 mRNA

NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698

G

mitogen activated protein kinase binding protein 1

increases expression

Vincristine results in increased expression of MAPKBP1 mRNA

NCBI chr 3:106,947,342...106,998,368
Ensembl chr 3:106,947,827...106,996,199

G

microtubule-associated protein, RP/EB family, member 1

decreases localization
multiple interactions

Vincristine results in decreased localization of MAPRE1 protein
olesoxime inhibits the reaction [Vincristine results in decreased localization of MAPRE1 protein]

NCBI chr 3:142,218,846...142,246,990
Ensembl chr 3:142,212,955...142,246,983

G

microtubule-associated protein, RP/EB family, member 3

multiple interactions
affects localization

olesoxime inhibits the reaction [Vincristine results in decreased localization of MAPRE3 protein]
Vincristine affects the localization of MAPRE3 protein

NCBI chr 6:25,513,800...25,558,876
Ensembl chr 6:25,513,800...25,558,881

G

membrane associated ring-CH-type finger 7

increases expression

Vincristine results in increased expression of MARCHF7 mRNA

NCBI chr 3:44,680,229...44,720,172
Ensembl chr 3:44,681,632...44,720,168

G

myristoylated alanine rich protein kinase C substrate

increases expression

Vincristine results in increased expression of MARCKS mRNA

NCBI chr20:40,685,315...40,691,012
Ensembl chr20:40,685,315...40,691,012

G

methionyl-tRNA synthetase 1

decreases expression

Vincristine results in decreased expression of MARS1 mRNA

NCBI chr 7:63,121,142...63,138,550
Ensembl chr 7:63,121,142...63,138,495

G

methionyl-tRNA synthetase 2, mitochondrial

decreases expression

Vincristine results in decreased expression of MARS2 mRNA

NCBI chr 9:56,720,408...56,729,991
Ensembl chr 9:56,720,983...56,723,820

G

matrilin 2

decreases response to substance

MATN2 mRNA results in decreased susceptibility to Vincristine

NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113

G

matrin 3

decreases expression

Vincristine results in decreased expression of MATR3 mRNA

NCBI chr18:27,154,098...27,193,212
Ensembl chr18:27,163,714...27,193,166

G

MYC associated factor X

decreases expression

Vincristine results in decreased expression of MAX mRNA

NCBI chr 6:95,636,859...95,662,204
Ensembl chr 6:95,636,858...95,662,137

G

methyl-CpG binding domain 4 DNA glycosylase

decreases expression

Vincristine results in decreased expression of MBD4 mRNA

NCBI chr 4:148,893,049...148,904,833
Ensembl chr 4:148,894,280...148,904,982

G

muscleblind-like splicing regulator 3

decreases expression

Vincristine results in decreased expression of MBNL3 mRNA

NCBI chr X:130,641,942...130,737,179
Ensembl chr X:130,648,538...130,737,056

G

mbt domain containing 1

increases expression

Vincristine results in increased expression of MBTD1 mRNA

NCBI chr10:78,839,140...78,895,413
Ensembl chr10:78,839,036...78,893,720

G

methylcrotonyl-CoA carboxylase subunit 2

increases expression

Vincristine results in increased expression of MCCC2 mRNA

NCBI chr 2:31,304,927...31,375,978
Ensembl chr 2:31,304,932...31,375,972

G

MCL1 apoptosis regulator, BCL2 family member

increases expression

Vincristine results in increased expression of MCL1 mRNA

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

minichromosome maintenance complex component 4

decreases expression

Vincristine results in decreased expression of MCM4 mRNA

NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144

G

minichromosome maintenance complex binding protein

increases expression

Vincristine results in increased expression of MCMBP mRNA

NCBI chr 1:183,270,598...183,316,975
Ensembl chr 1:183,271,980...183,316,975

G

mucolipin TRP cation channel 2

increases expression

Vincristine results in increased expression of MCOLN2 mRNA

NCBI chr 2:235,053,816...235,102,703
Ensembl chr 2:235,053,816...235,102,702

G

MDM2 proto-oncogene

increases expression
decreases expression

Vincristine results in increased expression of MDM2 mRNA
Vincristine results in decreased expression of MDM2 mRNA

PMID:16001973 PMID:23649840

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

midasin AAA ATPase 1

increases expression

Vincristine results in increased expression of MDN1 mRNA

NCBI chr 5:47,055,435...47,190,426
Ensembl chr 5:47,055,447...47,186,332

G

mediator complex subunit 29

decreases expression

Vincristine results in decreased expression of MED29 mRNA

NCBI chr 1:83,677,961...83,683,365
Ensembl chr 1:83,677,961...83,683,365

G

mediator complex subunit 31

decreases expression

Vincristine results in decreased expression of MED31 mRNA

NCBI chr10:56,836,944...56,840,326
Ensembl chr10:56,836,944...56,840,326

G

methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit

decreases expression

Vincristine results in decreased expression of METTL3 mRNA

NCBI chr15:25,002,505...25,014,097
Ensembl chr15:25,003,172...25,014,041

G

major facilitator superfamily domain containing 5

decreases expression

Vincristine results in decreased expression of MFSD5 mRNA

NCBI chr 7:133,409,096...133,411,377
Ensembl chr 7:133,402,537...133,411,396

G

major facilitator superfamily domain containing 6

decreases expression

Vincristine results in decreased expression of MFSD6 mRNA

NCBI chr 9:48,773,171...48,858,471
Ensembl chr 9:48,773,414...48,858,465

G

MAX dimerization protein MGA

increases expression

Vincristine results in increased expression of MGA mRNA

NCBI chr 3:106,851,216...106,942,908
Ensembl chr 3:106,851,140...106,941,043

G

alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A

decreases expression

Vincristine results in decreased expression of MGAT4A mRNA

NCBI chr 9:39,673,427...39,786,747
Ensembl chr 9:39,673,430...39,766,890

G

O-6-methylguanine-DNA methyltransferase

multiple interactions

[MGMT protein co-treated with ABCB1 protein] results in decreased susceptibility to Vincristine; MGMT affects the susceptibility to [Procarbazine co-treated with Vincristine co-treated with Nitrosourea Compounds]; MGMT protein affects the susceptibility to [Procarbazine co-treated with Lomustine co-treated with Vincristine]

PMID:11792417 PMID:16033832 PMID:16936459

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

microtubule associated monooxygenase, calponin and LIM domain containing 3

increases expression

Vincristine results in increased expression of MICAL3 mRNA

NCBI chr 4:154,152,776...154,353,274
Ensembl chr 4:154,153,834...154,302,590

G

microRNA 132

increases expression

Vincristine results in increased expression of MIR132 mRNA

NCBI chr10:60,023,696...60,023,796
Ensembl chr10:60,023,696...60,023,796

G

microRNA 497

multiple interactions

[MIR497 results in decreased expression of BCL2 protein] which results in increased susceptibility to Vincristine

NCBI chr10:54,951,514...54,951,582
Ensembl chr10:54,951,505...54,951,584

G

marker of proliferation Ki-67

increases response to substance

MKI67 gene SNP results in increased susceptibility to Vincristine

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

muskelin 1

increases expression

Vincristine results in increased expression of MKLN1 mRNA

NCBI chr 4:59,815,912...60,124,047
Ensembl chr 4:60,002,464...60,123,993

G

MAPK interacting serine/threonine kinase 2

increases expression

Vincristine results in increased expression of MKNK2 mRNA

NCBI chr 7:9,039,771...9,050,832
Ensembl chr 7:9,039,728...9,050,827

G

MLLT3, super elongation complex subunit

increases expression

Vincristine results in increased expression of MLLT3 mRNA

NCBI chr 5:102,259,075...102,515,447
Ensembl chr 5:102,260,011...102,515,361

G

monocyte to macrophage differentiation-associated

increases expression

Vincristine results in increased expression of MMD mRNA

NCBI chr10:75,073,278...75,101,528
Ensembl chr10:75,073,365...75,101,528

G

meiotic nuclear divisions 1

decreases expression

Vincristine results in decreased expression of MND1 mRNA

NCBI chr 2:169,433,523...169,496,081
Ensembl chr 2:169,433,540...169,496,096

G

myelin protein zero

increases response to substance

MPZ gene results in increased susceptibility to Vincristine

NCBI chr13:83,570,811...83,576,680
Ensembl chr13:83,570,811...83,576,679

G

major histocompatibility complex, class I-related

increases expression

Vincristine results in increased expression of MR1 mRNA

NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970

G

mitochondrial ribosomal protein L30

decreases expression

Vincristine results in decreased expression of MRPL30 mRNA

NCBI chr 9:40,125,352...40,136,189
Ensembl chr 9:40,125,430...40,137,257

G

mitochondrial ribosomal protein L39

decreases expression

Vincristine results in decreased expression of MRPL39 mRNA

NCBI chr11:23,779,655...23,795,146
Ensembl chr11:23,779,662...23,795,125

G

mitochondrial ribosomal protein L50

decreases expression

Vincristine results in decreased expression of MRPL50 mRNA

NCBI chr 5:63,867,437...63,872,591

G

mitochondrial ribosomal protein S16

decreases expression

Vincristine results in decreased expression of MRPS16 mRNA

NCBI chr15:3,918,621...3,921,024
Ensembl chr15:3,918,615...3,921,656

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

increases expression

Vincristine results in increased expression of ND6 mRNA

NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061

G

metallothionein 2A

increases expression

Vincristine results in increased expression of MT2A mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

metastasis associated 1 family, member 3

decreases expression

Vincristine results in decreased expression of MTA3 mRNA

NCBI chr 6:10,867,028...10,987,221
Ensembl chr 6:10,867,011...10,986,883

G

mature T-cell proliferation 1

decreases expression

Vincristine results in decreased expression of MTCP1 mRNA

NCBI chr18:126,189...130,123

G

mitochondrial fission regulator 2

decreases expression

Vincristine results in decreased expression of MTFR2 mRNA

NCBI chr 1:15,123,232...15,138,632
Ensembl chr 1:15,070,894...15,148,832

G

mitochondrial ribosome-associated GTPase 2

increases expression

Vincristine results in increased expression of MTG2 mRNA

NCBI chr 3:167,165,542...167,181,358
Ensembl chr 3:167,165,982...167,181,358

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like

decreases expression

Vincristine results in decreased expression of MTHFD2L mRNA

NCBI chr14:17,089,947...17,170,036
Ensembl chr14:17,089,952...17,170,112

G

mitochondrial translation release factor 1 like

decreases expression

Vincristine results in decreased expression of MTRF1L mRNA

NCBI chr 1:42,208,553...42,221,020
Ensembl chr 1:42,210,583...42,220,836

G

major vault protein

increases expression

Vincristine results in increased expression of MVP mRNA

NCBI chr 1:181,594,734...181,622,336
Ensembl chr 1:181,594,734...181,622,380

G

max dimerization protein 1

increases expression

Vincristine results in increased expression of MXD1 mRNA

NCBI chr 4:119,097,353...119,118,080
Ensembl chr 4:119,097,353...119,117,751

G

MYC proto-oncogene, bHLH transcription factor

decreases expression
increases expression

Vincristine results in decreased expression of MYC mRNA
Vincristine results in increased expression of MYC mRNA

PMID:16001973 PMID:20624997

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

MYCN proto-oncogene, bHLH transcription factor

decreases response to substance
multiple interactions

MYCN protein results in decreased susceptibility to Vincristine
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Vincristine

NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590

G

myosin heavy chain 11

increases expression

Vincristine results in increased expression of MYH11 mRNA

NCBI chr10:743,364...838,459
Ensembl chr10:743,685...838,459

G

myb-like, SWIRM and MPN domains 1

increases expression

Vincristine results in increased expression of MYSM1 mRNA

NCBI chr 5:109,761,345...109,826,652
Ensembl chr 5:109,776,286...109,819,967

G

marginal zone B and B1 cell-specific protein

decreases expression

Vincristine results in decreased expression of MZB1 mRNA

NCBI chr18:27,238,999...27,241,060
Ensembl chr18:27,239,001...27,241,094

G

NEDD4 binding protein 2-like 2

increases expression

Vincristine results in increased expression of N4BP2L2 mRNA

NCBI chr12:137,342...200,292
Ensembl chr12:103,590...197,784

G

N(alpha)-acetyltransferase 25, NatB auxiliary subunit

decreases expression

Vincristine results in decreased expression of NAA25 mRNA

NCBI chr12:35,098,256...35,150,498
Ensembl chr12:35,098,075...35,150,467

G

nucleic acid binding protein 1

increases expression

Vincristine results in increased expression of NABP1 mRNA

NCBI chr 9:50,098,552...50,133,982
Ensembl chr 9:50,126,726...50,134,107

G

nascent polypeptide associated complex subunit alpha

decreases expression

Vincristine results in decreased expression of NACA mRNA

NCBI chr 7:468,862...481,992
Ensembl chr 7:469,723...481,992

G

nicotinamide phosphoribosyltransferase

increases expression

Vincristine results in increased expression of NAMPT mRNA

NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100

G

NSF attachment protein beta

increases expression

Vincristine results in increased expression of NAPB mRNA

NCBI chr 3:136,132,248...136,179,280
Ensembl chr 3:136,133,428...136,179,345

G

nuclear autoantigenic sperm protein

decreases expression

Vincristine results in decreased expression of NASP mRNA

NCBI chr 5:130,057,363...130,083,003
Ensembl chr 5:130,057,363...130,082,928

G

nibrin

increases expression

Vincristine results in increased expression of NBN mRNA

NCBI chr 5:29,459,574...29,494,152
Ensembl chr 5:29,459,457...29,494,150

G

nuclear cap binding protein subunit 1

decreases expression

Vincristine results in decreased expression of NCBP1 mRNA

NCBI chr 5:60,416,023...60,449,004
Ensembl chr 5:60,415,982...60,449,089

G

neutral cholesterol ester hydrolase 1

increases expression

Vincristine results in increased expression of NCEH1 mRNA

NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588

G

neutrophil cytosolic factor 2

increases expression

Vincristine results in increased expression of NCF2 mRNA

NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277

G

nuclear receptor coactivator 7

increases expression

Vincristine results in increased expression of NCOA7 mRNA

NCBI chr 1:26,856,228...27,016,950
Ensembl chr 1:26,856,530...27,015,871

G

nudE neurodevelopment protein 1

increases expression

Vincristine results in increased expression of NDE1 mRNA

NCBI chr10:839,788...883,946
Ensembl chr10:839,788...883,869

G

NADH:ubiquinone oxidoreductase subunit B4

decreases expression

Vincristine results in decreased expression of NDUFB4 mRNA

NCBI chr11:63,063,723...63,070,426
Ensembl chr11:63,063,795...63,070,425

G

neurofilament light chain

increases expression
multiple interactions

Vincristine results in increased expression of NEFL protein
coenzyme Q10 inhibits the reaction [Vincristine results in increased expression of NEFL protein]

NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793

G

neuralized E3 ubiquitin protein ligase 3

increases expression

Vincristine results in increased expression of NEURL3 mRNA

NCBI chr 9:38,494,486...38,503,352
Ensembl chr 9:38,494,489...38,502,649

G

nuclear factor of activated T-cells 5

increases expression

Vincristine results in increased expression of NFAT5 mRNA

NCBI chr19:35,199,737...35,286,675
Ensembl chr19:35,199,016...35,286,675

G

nuclear factor of activated T-cells 2

increases response to substance

NFATC2 gene SNP results in increased susceptibility to Vincristine

NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325

G

NFE2 like bZIP transcription factor 1

increases expression

Vincristine results in increased expression of NFE2L1 mRNA

NCBI chr10:81,796,055...81,812,926
Ensembl chr10:81,800,366...81,832,318

G

NFE2 like bZIP transcription factor 2

decreases expression
multiple interactions

Vincristine results in decreased expression of NFE2L2 mRNA; Vincristine results in decreased expression of NFE2L2 protein
coenzyme Q10 inhibits the reaction [Vincristine results in decreased expression of NFE2L2 mRNA]; Quercetin inhibits the reaction [Vincristine results in decreased expression of NFE2L2 protein]

PMID:33038355 PMID:34939713 PMID:36808657

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFE2 like bZIP transcription factor 3

decreases expression

Vincristine results in decreased expression of NFE2L3 mRNA

NCBI chr 4:80,506,756...80,534,629
Ensembl chr 4:80,506,756...80,534,629

G

nerve growth factor

multiple interactions
decreases response to substance

Bicuculline inhibits the reaction [Propofol inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]]; Bicuculline inhibits the reaction [Thiopental inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]]; Propofol inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]; Thiopental inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]
NGF protein results in decreased susceptibility to Vincristine; Vincristine results in decreased susceptibility to NGF protein

PMID:9524088 PMID:9622663 PMID:10553948 PMID:11991087

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

NHS-like 1

increases expression

Vincristine results in increased expression of NHSL1 mRNA

NCBI chr 1:12,956,525...13,188,580
Ensembl chr 1:12,956,021...13,187,547

G

ninjurin 1

increases expression

Vincristine results in increased expression of NINJ1 mRNA

NCBI chr17:15,452,804...15,461,684
Ensembl chr17:15,452,813...15,461,704

G

nischarin

decreases expression

Vincristine results in decreased expression of NISCH mRNA

NCBI chr16:6,364,370...6,400,675
Ensembl chr16:6,364,374...6,400,668

G

nicotinamide nucleotide adenylyltransferase 3

decreases response to substance

NMNAT3 protein results in decreased susceptibility to Vincristine

NCBI chr 8:98,892,168...99,003,912
Ensembl chr 8:98,873,398...99,020,645

G

nicotinamide riboside kinase 2

decreases response to substance

ITGB1BP3 mRNA results in decreased susceptibility to Vincristine

NCBI chr 7:8,514,855...8,517,916
Ensembl chr 7:8,514,927...8,517,922

G

nicotinamide nucleotide transhydrogenase

decreases expression

Vincristine results in decreased expression of NNT mRNA

NCBI chr 2:51,411,413...51,505,125
Ensembl chr 2:51,411,413...51,504,823

G

nucleolar protein 12

decreases expression

Vincristine results in decreased expression of NOL12 mRNA

NCBI chr 7:110,493,294...110,498,908
Ensembl chr 7:110,493,246...110,498,907

G

nucleolar protein 4-like

increases expression

Vincristine results in increased expression of NOL4L mRNA

NCBI chr 3:141,884,840...142,007,668
Ensembl chr 3:141,884,840...142,008,976

G

nitric oxide synthase 1

decreases expression

Vincristine results in decreased expression of NOS1 protein

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

N-acetylneuraminate pyruvate lyase

increases expression

Vincristine results in increased expression of NPL mRNA

NCBI chr13:65,655,099...65,697,464
Ensembl chr13:65,655,118...65,697,372

G

NAD(P)H quinone dehydrogenase 1

decreases activity
multiple interactions

Vincristine results in decreased activity of NQO1 protein
Quercetin inhibits the reaction [Vincristine results in decreased activity of NQO1 protein]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

Vincristine inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
increases activity

[Vincristine results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; NR1I2 protein promotes the reaction [Vincristine results in increased expression of ABCB1 protein]

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 2, group F, member 2

decreases expression

Vincristine results in decreased expression of NR2F2 mRNA

NCBI chr 1:124,008,282...124,022,521
Ensembl chr 1:124,009,181...124,022,031

G

nuclear receptor subfamily 5, group A, member 2

increases expression

Vincristine results in increased expression of NR5A2 mRNA

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

neuronal regeneration related protein

decreases expression

Vincristine results in decreased expression of NREP mRNA

NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591

G

neuritin 1

decreases expression

Vincristine results in decreased expression of NRN1 mRNA

NCBI chr17:28,129,969...28,138,898
Ensembl chr17:28,129,977...28,138,896

G

NSE4 homolog A, SMC5-SMC6 complex component

decreases expression

Vincristine results in decreased expression of NSMCE4A mRNA

NCBI chr 1:185,102,075...185,109,166
Ensembl chr 1:185,094,360...185,109,166

G

5' nucleotidase, ecto

increases expression

Vincristine results in increased expression of NT5E mRNA

NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881

G

nudix hydrolase 7

decreases expression

Vincristine results in decreased expression of NUDT7 mRNA

NCBI chr19:42,125,679...42,151,198
Ensembl chr19:42,125,711...42,151,081

G

NUF2 component of NDC80 kinetochore complex

increases expression

Vincristine results in increased expression of NUF2 mRNA

NCBI chr13:81,693,675...81,722,765
Ensembl chr13:81,693,598...81,722,766

G

NUMB, endocytic adaptor protein

increases expression

Vincristine results in increased expression of NUMB mRNA

NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354

G

nucleoporin 153

increases expression

Vincristine results in increased expression of NUP153 mRNA

NCBI chr17:17,972,217...18,024,876
Ensembl chr17:17,972,217...18,024,876

G

nuclear transport factor 2-like export factor 1

decreases expression

Vincristine results in decreased expression of NXT1 mRNA

NCBI chr 3:136,108,975...136,111,897
Ensembl chr 3:136,108,862...136,111,907

G

O-GlcNAcase

increases expression

Vincristine results in increased expression of OGA mRNA

NCBI chr 1:244,598,285...244,633,835
Ensembl chr 1:244,598,292...244,634,359

G

8-oxoguanine DNA glycosylase

decreases expression

Vincristine results in decreased expression of OGG1 mRNA

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

O-linked N-acetylglucosamine (GlcNAc) transferase

decreases expression

Vincristine results in decreased expression of OGT mRNA

NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146

G

oleoyl-ACP hydrolase

increases expression

Vincristine results in increased expression of OLAH mRNA

NCBI chr17:74,877,651...74,902,517
Ensembl chr17:74,877,655...74,902,518

G

ORAI calcium release-activated calcium modulator 1

decreases expression

Vincristine results in decreased expression of ORAI1 mRNA

NCBI chr12:33,533,151...33,548,361
Ensembl chr12:33,534,344...33,548,405

G

orthopedia homeobox

increases expression

Vincristine results in increased expression of OTP mRNA

NCBI chr 2:26,108,158...26,116,359
Ensembl chr 2:26,108,163...26,116,359

G

oxytocin receptor

affects response to substance

OXTR protein affects the susceptibility to Vincristine

NCBI chr 4:145,598,549...145,614,674
Ensembl chr 4:145,599,561...145,614,674

G

purinergic receptor P2X 5

decreases expression

Vincristine results in decreased expression of P2RX5 mRNA

NCBI chr10:57,777,737...57,789,426
Ensembl chr10:57,777,819...57,789,423

G

purinergic receptor P2X 7

multiple interactions

[(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) binds to and results in decreased activity of P2RX7 protein] which results in decreased susceptibility to Vincristine

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

prolyl 4-hydroxylase subunit alpha 1

decreases expression

Vincristine results in decreased expression of P4HA1 mRNA

NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786

G

poly(A) binding protein, cytoplasmic 1-like

decreases expression

Vincristine results in decreased expression of PABPC1L mRNA

NCBI chr 3:152,692,825...152,725,997
Ensembl chr 3:152,693,700...152,725,997

G

poly(A) binding protein, nuclear 1

decreases expression

Vincristine results in decreased expression of PABPN1 mRNA

NCBI chr15:28,368,100...28,372,712
Ensembl chr15:28,368,100...28,372,703

G

poly(A) binding protein interacting protein 1

decreases expression

Vincristine results in decreased expression of PAIP1 mRNA

NCBI chr 2:51,523,190...51,550,241
Ensembl chr 2:51,522,921...51,550,241

G

pantothenate kinase 2

decreases expression

Vincristine results in decreased expression of PANK2 mRNA

NCBI chr 3:118,483,382...118,519,551
Ensembl chr 3:118,483,444...118,518,320

G

progestin and adipoQ receptor family member 4

decreases expression

Vincristine results in decreased expression of PAQR4 mRNA

NCBI chr10:12,758,970...12,762,649
Ensembl chr10:12,758,972...12,762,584

G

poly (ADP-ribose) polymerase 1

multiple interactions

[CEP 33779 results in increased susceptibility to Vincristine] which results in increased cleavage of PARP1 protein; [NVP-BSK805 results in increased susceptibility to Vincristine] which results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

poly (ADP-ribose) polymerase 2

decreases expression

Vincristine results in decreased expression of PARP2 mRNA

NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338

G

poly (ADP-ribose) polymerase family, member 9

increases expression

Vincristine results in increased expression of PARP9 mRNA

NCBI chr11:64,780,977...64,814,995
Ensembl chr11:64,780,981...64,815,455

G

PAT1 homolog 1, processing body mRNA decay factor

decreases expression

Vincristine results in decreased expression of PATL1 mRNA

NCBI chr 1:208,831,115...208,862,904
Ensembl chr 1:208,831,115...208,862,857

G

PBX homeobox interacting protein 1

increases expression

Vincristine results in increased expression of PBXIP1 mRNA

NCBI chr 2:174,856,339...174,868,922
Ensembl chr 2:174,856,397...174,868,919

G

PC-esterase domain containing 1B

decreases expression

Vincristine results in decreased expression of PCED1B mRNA

NCBI chr 7:128,394,388...128,528,231
Ensembl chr 7:128,391,319...128,528,231

G

PCF11 cleavage and polyadenylation factor subunit

decreases expression

Vincristine results in decreased expression of PCF11 mRNA

NCBI chr 1:146,694,045...146,724,030
Ensembl chr 1:146,697,646...146,724,124

G

polycomb group ring finger 2

decreases expression

Vincristine results in decreased expression of PCGF2 mRNA

NCBI chr10:82,682,563...82,694,563
Ensembl chr10:82,683,553...82,693,406

G

pecanex 1

increases expression

Vincristine results in increased expression of PCNX1 mRNA

NCBI chr 6:101,565,461...101,702,339
Ensembl chr 6:101,565,580...101,702,271

G

pecanex 2

increases expression

Vincristine results in increased expression of PCNX2 mRNA

NCBI chr19:53,718,920...53,869,559
Ensembl chr19:53,718,655...53,871,364

G

proprotein convertase subtilisin/kexin type 7

increases expression

Vincristine results in increased expression of PCSK7 mRNA

NCBI chr 8:46,202,079...46,224,699
Ensembl chr 8:46,202,131...46,224,705

G

programmed cell death 5

decreases expression

Vincristine results in decreased expression of PDCD5 mRNA

NCBI chr 1:88,305,869...88,311,200
Ensembl chr 1:88,305,869...88,311,200

G

phosphodiesterase 4B

increases expression

Vincristine results in increased expression of PDE4B mRNA

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

pyruvate dehydrogenase kinase 1

decreases expression

Vincristine results in decreased expression of PDK1 mRNA

NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038

G

pyruvate dehydrogenase kinase 3

decreases expression

Vincristine results in decreased expression of PDK3 mRNA

NCBI chr X:58,486,699...58,553,533
Ensembl chr X:58,486,554...58,553,557

G

PDS5 cohesin associated factor B

increases expression

Vincristine results in increased expression of PDS5B mRNA

NCBI chr12:202,481...345,596
Ensembl chr12:255,313...345,596

G

proliferation and apoptosis adaptor protein 15

increases expression

Vincristine results in increased expression of PEA15 mRNA

NCBI chr13:84,657,815...84,667,437
Ensembl chr13:84,654,870...84,667,499

G

pellino E3 ubiquitin protein ligase 1

decreases expression

Vincristine results in decreased expression of PELI1 mRNA

NCBI chr14:95,254,274...95,309,168
Ensembl chr14:95,254,589...95,308,285

G

peroxisomal biogenesis factor 11 beta

decreases expression

Vincristine results in decreased expression of PEX11B mRNA

NCBI chr 2:184,172,041...184,180,972
Ensembl chr 2:184,172,004...184,181,495

G

peroxisomal biogenesis factor 13

decreases expression

Vincristine results in decreased expression of PEX13 mRNA

NCBI chr14:97,602,829...97,621,233
Ensembl chr14:97,603,539...97,621,262

G

phosphoribosylformylglycinamidine synthase

decreases expression

Vincristine results in decreased expression of PFAS mRNA

NCBI chr10:53,690,301...53,711,811
Ensembl chr10:53,691,626...53,708,420

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4

decreases expression

Vincristine results in decreased expression of PFKFB4 mRNA

NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:109,643,937...109,685,634

G

phosphoglucomutase 1

decreases expression

Vincristine results in decreased expression of PGM1 mRNA

NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728

G

phosphoglycolate phosphatase

decreases expression

Vincristine results in decreased expression of PGP mRNA

NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858

G

PHD finger protein 11

increases expression

Vincristine results in increased expression of PHF11 mRNA

NCBI chr15:33,390,290...33,414,647
Ensembl chr15:33,390,292...33,413,009

G

PHD finger protein 6

decreases expression

Vincristine results in decreased expression of PHF6 mRNA

NCBI chr X:132,656,658...132,699,720
Ensembl chr X:132,656,672...132,699,127

G

putative homeodomain transcription factor 2

decreases expression

Vincristine results in decreased expression of PHTF2 mRNA

NCBI chr 4:14,215,190...14,330,549
Ensembl chr 4:14,215,263...14,330,513

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha

increases expression

Vincristine results in increased expression of PIK3C2A mRNA

NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472

G

phosphoinositide-3-kinase regulatory subunit 1

decreases phosphorylation
multiple interactions

Vincristine results in decreased phosphorylation of PIK3R1 protein
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Vincristine results in decreased phosphorylation of PIK3R1 protein]; bisphenol A inhibits the reaction [Vincristine results in decreased phosphorylation of PIK3R1 protein]; perfluorooctanoic acid inhibits the reaction [Vincristine results in decreased phosphorylation of PIK3R1 protein]

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

phosphoinositide-3-kinase regulatory subunit 2

decreases expression

Vincristine results in decreased expression of PIK3R2 mRNA

NCBI chr16:18,665,517...18,674,067
Ensembl chr16:18,665,457...18,674,065

G

paired immunoglobin-like type 2 receptor alpha

increases expression

Vincristine results in increased expression of PILRA mRNA

NCBI chr12:17,787,169...17,798,149
Ensembl chr12:17,787,127...17,798,094

G

Pim-2 proto-oncogene, serine/threonine kinase

increases expression

Vincristine results in increased expression of PIM2 mRNA

NCBI chr X:14,617,582...14,622,851
Ensembl chr X:14,617,582...14,622,851

G

phosphatidylinositol transfer protein, beta

decreases expression

Vincristine results in decreased expression of PITPNB mRNA

NCBI chr12:45,249,308...45,298,388
Ensembl chr12:45,249,333...45,298,314

G

cAMP-dependent protein kinase inhibitor gamma

increases expression

Vincristine results in increased expression of PKIG mRNA

NCBI chr 3:152,330,477...152,398,085
Ensembl chr 3:152,366,041...152,398,082

G

phospholipase A1 member A

increases expression

Vincristine results in increased expression of PLA1A mRNA

NCBI chr11:62,320,112...62,357,779
Ensembl chr11:62,320,493...62,357,779

G

phospholipase A2 group IVC

increases expression

Vincristine results in increased expression of PLA2G4C mRNA

NCBI chr 1:74,237,714...74,275,757
Ensembl chr 1:74,236,211...74,274,656

G

plasminogen activator, tissue type

increases expression

Vincristine results in increased expression of PLAT mRNA

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

plasminogen activator, urokinase receptor

increases expression

Vincristine results in increased expression of PLAUR mRNA

NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595

G

phosphatidylinositol-specific phospholipase C, X domain containing 1

decreases expression

Vincristine results in decreased expression of PLCXD1 mRNA

NCBI chr12:46,578,917...46,582,181
Ensembl chr12:46,579,225...46,582,392

G

pleckstrin

increases expression

Vincristine results in increased expression of PLEK mRNA

NCBI chr14:91,397,015...91,429,693
Ensembl chr14:91,397,019...91,454,131

G

pleckstrin homology domain containing A2

decreases expression

Vincristine results in decreased expression of PLEKHA2 mRNA

NCBI chr16:66,938,684...67,000,661
Ensembl chr16:66,939,109...66,999,395

G

pleckstrin homology and RhoGEF domain containing G1

increases expression

Vincristine results in increased expression of PLEKHG1 mRNA

NCBI chr 1:40,348,684...40,434,063
Ensembl chr 1:40,311,221...40,434,063

G

phospholipid phosphatase 3

increases expression

Vincristine results in increased expression of PLPP3 mRNA

NCBI chr 5:119,927,085...120,002,206
Ensembl chr 5:119,927,085...120,002,205

G

peptidase M20 domain containing 2

decreases expression

Vincristine results in decreased expression of PM20D2 mRNA

NCBI chr 5:47,566,059...47,586,334
Ensembl chr 5:47,566,072...47,586,212

G

peripheral myelin protein 22

increases response to substance

PMP22 gene mutant form results in increased susceptibility to Vincristine

NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714

G

PMS1 homolog 1, mismatch repair system component

decreases expression

Vincristine results in decreased expression of PMS1 mRNA

NCBI chr 9:48,229,403...48,340,237
Ensembl chr 9:48,253,410...48,340,237

G

PNN interacting serine and arginine rich protein

decreases expression

Vincristine results in decreased expression of PNISR mRNA

NCBI chr 5:35,395,965...35,422,852
Ensembl chr 5:35,395,965...35,422,844

G

prepronociceptin

decreases expression

Vincristine results in decreased expression of PNOC mRNA

NCBI chr15:39,624,635...39,652,463
Ensembl chr15:39,624,641...39,651,867

G

protein O-glucosyltransferase 1

increases expression

Vincristine results in increased expression of POGLUT1 mRNA

NCBI chr11:62,198,600...62,226,446
Ensembl chr11:62,198,513...62,226,434

G

pogo transposable element derived with ZNF domain

increases expression

Vincristine results in increased expression of POGZ mRNA

NCBI chr 2:182,394,269...182,440,711
Ensembl chr 2:182,380,768...182,440,707

G

DNA polymerase alpha 1, catalytic subunit

decreases expression

Vincristine results in decreased expression of POLA1 mRNA

NCBI chr X:58,034,617...58,348,612
Ensembl chr X:58,034,619...58,348,536

G

DNA polymerase delta 3, accessory subunit

decreases expression

Vincristine results in decreased expression of POLD3 mRNA

NCBI chr 1:154,417,893...154,456,687
Ensembl chr 1:154,418,084...154,456,665

G

DNA polymerase theta

increases expression

Vincristine results in increased expression of POLQ mRNA

NCBI chr11:63,673,796...63,775,905
Ensembl chr11:63,673,816...63,775,878

G

RNA polymerase I subunit B

decreases expression

Vincristine results in decreased expression of POLR1B mRNA

NCBI chr 3:116,333,910...116,358,385
Ensembl chr 3:116,333,889...116,358,379

G

RNA polymerase I subunit H

decreases response to substance
multiple interactions

POLR1H protein results in decreased susceptibility to Vincristine
Verapamil inhibits the reaction [POLR1H protein results in decreased susceptibility to Vincristine]

NCBI chr20:1,594,936...1,598,854
Ensembl chr20:1,594,936...1,598,854

G

periostin

decreases response to substance

POSTN mRNA results in decreased susceptibility to Vincristine

NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099

G

POU class 2 homeobox associating factor 1

decreases expression

Vincristine results in decreased expression of POU2AF1 mRNA

NCBI chr 8:51,521,813...51,548,819
Ensembl chr 8:51,474,015...51,548,819

G

POU class 2 homeobox 1

decreases expression

Vincristine results in decreased expression of POU2F1 mRNA

NCBI chr13:78,120,617...78,263,306
Ensembl chr13:78,130,685...78,263,363

G

PPARG coactivator 1 alpha

decreases expression
multiple interactions

Vincristine results in decreased expression of PPARGC1A protein
Quercetin inhibits the reaction [Vincristine results in decreased expression of PPARGC1A protein]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein phosphatase, Mg2+/Mn2+ dependent, 1A

increases expression

Vincristine results in increased expression of PPM1A mRNA

NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697

G

protein phosphatase 1, regulatory subunit 10

increases expression

Vincristine results in increased expression of PPP1R10 mRNA

NCBI chr20:2,822,995...2,838,125
Ensembl chr20:2,822,995...2,837,611

G

protein phosphatase 1, regulatory subunit 15A

increases expression

Vincristine results in increased expression of PPP1R15A mRNA

PMID:20624997 PMID:23649840

NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171

G

protein phosphatase 1, regulatory (inhibitor) subunit 1B

increases response to substance

PPP1R1B protein results in increased susceptibility to Vincristine

NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775

G

protein phosphatase 1, regulatory subunit 3E

decreases expression

Vincristine results in decreased expression of PPP1R3E mRNA

NCBI chr15:28,348,443...28,349,603
Ensembl chr15:28,347,854...28,349,603

G

protein phosphatase 4, regulatory subunit 3B

decreases expression

Vincristine results in decreased expression of PPP4R3B mRNA

NCBI chr14:102,917,043...102,965,210
Ensembl chr14:102,917,443...103,068,192

G

protein regulator of cytokinesis 1

increases expression

Vincristine results in increased expression of PRC1 mRNA

NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765

G

DNA primase subunit 1

decreases expression

Vincristine results in decreased expression of PRIM1 mRNA

NCBI chr 7:446,342...462,526
Ensembl chr 7:431,805...462,526

G

protein kinase C, delta

affects localization

Vincristine affects the localization of PRKCD protein

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

protein kinase C, epsilon

increases response to substance

PRKCE protein results in increased susceptibility to Vincristine

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

protein kinase, DNA-activated, catalytic subunit

increases expression

Vincristine results in increased expression of PRKDC mRNA

NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952

G

prolactin receptor

increases expression

Vincristine results in increased expression of PRLR mRNA

NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718

G

prion protein

decreases response to substance

PRNP protein results in decreased susceptibility to Vincristine

NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937

G

pre-mRNA processing factor 4B

decreases expression

Vincristine results in decreased expression of PRP4K mRNA

NCBI chr17:29,985,343...30,020,285
Ensembl chr17:29,985,343...30,019,625

G

proline rich 12

decreases expression

Vincristine results in decreased expression of PRR12 mRNA

NCBI chr 1:95,510,015...95,534,002
Ensembl chr 1:95,509,931...95,533,652

G

proline rich 3

decreases expression

Vincristine results in decreased expression of PRR3 mRNA

NCBI chr20:2,792,868...2,799,865
Ensembl chr20:2,792,860...2,799,865

G

proline rich and Gla domain 4

increases expression

Vincristine results in increased expression of PRRG4 mRNA

NCBI chr 3:91,214,646...91,243,347
Ensembl chr 3:91,214,653...91,243,273

G

pleckstrin and Sec7 domain containing 3

increases expression

Vincristine results in increased expression of PSD3 mRNA

NCBI chr16:21,465,643...22,035,846
Ensembl chr16:21,465,639...22,034,547

G

proteasome activator subunit 4

increases expression

Vincristine results in increased expression of PSME4 mRNA

NCBI chr14:104,505,716...104,609,410
Ensembl chr14:104,505,716...104,609,408

G

proteasome assembly chaperone 4

increases expression

Vincristine results in increased expression of PSMG4 mRNA

NCBI chr17:30,710,682...30,718,035
Ensembl chr17:30,710,682...30,718,082

G

paraspeckle component 1

decreases expression

Vincristine results in decreased expression of PSPC1 mRNA

NCBI chr15:30,828,617...30,911,315
Ensembl chr15:30,828,626...30,911,202

G

platelet-activating factor receptor

increases expression

Vincristine results in increased expression of PTAFR mRNA

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin E receptor 4

increases expression

Vincristine results in increased expression of PTGER4 mRNA

NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670

G

prostaglandin reductase 2

decreases expression

Vincristine results in decreased expression of PTGR2 mRNA

NCBI chr 6:103,931,367...103,963,113
Ensembl chr 6:103,931,409...103,963,111

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

Vincristine results in increased expression of PTGS2 mRNA; Vincristine results in increased expression of PTGS2 protein
KN 93 inhibits the reaction [Vincristine results in increased expression of PTGS2 mRNA]; KN 93 inhibits the reaction [Vincristine results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine kinase 2 beta

increases phosphorylation

Vincristine results in increased phosphorylation of PTK2B protein

NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282

G

protein tyrosine phosphatase, non-receptor type 11

decreases expression

Vincristine results in decreased expression of PTPN11 mRNA

NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925

G

protein tyrosine phosphatase, non-receptor type 13

increases expression

Vincristine results in increased expression of PTPN13 mRNA

NCBI chr14:6,108,202...6,282,619
Ensembl chr14:6,108,211...6,282,563

G

protein tyrosine phosphatase, non-receptor type 3

increases expression

Vincristine results in increased expression of PTPN3 mRNA

NCBI chr 5:71,908,520...72,027,323
Ensembl chr 5:71,911,135...72,065,443

G

protein tyrosine phosphatase, receptor type, K

increases expression

Vincristine results in increased expression of PTPRK mRNA

NCBI chr 1:16,738,896...17,236,687
Ensembl chr 1:16,850,576...17,103,605

G

protein tyrosine phosphatase, receptor type, O

increases expression

Vincristine results in increased expression of PTPRO mRNA

NCBI chr 4:170,164,071...170,374,790
Ensembl chr 4:170,164,431...170,374,771

G

protein tyrosine phosphatase, receptor type, R

increases expression

Vincristine results in increased expression of PTPRR mRNA

NCBI chr 7:51,662,595...51,929,605
Ensembl chr 7:51,662,595...51,929,603

G

PVR related immunoglobulin domain containing

decreases expression

Vincristine results in decreased expression of PVRIG mRNA

NCBI chr12:17,363,721...17,365,577
Ensembl chr12:17,364,080...17,365,280

G

peroxisomal testis enriched protein 1

increases expression

Vincristine results in increased expression of PXT1 mRNA

NCBI chr20:7,002,270...7,005,296
Ensembl chr20:7,002,271...7,006,780

G

glutamine-rich 1

increases phosphorylation

Vincristine results in increased phosphorylation of QRICH1 protein

NCBI chr 8:109,216,900...109,256,472
Ensembl chr 8:109,217,376...109,261,359

G

RAB11 family interacting protein 1

increases expression

Vincristine results in increased expression of RAB11FIP1 mRNA

NCBI chr16:64,886,902...64,917,491
Ensembl chr16:64,884,676...64,917,491

G

RAB11 family interacting protein 3

increases expression

Vincristine results in increased expression of RAB11FIP3 mRNA

NCBI chr10:15,002,650...15,086,382
Ensembl chr10:15,002,926...15,118,479

G

RAB12, member RAS oncogene family

increases expression

Vincristine results in increased expression of RAB12 mRNA

NCBI chr 9:106,480,301...106,506,895
Ensembl chr 9:106,480,301...106,506,910

G

RAB20, member RAS oncogene family

decreases expression

Vincristine results in decreased expression of RAB20 mRNA

NCBI chr16:78,019,337...78,043,529
Ensembl chr16:78,019,337...78,043,529

G

RAB21, member RAS oncogene family

increases expression

Vincristine results in increased expression of RAB21 mRNA

NCBI chr 7:50,904,050...50,928,890
Ensembl chr 7:50,904,057...50,928,839

G

RAB29, member RAS oncogene family

increases expression

Vincristine results in increased expression of RAB29 mRNA

NCBI chr13:43,307,757...43,313,420
Ensembl chr13:43,307,775...43,313,417

G

RAB8B, member RAS oncogene family

increases expression

Vincristine results in increased expression of RAB8B mRNA

NCBI chr 8:67,458,921...67,536,466
Ensembl chr 8:67,458,923...67,536,384

G

RAB9A, member RAS oncogene family

increases expression

Vincristine results in increased expression of RAB9A mRNA

NCBI chr X:27,955,552...28,009,870
Ensembl chr X:27,952,204...28,001,622

G

Rab geranylgeranyltransferase subunit beta

decreases expression

Vincristine results in decreased expression of RABGGTB mRNA

NCBI chr 2:242,844,758...242,850,951
Ensembl chr 2:242,844,762...242,851,050

G

RAB interacting factor

decreases expression

Vincristine results in decreased expression of RABIF mRNA

NCBI chr13:45,936,371...45,948,929
Ensembl chr13:45,936,369...45,949,775

G

Rac family small GTPase 2

affects response to substance

RAC2 protein affects the susceptibility to Vincristine

NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720

G

receptor for activated C kinase 1

decreases expression

Vincristine results in decreased expression of RACK1 mRNA

NCBI chr10:33,169,415...33,174,896
Ensembl chr10:33,169,169...33,174,975

G

RAD54 like

decreases expression

Vincristine results in decreased expression of RAD54L mRNA

NCBI chr 5:129,575,431...129,605,100
Ensembl chr 5:129,575,378...129,605,070

G

ral guanine nucleotide dissociation stimulator like 1

increases expression

Vincristine results in increased expression of RGL1 mRNA

NCBI chr13:64,634,489...64,904,170
Ensembl chr13:64,635,246...64,904,191

G

RAS and EF hand domain containing

increases expression

Vincristine results in increased expression of RASEF mRNA

NCBI chr 5:87,548,908...87,619,286
Ensembl chr 5:87,548,908...87,619,031

G

Ras association domain family member 1

increases expression

Vincristine results in increased expression of RASSF1 mRNA

NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164

G

Ras association domain family member 4

increases expression

Vincristine results in increased expression of RASSF4 mRNA

NCBI chr 4:149,897,525...149,932,658
Ensembl chr 4:149,897,543...149,932,411

G

RB transcriptional corepressor 1

multiple interactions

[CEP 33779 results in increased susceptibility to Vincristine] which results in increased phosphorylation of RB1 protein; [NVP-BSK805 results in increased susceptibility to Vincristine] which results in increased phosphorylation of RB1 protein; [XL019 compound co-treated with Vincristine] results in increased expression of and results in increased phosphorylation of RB1 protein modified form

PMID:28669723 PMID:29187454

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RB binding protein 4, chromatin remodeling factor

increases expression

Vincristine results in increased expression of RBBP4 mRNA

NCBI chr 5:141,655,863...141,675,157
Ensembl chr 5:141,638,421...141,675,284

G

RB binding protein 8, endonuclease

decreases expression

Vincristine results in decreased expression of RBBP8 mRNA

NCBI chr18:2,922,985...2,988,851
Ensembl chr18:2,921,286...2,988,846

G

RB transcriptional corepressor like 1

decreases expression

Vincristine results in decreased expression of RBL1 mRNA

NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330

G

RNA binding motif protein 12

decreases expression

Vincristine results in decreased expression of RBM12 mRNA

NCBI chr 3:144,609,661...144,629,911
Ensembl chr 3:144,611,623...144,629,915
Ensembl chr 3:144,611,623...144,629,915

G

RNA binding motif protein 15

decreases expression

Vincristine results in decreased expression of RBM15 mRNA

NCBI chr 2:194,945,974...194,954,498
Ensembl chr 2:194,945,974...194,954,703

G

RNA binding motif protein 17

decreases response to substance

RBM17 protein results in decreased susceptibility to Vincristine

NCBI chr17:66,937,140...66,954,034
Ensembl chr17:66,937,140...66,954,014

G

RNA binding motif protein 18

increases expression

Vincristine results in increased expression of RBM18 mRNA

NCBI chr 3:19,467,333...19,487,171
Ensembl chr 3:19,467,335...19,487,178

G

RNA binding motif protein 25

decreases expression

Vincristine results in decreased expression of RBM25 mRNA

NCBI chr 6:103,271,775...103,319,090
Ensembl chr 6:103,271,801...103,317,854

G

RNA binding motif protein 4B

decreases expression

Vincristine results in decreased expression of RBM4B mRNA

NCBI chr 1:202,047,934...202,058,025
Ensembl chr 1:202,047,927...202,058,020

G

RNA binding motif protein 5

decreases expression

Vincristine results in decreased expression of RBM5 mRNA

NCBI chr 8:108,420,220...108,449,481
Ensembl chr 8:108,420,222...108,449,430

G

RNA binding motif protein 6

decreases expression

Vincristine results in decreased expression of RBM6 mRNA

NCBI chr 8:108,452,687...108,552,783
Ensembl chr 8:108,452,687...108,552,771

G

RNA binding motif protein 8A

decreases expression

Vincristine results in decreased expression of RBM8A mRNA

NCBI chr 2:184,165,189...184,167,959
Ensembl chr 2:184,165,193...184,167,959

G

RCC1 like

increases expression

Vincristine results in increased expression of RCC1L mRNA

NCBI chr12:22,543,125...22,574,042
Ensembl chr12:22,543,734...22,574,036

G

RecQ like helicase 4

decreases expression

Vincristine results in decreased expression of RECQL4 mRNA

NCBI chr 7:108,423,453...108,430,790
Ensembl chr 7:108,423,455...108,430,619

G

REL proto-oncogene, NF-kB subunit

increases expression

Vincristine results in increased expression of REL mRNA

NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases expression
increases phosphorylation

coenzyme Q10 inhibits the reaction [Vincristine results in increased expression of RELA protein]; Sumatriptan inhibits the reaction [Vincristine results in increased phosphorylation of RELA protein]
KN 93 inhibits the reaction [Vincristine results in increased phosphorylation of RELA protein]

PMID:29958920 PMID:34286406 PMID:34939713

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RALBP1 associated Eps domain containing 1

increases expression

Vincristine results in increased expression of REPS1 mRNA

NCBI chr 1:12,697,742...12,775,562
Ensembl chr 1:12,697,747...12,775,561

G

REV1, DNA directed polymerase

decreases expression

Vincristine results in decreased expression of REV1 mRNA

NCBI chr 9:40,278,100...40,351,764
Ensembl chr 9:40,278,101...40,351,576

G

ring finger and FYVE-like domain containing E3 ubiquitin protein ligase

increases expression

Vincristine results in increased expression of RFFL mRNA

NCBI chr10:67,740,711...67,803,669
Ensembl chr10:67,740,712...67,824,434

G

raftlin lipid raft linker 1

increases expression

Vincristine results in increased expression of RFTN1 mRNA

NCBI chr 9:10,804,611...11,002,084
Ensembl chr 9:10,804,611...11,002,084

G

regulator of G-protein signaling 1

increases expression

Vincristine results in increased expression of RGS1 mRNA

NCBI chr13:56,018,546...56,022,889
Ensembl chr13:56,018,554...56,022,984

G

regulator of G-protein signaling 10

increases response to substance

RGS10 protein results in increased susceptibility to Vincristine

NCBI chr 1:182,946,334...182,987,729
Ensembl chr 1:182,946,336...182,987,697

G

regulator of G-protein signaling 16

increases expression

Vincristine results in increased expression of RGS16 mRNA

NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857

G

regulator of G-protein signaling 17

increases response to substance

RGS17 protein results in increased susceptibility to Vincristine

NCBI chr 1:42,222,248...42,324,625
Ensembl chr 1:42,227,070...42,324,609

G

ras homolog family member F, filopodia associated

increases expression

Vincristine results in increased expression of RHOF mRNA

NCBI chr12:33,422,375...33,446,689
Ensembl chr12:33,431,280...33,446,703

G

ras homolog family member Q

increases expression

Vincristine results in increased expression of RHOQ mRNA

NCBI chr 6:7,613,632...7,652,047

G

replication timing regulatory factor 1

decreases expression

Vincristine results in decreased expression of RIF1 mRNA

NCBI chr 3:36,554,689...36,607,961
Ensembl chr 3:36,554,697...36,603,617

G

receptor-interacting serine-threonine kinase 2

increases expression

Vincristine results in increased expression of RIPK2 mRNA

NCBI chr 5:29,630,806...29,662,804
Ensembl chr 5:29,631,570...29,662,657

G

ribonuclease A family member k6

decreases expression

Vincristine results in decreased expression of RNASE6 mRNA

NCBI chr15:24,354,305...24,357,289
Ensembl chr15:24,354,303...24,357,328

G

ring finger protein 144A

decreases expression

Vincristine results in decreased expression of RNF144A mRNA

NCBI chr 6:42,899,767...43,019,769
Ensembl chr 6:42,903,174...43,020,012

G

ring finger protein 19B

increases expression

Vincristine results in increased expression of RNF19B mRNA

NCBI chr 5:141,406,085...141,431,376
Ensembl chr 5:141,406,118...141,431,380

G

ring finger protein 213

decreases expression

Vincristine results in decreased expression of RNF213 mRNA

NCBI chr10:104,656,329...104,755,669
Ensembl chr10:104,656,883...104,757,918

G

ring finger protein 34

increases expression

Vincristine results in increased expression of RNF34 mRNA

NCBI chr12:33,703,655...33,724,606
Ensembl chr12:33,703,673...33,724,586

G

RAR-related orphan receptor A

increases expression

Vincristine results in increased expression of RORA mRNA

NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931

G

RPA interacting protein

decreases expression

Vincristine results in decreased expression of RPAIN mRNA

NCBI chr10:55,692,410...55,699,910
Ensembl chr10:55,692,417...55,699,933

G

ribosomal protein L10

decreases expression

Vincristine results in decreased expression of RPL10 mRNA

NCBI chr X:152,054,562...152,056,769
Ensembl chr X:152,054,452...152,056,761

G

ribosomal protein L13

decreases expression

Vincristine results in decreased expression of RPL13 mRNA

NCBI chr19:51,153,990...51,156,541
Ensembl chr19:51,153,924...51,163,014

G

ribosomal protein L17

decreases expression

Vincristine results in decreased expression of RPL17 mRNA

NCBI chr18:68,581,141...68,584,253
Ensembl chr18:68,581,098...68,584,253

G

ribosomal protein L31

decreases expression

Vincristine results in decreased expression of RPL31 mRNA

NCBI chr 9:41,647,397...41,651,441
Ensembl chr 9:41,647,426...41,662,129

G

ribosomal protein L37A

decreases expression

Vincristine results in decreased expression of RPL37A mRNA

NCBI chr 9:74,298,843...74,300,926

G

ribosomal protein L5

decreases expression

Vincristine results in decreased expression of RPL5 mRNA

NCBI chr14:1,843,856...1,850,301
Ensembl chr14:1,843,770...1,850,290

G

ribosomal protein L6

decreases response to substance

RPL6 protein results in decreased susceptibility to Vincristine

NCBI chr12:35,347,493...35,352,011
Ensembl chr12:35,347,497...35,351,921

G

ribosomal protein L7

decreases expression

Vincristine results in decreased expression of RPL7 mRNA

NCBI chr 5:3,217,184...3,220,192

G

regulation of nuclear pre-mRNA domain containing 1A

decreases expression

Vincristine results in decreased expression of RPRD1A mRNA

NCBI chr18:15,791,418...15,839,338
Ensembl chr18:15,791,418...15,839,338

G

ribosomal protein S24

decreases expression

Vincristine results in decreased expression of RPS24 mRNA

NCBI chr16:89,538...94,267
Ensembl chr16:89,604...94,279

G

ribosomal protein S27-like

increases expression

Vincristine results in increased expression of RPS27L mRNA

NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418

G

Ras-related GTP binding C

increases expression

Vincristine results in increased expression of RRAGC mRNA

NCBI chr 5:136,148,239...136,167,773
Ensembl chr 5:136,148,276...136,167,767

G

ribonucleotide reductase regulatory subunit M2

decreases expression

Vincristine results in decreased expression of RRM2 mRNA

NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773

G

ribosomal RNA processing 7 homolog A

decreases expression

Vincristine results in decreased expression of RRP7A mRNA

NCBI chr 7:114,262,929...114,272,817
Ensembl chr 7:114,256,472...114,272,817

G

ribosomal protein S6 kinase related

decreases expression

Vincristine results in decreased expression of RSKR mRNA

NCBI chr10:63,185,286...63,191,963
Ensembl chr10:63,156,044...63,191,141

G

arginine and serine rich protein 1

decreases expression

Vincristine results in decreased expression of RSRP1 mRNA

NCBI chr 5:147,147,774...147,151,523
Ensembl chr 5:147,147,784...147,151,523

G

RUNX family transcription factor 3

increases response to substance

RUNX3 protein results in increased susceptibility to Vincristine

NCBI chr 5:147,360,587...147,419,161
Ensembl chr 5:147,360,994...147,419,156

G

S100 calcium-binding protein A4

increases expression

Vincristine results in increased expression of S100A4 mRNA

NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254

G

S100 calcium binding protein A8

increases expression

Vincristine results in increased expression of S100A8 mRNA

PMID:20624997 PMID:21971985

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

increases expression

Vincristine results in increased expression of S100A9 mRNA

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1

decreases expression

Vincristine results in decreased expression of SAMHD1 mRNA

NCBI chr 3:145,761,549...145,794,420
Ensembl chr 3:145,761,558...145,794,386

G

SAM domain, SH3 domain and nuclear localization signals, 1

increases expression

Vincristine results in increased expression of SAMSN1 mRNA

NCBI chr11:14,484,523...14,534,900
Ensembl chr11:14,483,893...14,534,900

G

sterile alpha and TIR motif containing 1

increases expression
multiple interactions

Vincristine results in increased expression of SARM1 mRNA
coenzyme Q10 inhibits the reaction [Vincristine results in increased expression of SARM1 mRNA]

NCBI chr10:63,369,456...63,393,016
Ensembl chr10:63,369,456...63,392,822

G

SAM and SH3 domain containing 3

increases expression

Vincristine results in increased expression of SASH3 mRNA

NCBI chr X:127,326,815...127,341,521
Ensembl chr X:127,326,859...127,341,519

G

spermidine/spermine N1-acetyl transferase 1

increases expression

Vincristine results in increased expression of SAT1 mRNA

NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813

G

SET binding factor 2

increases expression

Vincristine results in increased expression of SBF2 mRNA

NCBI chr 1:164,352,892...164,719,883
Ensembl chr 1:164,353,444...164,719,807

G

strawberry notch homolog 1

increases expression

Vincristine results in increased expression of SBNO1 mRNA

NCBI chr12:32,175,176...32,234,200
Ensembl chr12:32,185,485...32,230,158

G

SR-related CTD-associated factor 11

increases expression

Vincristine results in increased expression of SCAF11 mRNA

NCBI chr 7:127,571,678...127,624,089
Ensembl chr 7:127,574,463...127,624,101

G

secretory carrier membrane protein 2

decreases expression

Vincristine results in decreased expression of SCAMP2 mRNA

NCBI chr 8:57,965,612...57,992,248
Ensembl chr 8:57,965,631...57,992,646

G

sodium channel and clathrin linker 1

increases expression

Vincristine results in increased expression of SCLT1 mRNA

NCBI chr 2:124,605,445...124,763,964
Ensembl chr 2:124,605,658...124,764,065

G

selenocysteine lyase

decreases expression

Vincristine results in decreased expression of SCLY mRNA

NCBI chr 9:91,890,269...91,910,947
Ensembl chr 9:91,890,306...91,910,941

G

syndecan binding protein

increases expression

Vincristine results in increased expression of SDCBP mRNA

NCBI chr 5:19,473,499...19,517,188
Ensembl chr 5:19,489,961...19,527,572

G

SEC31 homolog B, COPII coat complex component

decreases expression

Vincristine results in decreased expression of SEC31B mRNA

NCBI chr 1:243,376,283...243,404,557
Ensembl chr 1:243,378,456...243,404,557

G

SEC62 homolog, preprotein translocation factor

decreases expression

Vincristine results in decreased expression of SEC62 mRNA

NCBI chr 2:112,570,810...112,598,198
Ensembl chr 2:112,570,819...112,601,814

G

selectin E

increases expression

Vincristine results in increased expression of SELE mRNA

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

selenoprotein H

decreases expression

Vincristine results in decreased expression of SELENOH mRNA

NCBI chr 3:69,751,850...69,753,417
Ensembl chr 3:69,752,757...69,753,417

G

SUMO specific peptidase 1

decreases expression

Vincristine results in decreased expression of SENP1 mRNA

NCBI chr 7:129,163,173...129,226,766
Ensembl chr 7:129,165,774...129,221,598

G

septin 6

decreases expression

Vincristine results in decreased expression of SEPTIN6 mRNA

NCBI chr X:116,153,255...116,230,334
Ensembl chr X:116,153,255...116,230,115

G

serine incorporator 5

increases expression

Vincristine results in increased expression of SERINC5 mRNA

NCBI chr 2:23,846,899...23,950,346
Ensembl chr 2:23,846,900...23,950,346

G

serpin family B member 10

increases expression

Vincristine results in increased expression of SERPINB10 mRNA

NCBI chr13:23,553,348...23,571,182
Ensembl chr13:23,553,430...23,571,182

G

serpin family B member 2

increases expression

Vincristine results in increased expression of SERPINB2 mRNA

NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408

G

serpin family B member 8

increases expression

Vincristine results in increased expression of SERPINB8 mRNA

NCBI chr13:23,626,936...23,650,277
Ensembl chr13:23,626,945...23,650,835

G

serpin family E member 1

increases expression
increases response to substance

Vincristine results in increased expression of SERPINE1 mRNA
SERPINE1 gene SNP results in increased susceptibility to Vincristine

PMID:20624997 PMID:21245421

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

SERTA domain containing 3

decreases expression

Vincristine results in decreased expression of SERTAD3 mRNA

NCBI chr 1:82,763,535...82,767,271
Ensembl chr 1:82,763,149...82,769,001

G

sestrin 1

increases expression

Vincristine results in increased expression of SESN1 mRNA

NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697

G

sestrin 2

increases expression

Vincristine results in increased expression of SESN2 mRNA

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

SET binding protein 1

decreases expression

Vincristine results in decreased expression of SETBP1 mRNA

NCBI chr18:72,190,542...72,551,272
Ensembl chr18:72,191,035...72,552,556

G

SET domain containing 1B, histone lysine methyltransferase

decreases expression

Vincristine results in decreased expression of SETD1B mRNA

NCBI chr12:33,395,963...33,421,671
Ensembl chr12:33,396,120...33,426,934

G

SET domain containing 6, protein lysine methyltransferase

decreases expression

Vincristine results in decreased expression of SETD6 mRNA

NCBI chr19:9,343,309...9,350,477
Ensembl chr19:9,347,458...9,350,453

G

sideroflexin 3

increases expression

Vincristine results in increased expression of SFXN3 mRNA

NCBI chr 1:243,907,958...243,917,065
Ensembl chr 1:243,907,751...243,917,073

G

serum/glucocorticoid regulated kinase 1

increases expression

Vincristine results in increased expression of SGK1 mRNA

NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283

G

SH3 and SYLF domain containing 1

increases expression

Vincristine results in increased expression of SH3YL1 mRNA

NCBI chr 6:47,522,098...47,565,858
Ensembl chr 6:47,522,091...47,565,858

G

shisa family member 8

decreases expression

Vincristine results in decreased expression of SHISA8 mRNA

NCBI chr 7:113,722,408...113,727,858
Ensembl chr 7:113,722,408...113,727,858

G

siah E3 ubiquitin protein ligase 1

decreases expression

Vincristine results in decreased expression of SIAH1 mRNA

NCBI chr19:20,378,908...20,402,512
Ensembl chr19:20,378,439...20,403,808

G

siah E3 ubiquitin protein ligase 2

increases expression

Vincristine results in increased expression of SIAH2 mRNA

NCBI chr 2:142,913,924...142,931,752
Ensembl chr 2:142,914,003...142,931,950

G

SID1 transmembrane family, member 2

increases expression

Vincristine results in increased expression of SIDT2 mRNA

NCBI chr 8:46,232,379...46,248,913
Ensembl chr 8:46,232,383...46,248,700

G

sirtuin 1

decreases expression
multiple interactions

Vincristine results in decreased expression of SIRT1 protein
Quercetin inhibits the reaction [Vincristine results in decreased expression of SIRT1 protein]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

SIVA1, apoptosis-inducing factor

decreases expression

Vincristine results in decreased expression of SIVA1 mRNA

NCBI chr 6:131,705,323...131,709,697
Ensembl chr 6:131,705,323...131,709,690

G

SIX homeobox 1

decreases expression

Vincristine results in decreased expression of SIX1 mRNA

NCBI chr 6:91,746,739...91,751,975
Ensembl chr 6:91,746,739...91,751,975

G

SKI-like proto-oncogene

increases expression

Vincristine results in increased expression of SKIL mRNA

NCBI chr 2:112,247,047...112,275,176
Ensembl chr 2:112,247,051...112,275,080

G

S-phase kinase associated protein 2

decreases expression

Vincristine results in decreased expression of SKP2 mRNA

NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338

G

signaling lymphocytic activation molecule family member 1

increases expression

Vincristine results in increased expression of SLAMF1 mRNA

NCBI chr13:84,270,316...84,305,497
Ensembl chr13:84,270,316...84,305,497

G

SLAM family member 7

increases expression

Vincristine results in increased expression of SLAMF7 mRNA

NCBI chr13:84,135,656...84,154,528
Ensembl chr13:84,136,899...84,154,105

G

solute carrier family 10 member 2

increases response to substance

SLC10A2 gene SNP results in increased susceptibility to Vincristine

NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475

G

solute carrier family 15 member 4

decreases expression

Vincristine results in decreased expression of SLC15A4 mRNA

NCBI chr12:29,048,634...29,082,480
Ensembl chr12:29,063,015...29,082,480

G

solute carrier family 16, member 14

decreases expression

Vincristine results in decreased expression of SLC16A14 mRNA

NCBI chr 9:86,110,066...86,137,546
Ensembl chr 9:86,112,894...86,137,318

G

solute carrier family 20 member 1

decreases expression

Vincristine results in decreased expression of SLC20A1 mRNA

NCBI chr 3:116,427,095...116,441,049
Ensembl chr 3:116,427,098...116,441,051

G

solute carrier family 22, member 23

increases expression

Vincristine results in increased expression of SLC22A23 mRNA

NCBI chr17:30,544,106...30,709,790
Ensembl chr17:30,544,106...30,709,790

G

solute carrier family 25 member 1

decreases expression

Vincristine results in decreased expression of SLC25A1 mRNA

NCBI chr11:83,055,764...83,058,781
Ensembl chr11:83,055,748...83,058,781

G

solute carrier family 25 member 11

decreases expression

Vincristine results in decreased expression of SLC25A11 mRNA

NCBI chr10:55,357,590...55,360,441
Ensembl chr10:55,357,597...55,360,410

G

solute carrier family 25 member 37

decreases expression

Vincristine results in decreased expression of SLC25A37 mRNA

NCBI chr15:44,534,280...44,576,697
Ensembl chr15:44,536,727...44,577,199

G

solute carrier family 29 member 1

decreases expression

Vincristine results in decreased expression of SLC29A1 mRNA

NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203

G

solute carrier family 29 member 2

decreases expression

Vincristine results in decreased expression of SLC29A2 mRNA

NCBI chr 1:202,327,641...202,335,185
Ensembl chr 1:202,327,354...202,335,171

G

solute carrier family 2 member 1

decreases response to substance

SLC2A1 protein results in decreased susceptibility to Vincristine

NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416

G

solute carrier family 44, member 5

increases expression

Vincristine results in increased expression of SLC44A5 mRNA

NCBI chr 2:242,911,050...243,208,018
Ensembl chr 2:242,911,325...243,206,404

G

solute carrier family 4 member 7

decreases expression

Vincristine results in decreased expression of SLC4A7 mRNA

NCBI chr15:10,585,307...10,664,780
Ensembl chr15:10,588,979...10,664,781

G

solute carrier family 7 member 11

increases expression

Vincristine results in increased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

solute carrier family 9 member A9

increases expression

Vincristine results in increased expression of SLC9A9 mRNA

NCBI chr 8:95,232,889...95,797,262
Ensembl chr 8:95,232,905...95,796,318

G

solute carrier organic anion transporter family, member 4C1

decreases expression

Vincristine results in decreased expression of SLCO4C1 mRNA

NCBI chr 9:97,177,497...97,229,161
Ensembl chr 9:97,178,861...97,229,715

G

SMAD family member 1

increases expression

Vincristine results in increased expression of SMAD1 mRNA

NCBI chr19:28,513,130...28,573,665
Ensembl chr19:28,513,131...28,573,651

G

SMAD family member 2

decreases expression

Vincristine results in decreased expression of SMAD2 mRNA

NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323

G

SMAD family member 4

increases expression

Vincristine results in increased expression of SMAD4 mRNA

NCBI chr18:67,243,742...67,274,438
Ensembl chr18:67,243,742...67,274,438

G

structural maintenance of chromosomes 6

decreases expression

Vincristine results in decreased expression of SMC6 mRNA

NCBI chr 6:33,978,730...34,033,201
Ensembl chr 6:33,978,716...34,031,746

G

small nuclear RNA activating complex, polypeptide 3

decreases expression

Vincristine results in decreased expression of SNAPC3 mRNA

NCBI chr 5:97,817,827...97,868,494
Ensembl chr 5:97,817,947...97,844,650

G

stannin

increases expression

Vincristine results in increased expression of SNN mRNA

NCBI chr10:4,572,933...4,581,606
Ensembl chr10:4,572,376...4,584,021

G

small nucleolar RNA, C/D box 104

decreases expression

Vincristine results in decreased expression of SNORD104 mRNA

NCBI chr10:91,435,313...91,435,382
Ensembl chr10:91,435,313...91,435,382

G

small nuclear ribonucleoprotein U5 subunit 200

increases expression

Vincristine results in increased expression of SNRNP200 mRNA

NCBI chr 3:114,428,854...114,458,194
Ensembl chr 3:114,428,854...114,458,182

G

small nuclear ribonucleoprotein polypeptide A'

increases expression

Vincristine results in increased expression of SNRPA1 mRNA

NCBI chr 1:119,641,402...119,654,653
Ensembl chr 1:119,638,481...119,654,653

G

small nuclear ribonucleoprotein polypeptide N

decreases expression

Vincristine results in decreased expression of SNRPN mRNA

NCBI chr 1:111,101,327...111,123,400
Ensembl chr 1:111,101,329...111,123,634

G

small nuclear ribonucleoprotein 13

decreases expression

Vincristine results in decreased expression of SNU13 mRNA

NCBI chr 7:113,565,293...113,570,887
Ensembl chr 7:113,565,295...113,570,872
Ensembl chr 1:113,565,295...113,570,872

G

sorting nexin 11

increases expression

Vincristine results in increased expression of SNX11 mRNA

NCBI chr10:81,742,020...81,752,778
Ensembl chr10:81,742,024...81,752,712

G

sorting nexin 25

decreases expression

Vincristine results in decreased expression of SNX25 mRNA

NCBI chr16:46,134,552...46,238,471
Ensembl chr16:46,125,804...46,238,440

G

sorting nexin 4

decreases expression

Vincristine results in decreased expression of SNX4 mRNA

NCBI chr11:67,460,872...67,518,143
Ensembl chr11:67,460,870...67,518,174

G

sorting nexin 5

decreases expression

Vincristine results in decreased expression of SNX5 mRNA

NCBI chr 3:131,621,875...131,641,127
Ensembl chr 3:131,621,880...131,641,192

G

sine oculis binding protein homolog

decreases expression

Vincristine results in decreased expression of SOBP mRNA

NCBI chr20:46,482,265...46,661,452
Ensembl chr20:46,482,765...46,663,541

G

suppressor of cytokine signaling 3

increases expression

Vincristine results in increased expression of SOCS3 mRNA

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

superoxide dismutase 2

multiple interactions
increases expression

bisindolylmaleimide I inhibits the reaction [Vincristine results in increased expression of SOD2 mRNA]; calphostin C inhibits the reaction [Vincristine results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vincristine results in increased expression of SOD2 mRNA]; Dactinomycin inhibits the reaction [Vincristine results in increased expression of SOD2 mRNA]; Tetradecanoylphorbol Acetate inhibits the reaction [Vincristine results in increased expression of SOD2 mRNA]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

SON DNA and RNA binding protein

decreases expression

Vincristine results in decreased expression of SON mRNA

NCBI chr11:30,850,890...30,923,167
Ensembl chr11:30,892,005...30,923,167

G

SOS Ras/Rac guanine nucleotide exchange factor 1

increases expression

Vincristine results in increased expression of SOS1 mRNA

NCBI chr 6:14,533,870...14,613,348
Ensembl chr 6:14,533,360...14,611,107

G

Sp1 transcription factor

decreases expression

Vincristine results in decreased expression of SP1 mRNA

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

SP100 nuclear antigen

increases expression

Vincristine results in increased expression of SP100 mRNA

NCBI chr 9:86,310,990...86,377,036
Ensembl chr 9:86,311,032...86,377,034

G

Sp4 transcription factor

decreases expression

Vincristine results in decreased expression of SP4 mRNA

NCBI chr 6:139,187,458...139,252,741
Ensembl chr 6:139,192,147...139,252,126

G

spartin

decreases expression

Vincristine results in decreased expression of SPART mRNA

NCBI chr 2:139,292,630...139,319,248
Ensembl chr 2:139,292,355...139,319,248

G

Spi-C transcription factor

increases expression

Vincristine results in increased expression of SPIC mRNA

NCBI chr 7:23,069,815...23,077,517
Ensembl chr 7:23,069,821...23,077,548

G

spindlin family, member 4

decreases expression

Vincristine results in decreased expression of SPIN4 mRNA

NCBI chr X:59,888,728...59,892,817
Ensembl chr X:59,891,581...59,892,330

G

spondin 1

increases expression

Vincristine results in increased expression of SPON1 mRNA

NCBI chr 1:167,929,049...168,228,239
Ensembl chr 1:167,928,972...168,228,226

G

sprouty-related, EVH1 domain containing 1

increases expression

Vincristine results in increased expression of SPRED1 mRNA

NCBI chr 3:103,983,120...104,050,321
Ensembl chr 3:103,983,072...104,049,718

G

sprouty RTK signaling antagonist 1

decreases expression

Vincristine results in decreased expression of SPRY1 mRNA

NCBI chr 2:120,557,256...120,561,917
Ensembl chr 2:120,556,706...120,566,189

G

sequestosome 1

multiple interactions
increases expression

[cotylenin A co-treated with Vincristine] results in increased degradation of SQSTM1 protein
Vincristine results in increased expression of SQSTM1 mRNA

PMID:23649840 PMID:25672400

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

decreases expression

Vincristine results in decreased expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

splicing regulatory glutamic acid and lysine rich protein 1

decreases expression

Vincristine results in decreased expression of SREK1 mRNA

NCBI chr 2:34,849,548...34,885,120
Ensembl chr 2:34,852,458...34,884,972

G

serglycin

increases expression

Vincristine results in increased expression of SRGN mRNA

NCBI chr20:30,442,810...30,479,549
Ensembl chr20:30,442,813...30,457,406

G

sorcin

decreases response to substance

SRI protein results in decreased susceptibility to Vincristine

NCBI chr 4:25,973,493...25,997,879
Ensembl chr 4:25,966,750...25,998,077

G

spermidine synthase

decreases expression

Vincristine results in decreased expression of SRM mRNA

NCBI chr 5:159,025,875...159,029,076
Ensembl chr 5:159,025,873...159,029,405

G

serine and arginine rich splicing factor 3

decreases expression

Vincristine results in decreased expression of SRSF3 mRNA

NCBI chr20:7,091,928...7,101,860
Ensembl chr20:7,091,910...7,101,078

G

serine and arginine rich splicing factor 7

decreases expression

Vincristine results in decreased expression of SRSF7 mRNA

NCBI chr 6:14,811,775...14,818,968
Ensembl chr 6:14,811,808...14,818,965

G

single stranded DNA binding protein 1

decreases expression

Vincristine results in decreased expression of SSBP1 mRNA

NCBI chr 4:69,266,024...69,276,135
Ensembl chr 4:69,266,102...69,276,135

G

somatostatin receptor 2

increases expression

Vincristine results in increased expression of SSTR2 mRNA

NCBI chr10:98,664,204...98,671,370
Ensembl chr10:98,664,216...98,674,351

G

STAG1 cohesin complex component

increases expression

Vincristine results in increased expression of STAG1 mRNA

NCBI chr 8:101,179,039...101,564,684
Ensembl chr 8:101,179,039...101,564,677

G

STAM binding protein-like 1

decreases expression

Vincristine results in decreased expression of STAMBPL1 mRNA

NCBI chr 1:231,699,620...231,745,034
Ensembl chr 1:231,699,995...231,745,032

G

signal transducer and activator of transcription 1

increases expression

Vincristine results in increased expression of STAT1 mRNA

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 3

multiple interactions
increases expression

Quercetin inhibits the reaction [Vincristine results in increased expression of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

stress-induced phosphoprotein 1

decreases expression

Vincristine results in decreased expression of STIP1 mRNA

NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476

G

serine/threonine kinase 4

increases expression

Vincristine results in increased expression of STK4 mRNA

NCBI chr 3:152,745,958...152,827,747
Ensembl chr 3:152,745,681...152,827,744

G

striatin interacting protein 2

decreases expression

Vincristine results in decreased expression of STRIP2 mRNA

NCBI chr 4:58,536,034...58,578,279
Ensembl chr 4:58,536,055...58,578,291

G

steroid sulfatase

decreases expression

Vincristine results in decreased expression of STS mRNA

NCBI chr X:42,225,131...42,233,403
Ensembl chr X:42,225,372...42,233,402

G

syntaxin 12

increases expression

Vincristine results in increased expression of STX12 mRNA

NCBI chr 5:145,062,978...145,092,423
Ensembl chr 5:145,063,587...145,092,377

G

Sad1 and UNC84 domain containing 2

increases expression

Vincristine results in increased expression of SUN2 mRNA

NCBI chr 7:111,275,374...111,292,565
Ensembl chr 7:111,275,380...111,292,553

G

SPT20 homolog, SAGA complex component

increases expression

Vincristine results in increased expression of SUPT20H mRNA

NCBI chr 2:138,897,316...138,930,493
Ensembl chr 2:138,897,416...138,930,495

G

SUZ12 polycomb repressive complex 2 subunit

increases expression

Vincristine results in increased expression of SUZ12 mRNA

NCBI chr10:64,967,035...65,012,916
Ensembl chr10:64,966,967...65,012,738

G

SYF2 pre-mRNA-splicing factor

increases expression

Vincristine results in increased expression of SYF2 mRNA

NCBI chr 5:147,156,492...147,164,416
Ensembl chr 5:147,156,480...147,164,414

G

synaptotagmin binding, cytoplasmic RNA interacting protein

decreases expression

Vincristine results in decreased expression of SYNCRIP mRNA

NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515

G

spectrin repeat containing nuclear envelope protein 2

decreases expression

Vincristine results in decreased expression of SYNE2 mRNA

NCBI chr 6:94,537,088...94,848,085
Ensembl chr 6:94,537,088...94,848,064

G

synaptophysin-like 2

increases expression

Vincristine results in increased expression of SYPL2 mRNA

NCBI chr 2:195,849,062...195,863,794
Ensembl chr 2:195,849,062...195,863,794

G

synaptotagmin-like 3

increases expression

Vincristine results in increased expression of SYTL3 mRNA

NCBI chr 1:46,896,308...46,967,461
Ensembl chr 1:46,911,217...46,967,460

G

TATA-box binding protein associated factor 15

increases expression

Vincristine results in increased expression of TAF15 mRNA

NCBI chr10:68,272,921...68,304,951
Ensembl chr10:68,272,969...68,304,949

G

TATA-box binding protein associated factor, RNA polymerase I subunit D

decreases expression

Vincristine results in decreased expression of TAF1D mRNA

NCBI chr 8:12,146,511...12,156,647
Ensembl chr 8:12,146,605...12,156,618

G

TATA-box binding protein associated factor 5 like 1

decreases expression

Vincristine results in decreased expression of TAF5L mRNA

NCBI chr19:51,991,704...52,011,001
Ensembl chr19:51,991,708...52,011,295

G

TRAF family member-associated NFKB activator

decreases expression
increases expression

Vincristine results in decreased expression of TANK mRNA
Vincristine results in increased expression of TANK mRNA

NCBI chr 3:46,114,230...46,190,270
Ensembl chr 3:46,114,274...46,190,264

G

transporter 1, ATP binding cassette subfamily B member

increases expression

Vincristine results in increased expression of TAP1 mRNA

NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901

G

transcription activation suppressor family member 2

increases expression

Vincristine results in increased expression of TASOR2 mRNA

NCBI chr17:66,583,554...66,650,127
Ensembl chr17:66,594,908...66,649,135

G

TBC1 domain family, member 12

decreases expression

Vincristine results in decreased expression of TBC1D12 mRNA

NCBI chr 1:236,603,597...236,685,859
Ensembl chr 1:236,603,607...236,685,859

G

TBC1 domain family, member 4

increases expression

Vincristine results in increased expression of TBC1D4 mRNA

NCBI chr15:78,256,030...78,434,168
Ensembl chr15:78,257,121...78,434,265

G

TBC1 domain family member 8B

decreases expression

Vincristine results in decreased expression of TBC1D8B mRNA

NCBI chr X:103,319,181...103,407,137
Ensembl chr X:103,319,340...103,407,133

G

T-box transcription factor 22

increases expression

Vincristine results in increased expression of TBX22 mRNA

NCBI chr X:72,723,619...72,774,647
Ensembl chr X:72,723,617...72,774,647

G

TRPM8 channel-associated factor 1

decreases expression

Vincristine results in decreased expression of TCAF1 mRNA

NCBI chr 4:71,589,674...71,639,274
Ensembl chr 4:71,591,200...71,613,309

G

transcription elongation factor A2

increases expression

Vincristine results in increased expression of TCEA2 mRNA

NCBI chr 3:168,796,244...168,804,125
Ensembl chr 3:168,796,331...168,804,116

G

transcription factor 19

decreases expression

Vincristine results in decreased expression of TCF19 mRNA

NCBI chr20:3,218,756...3,222,861
Ensembl chr20:3,218,693...3,223,271

G

T-cell immune regulator 1, ATPase H+ transporting V0 subunit A3

decreases expression

Vincristine results in decreased expression of TCIRG1 mRNA

NCBI chr 1:201,127,034...201,138,787
Ensembl chr 1:201,127,034...201,138,742

G

tudor domain containing 9

increases expression

Vincristine results in increased expression of TDRD9 mRNA

NCBI chr 6:131,029,644...131,145,076
Ensembl chr 6:131,029,652...131,144,651

G

teneurin transmembrane protein 2

increases expression

Vincristine results in increased expression of TENM2 mRNA

NCBI chr10:20,480,662...21,706,415
Ensembl chr10:20,481,854...21,705,597

G

terminal nucleotidyltransferase 2

increases expression

Vincristine results in increased expression of TENT2 mRNA

NCBI chr 2:24,380,135...24,432,099
Ensembl chr 2:24,380,225...24,432,099

G

terminal nucleotidyltransferase 5C

decreases expression

Vincristine results in decreased expression of TENT5C mRNA

NCBI chr 2:187,853,026...187,875,260
Ensembl chr 2:187,853,024...187,894,744

G

transcription factor AP-2 alpha

decreases expression

Vincristine results in decreased expression of TFAP2A mRNA

NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507

G

tissue factor pathway inhibitor

increases expression

Vincristine results in increased expression of TFPI mRNA

NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880

G

TDP-glucose 4,6-dehydratase

increases expression

Vincristine results in increased expression of TGDS mRNA

NCBI chr15:95,175,064...95,195,555
Ensembl chr15:95,174,608...95,195,554

G

transforming growth factor, beta induced

decreases response to substance

TGFBI mRNA results in decreased susceptibility to Vincristine

NCBI chr17:7,955,603...7,984,903
Ensembl chr17:7,955,603...7,985,240

G

transforming growth factor beta receptor 3

decreases expression

Vincristine results in decreased expression of TGFBR3 mRNA

NCBI chr14:2,489,397...2,665,383
Ensembl chr14:2,489,397...2,663,341

G

THADA, armadillo repeat containing

increases expression

Vincristine results in increased expression of THADA mRNA

NCBI chr 6:10,183,942...10,488,007
Ensembl chr 6:10,183,982...10,487,159

G

thrombomodulin

decreases response to substance

THBD protein results in decreased susceptibility to Vincristine

NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193

G

thrombospondin 1

increases expression

Vincristine results in increased expression of THBS1 mRNA

NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440

G

thioesterase superfamily member 6

decreases expression

Vincristine results in decreased expression of THEM6 mRNA

NCBI chr 7:106,606,570...106,609,747
Ensembl chr 7:106,606,570...106,609,746

G

thymocyte selection associated family member 2

increases expression

Vincristine results in increased expression of THEMIS2 mRNA

NCBI chr 5:144,991,110...145,006,362
Ensembl chr 5:144,991,112...145,006,400

G

thyroid hormone receptor alpha

multiple interactions

Vincristine binds to and results in decreased activity of THRA protein

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

TP53 induced glycolysis regulatory phosphatase

increases expression

Vincristine results in increased expression of TIGAR mRNA

NCBI chr 4:159,927,136...159,946,077
Ensembl chr 4:159,927,139...159,946,029

G

TIMP metallopeptidase inhibitor 1

increases expression

Vincristine results in increased expression of TIMP1 mRNA

PMID:20624997 PMID:23649840

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tubulointerstitial nephritis antigen

decreases expression

Vincristine results in decreased expression of TINAG mRNA

NCBI chr 8:77,800,031...77,885,077
Ensembl chr 8:77,800,032...77,885,077

G

TIR domain containing adaptor protein

decreases expression

Vincristine results in decreased expression of TIRAP mRNA

NCBI chr 8:33,531,724...33,548,508
Ensembl chr 8:33,531,725...33,547,432

G

TLC domain containing 1

decreases expression

Vincristine results in decreased expression of TLCD1 mRNA

NCBI chr10:63,074,469...63,076,502
Ensembl chr10:63,074,469...63,076,501

G

toll-like receptor 10

decreases expression

Vincristine results in decreased expression of TLR10 mRNA

NCBI chr14:43,400,843...43,414,056
Ensembl chr14:43,406,217...43,413,917

G

TM2 domain containing 1

decreases expression

Vincristine results in decreased expression of TM2D1 mRNA

NCBI chr 5:113,020,793...113,062,134
Ensembl chr 5:113,020,760...113,050,933

G

transmembrane and coiled-coil domain family 3

increases expression

Vincristine results in increased expression of TMCC3 mRNA

NCBI chr 7:28,893,972...29,171,935
Ensembl chr 7:28,893,967...29,171,926

G

transmembrane and coiled-coil domains 6

decreases expression

Vincristine results in decreased expression of TMCO6 mRNA

NCBI chr18:28,349,248...28,355,843
Ensembl chr18:28,349,248...28,355,843

G

transmembrane protein 106C

decreases expression

Vincristine results in decreased expression of TMEM106C mRNA

NCBI chr 7:129,088,468...129,094,128
Ensembl chr 7:129,088,498...129,094,130

G

transmembrane protein 107

decreases expression

Vincristine results in decreased expression of TMEM107 mRNA

NCBI chr10:53,772,153...53,774,685
Ensembl chr10:53,771,784...53,774,676

G

transmembrane protein 163

increases expression

Vincristine results in increased expression of TMEM163 mRNA

NCBI chr13:38,967,913...39,141,664
Ensembl chr13:38,968,101...39,141,452

G

transmembrane protein 177

decreases expression

Vincristine results in decreased expression of TMEM177 mRNA

NCBI chr13:31,023,893...31,027,368
Ensembl chr13:31,023,455...31,027,378

G

transmembrane protein 200A

decreases expression

Vincristine results in decreased expression of TMEM200A mRNA

NCBI chr 1:19,323,646...19,408,324
Ensembl chr 1:19,323,829...19,406,453

G

transmembrane protein 223

decreases expression

Vincristine results in decreased expression of TMEM223 mRNA

NCBI chr 1:205,668,716...205,670,077
Ensembl chr 1:205,662,063...205,670,056

G

transmembrane protein 267

increases expression

Vincristine results in increased expression of TMEM267 mRNA

NCBI chr 2:51,580,210...51,588,937
Ensembl chr 2:51,581,252...51,587,636

G

transmembrane protein 38a

decreases expression

Vincristine results in decreased expression of TMEM38A mRNA

NCBI chr16:17,258,160...17,274,204
Ensembl chr16:17,258,164...17,273,415

G

transmembrane protein 43

increases expression

Vincristine results in increased expression of TMEM43 mRNA

NCBI chr 4:123,977,680...123,992,823
Ensembl chr 4:123,977,625...123,992,825

G

transmembrane protein 80

decreases expression

Vincristine results in decreased expression of TMEM80 mRNA

NCBI chr 1:196,435,999...196,444,368
Ensembl chr 1:196,436,003...196,444,367
Ensembl chr 1:196,436,003...196,444,367

G

TATA element modulatory factor 1

increases expression

Vincristine results in increased expression of TMF1 mRNA

NCBI chr 4:129,759,952...129,785,705
Ensembl chr 4:129,763,114...129,785,629

G

thioredoxin-related transmembrane protein 4

decreases expression

Vincristine results in decreased expression of TMX4 mRNA

NCBI chr 3:121,856,237...121,899,680
Ensembl chr 3:121,856,261...121,899,641

G

tumor necrosis factor

multiple interactions
increases expression

coenzyme Q10 inhibits the reaction [Vincristine results in increased expression of TNF protein]; Pregabalin inhibits the reaction [Vincristine results in increased expression of TNF protein]; Sumatriptan inhibits the reaction [Vincristine results in increased expression of TNF mRNA]; tetrahydrocurcumin inhibits the reaction [Vincristine results in increased expression of TNF protein]; Tropisetron inhibits the reaction [Vincristine results in increased expression of TNF protein]
KN 93 inhibits the reaction [Vincristine results in increased expression of TNF mRNA]
Vincristine results in increased expression of TNF mRNA; Vincristine results in increased expression of TNF protein

PMID:23649840 PMID:24374478 PMID:26102012 PMID:29958920 PMID:34286406 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 3

increases expression

Vincristine results in increased expression of TNFAIP3 mRNA

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

TNF alpha induced protein 6

increases expression

Vincristine results in increased expression of TNFAIP6 mRNA

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

G

TNF alpha induced protein 8 like 1

increases expression

Vincristine results in increased expression of TNFAIP8L1 mRNA

NCBI chr 9:988,587...999,342
Ensembl chr 9:988,594...1,002,254

G

TNF receptor superfamily member 17

decreases expression

Vincristine results in decreased expression of TNFRSF17 mRNA

NCBI chr10:4,301,023...4,306,889
Ensembl chr10:4,301,038...4,306,788

G

TNF receptor superfamily member 19

decreases expression

Vincristine results in decreased expression of TNFRSF19 mRNA

NCBI chr15:35,092,206...35,158,472
Ensembl chr15:35,092,206...35,180,795

G

TNF receptor superfamily member 9

increases expression

Vincristine results in increased expression of TNFRSF9 mRNA

NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000

G

TNF superfamily member 10

increases expression

Vincristine results in increased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TNF superfamily member 4

increases expression

Vincristine results in increased expression of TNFSF4 mRNA

NCBI chr13:73,723,329...73,746,809
Ensembl chr13:73,723,329...73,746,788

G

TNF superfamily member 9

increases expression

Vincristine results in increased expression of TNFSF9 mRNA

NCBI chr 9:1,944,017...1,946,351
Ensembl chr 9:1,944,017...1,946,345

G

TNFAIP3 interacting protein 2

increases expression

Vincristine results in increased expression of TNIP2 mRNA

NCBI chr14:76,228,350...76,245,553
Ensembl chr14:76,228,371...76,275,265

G

troponin I3, cardiac type

increases expression

Vincristine results in increased expression of TNNI3 protein

NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580

G

troponin T2, cardiac type

multiple interactions

Vincristine inhibits the reaction [Isoproterenol results in increased secretion of TNNT2 protein]

NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388

G

translocase of outer mitochondrial membrane 70

decreases expression

Vincristine results in decreased expression of TOMM70 mRNA

NCBI chr11:43,378,719...43,417,166
Ensembl chr11:43,377,216...43,417,202

G

DNA topoisomerase II alpha

decreases expression

Vincristine results in decreased expression of TOP2A mRNA

NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874

G

DNA topoisomerase II binding protein 1

decreases expression

Vincristine results in decreased expression of TOPBP1 mRNA

NCBI chr 8:103,887,805...103,931,662
Ensembl chr 8:103,887,865...103,931,674

G

tumor protein p53

increases response to substance
increases glutathionylation
increases expression
multiple interactions
increases activity

TP53 protein results in increased susceptibility to Vincristine
Vincristine results in increased glutathionylation of TP53 protein
Vincristine results in increased expression of TP53 protein
[Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of TP53 protein
Vincristine results in increased activity of TP53 protein

PMID:9815696 PMID:12082016 PMID:14704126 PMID:15131059 PMID:17555331 More...

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein p53 inducible protein 3

increases expression

Vincristine results in increased expression of TP53I3 mRNA

NCBI chr 6:27,818,327...27,825,753

G

tumor protein p53 inducible nuclear protein 1

increases expression

Vincristine results in increased expression of TP53INP1 mRNA

NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968

G

two pore segment channel 2

increases expression

Vincristine results in increased expression of TPCN2 mRNA

NCBI chr 1:200,416,538...200,446,252
Ensembl chr 1:200,416,540...200,446,236

G

tumor protein D52

decreases expression

Vincristine results in decreased expression of TPD52 mRNA

NCBI chr 2:92,735,365...92,816,079
Ensembl chr 2:92,735,620...92,816,622

G

TPD52 like 1

increases expression

Vincristine results in increased expression of TPD52L1 mRNA

NCBI chr 1:26,172,038...26,290,704
Ensembl chr 1:26,172,170...26,291,109

G

triosephosphate isomerase 1

affects response to substance

TPI1 protein affects the susceptibility to Vincristine

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

tropomyosin 4

increases expression

Vincristine results in increased expression of TPM4 mRNA

NCBI chr16:17,684,415...17,698,456
Ensembl chr16:17,683,195...17,705,984

G

tumor protein p63 regulated 1-like

increases expression

Vincristine results in increased expression of TPRG1L mRNA

NCBI chr 5:164,722,151...164,725,358
Ensembl chr 5:164,710,285...164,725,425

G

transformer 2 alpha

increases expression

Vincristine results in increased expression of TRA2A mRNA

NCBI chr 4:78,220,838...78,239,737
Ensembl chr 4:78,220,883...78,239,712

G

TNF receptor-associated factor 1

increases expression

Vincristine results in increased expression of TRAF1 mRNA

NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807

G

TRAF3 interacting protein 3

decreases expression

Vincristine results in decreased expression of TRAF3IP3 mRNA

NCBI chr13:104,694,802...104,719,655
Ensembl chr13:104,694,805...104,719,673

G

trafficking protein particle complex subunit 10

increases expression

Vincristine results in increased expression of TRAPPC10 mRNA

NCBI chr20:10,438,737...10,499,074
Ensembl chr20:10,438,737...10,499,074

G

three prime repair exonuclease 1

decreases expression

Vincristine results in decreased expression of TREX1 mRNA

NCBI chr 8:109,706,613...109,707,913
Ensembl chr 8:109,706,613...109,708,796

G

tribbles pseudokinase 1

decreases expression

Vincristine results in decreased expression of TRIB1 mRNA

NCBI chr 7:91,206,579...91,213,126
Ensembl chr 7:91,206,579...91,214,731

G

tripartite motif-containing 13

decreases expression

Vincristine results in decreased expression of TRIM13 mRNA

NCBI chr15:35,733,548...35,772,676
Ensembl chr15:35,734,107...35,772,677

G

tripartite motif-containing 29

increases expression

Vincristine results in increased expression of TRIM29 mRNA

NCBI chr 8:43,682,221...43,706,992
Ensembl chr 8:43,682,221...43,706,992

G

tripartite motif-containing 45

decreases expression

Vincristine results in decreased expression of TRIM45 mRNA

NCBI chr 2:188,349,979...188,359,205
Ensembl chr 2:188,349,744...188,359,204

G

trio Rho guanine nucleotide exchange factor

increases expression

Vincristine results in increased expression of TRIO mRNA

NCBI chr 2:78,505,069...78,801,384
Ensembl chr 2:78,505,070...78,803,135

G

telomerase RNA component interacting RNase

decreases expression

Vincristine results in decreased expression of TRIR mRNA

NCBI chr19:23,125,083...23,128,502
Ensembl chr19:23,125,083...23,128,510

G

transient receptor potential cation channel, subfamily V, member 2

increases expression

Vincristine results in increased expression of TRPV2 mRNA

NCBI chr10:47,265,524...47,294,263
Ensembl chr10:47,272,931...47,294,260

G

transient receptor potential cation channel, subfamily V, member 4

increases response to substance

TRPV4 protein results in increased susceptibility to Vincristine

NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517

G

TSC22 domain family, member 1

decreases expression

Vincristine results in decreased expression of TSC22D1 mRNA

NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958

G

tRNA splicing endonuclease subunit 15

decreases expression

Vincristine results in decreased expression of TSEN15 mRNA

NCBI chr13:64,490,216...64,505,591
Ensembl chr13:64,490,218...64,505,617

G

tumor susceptibility 101

affects response to substance

TSG101 affects the susceptibility to Vincristine

NCBI chr 1:97,412,689...97,442,589
Ensembl chr 1:97,410,848...97,442,554

G

teashirt zinc finger homeobox 1

decreases expression

Vincristine results in decreased expression of TSHZ1 mRNA

NCBI chr18:77,376,399...77,452,815
Ensembl chr18:77,377,394...77,453,509

G

tetratricopeptide repeat domain 3

decreases expression

Vincristine results in decreased expression of TTC3 mRNA

NCBI chr11:33,689,119...33,788,976
Ensembl chr11:33,688,952...33,788,975

G

tetratricopeptide repeat domain 9C

increases expression
decreases expression

Vincristine results in increased expression of TTC9C mRNA
Vincristine results in decreased expression of TTC9C mRNA

NCBI chr 1:205,701,768...205,712,782
Ensembl chr 1:205,701,768...205,712,773

G

tweety family member 2

increases expression

Vincristine results in increased expression of TTYH2 mRNA

NCBI chr10:99,709,063...99,753,449
Ensembl chr10:99,709,007...99,753,444

G

tubulin, alpha 1B

decreases expression

Vincristine results in decreased expression of TUBA1B mRNA

PMID:20624997 PMID:23649840

NCBI chr 7:130,090,663...130,093,644
Ensembl chr 7:130,081,032...130,196,186

G

tubulin, alpha 1C

decreases expression

Vincristine results in decreased expression of TUBA1C mRNA

NCBI chr 7:130,192,050...130,199,655
Ensembl chr 7:130,192,016...130,199,647
Ensembl chr X:130,192,016...130,199,647

G

tubulin, alpha 3B

decreases expression

Vincristine results in decreased expression of TUBA3D mRNA

NCBI chr 4:178,588,779...178,594,328
Ensembl chr 4:178,588,779...178,594,326

G

tubulin, alpha 4A

decreases expression

Vincristine results in decreased expression of TUBA4A mRNA

PMID:20624997 PMID:23649840

NCBI chr 9:76,709,617...76,714,327
Ensembl chr 9:76,709,614...76,713,918

G

tubulin, beta 3 class III

decreases expression

Vincristine results in decreased expression of TUBB3 mRNA

NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243

G

tubulin, beta 4B class IVb

decreases expression

Vincristine results in decreased expression of TUBB4B mRNA

PMID:20624997 PMID:23649840

NCBI chr 3:8,037,838...8,040,294
Ensembl chr 3:8,037,799...8,040,296

G

tubulin, beta 5 class I

decreases expression

Vincristine results in decreased expression of TUBB mRNA
Vincristine results in decreased expression of TUBB5 mRNA

PMID:20624997 PMID:23649840

NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940

G

tubulin, gamma 1

decreases expression

Vincristine results in decreased expression of TUBG1 mRNA

PMID:20624997 PMID:23649840

NCBI chr10:86,052,845...86,059,436
Ensembl chr10:86,052,743...86,059,433

G

tubulin gamma complex component 5

decreases expression

Vincristine results in decreased expression of TUBGCP5 mRNA

NCBI chr 1:106,636,526...106,672,175
Ensembl chr 1:106,636,526...106,672,175

G

TUB like protein 4

increases expression

Vincristine results in increased expression of TULP4 mRNA

NCBI chr 1:46,682,416...46,813,167
Ensembl chr 1:46,682,863...46,809,688

G

twinfilin actin-binding protein 1

affects response to substance

TWF1 protein affects the susceptibility to Vincristine

NCBI chr 7:125,715,938...125,727,834
Ensembl chr 7:125,716,015...125,727,894

G

thioredoxin interacting protein

increases expression

Vincristine results in increased expression of TXNIP mRNA

NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886

G

thymidine phosphorylase

multiple interactions

TYMP inhibits the reaction [Vincristine results in increased phosphorylation of BCL2 protein]

NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874

G

thymidylate synthetase

affects response to substance

TYMS gene polymorphism affects the susceptibility to Vincristine

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

G

U2 snRNP-associated SURP domain containing

increases expression

Vincristine results in increased expression of U2SURP mRNA

NCBI chr 8:96,018,932...96,075,795
Ensembl chr 8:96,022,957...96,075,691

G

UBA-like domain containing 2

increases expression

Vincristine results in increased expression of UBALD2 mRNA

NCBI chr10:101,662,507...101,667,089
Ensembl chr10:101,658,127...101,667,061

G

ubiquitin-associated protein 2

decreases expression

Vincristine results in decreased expression of UBAP2 mRNA

NCBI chr 5:56,348,243...56,437,403
Ensembl chr 5:56,348,246...56,437,049

G

ubiquitin C

decreases expression

Vincristine results in decreased expression of UBC mRNA

NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925

G

ubiquitin-conjugating enzyme E2C

decreases expression

Vincristine results in decreased expression of UBE2C mRNA

NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339

G

ubiquitin-conjugating enzyme E2G 1

decreases expression

Vincristine results in decreased expression of UBE2G1 mRNA

NCBI chr10:57,225,963...57,306,748
Ensembl chr10:57,225,952...57,308,568

G

ubiquitin-conjugating enzyme E2I

decreases expression

Vincristine results in decreased expression of UBE2I mRNA

NCBI chr10:14,277,749...14,294,681
Ensembl chr10:69,701,618...69,702,443
Ensembl chr10:69,701,618...69,702,443

G

ubiquitin-conjugating enzyme E2, J1

decreases expression

Vincristine results in decreased expression of UBE2J1 mRNA

NCBI chr 5:47,422,476...47,441,476
Ensembl chr 5:47,422,587...47,441,461

G

ubiquitin protein ligase E3 component n-recognin 2

increases expression

Vincristine results in increased expression of UBR2 mRNA

NCBI chr 9:13,982,427...14,062,315
Ensembl chr 9:13,982,329...14,062,139

G

ubiquitin protein ligase E3 component n-recognin 4

increases expression

Vincristine results in increased expression of UBR4 mRNA

NCBI chr 5:151,635,825...151,743,931
Ensembl chr 5:151,635,868...151,743,784

G

ubiquitin C-terminal hydrolase L1

increases expression

Vincristine results in increased expression of UCHL1 protein

NCBI chr14:41,485,031...41,495,590
Ensembl chr14:41,485,031...41,495,590

G

uncoupling protein 2

decreases expression

Vincristine results in decreased expression of UCP2 mRNA

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

UDP-glucose ceramide glucosyltransferase

increases expression

Vincristine results in increased expression of UGCG mRNA

NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393

G

UDP-glucose glycoprotein glucosyltransferase 2

increases expression

Vincristine results in increased expression of UGGT2 mRNA

NCBI chr15:96,074,557...96,239,365
Ensembl chr15:96,074,564...96,237,806

G

unc-119 lipid binding chaperone

increases expression

Vincristine results in increased expression of UNC119 mRNA

NCBI chr10:63,237,862...63,243,339
Ensembl chr10:63,237,903...63,243,339

G

beta-ureidopropionase 1

increases expression

Vincristine results in increased expression of UPB1 mRNA

NCBI chr20:13,217,252...13,243,590
Ensembl chr20:13,217,258...13,243,590

G

uroporphyrinogen decarboxylase

decreases expression

Vincristine results in decreased expression of UROD mRNA

NCBI chr 5:130,464,695...130,468,783
Ensembl chr 5:130,455,217...130,468,808

G

ubiquitin specific peptidase 12

increases expression

Vincristine results in increased expression of USP12 mRNA

NCBI chr12:8,309,845...8,363,686
Ensembl chr12:8,309,750...8,363,656

G

ubiquitin specific peptidase 25

decreases expression

Vincristine results in decreased expression of USP25 mRNA

NCBI chr11:15,603,654...15,711,356
Ensembl chr11:15,603,881...15,711,348

G

ubiquitin specific peptidase 34

increases expression

Vincristine results in increased expression of USP34 mRNA

NCBI chr14:97,285,799...97,476,376
Ensembl chr14:97,286,018...97,476,376

G

ubiquitin specific peptidase 37

decreases expression

Vincristine results in decreased expression of USP37 mRNA

NCBI chr 9:76,018,863...76,118,732
Ensembl chr 9:76,018,991...76,084,044

G

vesicle-associated membrane protein 2

decreases expression

Vincristine results in decreased expression of VAMP2 mRNA

NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809

G

vasodilator-stimulated phosphoprotein

increases expression

Vincristine results in increased expression of VASP mRNA

NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061

G

vascular cell adhesion molecule 1

increases expression

Vincristine results in increased expression of VCAM1 mRNA

PMID:20624997 PMID:23649840

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vitamin D receptor

affects response to substance

VDR gene polymorphism affects the susceptibility to Vincristine

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

G

vascular endothelial growth factor A

decreases expression

Vincristine results in decreased expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vascular endothelial zinc finger 1

decreases expression

Vincristine results in decreased expression of VEZF1 mRNA

NCBI chr10:72,859,669...72,876,111
Ensembl chr10:72,859,877...72,876,111

G

vitrin

increases response to substance

VIT mRNA results in increased susceptibility to Vincristine

NCBI chr 6:16,445,966...16,565,644
Ensembl chr 6:16,445,955...16,565,665

G

vacuolar protein sorting 13 homolog A

decreases expression

Vincristine results in decreased expression of VPS13A mRNA

NCBI chr 1:213,901,999...214,128,638
Ensembl chr 1:213,901,999...214,128,555

G

vacuolar protein sorting 13 homolog D

increases expression

Vincristine results in increased expression of VPS13D mRNA

NCBI chr 5:156,830,509...157,055,895
Ensembl chr 5:156,830,512...157,055,891

G

vacuolar protein sorting 25 homolog

decreases expression

Vincristine results in decreased expression of VPS25 mRNA

NCBI chr10:86,196,062...86,201,606
Ensembl chr10:86,188,812...86,231,829

G

VPS53 subunit of GARP complex

increases expression

Vincristine results in increased expression of VPS53 mRNA

NCBI chr10:60,919,820...61,038,674
Ensembl chr10:60,919,820...61,038,676

G

vacuolar protein sorting 72 homolog

decreases expression

Vincristine results in decreased expression of VPS72 mRNA

NCBI chr 2:182,678,594...182,690,185
Ensembl chr 2:182,678,609...182,690,182

G

vesicle transport through interaction with t-SNAREs 1A

decreases expression

Vincristine results in decreased expression of VTI1A mRNA

NCBI chr 1:254,356,343...254,661,854
Ensembl chr 1:254,356,429...254,661,852

G

von Willebrand factor

increases expression

Vincristine results in increased expression of VWF mRNA

NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539

G

WD repeat and HMG-box DNA binding protein 1

decreases expression

Vincristine results in decreased expression of WDHD1 mRNA

NCBI chr15:20,478,310...20,523,106
Ensembl chr15:20,489,291...20,523,096

G

WD repeat domain 17

decreases expression

Vincristine results in decreased expression of WDR17 mRNA

NCBI chr16:37,059,923...37,191,125
Ensembl chr16:37,059,895...37,191,122

G

WD repeat domain 33

decreases expression

Vincristine results in decreased expression of WDR33 mRNA

NCBI chr18:23,432,233...23,535,460
Ensembl chr18:23,432,191...23,468,597

G

WD repeat domain 72

decreases expression

Vincristine results in decreased expression of WDR72 mRNA

NCBI chr 8:74,838,338...75,020,938
Ensembl chr 8:74,838,318...75,018,229

G

WD repeat domain 76

decreases expression

Vincristine results in decreased expression of WDR76 mRNA

NCBI chr 3:108,456,784...108,491,528
Ensembl chr 3:108,456,815...108,490,840

G

WD repeat domain 90

decreases expression

Vincristine results in decreased expression of WDR90 mRNA

NCBI chr10:14,864,672...14,881,285
Ensembl chr10:14,864,670...14,881,292

G

WEE1 G2 checkpoint kinase

decreases expression

Vincristine results in decreased expression of WEE1 mRNA

NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688

G

WNK lysine deficient protein kinase 1

increases expression

Vincristine results in increased expression of WNK1 mRNA

NCBI chr 4:153,128,334...153,253,905
Ensembl chr 4:153,128,334...153,253,905

G

WD repeat and SOCS box-containing 1

decreases expression

Vincristine results in decreased expression of WSB1 mRNA

NCBI chr10:64,202,761...64,219,039
Ensembl chr10:64,202,763...64,219,019

G

xin actin-binding repeat containing 2

decreases expression

Vincristine results in decreased expression of XIRP2 mRNA

NCBI chr 3:52,126,213...52,213,094
Ensembl chr 3:51,870,092...52,213,091

G

X-prolyl aminopeptidase 3

increases expression

Vincristine results in increased expression of XPNPEP3 mRNA

NCBI chr 7:112,926,154...112,978,793
Ensembl chr 7:112,926,248...112,974,878

G

yippee-like 5

increases expression

Vincristine results in increased expression of YPEL5 mRNA

NCBI chr 6:22,656,284...22,671,741
Ensembl chr 6:22,656,285...22,671,691

G

YTH N6-methyladenosine RNA binding protein C2

decreases expression

Vincristine results in decreased expression of YTHDC2 mRNA

NCBI chr18:37,266,559...37,331,681
Ensembl chr18:37,265,836...37,331,023

G

YTH N6-methyladenosine RNA binding protein F3

increases expression

Vincristine results in increased expression of YTHDF3 mRNA

NCBI chr 2:98,350,304...98,384,608
Ensembl chr 2:98,350,588...98,384,606

G

zinc finger and BTB domain containing 10

increases expression

Vincristine results in increased expression of ZBTB10 mRNA

NCBI chr 2:92,475,254...92,509,892
Ensembl chr 2:92,479,014...92,512,515

G

zinc finger and BTB domain containing 14

decreases expression

Vincristine results in decreased expression of ZBTB14 mRNA

NCBI chr 9:109,333,440...109,338,646
Ensembl chr 9:109,331,028...109,338,632

G

zinc finger and BTB domain containing 24

decreases expression

Vincristine results in decreased expression of ZBTB24 mRNA

NCBI chr20:44,943,302...44,965,329
Ensembl chr20:44,947,297...44,963,963

G

zinc finger CCCH type containing 12A

increases expression

Vincristine results in increased expression of ZC3H12A mRNA

NCBI chr 5:137,376,562...137,385,351
Ensembl chr 5:137,376,564...137,385,351

G

zinc finger CCHC-type containing 2

decreases expression

Vincristine results in decreased expression of ZCCHC2 mRNA

NCBI chr13:22,118,677...22,193,626
Ensembl chr13:22,119,568...22,166,373

G

zinc finger protein 207

decreases expression
increases expression

Vincristine results in decreased expression of ZNF207 mRNA
Vincristine results in increased expression of ZNF207 mRNA

NCBI chr10:65,385,807...65,398,086
Ensembl chr10:65,385,740...65,397,386

G

zinc finger protein 395

decreases expression

Vincristine results in decreased expression of ZNF395 mRNA

NCBI chr15:39,581,603...39,621,911
Ensembl chr15:39,608,080...39,619,950

G

zinc finger protein 503

decreases expression

Vincristine results in decreased expression of ZNF503 mRNA

NCBI chr15:2,313,060...2,316,848
Ensembl chr15:2,313,060...2,316,848

G

zinc finger protein 638

increases expression

Vincristine results in increased expression of ZNF638 mRNA

NCBI chr 4:116,355,934...116,475,051
Ensembl chr 4:116,402,428...116,479,845

G

zinc finger protein 652

decreases expression

Vincristine results in decreased expression of ZNF652 mRNA

NCBI chr10:80,626,555...80,706,397
Ensembl chr10:80,649,400...80,698,674

G

zinc finger protein 672

decreases expression

Vincristine results in decreased expression of ZNF672 mRNA

NCBI chr10:42,496,558...42,512,134
Ensembl chr10:42,495,476...42,504,852

G

zinc finger protein 691

decreases expression

Vincristine results in decreased expression of ZNF691 mRNA

NCBI chr 5:132,780,259...132,784,954
Ensembl chr 5:132,780,181...132,785,000

G

zinc finger protein 692

decreases expression

Vincristine results in decreased expression of ZNF692 mRNA

NCBI chr10:42,484,576...42,496,573
Ensembl chr10:42,488,588...42,496,018

G

zinc finger protein 709

decreases expression

Vincristine results in decreased expression of ZNF443 mRNA

NCBI chr16:17,907,599...17,920,047
Ensembl chr16:17,909,641...17,919,700

G

zinc finger protein 830

decreases expression

Vincristine results in decreased expression of ZNF830 mRNA

NCBI chr10:67,701,340...67,702,804
Ensembl chr10:67,701,073...67,704,523

G

zinc finger FYVE-type containing 16

increases expression

Vincristine results in increased expression of ZFYVE16 mRNA

NCBI chr 2:23,713,018...23,757,576
Ensembl chr 2:23,713,766...23,756,990

G

zinc finger, matrin type 3

increases expression

Vincristine results in increased expression of ZMAT3 mRNA

NCBI chr 2:115,106,046...115,136,888
Ensembl chr 2:115,106,966...115,136,863

G

zinc finger, MIZ-type containing 2

increases expression

Vincristine results in increased expression of ZMIZ2 mRNA

NCBI chr14:81,251,391...81,267,936
Ensembl chr14:81,251,417...81,267,936

G

zinc finger, MYND-type containing 8

increases expression

Vincristine results in increased expression of ZMYND8 mRNA

NCBI chr 3:154,528,917...154,629,532
Ensembl chr 3:154,529,043...154,628,463

G

zinc finger, NFX1-type containing 1

increases expression

Vincristine results in increased expression of ZNFX1 mRNA

NCBI chr 3:155,764,073...155,791,777
Ensembl chr 3:155,764,980...155,821,242

G

zinc and ring finger 2

decreases expression

Vincristine results in decreased expression of ZNRF2 mRNA

NCBI chr 4:83,950,406...84,032,676
Ensembl chr 4:83,949,309...84,027,818

vindesine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions
decreases expression

Tamoxifen promotes the reaction [Vindesine results in decreased expression of BAX mRNA]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
increases expression

Tamoxifen promotes the reaction [Vindesine results in increased expression of BCL2 mRNA]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

nerve growth factor

decreases response to substance

Vindesine results in decreased susceptibility to NGF protein

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

vinorelbine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

multiple interactions

[pifithrin co-treated with vinorelbine] results in increased cleavage of and results in increased activity of CASP3 protein
[Cisplatin co-treated with vinorelbine] results in increased activity of CASP3 protein

PMID:18516295 PMID:21544650

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

multiple interactions

[Cisplatin co-treated with vinorelbine] results in decreased expression of CASP7 mRNA

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

CD40 ligand

multiple interactions

[Cisplatin co-treated with vinorelbine] results in decreased expression of CD40LG mRNA

NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306

G

cyclin-dependent kinase inhibitor 2A

decreases expression

vinorelbine results in decreased expression of CDKN2A protein

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

epithelial cell adhesion molecule

multiple interactions
increases expression

[vinorelbine co-treated with Cisplatin] results in increased expression of EPCAM protein
vinorelbine results in increased expression of EPCAM protein

NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127

G

Fas cell surface death receptor

multiple interactions

[Cisplatin co-treated with vinorelbine] results in increased expression of FAS protein

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions

[Cisplatin co-treated with vinorelbine] results in decreased expression of FASL mRNA

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

interleukin 10

multiple interactions

[Cisplatin co-treated with vinorelbine] results in decreased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 7

multiple interactions

[Cisplatin co-treated with vinorelbine] results in increased expression of IL7 protein

NCBI chr 2:94,235,219...94,280,075
Ensembl chr 2:94,234,766...94,280,075

G

keratin 18

increases expression
increases metabolic processing

vinorelbine results in increased expression of KRT18 protein
vinorelbine results in increased metabolism of KRT18 protein

NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166

G

LIM homeobox 4

multiple interactions

[Cisplatin co-treated with vinorelbine] results in decreased expression of LHX4 mRNA

NCBI chr13:67,877,109...67,917,219
Ensembl chr13:67,877,109...67,927,003

G

nucleophosmin 1

decreases response to substance

NPM1 protein results in decreased susceptibility to vinorelbine

NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

vinorelbine inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

p21 (RAC1) activated kinase 5

multiple interactions

[Cisplatin co-treated with Vinorelbine] results in decreased expression of PAK5 mRNA

NCBI chr 3:123,395,678...123,703,967
Ensembl chr 3:123,396,497...123,703,930

G

protein C, inactivator of coagulation factors Va and VIIIa

decreases expression

vinorelbine results in decreased expression of PROC protein

NCBI chr18:23,764,367...23,774,816
Ensembl chr18:23,764,368...23,775,133

G

prostaglandin-endoperoxide synthase 2

decreases expression

vinorelbine results in decreased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RNA binding motif protein 17

decreases response to substance

RBM17 protein results in decreased susceptibility to vinorelbine

NCBI chr17:66,937,140...66,954,034
Ensembl chr17:66,937,140...66,954,014

G

solute carrier family 29 member 1

affects response to substance

SLC29A1 protein affects the susceptibility to vinorelbine

NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203

G

transforming growth factor, beta 1

decreases activity

Vinorelbine results in decreased activity of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

[Cisplatin co-treated with vinorelbine] results in decreased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor-associated factor 1

multiple interactions

[Cisplatin co-treated with vinorelbine] results in decreased expression of TRAF1 mRNA

NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807

yohimbine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases expression

Yohimbine analog results in increased expression of ABCB1 mRNA

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

actin, gamma 1

increases expression

Yohimbine results in increased expression of ACTG1 mRNA

NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232
Ensembl chr 3:105,619,737...105,624,232

G

ADAM metallopeptidase domain 9

decreases expression

Yohimbine results in decreased expression of ADAM9 mRNA

NCBI chr16:67,022,538...67,101,647
Ensembl chr16:67,022,655...67,100,917

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

increases expression

Yohimbine results in increased expression of ADAMTS4 mRNA

NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065

G

adrenoceptor alpha 2A

multiple interactions

Yohimbine inhibits the reaction [Brimonidine Tartrate promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA2A protein]]; Yohimbine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]
Yohimbine binds to and results in decreased activity of ADRA2A protein

PMID:8397342 PMID:10742289 PMID:17666864

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor beta 1

multiple interactions

[Imipramine co-treated with Yohimbine] results in decreased activity of ADRB1 protein

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

arginine vasopressin receptor 1A

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA

NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215

G

betaine-homocysteine S-methyltransferase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA

NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742

G

calumenin

increases expression

Yohimbine results in increased expression of CALU mRNA

NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593

G

catalase

multiple interactions

Yohimbine inhibits the reaction [[COL2A1 protein co-treated with Adjuvants, Immunologic co-treated with Freund's Adjuvant] results in decreased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin G1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

CD36 molecule

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cell division cycle 14B

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA

NCBI chr17:844,686...934,787
Ensembl chr17:844,685...933,235

G

cell migration inducing hyaluronidase 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA

NCBI chr 1:219,330,295...219,407,760
Ensembl chr 1:219,337,985...219,407,760

G

chloride intracellular channel 1

decreases expression

Yohimbine results in decreased expression of CLIC1 mRNA

NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712

G

collagen type II alpha 1 chain

multiple interactions

Yohimbine inhibits the reaction [[COL2A1 protein co-treated with Adjuvants, Immunologic co-treated with Freund's Adjuvant] results in decreased activity of CAT protein]; Yohimbine inhibits the reaction [[COL2A1 protein co-treated with Adjuvants, Immunologic co-treated with Freund's Adjuvant] results in increased expression of PTGS2 protein]; Yohimbine inhibits the reaction [[COL2A1 protein co-treated with Adjuvants, Immunologic co-treated with Freund's Adjuvant] results in increased expression of RELA protein]; Yohimbine inhibits the reaction [[COL2A1 protein co-treated with Adjuvants, Immunologic co-treated with Freund's Adjuvant] results in increased expression of TNF protein]

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

corticotropin releasing hormone

multiple interactions

Yohimbine affects the reaction [Norepinephrine affects the expression of and affects the secretion of CRH protein]; Yohimbine inhibits the reaction [Nitroprusside results in increased expression of and results in increased secretion of CRH protein]

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

C-X-C motif chemokine ligand 12

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects metabolic processing
affects response to substance

CYP2D6 gene polymorphism affects the metabolism of Yohimbine
CYP2D6 protein affects the susceptibility to Yohimbine

PMID:15289791 PMID:34027562

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
affects metabolic processing

Yohimbine analog inhibits the reaction [Calcitriol results in increased expression of CYP3A4 protein]
CYP3A4 gene polymorphism affects the metabolism of Yohimbine

PMID:15289791 PMID:29782822

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

fatty acid synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutathione-disulfide reductase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

5-hydroxytryptamine receptor 2A

multiple interactions

[Yohimbine co-treated with Cocaine] affects the reaction [HTR2A protein results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine]

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

lipoprotein lipase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

lanosterol synthase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

monoamine oxidase A

decreases activity

Yohimbine results in decreased activity of MAOA protein

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

microRNA 101a

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA

NCBI chr 5:115,966,332...115,966,406
Ensembl chr 5:115,966,328...115,966,410

G

microRNA 122

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA

NCBI chr18:58,758,703...58,758,787

G

microRNA 192

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA

NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055

G

MLX interacting protein-like

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA

NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112

G

myc target 1

increases expression

Yohimbine results in increased expression of MYCT1 mRNA

NCBI chr 1:42,018,137...42,029,410
Ensembl chr 1:42,018,137...42,029,410

G

NFKB inhibitor zeta

increases expression

Yohimbine results in increased expression of NFKBIZ mRNA

NCBI chr11:44,782,676...44,810,722
Ensembl chr11:44,782,676...44,810,723

G

nitric oxide synthase 2

multiple interactions

Yohimbine inhibits the reaction [endotoxin, Escherichia coli results in increased expression of NOS2 protein]; Yohimbine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neuropeptide Y

multiple interactions

Yohimbine inhibits the reaction [Clonidine results in decreased expression of NPY mRNA]

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor interacting protein 3

increases expression

Yohimbine results in increased expression of NRIP3 mRNA

NCBI chr 1:163,789,738...163,815,036
Ensembl chr 1:163,789,738...163,815,600

G

phospholipase A2, group XIIA

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA

NCBI chr 2:218,436,497...218,452,742
Ensembl chr 2:218,436,513...218,452,740

G

proopiomelanocortin

multiple interactions

Yohimbine inhibits the reaction [Ethanol results in increased secretion of POMC protein]

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

prolactin

increases expression

Yohimbine results in increased expression of PRL protein

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

prostaglandin-endoperoxide synthase 2

multiple interactions

Yohimbine inhibits the reaction [[COL2A1 protein co-treated with Adjuvants, Immunologic co-treated with Freund's Adjuvant] results in increased expression of PTGS2 protein]; Yohimbine inhibits the reaction [endotoxin, Escherichia coli results in increased expression of PTGS2 protein]; Yohimbine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]

PMID:17637181 PMID:27028940

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Yohimbine inhibits the reaction [[COL2A1 protein co-treated with Adjuvants, Immunologic co-treated with Freund's Adjuvant] results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

renin

multiple interactions
increases expression

Chlorisondamine inhibits the reaction [Yohimbine results in increased expression of REN protein]; Indomethacin inhibits the reaction [Yohimbine results in increased expression of REN protein]; Meclofenamic Acid inhibits the reaction [Yohimbine results in increased expression of REN protein]; Propranolol inhibits the reaction [Yohimbine results in increased expression of REN protein]

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

stearoyl-CoA desaturase

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

thyroid hormone responsive

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA

NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075

G

tumor necrosis factor

multiple interactions

Yohimbine inhibits the reaction [[COL2A1 protein co-treated with Adjuvants, Immunologic co-treated with Freund's Adjuvant] results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

thioredoxin reductase 1

multiple interactions

[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

zolmitriptan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2-associated agonist of cell death

multiple interactions

zolmitriptan inhibits the reaction [Diethylnitrosamine results in decreased expression of BAD mRNA]; zolmitriptan inhibits the reaction [Diethylnitrosamine results in decreased expression of BAD protein]

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

multiple interactions

zolmitriptan inhibits the reaction [Diethylnitrosamine results in decreased expression of BAX mRNA]; zolmitriptan inhibits the reaction [Diethylnitrosamine results in decreased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

zolmitriptan inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 mRNA]; zolmitriptan inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

zolmitriptan inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2L1 mRNA]; zolmitriptan inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2L1 protein]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

caspase 3

multiple interactions

zolmitriptan inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP3 mRNA]; zolmitriptan inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

zolmitriptan inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP9 mRNA]; zolmitriptan inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity

zolmitriptan results in decreased activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

glutamic--pyruvic transaminase

multiple interactions

zolmitriptan inhibits the reaction [Diethylnitrosamine results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

nitric oxide synthase 2

multiple interactions

zolmitriptan inhibits the reaction [Diethylnitrosamine results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions

zolmitriptan inhibits the reaction [Diethylnitrosamine results in decreased expression of NOS3 mRNA]

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19838
chemical entity	19836
group	19795
organic group	18962
cyclic organic group	1943
organic heterobicyclic ring	1943
indole skeleton +	1943
indolizidine skeleton	0
Path 2
Term	Annotations
CHEBI ontology	19838
subatomic particle	19836
composite particle	19836
hadron	19836
baryon	19836
nucleon	19836
atomic nucleus	19836
atom	19836
group	19795
organic group	18962
cyclic organic group	1943
organic heterobicyclic ring	1943
indole skeleton +	1943
indolizidine skeleton	0

paths to the root